
<html lang="en"     class="pb-page"  data-request-id="0a90500b-64cb-48c6-8fce-4e3b29da4c6f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.1c00159;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-13;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer" /></meta><meta name="dc.Creator" content="Kevin D.  Freeman-Cook" /></meta><meta name="dc.Creator" content="Robert L.  Hoffman" /></meta><meta name="dc.Creator" content="Douglas C.  Behenna" /></meta><meta name="dc.Creator" content="Britton  Boras" /></meta><meta name="dc.Creator" content="Jordan  Carelli" /></meta><meta name="dc.Creator" content="Wade  Diehl" /></meta><meta name="dc.Creator" content="Rose Ann  Ferre" /></meta><meta name="dc.Creator" content="You-Ai  He" /></meta><meta name="dc.Creator" content="Andrea  Hui" /></meta><meta name="dc.Creator" content="Buwen  Huang" /></meta><meta name="dc.Creator" content="Nanni  Huser" /></meta><meta name="dc.Creator" content="Rhys  Jones" /></meta><meta name="dc.Creator" content="Susan E.  Kephart" /></meta><meta name="dc.Creator" content="John  Lapek" /></meta><meta name="dc.Creator" content="Michele  McTigue" /></meta><meta name="dc.Creator" content="Nichol  Miller" /></meta><meta name="dc.Creator" content="Brion W.  Murray" /></meta><meta name="dc.Creator" content="Asako  Nagata" /></meta><meta name="dc.Creator" content="Lisa  Nguyen" /></meta><meta name="dc.Creator" content="Sherry  Niessen" /></meta><meta name="dc.Creator" content="Sacha  Ninkovic" /></meta><meta name="dc.Creator" content="Inish  O’Doherty" /></meta><meta name="dc.Creator" content="Martha A.  Ornelas" /></meta><meta name="dc.Creator" content="James  Solowiej" /></meta><meta name="dc.Creator" content="Scott C.  Sutton" /></meta><meta name="dc.Creator" content="Khanh  Tran" /></meta><meta name="dc.Creator" content="Elaine  Tseng" /></meta><meta name="dc.Creator" content="Ravi  Visswanathan" /></meta><meta name="dc.Creator" content="Meirong  Xu" /></meta><meta name="dc.Creator" content="Luke  Zehnder" /></meta><meta name="dc.Creator" content="Qin  Zhang" /></meta><meta name="dc.Creator" content="Cathy  Zhang" /></meta><meta name="dc.Creator" content="Stephen  Dann" /></meta><meta name="dc.Description" content="Control of the cell cycle through selective pharmacological inhibition of CDK4/6 has proven beneficial in the treatment of breast cancer. Extending this level of control to additional cell cycle CD..." /></meta><meta name="Description" content="Control of the cell cycle through selective pharmacological inhibition of CDK4/6 has proven beneficial in the treatment of breast cancer. Extending this level of control to additional cell cycle CD..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 10, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00159" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00159" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00159" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00159" /></link>
        
    
    

<title>Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00159" /></meta><meta property="og:title" content="Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0016.jpeg" /></meta><meta property="og:description" content="Control of the cell cycle through selective pharmacological inhibition of CDK4/6 has proven beneficial in the treatment of breast cancer. Extending this level of control to additional cell cycle CDK isoforms represents an opportunity to expand to additional tumor types and potentially provide benefits to patients that develop tumors resistant to selective CDK4/6 inhibitors. However, broad-spectrum CDK inhibitors have a long history of failure due to safety concerns. In this approach, we describe the use of structure-based drug design and Free–Wilson analysis to optimize a series of CDK2/4/6 inhibitors. Further, we detail the use of molecular dynamics simulations to provide insights into the basis for selectivity against CDK9. Based on overall potency, selectivity, and ADME profile, PF-06873600 (22) was identified as a candidate for the treatment of cancer and advanced to phase 1 clinical trials." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00159"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00159">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00159&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00159&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00159&amp;href=/doi/10.1021/acs.jmedchem.1c00159" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 9056-9077</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00158" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00174" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Kevin D. Freeman-Cook</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kevin D. Freeman-Cook</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#4a212f3c2324642c382f2f272b2467292525210a3a2c23302f3864292527"><span class="__cf_email__" data-cfemail="09626c7f6067276f7b6c6c646867246a66666249796f60736c7b276a6664">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+D.++Freeman-Cook">Kevin D. Freeman-Cook</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-9014-2309" title="Orcid link">https://orcid.org/0000-0001-9014-2309</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert L. Hoffman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert L. Hoffman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+L.++Hoffman">Robert L. Hoffman</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-2030-9094" title="Orcid link">https://orcid.org/0000-0002-2030-9094</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Douglas C. Behenna</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Douglas C. Behenna</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Douglas+C.++Behenna">Douglas C. Behenna</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Britton Boras</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Britton Boras</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Britton++Boras">Britton Boras</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jordan Carelli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jordan Carelli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jordan++Carelli">Jordan Carelli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wade Diehl</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wade Diehl</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wade++Diehl">Wade Diehl</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rose Ann Ferre</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rose Ann Ferre</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rose+Ann++Ferre">Rose Ann Ferre</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">You-Ai He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">You-Ai He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=You-Ai++He">You-Ai He</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrea Hui</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrea Hui</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Hui">Andrea Hui</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Buwen Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Buwen Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Buwen++Huang">Buwen Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nanni Huser</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nanni Huser</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nanni++Huser">Nanni Huser</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rhys Jones</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rhys Jones</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rhys++Jones">Rhys Jones</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Susan E. Kephart</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susan E. Kephart</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susan+E.++Kephart">Susan E. Kephart</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John Lapek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John Lapek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John++Lapek">John Lapek</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-6578-5350" title="Orcid link">https://orcid.org/0000-0002-6578-5350</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michele McTigue</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michele McTigue</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michele++McTigue">Michele McTigue</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nichol Miller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nichol Miller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nichol++Miller">Nichol Miller</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brion W. Murray</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brion W. Murray</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brion+W.++Murray">Brion W. Murray</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Asako Nagata</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Asako Nagata</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Asako++Nagata">Asako Nagata</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lisa Nguyen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lisa Nguyen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lisa++Nguyen">Lisa Nguyen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sherry Niessen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sherry Niessen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sherry++Niessen">Sherry Niessen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sacha Ninkovic</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sacha Ninkovic</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sacha++Ninkovic">Sacha Ninkovic</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Inish O’Doherty</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Inish O’Doherty</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Inish++O%E2%80%99Doherty">Inish O’Doherty</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martha A. Ornelas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martha A. Ornelas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martha+A.++Ornelas">Martha A. Ornelas</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James Solowiej</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James Solowiej</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++Solowiej">James Solowiej</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Scott C. Sutton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Scott C. Sutton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Scott+C.++Sutton">Scott C. Sutton</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Khanh Tran</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Khanh Tran</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Khanh++Tran">Khanh Tran</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elaine Tseng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elaine Tseng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elaine++Tseng">Elaine Tseng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ravi Visswanathan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ravi Visswanathan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ravi++Visswanathan">Ravi Visswanathan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Meirong Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Meirong Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Meirong++Xu">Meirong Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luke Zehnder</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luke Zehnder</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luke++Zehnder">Luke Zehnder</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qin Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qin Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qin++Zhang">Qin Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cathy Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cathy Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cathy++Zhang">Cathy Zhang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Stephen Dann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen Dann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Dann">Stephen Dann</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00159&amp;href=/doi/10.1021%2Facs.jmedchem.1c00159" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 9056–9077</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 10, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 January 2021</li><li><span class="item_label"><b>Published</b> online</span>10 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00159" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00159</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9056%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DKevin%2BD.%2BFreeman-Cook%252C%2BRobert%2BL.%2BHoffman%252C%2BDouglas%2BC.%2BBehenna%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D13%26contentID%3Dacs.jmedchem.1c00159%26title%3DDiscovery%2Bof%2BPF-06873600%252C%2Ba%2BCDK2%252F4%252F6%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9077%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00159"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2964</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00159" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;D. Freeman-Cook&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;L. Hoffman&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;C. Behenna&quot;},{&quot;first_name&quot;:&quot;Britton&quot;,&quot;last_name&quot;:&quot;Boras&quot;},{&quot;first_name&quot;:&quot;Jordan&quot;,&quot;last_name&quot;:&quot;Carelli&quot;},{&quot;first_name&quot;:&quot;Wade&quot;,&quot;last_name&quot;:&quot;Diehl&quot;},{&quot;first_name&quot;:&quot;Rose&quot;,&quot;last_name&quot;:&quot;Ann Ferre&quot;},{&quot;first_name&quot;:&quot;You-Ai&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Hui&quot;},{&quot;first_name&quot;:&quot;Buwen&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Nanni&quot;,&quot;last_name&quot;:&quot;Huser&quot;},{&quot;first_name&quot;:&quot;Rhys&quot;,&quot;last_name&quot;:&quot;Jones&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;E. Kephart&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Lapek&quot;},{&quot;first_name&quot;:&quot;Michele&quot;,&quot;last_name&quot;:&quot;McTigue&quot;},{&quot;first_name&quot;:&quot;Nichol&quot;,&quot;last_name&quot;:&quot;Miller&quot;},{&quot;first_name&quot;:&quot;Brion&quot;,&quot;last_name&quot;:&quot;W. Murray&quot;},{&quot;first_name&quot;:&quot;Asako&quot;,&quot;last_name&quot;:&quot;Nagata&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;Nguyen&quot;},{&quot;first_name&quot;:&quot;Sherry&quot;,&quot;last_name&quot;:&quot;Niessen&quot;},{&quot;first_name&quot;:&quot;Sacha&quot;,&quot;last_name&quot;:&quot;Ninkovic&quot;},{&quot;first_name&quot;:&quot;Inish&quot;,&quot;last_name&quot;:&quot;O’Doherty&quot;},{&quot;first_name&quot;:&quot;Martha&quot;,&quot;last_name&quot;:&quot;A. Ornelas&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Solowiej&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;C. Sutton&quot;},{&quot;first_name&quot;:&quot;Khanh&quot;,&quot;last_name&quot;:&quot;Tran&quot;},{&quot;first_name&quot;:&quot;Elaine&quot;,&quot;last_name&quot;:&quot;Tseng&quot;},{&quot;first_name&quot;:&quot;Ravi&quot;,&quot;last_name&quot;:&quot;Visswanathan&quot;},{&quot;first_name&quot;:&quot;Meirong&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Luke&quot;,&quot;last_name&quot;:&quot;Zehnder&quot;},{&quot;first_name&quot;:&quot;Qin&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Cathy&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Dann&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;9056-9077&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00159&quot;},&quot;abstract&quot;:&quot;Control of the cell cycle through selective pharmacological inhibition of CDK4/6 has proven beneficial in the treatment of breast cancer. Extending this level of control to additional cell cycle CDK isoforms represents an opportunity to expand to additional tumor types and potentially provide benefits to patients that develop tumors resistant to selective CDK4/6 inhibitors. However, broad-spectrum CDK inhibitors have a long history of failure due to safety concerns. In this approach, we describe the use of structure-based drug design and Free–Wilson analysis to optimize a series of CDK2/4/6 inhibitors. Further, we detail the use of molecular dynamics simulations to provide insights into the basis for selectivity against CDK9. Based on overall potency, selectivity, and ADME profile, PF-06873600 (22) was identified as a candidate for the treatment of cancer and advanced to phase 1 clinical trials.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00159&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00159" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00159&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00159" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00159&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00159" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00159&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00159&amp;href=/doi/10.1021/acs.jmedchem.1c00159" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00159" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00159" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00159%26sid%3Dliteratum%253Aachs%26pmid%3D34110834%26genre%3Darticle%26aulast%3DFreeman-Cook%26date%3D2021%26atitle%3DDiscovery%2Bof%2BPF-06873600%252C%2Ba%2BCDK2%252F4%252F6%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D13%26spage%3D9056%26epage%3D9077%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292349" title="Alkyls">Alkyls</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Control of the cell cycle through selective pharmacological inhibition of CDK4/6 has proven beneficial in the treatment of breast cancer. Extending this level of control to additional cell cycle CDK isoforms represents an opportunity to expand to additional tumor types and potentially provide benefits to patients that develop tumors resistant to selective CDK4/6 inhibitors. However, broad-spectrum CDK inhibitors have a long history of failure due to safety concerns. In this approach, we describe the use of structure-based drug design and Free–Wilson analysis to optimize a series of CDK2/4/6 inhibitors. Further, we detail the use of molecular dynamics simulations to provide insights into the basis for selectivity against CDK9. Based on overall potency, selectivity, and ADME profile, PF-06873600 (<b>22</b>) was identified as a candidate for the treatment of cancer and advanced to phase 1 clinical trials.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84082" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84082" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The cyclin-dependent kinases (CDKs) are a 21-member family of serine–threonine kinases that are regulated by the formation of heterodimeric complexes with their cyclin-binding partners. CDK–cyclin complexes are involved in a diverse array of cellular processes, including transcriptional regulation (CDKs 7, 8, 9, 10, 11, 12, 13, 19, and 20), splicing (CDK 12), DNA repair (CDK 2, 9, and 12),<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> and regulation of the cell cycle (CDKs 1, 2, 4, and 6).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> While each of the above could play an important role in the development of cancers, our research program focused on controlling the regulation of the cell cycle. The sequenced activation of the cell cycle CDKs orchestrates progression through each of the four distinct phases of the cell cycle (G1, S, G2, and M).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> First, CDK4 and CDK6 form complexes with cyclinD that phosphorylate the retinoblastoma (RB1) tumor suppressor. This step is followed by the CDK2–cyclinE complex performing additional phosphorylations on RB1.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The entire process releases E2F transcription factors from the RB1 complex and allows E2F-dependent transcription,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> permitting cells to move through the G1 phase and into the later phases of the cell cycle.</div><div class="NLM_p">Sustained, unregulated progression through the cell cycle is a hallmark of cancer.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The dysregulation of CDKs can cause continuous cell proliferation and can influence cancer progression and severity.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Cyclin D amplification is a well-established oncogenic lesion, and targeting cyclin D activity with CDK4/6 inhibitors is a successful therapeutic strategy for treating some cancers.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> CDK2 has been proposed as a therapeutic target in multiple tumor types such as KRAS-driven lung cancer,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> MYC-amplified neuroblastoma,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> melanoma,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> acute myeloid leukemia,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> hepatocellular carcinoma,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> glioblastoma,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> prostate cancer,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and breast cancer.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a> The cyclin-binding partners of CDK2 (cyclin E1 and cyclin E2) are amplified in a significant percentage of human cancers and this phenotype predicts poorer overall survival for patients.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a></div><div class="NLM_p">The CDK4/6 dual inhibitor palbociclib (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was approved in combination with letrozole in 2015 for the treatment of estrogen receptor-positive (ER+) breast cancer. This was closely followed by two additional CDK4/6 inhibitors with roughly similar profiles, abemaciclib and ribociclib.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> While CDK4/6 inhibition in combination with endocrine therapy provides a therapeutic benefit in ER+ breast cancer, intrinsic and acquired resistance to CDK4/6 inhibition is expected. CDK2 activation may act as a compensatory mechanism for progressing through the cell cycle despite CDK4/6 inhibition. For instance, in the ER+ breast cancer cell line MCF7, siRNA knockdown of CDK2 alone appears to have very little effect on cell growth but synergizes with CDK4/6 inhibition.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> More intriguingly, palbociclib-resistant MCF7 cells, generated through chronic palbociclib exposure, display relative amplification of cyclin E1, which has been shown to be oncogenic and indicative of high CDK2 activity.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> In this context, the siRNA knockdown of CDK2 or cyclin E1 re-sensitizes cells to palbociclib.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Indeed, a recent analysis of a palbociclib clinical trial revealed that patients with high cyclin E1 expression levels benefit less from palbociclib treatment than those with low cyclin E1 expression levels.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Therefore, adding inhibition of CDK2 to CDK4/6 could potentially help to control resistant tumors. Additionally, the broader control of CDK2, 4, and 6 could potentially benefit a wider scope of patients with tumors where CDK4/6 inhibitors have not yet been approved.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Palbociclib (<b>1</b>) and early file screening hit for CDK2/cyclinE1 (<b>2</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Work to develop CDK inhibitors has been ongoing for more than 20 years in the pharmaceutical industry. Flavopiridol, identified in 1992 from a plant source in India, was advanced into clinical trials in the late 1990s.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Over the next two decades, academic and industrial researchers produced thousands of pre-clinical CDK inhibitors with widely varying activities, physical properties, and most importantly selectivity profiles. Generally, these compounds suffered from a lack of selectivity, both from within the CDK family and also from the broader kinome.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> When nonselective CDK inhibitors were dosed in clinical trials, they generally displayed cytotoxicity across gastrointestinal tissues, which could include irritation, nausea, diarrhea, and vomiting.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In addition, these compounds could cause pronounced cytotoxic effects on bone marrow cells, which resulted in the loss of peripheral leukocytes after 1–2 weeks of dosing.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Thus, while more than 20 CDK inhibitors started clinical trials over almost 30 years, to date only the selective CDK4/6 inhibitors (palbociclib, abemaciclib, and ribociclib) have been approved as cancer therapies. We hypothesized that much of the unwanted cytotoxicity in failed clinical candidates could arise from the inhibition of CDK1 because it had been shown to be essential in embryonic development in mice and because it has a central role in G2/M progression.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Recognizing the overall challenge of designing selective chemical matter in a large kinase family, we embarked on a program attempting to develop compounds that would potently and selectively inhibit CDK2, as well as CDK4/6 while at the same time spare CDK1.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85652" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85652" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Screening for biochemical CDK2 inhibition by mobility shift assay identified the truncated palbociclib derivative <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Compound <b>2</b> replaces the piperazine–pyridine ring system of the palbociclib structure with a methyl sulfonamide capped piperidine. This modification results in a greater than 500-fold increase in CDK2 potency compared to palbociclib but gives only modest CDK1 selectivity (8-fold). An examination of the crystal structure of compound <b>2</b> in complex with CDK2 is shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A and highlights the interactions leading to the dramatic increase in CDK2 activity. The piperidine sulfonamide motif made direct interactions with the CDK2 protein as a hydrogen bond acceptor from the backbone −NH of Asp86 and the sidechain −NH<sub>3</sub> of Lys89. Additionally, the piperidine ring was oriented within a lipophilic pocket with one edge forming van der Waals interactions with the phenyl sidechain of Phe82. Compound <b>2</b> was bound to CDK2 through a classical kinase hinge acceptor–donor–acceptor motif. Leu83 provided a carbonyl oxygen as an acceptor and a backbone NH as a donor, while Glu 81 presented a carbonyl oxygen as an acceptor. The methyl group at the 5-position of the pyridopyrimidinone ring system extended toward the gatekeeper Phe80 residue but primarily functioned to rotate the adjacent acetyl group out of the plane of the core bicyclic aromatic system. When oriented in this orthogonal conformation, the carbonyl oxygen served as a hydrogen bond acceptor for the backbone NH of Asp145. The lipophilic cyclopentyl ring was oriented within a lipophilic pocket formed by Val64, Leu134, and Ala144 with one edge that extended out toward a solvent accessible region.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Crystal structure of <b>2</b> in complex with CDK2. The protein surface is rendered in gray with key molecular interaction distances highlighted with dashed lines and measurements in Å. Sidechains of Phe80, Phe82, and Lys89 are bolded in the protein. The piperidine ring system orients a lipophilic edge toward Phe82. This group is similarly accommodated in other CDK isoforms as a relatively nonselective CDK inhibitor. (B) Crystal structure of palbociclib (<b>1</b>) in complex with CDK6. The protein surface is rendered in gray with key molecular interaction distances highlighted with dashed lines and measurements in Å. The His100 residue (bold) in CDK6 is aligned with the pyridyl nitrogen of palbociclib avoiding any de-solvation penalty between the protein and ligand.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The crystal structure of palbociclib (<b>1</b>) in complex with CDK6 is shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B. Many of the same interactions observed in the crystal structure of <b>2</b> in complex with CDK2 were present in the crystal structure of palbociclib in complex with CDK6. For example, the hydrophobic and hydrophilic interactions between the cyclopentyl ring, methyl ketone, and hinge interactions were similar in both protein–ligand complexes. Regarding primary sequence alignment, however, a single amino acid difference between these two protein–ligand complexes played a large role in driving significant differences in CDK2 potency and broader CDK isoform selectivity. While the hinge Phe residue is common to many CDK family members, including CDK1, 3, 5, 7, and 9, the analogous residue in CDK4 is His95 and is His100 in CDK6. This key difference in the active site underpins the CDK isoform selectivity of palbociclib and the other marketed CDK4/6 dual inhibitors. Each of those molecules contains a pyridyl nitrogen atom which is placed in proximity to the histidine residue in the CDK4 and CDK6 complexes (shown for palbociclib in CDK6, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). The polar environment around this His residue effectively solvated the pyridyl nitrogen in both CDK4 and CDK6 complexes, but the nonpolar Phe in other family members created a de-solvation penalty with the pyridine nitrogen on palbociclib and the other CDK4/6 inhibitors. This forms the basis of their extraordinary isoform selectivity. The aminopiperidine sulfonamide <b>2</b> (see <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) lacked the pyridyl nitrogen and oriented the hydrophobic edge of the piperidine ring toward the same Phe/His region. This change was tolerated by both an adjacent Phe or His residue, and thus <b>2</b> effectively inhibited multiple CDK/cyclin complexes (see <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The significant increase in CDK2 potency and modest level of CDK1 selectivity achieved with <b>2</b> provided an attractive starting point for designs to further increase CDK2 potency and CDK isoform selectivity.</div><div class="NLM_p">A detailed examination of the crystal structure of <b>2</b> in complex with CDK2 suggested that the 5-methyl may have altered the position of the pyridopyrimidinone core within the adenosine 5′-phosphate (ATP) binding pocket due to a potential close-contact with the gatekeeper Phe residue. Removal of both the 5-methyl and 6-acetyl groups from the pyridopyrimidinone core of <b>2</b> provided <b>3</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) which afforded a 7-fold improvement in CDK2 potency and a modest increase in CDK1 selectivity (16-fold). The CDK2 potency was further increased with compound <b>4</b> which was unsubstituted at the 5-position but incorporated a methyl at the 6-position. The addition of this methyl group resulted in 29-fold CDK1 selectivity, an improvement of 2-fold relative to the CDK1 selectivity of compound <b>3</b>. A crystal structure of compound <b>4</b> in complex with CDK2 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) revealed similar sulfonamide and hinge interactions observed with compound <b>2</b>. The 6-methyl was positioned at the opening of a pocket formed by Val64, Leu55, and Phe80, suggesting the opportunity to build additional interactions to increase CDK2 potency and potentially CDK isoform selectivity. Additionally, the cyclopentyl ring of compound <b>4</b> appeared to only partially fill a lipophilic pocket formed by Val64, Leu134, and Ala144.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Crystal structure of <b>4</b> in complex with CDK2. The protein surface is rendered in gray. Lys89, Phe82, and Phe80 are bolded in the protein. The 6-position methyl is oriented towards a pocket formed by the sidechains from the C-α-helix and the gatekeeper Phe80. (B) Matched pairs of compounds which differ only by the presence of a methyl group (blue circles) or hydrogen atom (yellow circles) and the effect on biochemical selectivity <i>vs</i> CDK1 (ratio of biochemical <i>K</i><sub>i</sub> CDK1/biochemical <i>K</i><sub>i</sub> CDK2). (C) Box and whisker plot of pairwise data from (B). (D) Surface representations of CDK2 (wireframe, teal) and CDK1 (solid, yellow) around the inhibitor binding pocket formed by <b>4</b>. Phenylalanine gatekeeper residues are also highlighted for CDK2 (teal) and CDK1 (yellow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Modifications at the 6-Position (R<sub>1</sub>) of the Pyridopyrimidinone Core<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0012.gif" alt="" id="GRAPHIC-d7e682-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0013.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>i</sub> values are the arithmetic mean of at least three independent replicates ± SEM, except where noted. Each individual <i>K</i><sub>i</sub> value is generated from at least 10 single-point inhibition data points run in duplicate. LipE values are calculated using the CDK2 <i>K</i><sub>i</sub> value, according to the formula LipE = p<i>K</i><sub>i</sub> – log <i>D</i>.</p></div></div><div></div></div><div class="NLM_p">A focus on lipophilic efficiency (LipE) informed the overall project objectives, medicinal chemistry analysis, and optimization strategy. As lipophilicity is a key parameter that influences metabolic stability, solubility, permeability, and overall safety risk,<a onclick="showRef(event, 'ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34 ref35">(32−35)</a> LipE was used to normalize potency differences relative to log <i>D</i>.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> A comparison of compounds <b>3–5</b> which differ by only 6-position modifications (-H, −CH<sub>3</sub>, and −Cl, respectively) demonstrated that all three analogues displayed relatively potent CDK2 <i>K</i><sub>i</sub> values. Compounds <b>4</b> and <b>5</b> are more lipophilic than compound <b>3</b>. Their additional lipophilicity was not used efficiently to improve their CDK2 binding potency relative to <b>3</b>. Consequently, the lipophilic efficiency suffered (LipE drops by 0.5 and 0.7 units, respectively, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Polarity was tolerated at the 6-position and analogues <b>6</b> and <b>7</b> gave LipE values which were essentially equivalent to parent analogue <b>3</b>. This argued that polar features could be accommodated without paying high de-solvation penalties and provided an opportunity to lower lipophilicity as a strategy to improve clearance and solubility. Hydroxyethyl analogue <b>8</b> possessed a similar LipE for CDK2 as <b>3</b> and one of the largest CDK2 versus CDK1 selectivity values (46-fold) observed in this series. The methyl ether analogue <b>9</b> also displayed similarly impressive CDK1 selectivity and suggested this selectivity was not dependent on the free hydroxyl group in <b>8</b>. However, the LipE drop of ∼1 unit between compounds <b>8</b> and <b>9</b> suggested that the methyl group was not being used efficiently in binding to CDK2. The additional lipophilicity of <b>9</b> led to a large increase in HLM clearance. Repositioning of the oxygen atom within the ether chain of <b>9</b> to produce compound <b>10</b> caused a 40-fold reduction in CDK2 potency to 80 nM (<i>K</i><sub>i</sub>). Cyclopropyl derivative <b>11</b> recovered only a small amount of potency (35 nM, <i>K</i><sub>i</sub>) and compounds with larger 6-substituent groups such as <b>12</b> were completely inactive.</div><div class="NLM_p">The impact on CDK1 selectivity with substitution at the 6-position of the pyridopyrimidinone core was noteworthy because CDK2 and CDK1 share a common Phe residue near this position. Despite this fact, installation of groups at the 6-position gave a small but generally consistent improvement in CDK1 selectivity. Compound <b>3</b> (6-hydrogen) displays a moderate 16-fold selectivity favoring CDK2 over CDK1 but, as noted earlier, replacement with the 6-methyl of <b>4</b> doubles this CDK isoform selectivity. This same improvement in CDK1 selectivity was seen in a series of 19 matched molecular pairs (MMPs) comparing a methyl versus hydrogen (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). An examination of the overall trend within these MMPs highlighted an average 2.3-fold improvement in CDK1 selectivity (CDK1 <i>K</i><sub>i</sub>/CDK2 <i>K</i><sub>i</sub>) when comparing hydrogen versus methyl in this position (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C), and in some instances this isoform selectivity improvement reached over 6-fold. These results suggested that CDK1 was generally less tolerant of steric bulk in this region. This is despite the fact that the Phe gatekeeper residue is the same in both CDK1 and CDK2, and the 3-dimensional surface that surrounds compound <b>4</b> is also quite similar between CDK1 and CDK2 (see <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D). This surprising difference in potency between the two isoforms may be a result of very small differences in protein strain energy between CDK1 and CDK2, which are difficult to accurately predict.</div><div class="NLM_p">Because compound <b>8</b> displayed one of the highest levels of CDK1 selectivity, it was selected as a tool compound to evaluate the potential for the translation of biochemical activity and selectivity into cellular systems. Both Kuramochi and OVCAR3 ovarian cancer cell lines were selected as model systems due to their similar dependence on CDK2 as a primary oncogenic driver. In these cell lines, compound <b>8</b> inhibited the phosphorylation of RB1 while selective CDK4/6 inhibitors such as palbociclib (<b>1</b>) were unable to do so (see <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). The inhibition of the phosphorylation of RB1 led to the inhibition of proliferation (see <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B) and produced a strong G1 arrest, with a significant reduction of the population of cells in the S-phase (see <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). Palbociclib was inactive in each of these experiments with CDK2-driven cell lines but did show analogous activity in similar experiments using CDK4-driven ER+ breast cancer cell lines.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Live cell target engagements for both CDK2 and CDK1 were measured in order to evaluate how the biochemical selectivity ratios translated into the cell context (see <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D). Kuramochi cells were pre-incubated with compound <b>8</b>, followed by treatment with the broad-spectrum covalent kinase probe XO44 (PF-6808472),<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> then lysed and subjected to a copper catalyzed azide–alkyne cycloaddition reaction with biotin-linked azide. After enrichment with streptavidin beads, elution, and SDS-PAGE, western blots could quantitate the occupancy of <b>8</b> on different CDK isoforms. In line with biochemical <i>K</i><sub>i</sub> measurements, pre-incubation of <b>8</b> efficiently prevented the binding of XO44 to CDK2. As a less potent inhibitor of CDK1, compound <b>8</b> was much less effective in blocking XO44 binding to CDK1. From these experiments, a concentration to give 50% kinase occupancy (OC<sub>50</sub>) for <b>8</b> in the cells was calculated for each isoform. The OC<sub>50</sub> values for CDK2 of 200 nM and 4 μM for CDK1 (20-fold ratio) were consistent with the CDK2 pRB1 cellular inhibition IC<sub>50</sub> (270 nM), the cellular growth inhibition IC<sub>50</sub> (240 nM), and the biochemical CDK1/CDK2 <i>K</i><sub>i</sub> ratio of 46-fold.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Inhibition of the phosphorylation of RB1 in OVCAR3 cells for both palbociclib and <b>8</b>. (B) Inhibition of proliferation in OVCAR3 cells for both palbociclib and <b>8</b>. (C) BRDU cell cycle analysis of cell cycle arrest in OVCAR3 cells for <b>8</b> at 24 and 72 h. Compound concentration (nM) is shown below each bar, and the proportion of cells in G1 (black), S (red), and G2/M (blue) are shown. (D) Western blot of compound <b>8</b> showing the differential blocking of XO44 binding in CDK2 and CDK1 in Kuramochi cells demonstrating differential cellular target engagement. Compound concentration (nM) is shown above each lane of the blot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To rapidly evaluate potential opportunities that the vector for the 8-position provided for increasing CDK2 potency and isoform selectivity, a combination of the structure-based drug design and Free–Wilson analysis was used. As noted in the crystal structure of <b>2</b> in complex with CDK2, the hydrophobic pocket formed by Val64, Leu134, and Ala144 suggested that increasing lipophilicity in this region of the protein could provide increases to CDK2 potency. Steric interactions would predispose cyclic structures to orient orthogonally to the plane of the pyridopyrimidinone core, and it appeared that this orientation would provide additional positions for further substituents to optimize binding to CDK2. Computational deconstruction of pyridopyrimidinone analogues from the Pfizer compound collection using a Free–Wilson technique<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> gave further insights into features that would provide both high potency and high LipE.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In this analysis, 151 variations in R<sub>3</sub> (see <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A) and 92 different substituent variations from the combination of R<sub>1</sub>/R<sub>2</sub> from a total of 324 analogues were analyzed to determine their mathematical contribution to potency and lipophilic efficiency. To assess this analysis, all the historical analogues were subjected to a leave-one-out (LOO) validation method, which produced an <i>R</i><sup>2</sup> value of 0.74 for the 148 resulting analogues (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). This LOO technique suggested a high degree of consistent binding in the historical data set and the potential for good predictivity of new combinations. Potential groups in both vectors were then ranked and prioritized for synthesis.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Free-Wilson schematic. 324 Pyridopyrimidinone analogues were computationally deconstructed to form hypothetical fragments and determine each fragment’s contribution to LipE. (B) Leave-one out analysis of 148 analogues. Blue circles designate compounds which differed in actual <i>vs</i> predicted LipE by more than 1 unit. 141/148 (95%) of analogues (green circles) differed by less than 1 LipE unit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Combining the observations from the structural analysis of inhibitor CDK2 complexes with the Free–Wilson methodology, designs were selected for synthesis. Considerations included the potential for delivering analogues with high potency as well as a focus on balancing lipophilicity to provide the potential for low human liver microsomal clearance (HLM Cl<sub>int</sub>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In the R<sub>3</sub> vector, no groups provided any predicted improvement from the established amino-piperidine sulfonamide motif. While some variations were attempted, efforts to improve the potency of compounds by modifications in this region were generally unsuccessful and, in many cases, only increased synthetic complexity. On the other hand, in the vector formed from R<sub>1</sub>/R<sub>2</sub>, the Free–Wilson methodology provided many possible alternatives to improve potency and LipE. These modifications became the focus of further optimization efforts. Swapping cyclopentyl (<b>3</b>) with cycloheptyl (<b>13</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) improved CDK2 potency and maintained a similar LipE. The increased HLM clearance observed for <b>13</b> was a consequence of increased lipophilicity compared with <b>3</b>. Cyclohexyl derivative <b>14</b> showed a significant drop in LipE as the CDK2 potency was reduced while lipophilicity increased. The addition of a methyl group to the cyclopentyl ring formed the (1<i>R</i>,2<i>S</i>)-2-methylcyclopentyl derivative <b>15</b>. This analogue oriented the methyl group to occupy the bottom of the lipophilic pocket in CDK2 formed by Ala144, Leu134, and Val64. This became a key design feature. Both CDK2 potency (0.09 nM <i>K</i><sub>i</sub>) and CDK1 selectivity (26-fold) were improved. Not unexpectedly, the increase in lipophilicity that accompanied the additional methyl group substituent in <b>15</b> led to an increased turnover in human liver microsomes. Some of the higher clearance was alleviated in isobutyl analogues <b>16</b> and <b>17</b> which had lower SFlogD values (<i>ca.</i> 2.2). Although these derivatives had all the atoms necessary to reach into the same lipophilic pocket as <b>15</b>, the more polar acyclic structures provided less binding efficiency and lower CDK1 selectivity. This may be due to small amounts of strain required in these acyclic systems to optimally reach the pocket. Another possibility is that cyclic structures such as <b>15</b> not only benefited from the lipophilic pocket interactions as described but also van der Waals interactions between ring carbons and residues Gly11 and Val18 that form the G-loop which sits adjacent to the inhibitor. These interactions from ring carbons would be missing in acyclic systems. Finally, the data for isopropyl derivative <b>18</b> suggested that while low HLM clearance was possible with much lower SFlogD, potency suffered as the occupation of the lipophilic pocket was not possible.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Modifications at the 6-Position (R<sub>1</sub>) and 8-Position (R<sub>2</sub>) of the Pyridopyrimidinone Core<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0014.gif" alt="" id="GRAPHIC-d7e1065-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0015.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>i</sub> values are the arithmetic mean of at least three independent replicates ± SEM. Each individual <i>K</i><sub>i</sub> value is generated from at least 10 single-point inhibition data points run in duplicate. LipE values are calculated using the CDK2 <i>K</i><sub>i</sub> value, according to the formula LipE = p<i>K</i><sub>i</sub> – log <i>D</i>.</p></div></div><div></div></div><div class="NLM_p">The group which was identified from the Free–Wilson analysis as providing the overall highest contribution to LipE was the (1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl moiety. Computational modeling and analysis of the separate roles of the methyl and hydroxyl groups revealed important details of the likely binding mode. The methyl group appeared to fill the lipophilic pocket in CDK2 in a manner as described above for compound <b>15</b>. The modeling also showed that the hydroxyl group could be positioned to form a hydrogen bond with a backbone carbonyl from Gln131, and importantly, it reduced the calculated SFlogD by ∼1 unit. Compound <b>19</b> which contains the (1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl substituent was a breakthrough compound with impressive CDK2 potency (0.2 nM), LipE (8.2), and the potential for optimization for further improvements in selectivity and HLM Cl<sub>int</sub>. An additional feature of lead compound <b>19</b> was the high level of CDK9 selectivity. The presence of the piperidine sulfonamide group pre-disposed our compounds toward a high level of selectivity against CDK9 (see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). Additionally, the installation of the (1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl group appeared to enhance that selectivity. To investigate this improved CDK9 selectivity, we employed molecular dynamics (MD) simulations to compare ligand–protein dynamics for compound <b>19</b> in both CDK2 and CDK9 (see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Scatter plot of CDK2 <i>vs</i> CDK9 potency (<i>K</i><sub>i</sub> in μM). Lines of equal selectivity are plotted as diagonals, with selectivity increasing to the top left of the plot. Compounds containing the piperidine sulfonamide motif are plotted as blue dots, all other compounds are plotted as red dots. (B) Snapshots from MD simulation of compound <b>19</b> in CDK2 (top left) and CDK9 (top right). Root-mean-squared deviation (rmsd) plots showing movement over the course of the entire simulation are plotted below each snapshot <i>vs</i> time in picoseconds (CDK2 in green and CDK9 in blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The MD simulation with CDK2 suggested that the sulfonamide formed a hydrogen bond interaction with the backbone NH of Asp86, which was shielded from bulk water molecules by a large hydrophobic sidechain (Lys89). This hydrogen bond caused the sulfonamide region to remain stable and tightly bind to CDK2 throughout the course of the simulation. That tight binding influenced similar tight binding in the adjacent lipophilic pocket where the tertiary hydroxyl and the methyl group from the cyclopentyl ring formed favorable interactions with CDK2. Specifically, the hydroxyl formed a hydrogen bond with a backbone carbonyl of Gln131 while the methyl group occupied the lipophilic pocket previously described. Together, this entire set of interactions caused compound <b>19</b> to remain tightly associated with the CDK2 protein. In contrast, CDK9 lacks Lys89 and the corresponding residue is Gly112 which creates a much more open pocket. This additional space allowed bulk water to more easily solvate the backbone NH of Asp109. Without the oxygen atom of the sulfonamide being fully engaged in a direct hydrogen bonding interaction, the sulfonamide moiety fluctuated in position throughout the simulation. Occasionally, this movement resulted in direct hydrogen bonding between the inhibitor’s sulfonamide and the backbone NH of Asp109, but more often the sulfonamide group moved away and allowed a bulk water molecule to solvate this NH. This fluctuation resulted in the movement of the core of the inhibitor itself and caused the tertiary hydroxyl to interact less effectively with the backbone carbonyl. The net result of the inhibitor fluctuation in the CDK9 protein was that both ligand and protein experienced partial de-solvation penalties and thus reduced binding affinity. Additionally, primary sequence differences between CDK9 and CDK2 around the backbone carbonyl account for increased flexibility. The sequence in CDK9 is Ala152-Ala153, while in CDK2 the corresponding residues are Pro130-Gln131. These differences appear to have accentuated the increased movement observed in the CDK9 protein and correspondingly led to weaker CDK9 binding through the hydrogen bond to the tertiary hydroxyl group of <b>19</b>. The differences in movement throughout the simulation are shown in the CDK2 (green) and CDK9 (blue) rmsd plots in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B. While the MD simulation was only a calculation of potential protein–ligand interactions, it appeared to highlight the structural features in both the ligand as well as the two proteins which help explain the observed tight binding of <b>19</b> to CDK2 and weaker binding to CDK9.</div><div class="NLM_p">Compound <b>19</b> possessed many of the characteristics which were desired in a final clinical candidate but poor microsomal stability led to a predicted short human half-life inconsistent with once or twice daily dosing. The examination of the site of metabolism in <b>19</b> revealed a propensity for metabolic oxidation occurring at the 6-position of the pyridopyrimidinone core. New derivatives were designed to reduce or block oxidative metabolism at that position. As discussed earlier for 6-substituents, this strategy could additionally provide the added benefit of a slight (∼2×) improvement to the CDK1 selectivity. Synthesis of the 6-chloro substituent gave <b>20</b>, an analogue with improved HLM clearance and favorable CDK1 selectivity. The methyl derivative <b>21</b> possessed improved CDK1 selectivity but significantly increased the human microsomal clearance. Analysis of the site of metabolism for <b>21</b> indicated that significant p450 mediated oxidation occurred on the 6-methyl substituent. Difluoromethyl analogue <b>22</b> (PF-06873600) was designed to maintain favorable CDK1 selectivity and to specifically address HLM clearance liability. Replacing the 6-methyl with the −CHF<sub>2</sub> substituent reduced the oxidative metabolic liability and gave an analogue with significantly improved microsomal clearance and still high CDK1 selectivity (∼34×). One consideration with <b>22</b> was a lower CDK4/D1 potency than for some other analogues and as a result, a low selectivity ratio between CDK4/D1 and CDK1/A2. Di-fluoroethyl derivative <b>23</b> was a similarly noteworthy design with improved CDK4 potency compared to compound <b>22</b>, albeit with higher HLM Cl<sub>int</sub>, which makes the overall profile of <b>23</b> less attractive.</div><div class="NLM_p">A crystal structure of compound <b>22</b> in complex with CDK2/cyclinE (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) highlighted several of the key interactions which were very similar to those described for compound <b>4</b>. The 4-aminopiperidine sulfonamide moiety provided lipophilic and polar interactions with the CDK2 protein. The piperidine ring was oriented within a lipophilic pocket with one edge forming van der Waals interactions with the sidechain phenyl of Phe82. One of the oxygen atoms from the sulfonamide group served as a hydrogen bond acceptor for the backbone −NH of Asp86, while the other oxygen was engaged in a hydrogen bond with the sidechain −NH<sub>3</sub> of Lys89. The 4-amino −NH of the piperidine ring along with the 3-position nitrogen and 4-hydrogen of the pyridopyrimidinone core provided the canonical hinge hydrogen bonds with the NH and carbonyl of Leu83 and backbone carbonyl of Glu81. As expected, the (1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl ring system filled a lipophilic pocket formed at the top by the G-loop residues Gly11 and Val18 and at the bottom by Val64, Leu134, and Ala144. The methyl substituent appeared to optimally fill this bottom lipophilic pocket, while the hydroxyl group was positioned to form a hydrogen bond with the backbone carbonyl of Gln131 and a water molecule. Finally, the 6-difluoromethyl substituent made van der Waals interactions with the sidechain phenyl of gatekeeper residue Phe80. Together, these interactions produced a potent and selective CDK2/4/6 inhibitor. More information on the biochemical profile of <b>22</b> is available in the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00159/suppl_file/jm1c00159_si_002.pdf" class="ext-link">Supporting Information</a>. This includes biochemical <i>K</i><sub>i</sub> data across a cohort of closely related CDK-family isoforms, and the related kinase GSK3β. Additionally, it includes the results of kinase panel screening of <b>22</b> against 276 kinases.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Crystal structure of <b>22</b> in complex with CDK2. The protein surface is rendered in gray with key molecular interaction distances highlighted with dashed lines and measurements in Å. Lys89, Asp86, Phe82, Phe80, and Gln131 are bolded in the protein. The methyl group on the cyclopentyl ring is positioned in a lipophilic pocket formed by residues Val64, Leu134, and Ala144.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>22</b> provided the best combination of potency for CDK2, selectivity versus both CDK1 and CDK9, and low HLM Cl<sub>int</sub>. Assessing the effects of CDK2 inhibition on cellular markers of CDK2 activity in an ovarian cancer cellular model (OVCAR3), compound <b>22</b> blocked the phosphorylation of RB1 with an EC<sub>50</sub> of 19 nM and limited cell growth in this model with an EC<sub>50</sub> of 45 nM for antiproliferation.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Notably, CDK4/6 inhibitors such as palbociclib (<b>1</b>) displayed no activity in these cells. In line with the measured biochemical selectivity, we measured the cellular CDK2 isoform engagement of <b>22</b> by the displacement of probe compound XO44<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> in triple negative breast cancer (HCC1806) cells (OC<sub>50</sub> = 9 nM). In the same experiment, the engagement of CDK1 was also determined (OC<sub>50</sub> = 597 nM). This ∼60× isoform selectivity provided a compelling confirmation that a biochemical <i>K</i><sub>i</sub> ratio of 35× was similar to target engagement ratios in a cellular system.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Compound <b>22</b> also gave a strong phenotypic cellular response and arrested OVCAR3 cells in G1 at concentrations up to ∼100 nM, and at higher concentrations generated a mixed population of G1 and G2 blocked cells.</div><div class="NLM_p">Compound <b>22</b>, a neutral molecule, was anticipated to be absorbed mainly by the transcellular route based upon an analysis of physicochemical properties (SF log <i>D</i> at pH 7.4 = 1.9, molecular weight = 471.5, total polar surface area = 126, hydrogen bond donor count = 2, and hydrogen bond acceptor count = 5) and solubility at pH 7.4 = 265 μM. <b>22</b> demonstrated high passive permeability (A/B ∼ 14 × 10<sup>–6</sup> cm/s) <i>in vitro</i> in the RRCK(MDCK-LE) cell line, which was consistent with high transcellular absorption.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> In addition, after oral administration <i>in vivo</i> in mice and dogs, <b>22</b> exhibited high absorption (<i>f</i><sub>a</sub>*<i>f</i><sub>g</sub> ∼ 1.0 and 0.8) with time to maximal absorption (<i>T</i><sub>max</sub>) of 0.25 and 1 h, respectively. In an NSG strain of mice, <b>22</b> displayed a plasma clearance (CL<sub>p</sub>) of 63 mL/min/kg, a volume of distribution (<i>V</i><sub>ss</sub>) of 0.9 L/kg, and an oral bioavailability (<i>F</i>) of 13%. Similarly, in beagle dogs, <b>22</b> showed a CL<sub>p</sub> of 8.4 mL/min/kg, a <i>V</i><sub>ss</sub> of 1.1 L/kg, and an <i>F</i> of 59%. Based on these observed mean <i>in vivo</i> pharmacokinetic (PK) results in both mice and dogs, <b>22</b> was predicted to exhibit favorable oral drug properties in the clinic.</div><div class="NLM_p">The pre-clinical <i>in vivo</i> anti-tumor activity for <b>22</b> was similarly promising. In mice-bearing OVCAR3 tumors, orally dosed <b>22</b> was shown to potently inhibit the phosphorylation of RB1 in the tumor cells, with an EC<sub>50</sub> of 40 nM, and tumor growth inhibition studies showed 90% growth inhibition as a single agent at 50 mg per kg body weight with BID oral dosing.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> CDK2 orchestrates progression through the cell cycle <i>via</i> the phosphorylation of RB1 when complexed with cyclin E or <i>via</i> the regulation of DNA synthesis and DNA repair machinery when complexed with cyclin A. Although modulation of RB1 phosphorylation tracks well with the efficacy and potency of <b>22</b>, we cannot rule out the fact that CDK2/cyclin A complexes also play a significant role in inhibitor function. Hyperactivation of cyclin E1/CDK2 signaling in tumors often occurs due to impaired cyclin E1 degradation pathways governed by the tumor suppressor E3 ligase FBXW7.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> FBXW7 is commonly mutated or deleted in a number of tumor types including non-small cell lung cancer (NSCLC), where 5% of patients present with homozygous deletions or loss of function mutation.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a><a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> shows tumor growth inhibition studies performed in FBXW7 mutated PDX models of NSCLC, where <b>22</b> demonstrated 93% growth inhibition in the CTG-0464 model (<i>P</i> < 0.001) and 103% growth inhibition in the CTG-0192 model (<i>P</i> < 0.001).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) <i>In vivo</i> tumor growth inhibition of <b>22</b> (PF-06873600) in PDX model CTG-0464 NSCLC. (B) <i>In vivo</i> tumor growth inhibition of <b>22</b> in PDX model CTG-0192 NSCLC. Both models are run with a vehicle arm and a twice daily dose of <b>22</b> given orally at 30 mg/kg.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56427" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56427" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of <b>22</b> is shown in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> describes the preparation of the chiral amino methylcyclopentanol (<b>25</b>), which was identified in the Free–Wilson analysis and is used in the 8-position of the pyridopyrimidinone ring system to provide potency and modulate lipophilicity. This route begins with the commercially available epoxide of methylcyclopentene which is opened by heating with benzylamine to give racemic <b>24</b>. A classical resolution of <b>24</b> with the 3,5-dinitobenzamide derivative of 2-(<i>S</i>)-phenylglycine gave the desired stereoisomer in 96% ee, and this step can be repeated for further enhancement of enantiomeric purity (>98% ee). Finally, the benzyl group can be removed under standard Pd-catalyzed hydrogenative deprotection conditions to provide <b>25</b>.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of (1<i>R</i>,2<i>R</i>)-2-Amino-1-methylcyclopentan-1-ol (<b>25</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) BnNH<sub>2</sub> and H<sub>2</sub>O, 100 °C, 66%; (b) (2<i>S</i>)-[(3,5-dinitrobenzoyl)amino](phenyl) ethanoic acid (0.5 equiv) and EtOH, 80 °C to rt overnight, 82%, 96% ee; (c) repeat step b, but with 1 equiv of (2<i>S</i>)-[(3,5-dinitrobenzoyl)amino](phenyl) ethanoic acid, 97%, 98% ee; and (d) 20% Pd(OH)<sub>2</sub>/C H<sub>2</sub> (1 atm), and isopropanol, 23 °C.</p></p></figure><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>22</b> (PF-06873600)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) DIPEA and 2-propanol, 80 °C, 97%; (b) MnO<sub>2</sub> and EtOAc, 50 °C, 93%; (c) CH<sub>3</sub>CO<sub>2</sub>Et, LiHMDS, THF, −5 °C, EtOH, and AcOH, 71%; (d) oxone, 2-methyl-THF, and H<sub>2</sub>O, 84%; (e) 1-(methylsulfonyl)piperidin-4-amine and 2-methyl-THF, 60 °C, 63%, >99% ee; and (f) CHF<sub>2</sub>SO<sub>2</sub>Na, t-BuOOH, FeCl<sub>3</sub>/silica, DMSO, and H<sub>2</sub>O, 57%.</p></p></figure><div class="NLM_p">At this point, compound <b>25</b> is reacted with commercially available [4-chloro-2-(methylthio)pyrimidin-5-yl]methanol (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Following S<sub>N</sub>Ar displacement of the chlorine, the resulting intermediate which contains a primary alcohol is oxidized with MnO<sub>2</sub> to give aldehyde <b>26</b> in 90% yield over 2 steps. With intermediates such as <b>26</b>, there are several viable approaches to construct and further functionalize the pyridopyrimidinone core, including Horner–Wadsworth–Emmons methodology as reported previously.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> In this work, the generation of the lithium enolate of ethyl acetate allowed carbon–carbon bond formation by condensation with aldehyde <b>26</b> and spontaneous ring closure during a quench with ethanol and acetic acid to form pyridopyrimidinone <b>27</b> in 71% yield.</div><div class="NLM_p last">Intermediates such as <b>27</b> also represent flexible precursors for final derivatization. The thioether at the 2-position of the pyridopyrimidinone system can be oxidized efficiently with oxone to form a sulfone. The resulting 2-position sulfone is then subjected to S<sub>N</sub>Ar displacement with amines to give 2-aminopyridopyrimidinone analogues.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> In this sequence, this allows the installation of the amino-piperidine sulfonamide moiety to give <b>19</b>, a compound which represented the first breakthrough result from the installation of (1<i>R</i>,2<i>R</i>)-2-amino-1-methylcyclopentan-1-ol <b>25</b>. To complete the synthesis of <b>22</b>, a Langlois–Baran difluoromethyl functionalization reaction is utilized. In these reactions, a difluoromethyl radical is generated from a sulfinate precursor and <i>tert</i>-butyl hydroperoxide in the presence of iron or other inorganic counterions. In this system, the resultant difluoromethyl radical species reacts regioselectively at the 6-position of the pyridopyrimidinone core and provides <b>22</b> in 57% yield.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> Further details of these reactions, as well as synthetic experimental details for all compounds described in this work are available in the experimental section.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13064" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13064" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have outlined a medicinal chemistry program that started with <b>2</b>, a promising but relatively isoform nonselective lead for CDK2. This approach used a combination of structure-based drug design and property space analysis to design improved lead analogues, and a combination of cellular occupancy and mechanistic studies confirmed that these leads achieve the desired cellular functional effects. Free–Wilson analysis identified the highly efficient (1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl moiety, which provided a key improvement in lipophilic efficiency that translated to both better potency as well as better metabolic stability. MD simulations were used to help understand the selectivity ratios observed between CDK2 and CDK9 and further refine the hypotheses around the structure-based drug design models. Subsequent modifications to improve the selectivity and ADME characteristics of these lead compounds provided advanced leads, including <b>22</b> (PF-06873600) which performed well in both <i>in vitro</i> and <i>in vivo</i> studies. PF-06873600 entered phase 1 clinical trials in 2018 and further communications regarding safety and efficacy will be reported in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54711" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54711" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> General Methods</h3><div class="NLM_p">Unless otherwise noted, materials were obtained from commercial suppliers and were used without further purification. Unless otherwise stated, all reactions were performed under a positive pressure of nitrogen, argon, or with a drying tube; at ambient temperature; and in commercially purchased anhydrous solvents. Microwave-assisted reactions were run in a Biotage Initiator. Removal of the solvent under reduced pressure or concentration refers to distillation using a Büchi rotary evaporator attached to a vacuum pump (3 mm Hg). Products obtained as solids or high boiling oils were dried under vacuum (1 mm Hg) at ambient temperature, unless otherwise noted. Silica gel chromatography was performed on Teledyne Isco or Biotage purification systems using the manufacturer’s pre-packed columns.</div><div class="NLM_p">The reactions were assayed by high-performance liquid chromatography–mass spectrometry (LCMS) or thin-layer chromatography (TLC) and terminated as judged by the consumption of the starting material. Analytical TLC was performed on a glass-backed Silica gel 60 F<sub>254</sub> plates (Analtech, 0.25 mm) and eluted with the appropriate solvent ratios (v/v). The TLC plates were visualized by UV, <i>p</i>-anisaldehyde, phosphomolybdic acid, or iodine staining. LCMS utilized 254 and 220 nm wavelengths and either electrospray ionization (ESI) positive mode or atmospheric pressure chemical ionization (APCI) in positive mode.</div><div class="NLM_p"><sup>1</sup>H NMR spectra were recorded on a Bruker XWIN-NMR (400 or 700 MHz) spectrometer. Proton resonances are reported in parts per million (ppm) downfield from tetramethylsilane. <sup>1</sup>H NMR data are reported as multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; quint, quintuplet; dd, doublet of doublets; dt, doublet of triplets; and br s, broad singlet). For spectra obtained in CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, and CD<sub>3</sub>OD, the residual protons (7.27, 2.50, and 3.31 ppm, respectively) were used as the internal reference. Optical rotations were determined on a JASCO P-2000 or a Rudolph Autopol IV polarimeter. All final compounds were purified to ≥ 95% purity, unless otherwise specified. For most compounds, purity was determined by Agilent 1200 or 1260 Series HPLCs coupled to an Agilent 6120 or 6140 Quadrupole LCMS with simultaneous UV (220 and 254 nm) and TIC detection (either APCI or ESI) or using a Shimadzu LC-20 HPLC with UV 220 nm detection.</div><div class="NLM_p">Where specified, some analogues were synthesized as racemic mixtures with known relative stereochemistry and chiral preparative SFC was used to separate the enantiomers as the final stage. In these cases, absolute stereochemistry was not known for the separated enantiomers.</div><div class="NLM_p">IUPAC names were generated from structures using ACD/Name 2017 software from ACD/Labs. When absolute stereochemistry is known, (<i>R</i>,<i>S</i>) labels are used. When absolute stereochemistry is not known, the software-generated names are modified to include (+)- and (−)-prefixes according to the optical rotations, and (<i>R</i>*/<i>S</i>*) labels are used to show relative configuration.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> 6-Acetyl-8-cyclopentyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}-5-methylpyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>2</b>)</h4><div class="NLM_p last">Two parallel solutions of 6-acetyl-8-cyclopentyl-5-methyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (29.0 g, 91.4 mmol each) in THF (300 mL each) and water (100 mL each) were treated with oxone (84.3 g, 137 mmol each) and stirred at rt for 1.5 h. The solutions were combined and filtered, and the filtrate was extracted with EtOAc (2 × 300 mL). The combined organics were washed with saturated aqueous NaCl, dried over sodium sulfate, filtered, and concentrated. The crude product was recrystallized with petroleum ether/EtOAc (20/1) to give 6-acetyl-8-cyclopentyl-2-(methanesulfonyl)-5-methylpyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (54.9 g, 42% for the combined batches) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.11 (s, 1H), 5.88–5.92 (m, 1H), 3.38 (s, 3H), 2.56 (s, 3H), 2.45 (s, 3H), 2.24–2.29 (m, 2H), 2.14–2.15 (m, 2H), 1.95–1.96 (m, 2H), 1.70–1.72 (m, 2H); LCMS <i>m</i>/<i>z</i>: 350.1 [M + H]<sup>+</sup>. A sealed tube containing a solution of 6-acetyl-8-cyclopentyl-2-(methanesulfonyl)-5-methylpyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (200 mg, 0.572 mmol), 1-(methylsulfonyl)piperidin-4-amine (133 mg, 0.744 mmol), and CsF (261 mg, 1.72 mmol) in DMSO (8 mL) was irradiated in a microwave at 140 °C for 15 min. After cooling to rt, the mixture was washed with water and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried over sodium sulfate, concentrated, and the residue recrystallized from methanol to give <b>2</b> (140 mg, 55%) as an orange solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.64 (s, 1H), 5.83 (quin, 1H<i>, J</i> = 8.8 Hz), 5.59–5.09 (m, 1H), 4.15–3.99 (m, 1H), 3.89–3.73 (m, 2H), 2.99–2.90 (m, 2H), 2.84 (s, 3H), 2.54 (s, 3H), 2.34 (s, 3H), 2.43–2.28 (m, 2H), 2.25–2.15 (m, 2H), 2.09–1.96 (m, 2H), 1.91–1.79 (m, 2H), 1.77–1.65 (m, 4H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 101 MHz): δ 202.4, 161.5, 161.2, 158.6, 155.7, 142.8, 128.6, 105.7, 53.3, 47.9, 44.7, 35.8, 31.6, 31.2, 28.1, 25.5, 13.8; HRMS: calcd for C<sub>21</sub>H<sub>29</sub>N<sub>5</sub>O<sub>4</sub>S (M + H)<sup>+</sup>, 448.2013; found, 448.20176.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> 8-Cyclopentyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one</h4><div class="NLM_p last">Two parallel batches were run using the following procedure, then combined for purification as noted below. To a solution of 4-(cyclopentylamino)-2-(methylthio)pyrimidine-5-carbaldehyde<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (30.0 g, 130 mmol) in anhydrous THF (600 mL) was added EtOAc (33.4 g, 379 mmol) at −70 °C. The mixture was stirred at this temperature for 15 min, then LiHMDS (1.0 M in THF, 442 mL, 442 mmol) was added dropwise. The reaction was stirred at −70 °C for 30 min and then at rt (15 °C) for 16 h. The reaction mixture was slowly added to ice water (800 mL) and then extracted with EtOAc (3 × 500 mL). The combined organic layers were washed with saturated aqueous NH<sub>4</sub>Cl (2 × 800 mL) and saturated aqueous NaCl (2 × 600 mL), dried over sodium sulfate, and concentrated. The crude products from both batches were combined and purified by silica gel chromatography (eluting with petroleum ether/EtOAc 10/1 to 5/1) to give 8-cyclopentyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (59.0 g, 87% combined yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.57 (s, 1H), 7.52 (d, 1H, <i>J</i> = 1.0 Hz), 6.58 (d, 1H, <i>J</i> = 1.0 Hz), 5.96–5.86 (m, 1H), 2.60 (s, 3H), 2.38–2.27 (m, 2H), 2.11–1.99 (m, 2H), 1.91–1.82 (m, 2H), 1.73–1.63 (m, 2H); LCMS <i>m</i>/<i>z</i>: 261.8 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> 8-Cyclopentyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>3</b>)</h4><div class="NLM_p last">Oxone (23.5 g, 38.3 mmol) was added to a cooled (0 °C) solution of 8-cyclopentyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (5.0 g, 19.13 mmol) in THF (100 mL) and water (20 mL), and the mixture was stirred at rt for 2 h. The mixture was diluted with EtOAc (300 mL), washed with water (100 mL), dried over sodium sulfate, and concentrated to give crude 8-cyclopentyl-2-(methanesulfonyl)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (5.40 g, 96%, ∼90% purity) as a gray solid. LCMS <i>m</i>/<i>z</i>: 315.8 [M + H]<sup>+</sup>. A solution of this crude 8-cyclopentyl-2-(methanesulfonyl)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (5.40 g of ∼90% purity, ∼17.0 mmol), 1-(methylsulfonyl)piperidin-4-amine (5.34 g, 24.9 mmol), and DIPEA (14.7 mL, 82.8 mmol) in DMSO (70 mL) was stirred at 65 °C for 18 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (150 mL), washed with saturated aqueous NH<sub>4</sub>Cl (2 × 80 mL), dried over sodium sulfate, and concentrated to dryness. Recrystallization with 1/2 EtOAc/petroleum ether (50 mL) gave <b>3</b> (4.65 g, 72%) as a gray solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.68–8.54 (m, 1H), 7.88 (d, 1H, <i>J</i> = 6.3 Hz), 7.68 (d, 1H, <i>J</i> = 9.3 Hz), 6.28–6.16 (m, 1H), 5.92–5.74 (m, 1H), 4.02–3.82 (m, 1H), 3.58 (d, 2H, <i>J</i> = 10.8 Hz), 2.96–2.82 (m, 5H), 2.33 (d, 1H, <i>J</i> = 1.8 Hz), 2.19 (br s, 1H), 2.03–1.91 (m, 4H), 1.78–1.55 (m, 6H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 101 MHz): δ 163.5, 161.1, 159.5, 156.6, 136.7, 117.2, 105.9, 53.1, 47.8, 44.8, 35.7, 31.2, 28.0, 25.5; HRMS: calcd for C<sub>18</sub>H<sub>25</sub>N<sub>5</sub>O<sub>3</sub>S (M + H)<sup>+</sup>, 392.17509; found, 392.17586.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> 8-Cyclopentyl-6-methyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one</h4><div class="NLM_p last">To a solution of 4-(cyclopentylamino)-2-(methylthio)pyrimidine-5-carbaldehyde<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (10.0 g, 42.1 mmol) in anhydrous THF (250 mL) was added ethyl propionate (12.9 g, 126 mmol) at −70 °C. The mixture was stirred at this temperature for 15 min, then LiHMDS (1.0 M in THF, 147 mL, 147 mmol) was added dropwise. The reaction was stirred at −70 °C for 30 min and then at rt (24 °C) for 16 h. At this time, TLC showed two product spots, which indicated that a significant amount of the cyclized but not yet dehydrated intermediate, 8-cyclopentyl-5-hydroxy-6-methyl-2-(methylthio)-5,8-dihydropyrido[2,3-<i>d</i>]pyrimidin-7(6<i>H</i>)-one, was still present. The reaction mixture was partitioned between water and EtOAc (2 × 30 mL), and the combined organics were washed with aqueous NH<sub>4</sub>Cl (30 mL) and saturated aqueous NaCl (30 mL), dried over sodium sulfate, filtered, and concentrated. To obtain the fully dehydrated product, the residue was dissolved in THF (200 mL), 1,8-diazabicyclo[5.4.0]undec-7-ene (7.06 g, 46.4 mmol) was added, and the mixture was heated to 60 °C for 3 h, at which time only the less polar product spot remained. The solution was diluted with EtOAc (200 mL) and washed with aqueous NH<sub>4</sub>Cl (3 × 200 mL) and saturated aqueous NaCl (300 mL). The combined organics were dried over sodium sulfate and concentrated. The residue was suspended in 1:5 EtOAc/petroleum ether (100 mL), the solids collected by filtration and dried to give 8-cyclopentyl-6-methyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (11 g, 95%, ∼90% purity by NMR) as a gray solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.50 (s, 1H), 7.40 (s, 1H), 5.94 (quin, 1H, <i>J</i> = 8.8 Hz), 2.56 (s, 3H), 2.34–2.27 (m, 2H), 2.17 (s, 3H), 2.08–2.00 (m, 2H), 1.86–1.83 (m, 2H), 1.68–1.65 (m, 2H).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 8-Cyclopentyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}-6-methylpyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>4</b>)</h4><div class="NLM_p last">According to the sulfur oxidation and amine displacement methods described for the synthesis of <b>3</b>, 8-cyclopentyl-6-methyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (2.50 g, 9.08 mmol), yielded, after final purification by silica gel chromatography, compound <b>4</b> (2.01 g, 54% 2-step yield) as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 8.49 (s, 1H), 7.51 (s, 1H), 7.27 (br s, 1H), 5.85 (quin, 1H, <i>J</i> = 8.7 Hz), 3.96 (br s, 1H), 3.62 (d, 2H, <i>J</i> = 12.0 Hz), 2.97–2.90 (m, 2H), 2.88 (s, 3H), 2.32 (br s, 2H), 2.04 (s, 3H), 2.03–1.92 (m, 4H), 1.83–1.72 (m, 2H), 1.72–1.54 (m, 4H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 101 MHz): δ 164.0, 160.6, 158.4, 155.7, 133.0, 125.0, 105.8, 53.3, 47.7, 44.8, 35.7, 31.3, 28.1, 25.6, 16.9; HRMS: calcd for C<sub>19</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub>S (M + H)<sup>+</sup>, 406.19704; found, 406.19115.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 6-Chloro-8-cyclopentyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>5</b>)</h4><div class="NLM_p last">A solution of compound <b>3</b> (840 mg, 2.15 mmol) and <i>N</i>-chlorosuccinimide (315 mg, 2.36 mmol) in DMF (21.5 mL) was stirred at rt for 16 h and then at 70 °C for 4 h. The mixture was quenched with saturated aqueous NaHCO<sub>3</sub> (20 mL), causing a white solid to precipitate out. The precipitate was collected, dried, and then triturated in 1:1 EtOAc/heptane to give <b>5</b> (778 mg, 85%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 8.59 (s, 1H), 8.01 (s, 1H), 7.65 (br s, 1H), 5.95–5.79 (m, 1H), 3.97 (br s, 1H), 3.61 (br d, 2H, <i>J</i> = 12.2 Hz), 2.96–2.84 (m, 5H), 2.28 (br s, 2H), 1.98 (br s, 4H), 1.80 (br s, 2H), 1.72–1.59 (m, 4H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 101 MHz): δ 161.0, 159.4, 159.3, 155.4, 134.6, 120.5, 105.2, 54.3, 47.9, 44.7, 35.7, 31.2, 28.1, 25.6; HRMS: calcd for C<sub>18</sub>H<sub>24</sub>ClN<sub>5</sub>O<sub>3</sub>S (M + H)<sup>+</sup>, 426.13611; found, 426.13662.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> [8-Cyclopentyl-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidin-6-yl]acetic Acid</h4><div class="NLM_p last">Diethyl succinate (44.0 g, 253 mmol) was added dropwise to a cooled (−70 °C) solution of LiHMDS (1.0 M in THF, 506 mL, 506 mmol) in THF (400 mL). After stirring for 10 min, a solution of 4-(cyclopentylamino)-2-(methylthio)pyrimidine-5-carbaldehyde<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (40 g, 170 mmol) in THF (80 mL) was added. The reaction was stirred at −70 °C for 30 min, then at rt overnight. The mixture was diluted with water (1 L) and EtOAc (1 L), stirred for 10 min, then the layers were separated. The aqueous layer was further extracted with EtOAc (2 × 500 mL). No product was observed in the combined organic layers by TLC. The aqueous layer was acidified to pH 2 with conc. HCl. The resulting precipitate was collected by suction filtration, washed with water and petroleum ether, dried under vacuum, and then purified by silica gel chromatography (eluting with 2–5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to give [8-cyclopentyl-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidin-6-yl]acetic acid (32 g, 59%) as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.36 (br s, 1H), 8.87 (s, 1H), 7.84 (s, 1H), 5.86 (quin, 1H, <i>J</i> = 8.8 Hz), 3.49 (s, 2H), 2.58 (s, 3H), 2.21–2.13 (m, 2H), 2.00–1.90 (m, 2H), 1.85–1.75 (m, 2H), 1.68–1.55 (m, 2H).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (8-Cyclopentyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidin-6-yl)acetonitrile (<b>6</b>)</h4><div class="NLM_p last">A suspension of [8-cyclopentyl-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidin-6-yl]acetic acid (5.00 g, 15.7 mmol) in EtOH (80 mL) was treated with conc. sulfuric acid (5 mL) and heated to 80 °C for 18 h, affording a clear yellow solution. After cooling to rt, the solution was concentrated to dryness, the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) and basified to pH ∼8 with saturated aqueous Na<sub>2</sub>CO<sub>3</sub>. The layers were separated, and the aqueous layer further extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 50 mL). The combined organics were dried over sodium sulfate, filtered, concentrated, and purified by silica gel chromatography (eluting with 0–20% EtOAc in CH<sub>2</sub>Cl<sub>2</sub>) to give ethyl 2-(8-cyclopentyl-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidin-6-yl)acetate (4.90 g, 90%) as a yellow solid. A portion of this solid (3.00 g, 8.63 mmol) was treated with oxone by the method described for the synthesis of <b>3</b>, affording 3.28 g of a crude mixture of sulfoxide (LCMS <i>m</i>/<i>z</i>: 364.1 [M + H]<sup>+</sup>, ∼70%) and sulfone (LCMS <i>m</i>/<i>z</i>: 380.1 [M + H]<sup>+</sup>; ∼30%) products, which were used without further purification. A portion of this mixture (500 mg, 1.32 mmol) was reacted with 1-(methylsulfonyl)piperidin-4-amine by the method described for the synthesis of <b>3</b>, affording crude ethyl (8-cyclopentyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidin-6-yl)acetate (260 mg, 41%) as a yellow gum. A solution of this gum (260 mg, 0.54 mmol) in ethanol (6 mL) was sparged with anhydrous ammonia gas for 10 min, the resulting solution stirred at 100 °C for 12 h, and then at 120 °C for an additional 12 h. The solution was concentrated to give 200 mg of crude 2-(8-cyclopentyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidin-6-yl)acetamide (LCMS <i>m</i>/<i>z</i>: 449.0 [M + H]<sup>+</sup>, ∼60%) as a mixture with unreacted starting ester (LCMS <i>m</i>/<i>z</i>: 478.0 [M + H]<sup>+</sup>, ∼40%). A portion of this crude mixture (100 mg, ∼0.13 mmol amide) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) and cooled to 0 °C was treated with triethylamine (67.7 mg, 0.67 mmol) and trifluoroacetic acid anhydride (56.2 mg, 0.27 mmol). The cooling bath was removed, and the mixture stirred at rt for 2 h. The resulting yellow suspension was washed with deionized water (20 mL) and saturated aqueous NaCl. The organic layer was dried over magnesium sulfate, filtered, and concentrated. This crude product was combined with the crude product from a parallel run (starting with 80 mg, 0.11 mmol, of crude amide) for purification by preparative HPLC [column: DuraShell 150*25mm*5 μm; mobile phase: from 36 to 56% acetonitrile in H<sub>2</sub>O (0.05% ammonium hydroxide v/v)] to give <b>6</b> (27.1 mg, 26% yield for the combined batches) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 8.65 (s, 1H), 7.80 (t, 1H, <i>J</i> = 0.9 Hz), 7.57 (br d, 1H, <i>J</i> = 7.3 Hz), 5.85 (quin, 1H, <i>J</i> = 8.9 Hz), 4.06–3.93 (m, 1H), 3.70 (d, 2H, <i>J</i> = 1.0 Hz), 3.62 (td, 2H, <i>J</i> = 3.4, 12.4 Hz), 2.96–2.89 (m, 2H), 2.88 (s, 3H), 2.37–2.24 (m, 2H), 2.08–1.95 (m, 4H), 1.86–1.74 (m, 2H), 1.73–1.59 (m, 4H); LCMS <i>m</i>/<i>z</i>: 430.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 8-Cyclopentyl-6-(hydroxymethyl)-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>7</b>)</h4><div class="NLM_p last">A suspension of 8-cyclopentyl-6-(ethoxymethyl)-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>10</b>) (100 mg, 0.22 mmol) and methane sulfonic acid (150 μL, 2.2 mmol) in acetonitrile (3.0 mL) and water (3.0 mL) was heated to 85 °C overnight. After cooling to rt, the mixture was quenched with saturated aqueous NaHCO<sub>3</sub>, extracted with CH<sub>2</sub>Cl<sub>2</sub> (4 × 10 mL), dried over sodium sulfate, concentrated, and purified by preparative SFC [ZymorSpher Diol Monol 150 × 21.2 mm column; gradient of 10–25% MeOH @ 3%min, 100 bar, 58 mL/min] to give <b>7</b> (15.7 mg, 17%) as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 8.59 (s, 1H), 7.64 (s, 1H), 7.33 (br s, 1H), 5.85 (quin, 1H, <i>J</i> = 8.8 Hz), 4.79 (br s, 1H), 4.36 (br s, 2H), 3.98 (br s, 1H), 3.66–3.58 (m, 2H), 2.96–2.90 (m, 2H), 2.88 (s, 3H), 2.40–2.25 (m, 2H), 2.07–1.95 (m, 4H), 1.85–1.73 (m, 2H), 1.72–1.60 (m, 4H); LCMS <i>m</i>/<i>z</i>: 422.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 8-Cyclopentyl-6-(2-hydroxyethyl)-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one</h4><div class="NLM_p last">By the procedure described for 8-cyclopentyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one but using ethyl 4-hydroxybutanoate instead of EtOAc, 6.0 g of 4-(cyclopentylamino)-2-(methylthio)pyrimidine-5-carbaldehyde was used to produce 8-cyclopentyl-6-(2-hydroxyethyl)-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (5.98 g, 77%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.57 (s, 1H), 7.49 (s, 1H), 5.96 (quin, 1H, <i>J</i> = 8.8 Hz), 3.89 (t, 2H, <i>J</i> = 5.8 Hz), 2.87 (t, 2H, <i>J</i> = 5.6 Hz), 2.73 (br s, 1H), 2.61 (s, 3H), 2.38–2.26 (m, 2H), 2.13–2.01 (m, 2H), 1.94–1.83 (m, 2H), 1.73–1.62 (m, 2H); LCMS <i>m</i>/<i>z</i>: 305.8 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 8-Cyclopentyl-6-(2-hydroxyethyl)-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>8</b>)</h4><div class="NLM_p last">According to the method described for the synthesis of <b>3</b>, 8-cyclopentyl-6-(2-hydroxyethyl)-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one was used to produce <b>8</b> (342 mg, 61% 2-step yield) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6,</sub> 80 °C): δ 8.52 (s, 1H), 7.51 (s, 1H), 7.34 (br d, 1H, <i>J</i> = 7.6 Hz), 5.85 (quin, 1H, <i>J</i> = 9.0 Hz), 4.29 (br s, 1H), 4.02–3.90 (m, 1H), 3.66–3.54 (m, 4H), 2.93–2.87 (m, 5H), 2.62 (t, 2H, <i>J</i> = 6.8 Hz), 2.37–2.24 (m, 2H), 2.06–1.93 (m, 4H), 1.82–1.71 (m, 2H), 1.71–1.58 (m, 4H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 101 MHz): δ 163.8, 160.6, 158.7, 155.6, 133.6, 126.5, 105.8, 60.2, 53.3, 47.8, 44.8, 35.7, 34.2, 31.3, 28.1, 25.6; HRMS: calcd for C<sub>20</sub>H<sub>29</sub>N<sub>5</sub>O<sub>4</sub>S (M + H)<sup>+</sup>, 436.2013; found, 436.20155.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 8-Cyclopentyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}-6-(2-methoxyethyl)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>9</b>)</h4><div class="NLM_p last">According to the cyclization method described for the synthesis of 8-cyclopentyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one, methyl 4-methoxybutanoate (668 mg, 5.1 mmol) and 4-(cyclopentylamino)-2-(methylthio)pyrimidine-5-carbaldehyde<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (400 mg, 1.69 mmol) afforded 8-cyclopentyl-6-(2-methoxyethyl)-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (428 mg, 79%) as a yellow gum. LCMS <i>m</i>/<i>z</i>: 319.9 [M + H]<sup>+</sup>. All of this material was subjected to the sulfur oxidation and amine displacement methods previously described for the synthesis of <b>3</b>, affording compound <b>9</b> (70.73 mg, 11.7% 2-step yield) as a yellow solid, after silica gel chromatography (eluting with 1% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) and lyophilization. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (s, 1H), 7.38 (s, 1H), 5.88 (quin, 1H, <i>J</i> = 8.8 Hz), 5.23 (br s, 1H), 4.03 (br d, 1H, <i>J</i> = 7.0 Hz), 3.80 (br d, 2H, <i>J</i> = 12.0 Hz), 3.65 (t, 2H, <i>J</i> = 6.1 Hz), 3.36 (s, 3H), 3.01–2.89 (m, 2H), 2.87–2.79 (m, 5H), 2.35 (br s, 2H), 2.20 (br dd, 2H, <i>J</i> = 3.1, 13.4 Hz), 2.10–1.99 (m, 2H), 1.92–1.79 (m, 2H), 1.76–1.63 (m, 4H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 101 MHz): δ 163.6, 160.7, 158.8, 155.7, 133.7, 125.9, 105.7, 70.9, 58.1, 53.3, 47.8, 44.8, 35.7, 31.3, 30.6, 28.1, 25.6; HRMS: calcd for C<sub>21</sub>H<sub>31</sub>N<sub>5</sub>O<sub>4</sub>S (M + H)<sup>+</sup>, 450.21695; found, 450.21791.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 8-Cyclopentyl-6-(ethoxymethyl)-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one</h4><div class="NLM_p last">By the procedure described for 8-cyclopentyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one but using ethyl 3-ethoxypropanoate instead of EtOAc, 1.00 g of 4-(cyclopentylamino)-2-(methylthio)pyrimidine-5-carbaldehyde<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> produced 8-cyclopentyl-6-(ethoxymethyl)-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (406 mg, 60%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.63 (s, 1H), 7.68 (t, 1H, <i>J</i> = 1.6 Hz), 5.98 (quin, 1H, <i>J</i> = 8.9 Hz), 4.49 (d, 2H, <i>J</i> = 1.5 Hz), 3.74–3.65 (m, 2H), 2.63 (s, 3H), 2.40–2.27 (m, 2H), 2.16–2.03 (m, 2H), 1.97–1.84 (m, 2H), 1.76–1.65 (m, 2H), 1.32 (t, 3H, <i>J</i> = 7.0 Hz); LCMS <i>m</i>/<i>z</i>: 319.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 8-Cyclopentyl-6-(ethoxymethyl)-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>10</b>)</h4><div class="NLM_p last">A solution of oxone (4.58 g, 7.45 mmol) in water (40 mL) was added to a cooled (0 °C) solution of 8-cyclopentyl-6-(ethoxymethyl)-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (1.19 g, 3.73 mmol) in THF (37.3 mL). The resulting suspension was stirred and allowed to slowly warm to rt over 1 h. More water (20 mL) was added, and the precipitate was collected and dried to give 8-cyclopentyl-6-(ethoxymethyl)-2-(methanesulfonyl)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (933 mg, 71%) as a solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.96 (s, 1H), 7.86 (t, 1H, <i>J</i> = 1.7 Hz), 5.97 (quin, 1H, <i>J</i> = 8.7 Hz), 4.54 (d, 2H, <i>J</i> = 1.7 Hz), 3.72 (q, 2H, <i>J</i> = 7.0 Hz), 3.39 (s, 3H), 2.38–2.23 (m, 2H), 2.24–2.12 (m, 2H), 2.06–1.87 (m, 2H), 1.78–1.64 (m, 2H), 1.34 (t, 3H, <i>J</i> = 7.0 Hz). A mixture of 8-cyclopentyl-6-(ethoxymethyl)-2-(methanesulfonyl)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (933 mg, 2.65 mmol), 1-(methylsulfonyl)piperidin-4-amine (855 mg, 3.98 mmol), and DIPEA (1.39 mL, 7.96 mmol) in DMSO (13.3 mL) was stirred at rt for 2 days, then at 60 °C for 4 h. Water (20 mL) was added, which caused a precipitate to form. The resulting solid was collected by filtration and dried in a 50 °C vacuum oven for 1 day, affording <b>10</b> (752 mg, 63%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 8.60 (s, 1H), 7.63 (s, 1H), 7.37 (d, 1H, <i>J</i> = 7.3 Hz), 5.84 (quin, 1H, <i>J</i> = 8.9 Hz), 4.32 (d, 2H, <i>J</i> = 1.0 Hz), 4.06–3.90 (m, 1H), 3.70–3.52 (m, 4H), 2.96–2.89 (m, 2H), 2.88 (s, 3H), 2.39–2.23 (m, 2H), 2.06–1.96 (m, 4H), 1.85–1.73 (m, 2H), 1.72–1.57 (m, 4H), 1.20 (t, 3H, <i>J</i> = 7.0 Hz); <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>, 70 °C): δ161.8, 160.0, 158.7, 154.9, 131.8, 124.9, 104.7, 66.5, 65.3, 52.3, 46.9, 44.0, 34.7, 30.4, 27.3, 24.8, 14.7; HRMS: calcd for C<sub>21</sub>H<sub>31</sub>N<sub>5</sub>O<sub>4</sub>S [M + H]<sup>+</sup>, 450.2170; found 450.2177.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Ethyl 3-(Cyclopropyloxy)propanoate</h4><div class="NLM_p last">To a solution of cyclopropanol (5 g, 90 mmol) and ethyl acrylate (13.8 g, 138 mmol) in DMSO (50 mL) was added 5 M aqueous NaOH solution (1.72 mL, 8.6 mmol) dropwise. The solution color changed from yellow to blue and back to yellow again during the addition. Stirring was continued at rt (16 °C) for 48 h. The mixture was partitioned between EtOAc (150 mL) and water (100 mL). The aqueous layer was further extracted with MTBE (3 × 100 mL). The combined organic phases were washed with water (3 × 100 mL) and saturated aqueous NaCl (100 mL), dried over sodium sulfate, filtered, and concentrated to a light-yellow liquid. Purification by silica gel chromatography (eluting with 0–10% EtOAc in petroleum ether) afforded ethyl 3-(cyclopropyloxy)propanoate (8.0 g, 59%, ∼90% purity) as colorless liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.15 (q, 2H, <i>J</i> = 7.1 Hz), 3.77 (t, 2H, <i>J</i> = 6.4 Hz), 3.29 (tt, 1H, <i>J</i> = 3.0, 6.0 Hz), 2.56 (t, 2H, <i>J</i> = 6.4 Hz), 1.26 (t, 3H, <i>J</i> = 7.1 Hz), 0.59–0.53 (m, 2H), 0.48–0.41 (m, 2H).</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 8-Cyclopentyl-6-[(cyclopropyloxy)methyl]-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>11</b>)</h4><div class="NLM_p last">A three-necked flask containing a solution of 4-(cyclopentylamino)-2-(methylthio)pyrimidine-5-carbaldehyde<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (150 mg, 0.632 mmol) and ethyl 3-(cyclopropyloxy)propanoate (300 mg, 1.9 mmol) in freshly distilled anhydrous THF (5 mL) under argon was cooled in an ice–water bath. A 1 M solution of NaHMDS in THF (1.9 mL, 1.9 mmol) was added dropwise over 2 min, slowly enough to maintain the internal temperature below 3 °C. The resulting turbid mixture was stirred at this temperature for 40 min, quenched with aqueous NH<sub>4</sub>Cl (0.5 mL), and stirring was continued at rt (25 °C) overnight. The solution was concentrated and purified by silica gel chromatography (eluting with 0–10% EtOAc in petroleum ether) to give a 2:1 mixture of 8-cyclopentyl-6-[(cyclopropyloxy)methyl]-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one and unreacted aldehyde starting material (120 mg combined). LCMS <i>m</i>/<i>z</i>: 332.2 [M + H]<sup>+</sup>. A solution of this mixture in THF (6 mL) was treated with oxone (334 mg, 0.543 mmol) and water (1 mL) and stirred at rt (28 °C) for 1 h. The mixture was partitioned between EtOAc (10 mL) and saturated aqueous NaCl (3 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated to give crude 8-cyclopentyl-6-[(cyclopropyloxy)methyl]-2-(methanesulfonyl)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (130 mg) as a yellow gum. This crude product was dissolved in DMSO (1 mL) in a sealed tube. DIPEA (0.187 mL, 1.07 mmol) and 1-(methylsulfonyl)piperidin-4-amine (130 mg, 0.729 mmol) were added, the tube was sealed, and the mixture was heated at 60 °C for 1.5 h. After standing at rt overnight, excess DIPEA was removed by a syringe. The DMSO phase was diluted with CH<sub>2</sub>Cl<sub>2</sub> (30 mL), washed with water (10 mL), aqueous NH<sub>4</sub>Cl (10 mL), and saturated aqueous NaCl (10 mL), dried over sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel chromatography (eluting with 0–10% EtOAc in CH<sub>2</sub>Cl<sub>2</sub>) and then lyophilized to give <b>11</b> (42.4 mg, 15% over 3 steps) as a pale solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6,</sub> 80 °C): δ 8.60 (s, 1H), 7.70–7.57 (m, 1H), 7.43 (br d, 1H, <i>J</i> = 6.2 Hz), 5.84 (quin, 1H, <i>J</i> = 8.8 Hz), 4.37 (d, 2H, <i>J</i> = 1.1 Hz), 4.04–3.91 (m, 1H), 3.61 (td, 2H, <i>J</i> = 3.4, 12.4 Hz), 3.42 (tt, 1H, <i>J</i> = 3.0, 6.0 Hz), 2.96–2.89 (m, 2H), 2.88 (s, 3H), 2.38–2.25 (m, 2H), 2.06–1.95 (m, 4H), 1.83–1.73 (m, 2H), 1.72–1.59 (m, 4H), 0.60–0.42 (m, 4H); LCMS <i>m</i>/<i>z</i>: 462.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 6-Bromo-8-cyclopentyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one</h4><div class="NLM_p last">A solution of 8-cyclopentyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (20.0 g, 76.5 mmol) and <i>N</i>-bromosuccinimide (20.4 g, 115 mmol) in acetonitrile (160 mL) and CH<sub>2</sub>Cl<sub>2</sub> (160 mL) was stirred at 50 °C for 17 h. The mixture was concentrated to dryness, affording a crude mixture of 6-bromo-8-cyclopentyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one and 6-bromo-8-cyclopentyl-2-(methanesulfinyl)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one. (38 g total, yellow solid). LCMS <i>m</i>/<i>z</i>: 341.9 and 358.0 [M + H]<sup>+</sup>, both Br doublets. The crude product mixture was dissolved in THF (350 mL) and water (175 mL), oxone (94.1 g, 153 mmol) was added, and the mixture was stirred at 50 °C for 11 h. After standing at rt overnight, the reaction mixture was concentrated to dryness, and the residue was partitioned between water (500 mL) and EtOAc (3 × 300 mL). The combined organics were washed with saturated aqueous NaCl (300 mL), dried over sodium sulfate, filtered, concentrated, and purified by silica gel chromatography (eluting with 0–60% EtOAc in petroleum ether) to give 16.5 g of a yellow solid, still contaminated with succinimide. This solid was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (500 mL), washed with saturated aqueous sodium carbonate (2 × 200 mL) and saturated aqueous NaCl (200 mL), dried over sodium sulfate, filtered, and concentrated. The residue was triturated with CH<sub>2</sub>Cl<sub>2</sub> (5 mL) and MTBE (100 mL). The solid was collected by filtration and dried to give 6-bromo-8-cyclopentyl-2-(methanesulfonyl)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (15 g, 53% 2-step yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.94 (s, 1H), 8.20 (s, 1H), 6.02 (quin, 1H, <i>J</i> = 7.8), 3.40 (s, 3H), 2.26–2.17 (m, 4H), 1.99–1.97 (m, 2H), 1.74–1.71 (m, 2H); LCMS <i>m</i>/<i>z</i>: 373.8 [M + H]<sup>+</sup>. A portion of this sulfone intermediate (1.31 g, 3.519 mmol) was reacted with 1-(methylsulfonyl)piperidin-4-amine by the method described for the synthesis of <b>3</b>, to give 6-bromo-8-cyclopentyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (1.07 g, 65%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 8.60 (s, 1H), 8.20 (s, 1H), 7.64 (d, 1H, <i>J</i> = 7.0 Hz), 5.89 (quin, 1H, <i>J</i> = 8.7 Hz), 3.99 (d, 1H, <i>J</i> = 6.4 Hz), 3.73–3.52 (m, 2H), 2.98–2.90 (m, 2H), 2.89 (s, 3H), 2.35–2.21 (m, 2H), 2.06–1.95 (m, 4H, <i>J</i> = 8.8 Hz), 1.87–1.76 (m, 2H), 1.74–1.61 (m, 4H); LCMS <i>m</i>/<i>z</i>: 471.65/469.75 [M + H]<sup>+</sup>(Br doublet).</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 8-Cyclopentyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}-6-{[(propan-2-yl)oxy]methyl}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>12</b>)</h4><div class="NLM_p last">In a microwave vial, a solution of 6-bromo-8-cyclopentyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (50 mg, 0.11 mmol), potassium isopropoxymethyltrifluoroborate (190 mg, 1.06 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (5.06 mg, 0.0069 mmol), and potassium phosphate (tribasic, 1 mL of a 7 M aqueous solution, 7 mmol) in THF (10 mL) was purged with nitrogen gas for 5 min, then irradiated in a microwave reactor at 100 °C for 6 h. After cooling to rt, the mixture was partitioned between water (5 mL) and CH<sub>2</sub>Cl<sub>2</sub> (5 × 5 mL). The combined organics were concentrated to dryness and purified by preparative SFC [ZymorSpher Pyridine Diol 150 × 21.2 mm column; gradient of 5–15% MeOH @ 3%/min then ramped to 15–40% MeOH at 99%/min, 100 bar, 58 mL/min] to give <b>12</b> (12.8 mg, 26%) as a solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 80 °C): δ 8.61 (s, 1H) 7.63 (s, 1H) 7.30–7.47 (m, 1H) 5.68–5.97 (m, 1H) 4.32 (d, 2H, <i>J</i> = 1.2 Hz) 3.89–4.06 (m, 1H) 3.72 (d, 1H, <i>J</i> = 6.1 Hz) 3.63 (d, 2H, <i>J</i> = 12.5 Hz) 2.93 (br s, 2H) 2.88 (s, 3H) 2.25–2.39 (m, 2H) 1.95–2.08 (m, 4H) 1.74–1.85 (m, 2H) 1.67 (d, 4H, <i>J</i> = 10.2 Hz) 1.19 (d, 6H, <i>J</i> = 6.1 Hz); LCMS <i>m</i>/<i>z</i>: 464.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 4-(Cycloheptylamino)-2-(methylthio)pyrimidine-5-carbaldehyde</h4><div class="NLM_p last">A suspension of ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate (16 g, 68.7 mmol), cycloheptylamine (9.34 g, 82.5 mmol), and DIPEA (17.8 g, 138 mmol) in THF (150 mL) was stirred at rt for 18 h. Solvents were evaporated, the residue dissolved in water (150 mL), and the solution extracted with EtOAc (2 × 150 mL). The combined organics were washed with saturated aqueous NaCl (2 × 150 mL), dried over sodium sulfate, and concentrated to give ethyl 4-(cycloheptylamino)-2-(methylthio)pyrimidine-5-carboxylate (21 g, 99%) as yellow oil. LCMS <i>m</i>/<i>z</i>: 309.9 [M + H]<sup>+</sup>. A cooled (5 °C) solution of ethyl 4-(cycloheptylamino)-2-(methylthio)pyrimidine-5-carboxylate (21 g, 67.9 mmol) in THF (200 mL) was treated with lithium aluminum hydride (2.5 M solution in THF, 81.4 mL, 204 mmol) in portions over 1.5 h. The resulting suspension was stirred at 5–10 °C for an additional hour, then at rt (25 °C) for 18 h. The mixture was cooled slightly (15 °C), then water (10 mL) and 2 N NaOH (10 mL) were added dropwise to quench any residual hydride. After stirring for 1 h at rt, the suspension was filtered, and the flask and filter cake were rinsed with THF (4 × 300 mL). The combined filtrates were concentrated to remove most of the solvent, and the residue was partitioned between water (100 mL) and EtOAc (2 × 250 mL). The combined organic layers were washed with saturated aqueous NaCl (100 mL), dried over sodium sulfate, and concentrated to dryness. The crude product was recrystallized from petroleum ether/EtOAc (200 mL/50 mL) to give [4-(cycloheptylamino)-2-(methylthio)pyrimidin-5-yl]methanol (13.6 g, 75%) as a white solid. LCMS <i>m</i>/<i>z</i>: 267.9 [M + H]<sup>+</sup>. Activated manganese dioxide (43.3 g, 860 mmol) was added to a solution of [4-(cycloheptylamino)-2-(methylthio)pyrimidin-5-yl]methanol (13.6 g, 50 mmol) in chloroform (200 mL), and the resulting suspension stirred at rt for 15 h. The solids were removed by filtration. The flask and filter cake were rinsed with CH<sub>2</sub>Cl<sub>2</sub> (4 × 150 mL). The combined filtrates were filtered again to remove trace solids, then concentrated to give 4-(cycloheptylamino)-2-(methylthio)pyrimidine-5-carbaldehyde (12.9 g, 98%) as yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.68 (s, 1H), 8.63 (br s, 1H), 8.28 (s, 1H), 4.36–4.32 (m, 1H), 2.55 (s, 3H), 2.03–1.99 (m, 2H), 1.67–1.58 (m, 10H); LCMS <i>m</i>/<i>z</i>: 265.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 8-Cycloheptyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one</h4><div class="NLM_p last">By the same method used for 8-cyclopentyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one but with an initial reaction temperature of −5 °C instead of −70 °C, 4-(cycloheptylamino)-2-(methylthio)pyrimidine-5-carbaldehyde (9.9 g, 37 mmol) was reacted with EtOAc (9.79 g, 111 mmol) and LiHMDS (111 mL of a 1.0 M solution in THF) to give, after silica gel chromatography, 8-cycloheptyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (9.5 g, 89%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.57 (s, 1H), 7.52 (d, 1H, <i>J</i> = 9.6 Hz), 6.60 (br s, 1H), 5.72 and 5.44 (2 br s, 1H together), 2.75–2.51 (m, 5H), 1.95–1.62 (m, 10 H); LCMS <i>m</i>/<i>z</i>: 289.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 8-Cycloheptyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (13)</h4><div class="NLM_p last">According to the two-step method described for the synthesis of <b>3</b>, 8-cycloheptyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one was used to produce <b>13</b> (107 mg, 37% 2-step yield) after a final purification by preparative SFC. <sup>1</sup>H NMR (700 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.50 (br s, 1H) 7.80 (br s, 1H) 7.59 (d, 1H, <i>J</i> = 9.2 Hz) 6.30–5.98 (m, 1H) 5.49 and 5.21 (2 br s, 1H together) 4.04–3.81 (m, 1H) 3.54 (br s, 2H) 2.84 (s, 3H) 2.79 (br s, 2H) 2.52 (d, 1H, <i>J</i> = 9.9 Hz) 2.31 (br s, 1H) 2.08–1.84 (m, 2H) 1.70 (br s, 2H) 1.62–1.32 (m, 10H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ162.26, 160.14, 158.45, 154.97, 135.78, 116.24, 104.85, 53.79, 47.18, 43.94, 34.87, 31.02, 30.28, 27.12, 25.88; HRMS: calculated for C<sub>20</sub>H<sub>29</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 420.2064; found 420.2070.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 8-Cyclohexyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>14</b>)</h4><div class="NLM_p last">A mixture of 8-cyclohexyl-2-(methanesulfinyl)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> (60.0 mg, 0.206 mmol), 1-(methylsulfonyl)piperidin-4-amine (70.0 mg, 0.393 mmol), and cesium fluoride (59.7 mg, 0.393 mmol) in DMSO (3 mL, pre-treated with CaH<sub>2</sub>) was irradiated in a microwave reactor at 140 °C for 15 min. After cooling to rt, the mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (30 mL) and washed with water (2 × 10 mL) and saturated aqueous NaCl (10 mL). The organics were dried over sodium sulfate, filtered, concentrated, purified by preparative TLC (MeOH/CH<sub>2</sub>Cl<sub>2</sub> = 1/15), and lyophilized to give <b>14</b> (57.2 mg, 36%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (s, 1H), 7.40 (d, 1H), 6.37 (br s, 1H), 5.54 (br s, 1H), 5.40–5.25 (m, 1H), 4.05–3.95 (m, 1H), 3.83–3.81 (m, 2H), 3.00–2.90 (m, 2H), 2.85 (s, 3H), 2.75–2.60 (m, 2H), 2.24–2.21 (m, 2H), 1.90–1.85 (m, 2H), 1.73–1.68 (m, 5H), 1.42–1.25 (m, 3H); LCMS <i>m</i>/<i>z</i>: 406.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2-{[1-(Methanesulfonyl)piperidin-4-yl]amino}-8-[(1<i>R</i>,2<i>S</i>)-2-methylcyclopentyl]pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>15</b>)</h4><div class="NLM_p last">Prepared by the same method as used for <b>13</b> but starting with (1<i>R</i>,2<i>S</i>)-2-methylcyclopentan-1-amine.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (s, 1H), 7.41 (d, 1H, <i>J</i> = 9.3 Hz), 6.34 (d, 1H, <i>J</i> = 9.3 Hz), 6.01–5.86 (m, 1H), 4.10–3.95 (m, 1H), 3.79 (d, 2H, <i>J</i> = 10.5 Hz), 2.93 (br s, 2H), 2.83 (s, 3H), 2.79–2.51 (m, 1H), 2.34 (br s, 1H), 2.19 (d, 2H, <i>J</i> = 12.3 Hz), 2.10–1.99 (m, 1H), 1.89 (dd, 4H, <i>J</i> = 7.7, 18.7 Hz), 1.76–1.61 (m, 2H), 1.60–1.45 (m, 1H), 0.78 (d, 3H, <i>J</i> = 7.0 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 151 MHz): δ 164.5, 159.8, 157.5, 157.1, 135.3, 119.2, 106.3, 56.3, 47.8, 44.7, 38.0, 35.2, 35.1, 31.5, 28.0, 25.5, 15.1 95% ee by chiral analytical SFC/MS [Column: Chiralpak AD-3 100 × 4.6 mm I.D., 3 μm; Mobile phase: A: CO<sub>2</sub> B/ethanol (0.05% diethylamine); Gradient: from 5 to 40% of B in 4.5 min and hold 40%; for 2.5 min, then 5% of B for 1 min; Flow rate: 2.8 mL/min; 40 °C]; HRMS: calcd for C<sub>19</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 406.1835; found 406.1901.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>rac</i>-{4-[(Butan-2-yl)amino]-2-(methylthio)pyrimidin-5-yl}methanol</h4><div class="NLM_p last">A solution of [4-chloro-2-(methylthio)pyrimidin-5-yl]methanol (500 mg, 2.62 mmol), (±)-butan-2-amine (249 mg, 3.41 mmol), and triethylamine (796 mg, 7.78 mmol) in ethanol (2 mL) and acetonitrile (2 mL) was stirred at 80 °C for 18 h. After cooling to rt, the mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (100 mL) and washed with aqueous NH<sub>4</sub>Cl (50 mL) and saturated aqueous NaCl (50 mL). The organic layer was dried over sodium sulfate, filtered, concentrated, and purified by silica gel chromatography to give <i>rac</i>-{4-[(butan-2-yl)amino]-2-(methylthio)pyrimidin-5-yl}methanol (520 mg, 87%) as a light yellow solid. LCMS <i>m</i>/<i>z</i>: 227.8 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>rac</i> 4-[(Butan-2-yl)amino]-2-(methylthio)pyrimidine-5-carbaldehyde</h4><div class="NLM_p last">Activated manganese dioxide (1.75 g, 19.9 mmol) was added to a rt (25 °C) solution of <i>rac</i>-{4-[(butan-2-yl)amino]-2-(methylthio)pyrimidin-5-yl}methanol (520 mg, 2.29 mmol) in chloroform (50 mL), and the resulting suspension heated to 50 °C for 6 h. After filtration, the mixture was concentrated to a black gum and purified by silica gel chromatography, affording <i>rac</i> 4-[(butan-2-yl)amino]-2-(methylthio)pyrimidine-5-carbaldehyde (468 mg, 91%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.69 (s, 1H), 8.50 (br s, 1H), 8.28 (s, 1H), 4.31 (quin, 1H, <i>J</i> = 7.2 Hz), 2.54 (s, 3H), 1.68–1.61 (m, 2H), 1.26 (d, 3H, <i>J</i> = 6.4 Hz), 0.96 (t, 3H, <i>J</i> = 7.4 Hz); LCMS <i>m</i>/<i>z</i>: 225.8 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>rac</i> 8-(Butan-2-yl)-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one</h4><div class="NLM_p last">By the method described for the synthesis of 8-cyclopentyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one, <i>rac</i> 4-[(butan-2-yl)amino]-2-(methylthio)pyrimidine-5-carbaldehyde (350 mg, 1.5 mmol) was used to produce <i>rac</i> 8-(butan-2-yl)-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (340 mg, 77%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.57 (s, 1H), 7.53 (d, 1H, <i>J</i> = 9.6 Hz), 6.59 (br d, 1H, <i>J</i> = 9.6 Hz), 5.58 (br s, 1H), 2.63 (s, 3H), 2.32 (br s, 1H), 1.99 (br s, 1H), 1.61 (br d, 3H, <i>J</i> = 6.4 Hz), 0.83 (t, 3H, <i>J</i> = 7.6 Hz); LCMS <i>m</i>/<i>z</i>: 249.8 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (−)-8-(Butan-2-yl)-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>16</b>) and (+)-8-(Butan-2-yl)-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>16</b> and <b>17</b>)</h4><div class="NLM_p">By the same method as <b>3</b>, <i>rac</i>-8-(butan-2-yl)-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one was converted in two steps to <i>rac</i>-8-(butan-2-yl)-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (150 mg, 71% 2-step yield). LCMS <i>m</i>/<i>z</i>: 380.0 [M + H]<sup>+</sup>. The enantiomers were resolved by preparative chiral SFC.</div><div class="NLM_p">The earlier eluting peak afforded 38.56 mg of <b>16</b>: LCMS <i>m</i>/<i>z</i>: 380.0 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 8.55 (s, 1H), 7.64 (d, 1H, <i>J</i> = 9.3 Hz), 7.48 (br d, 1H, <i>J</i> = 6.2 Hz), 6.19 (d, 1H, <i>J</i> = 9.3 Hz), 5.46 (sxt, 1H, <i>J</i> = 7.4 Hz), 4.02–3.89 (m, 1H), 3.61 (ttd, 2H, <i>J</i> = 2.2, 4.2, 12.3 Hz), 2.97–2.89 (m, 2H), 2.88 (s, 3H), 2.27–2.15 (m, 1H), 2.06–1.97 (m, 2H), 1.91 (quind, 1H, <i>J</i> = 7.1, 13.9 Hz), 1.71–1.59 (m, 2H), 1.51 (d, 3H, <i>J</i> = 6.8 Hz), 0.77 (t, 3H, <i>J</i> = 7.5 Hz); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz, 70 °C): δ 162.95, 160.18, 158.70, 155.74, 136.15, 116.24, 104.87, 49.87, 47.01, 43.97, 34.67, 30.40, 25.49, 17.29, 10.78; [α]<sub class="stack">D</sub><sup class="stack">25</sup> −19.5 (<i>c</i> 0.087, CHCl<sub>3</sub>); 98.9% ee by chiral analytical SFC/MS [Column: Chiralpak AD-3 150 × 4.6 mm I.D., 3 μm; mobile phase: A: CO<sub>2</sub> B/ethanol (0.05% diethylamine); gradient: from 5 to 40% of B in 5.0 min and hold 40%; for 2.5 min, then 5% of B for 2.5 min; flow rate: 2.5 mL/min; column temperature: 35 °C]; HRMS: calculated for C<sub>17</sub>H<sub>25</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 380.1751; found 380.1755.</div><div class="NLM_p last">The later eluting peak afforded 28.92 mg of <b>17</b>: LCMS <i>m</i>/<i>z</i>: 379.9 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 8.54 (s, 1H), 7.64 (d, 1H, <i>J</i> = 9.3 Hz), 7.48 (br d, 1H, <i>J</i> = 6.8 Hz), 6.19 (d, 1H, <i>J</i> = 9.3 Hz), 5.52–5.40 (m, 1H), 4.01–3.89 (m, 1H), 3.61 (ttd, 2H, <i>J</i> = 2.0, 4.1, 12.2 Hz), 2.97–2.89 (m, 2H), 2.88 (s, 3H), 2.27–2.14 (m, 1H), 2.06–1.97 (m, 2H), 1.91 (quind, 1H, <i>J</i> = 7.2, 13.9 Hz), 1.72–1.59 (m, 2H), 1.51 (d, 3H, <i>J</i> = 6.8 Hz), 0.77 (t, 3H, <i>J</i> = 7.5 Hz); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 162.81, 160.12, 158.49, 155.66, 135.92, 116.20, 104.80, 49.83, 46.93, 43.80, 34.80, 30.32/30.29, 25.42, 17.13, 10.60; [α]<sub class="stack">D</sub><sup class="stack">25</sup> +7.56 (<i>c</i> 0.097, CHCl<sub>3</sub>); 99.5% ee by chiral analytical SFC/MS. HRMS: calculated for C<sub>17</sub>H<sub>25</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 380.1751; found 380.1758. The absolute stereochemistry was not determined for either enantiomer.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-{[1-(Methanesulfonyl)piperidin-4-yl]amino}-8-(propan-2-yl)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>18</b>)</h4><div class="NLM_p last">By the same method as <b>3</b>, 2-(methylthio)-8-(propan-2-yl)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> was converted in two steps to <b>18</b> (103.6 mg, 33% 2-step yield) as a solid, after purification by preparative HPLC and lyophilization. LCMS <i>m</i>/<i>z</i>: 366.1 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.39 (s, 1H), 7.41 (d, 1H, <i>J</i> = 9.3 Hz), 6.36 (br d, 1H, <i>J</i> = 9.3 Hz), 5.73 (sept, 1H, <i>J</i> = 7.0 Hz), 4.12–3.98 (m, 1H), 3.80 (br d, 2H, <i>J</i> = 11.5 Hz), 2.96 (br t, 2H, <i>J</i> = 11.2 Hz), 2.84 (s, 3H), 2.25–2.16 (m, 2H), 1.78–1.65 (m, 2H), 1.60 (br d, 6H, <i>J</i> = 7.0 Hz); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 162.58, 160.13, 158.46, 155.35, 135.82, 116.33, 104.93, 46.84, 43.88/43.78, 34.76, 30.32, 18.89, HRMS: calculated for C<sub>16</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 366.1594; found 366.1599.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (1<i>R</i>,2<i>R</i>)-2-{[5-(Hydroxymethyl)-2-(methylthio)pyrimidin-4-yl]amino}-1-methylcyclopentan-1-ol</h4><div class="NLM_p last">To a solution of (1<i>R</i>,2<i>R</i>)-2-amino-1-methylcyclopentan-1-ol<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a><b>25</b> (21.6 g, 188 mmol) in 2-propanol (∼350 mL) was added solid [4-chloro-2-(methylthio)pyrimidin-5-yl]methanol (CAS# 1044145-59-6) (34.8 g, 182 mmol) and DIPEA (95.3 mL, 547 mmol). The mixture was degassed with nitrogen, stirred under a nitrogen atmosphere at rt for 15 min, then at 80 °C for 40 h. The volatiles were removed, and the residual oil (95 g) was partitioned between EtOAc (800 mL) and saturated aqueous NaCl (250 mL). The aqueous layer was further extracted with EtOAc (3 × 500 mL). The combined organic extracts were dried over sodium sulfate, concentrated to oil (75 g), dissolved in EtOAc (200 mL), and heated to 60 °C. Some white solid was observed 5 min after initiation of heating. Heptane (400 mL) was added slowly to the suspension and stirring continued at 60 °C for 15 min. The suspension was cooled to rt and then in an ice–water bath for 15 min. The resulting precipitate was collected by filtration and dried to give (1<i>R</i>,2<i>R</i>)-2-{[5-(hydroxymethyl)-2-(methylthio)pyrimidin-4-yl]amino}-1-methylcyclopentan-1-ol (47.8 g, 97%, 98% ee). LCMS <i>m</i>/<i>z</i>: 270.2 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.76 (s, 1H), 6.01 (d, 1H, <i>J</i> = 4.6 Hz), 5.31 (br s, 1H), 4.55 (s, 2H), 4.26 (ddd, 1H, <i>J</i> = 5.7, 8.2, 10.5 Hz), 2.50 (s, 3H), 2.21 (ddd, 1H, <i>J</i> = 3.5, 8.2, 12.1 Hz), 1.97 (dt, 1H, <i>J</i> = 3.5, 7.7 Hz), 1.89–1.76 (m, 2H), 1.75–1.63 (m, 1H), 1.60–1.50 (m, 2H), 1.11 (s, 3H); [α]<sub class="stack">D</sub><sup class="stack">22</sup> +37.7 (<i>c</i> 1.0, MeOH); 98% ee by chiral analytical SFC/MS [Chiralpak IC-3, 4.6 × 150 mm, 3 μm column heated to 25 °C and eluted with a mobile phase of CO<sub>2</sub> and 30% ammonia in methanol (20 mM v/v) flowing at 4.0 mL/min and maintained at 160 bar outlet pressure].</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-{[(1<i>R</i>,2<i>R</i>)-2-Hydroxy-2-methylcyclopentyl]amino}-2-(methylthio)pyrimidine-5-carbaldehyde (<b>26</b>)</h4><div class="NLM_p last">To a 2 L 3-necked flask equipped with a mechanical stirrer and a reflux condenser were added solid manganese dioxide (10 μm mesh, reagent grade, 278 g, 2660 mmol), EtOAc (1.2 L), and solid (1<i>R</i>,2<i>R</i>)-2-{[5-(hydroxymethyl)-2-(methylthio)pyrimidin-4-yl]amino}-1-methylcyclopentanol (47.7 g, 177 mmol). The flask was heated in a 50 °C oil bath for 4 h. More manganese dioxide (80 g) was added; stirring and heating were continued for another 16 h, until the reaction was completed by LCMS. The solid was removed by filtration, and the flask and filter cake were washed with EtOAc (1 L). The combined filtrates were filtered again to completely remove trace insolubles and then evaporated to give 4-{[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]amino}-2-(methylthio)pyrimidine-5-carbaldehyde <b>26</b> (43.8 g, 93%, >98% ee) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.73 (s, 1H), 8.66 (br s, 1H), 8.35 (s, 1H), 4.39 (ddd, 1H, <i>J</i> = 6.5, 8.2, 9.6 Hz), 4.16 (s, 1H), 2.57 (s, 3H), 2.33–2.22 (m, 1H), 2.03–1.92 (m, 1H), 1.89–1.68 (m, 3H), 1.68–1.56 (m, 1H), 1.17 (s, 3H); [α]<sub class="stack">D</sub><sup class="stack">22</sup> +12.7 (<i>c</i> 1.0, CHCl<sub>3</sub>); >98% ee by chiral analytical SFC/MS [Chiralpak IC-3, 4.6 × 150 mm, 3 μm column heated to 25 °C and eluted with a mobile phase of CO<sub>2</sub> and 30% ammonia in methanol (20 mM v/v) flowing at 4.0 mL/min and maintained at 160 bar outlet pressure]; LCMS <i>m</i>/<i>z</i>: 268.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 8-[(1<i>R</i>,2<i>R</i>)-2-Hydroxy-2-methylcyclopentyl]-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one</h4><div class="NLM_p last">To a 2 L three-necked flask equipped with a mechanical stirrer and an internal thermometer were added solid 4-{[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]amino}-2-(methylthio)pyrimidine-5-carbaldehyde <b>26</b> (34.2 g, 128 mmol), THF (400 mL), and EtOAc (33.4 mL, 333 mmol). The solution was purged with nitrogen and cooled in a MeOH–ice bath to −5 °C internal. LiHMDS (1.0 M solution in THF, 4 × 100 mL freshly opened bottles, 400 mmol) was added by cannula, slowly enough to keep the internal temperature at −5 °C. A light yellow precipitate began to form after ∼300 mL LiHMDS solution had been added. Stirring was continued as the mixture gradually warmed to rt overnight. The resulting red solution was cooled in an ice–water bath to ∼3 °C internal and then EtOH (224 mL, 3840 mmol) was added using a cannula, slowly enough to keep the internal temp at ∼3 °C internal. The mixture was stirred in the ice bath for 1 h; then, the cooling bath was removed, the solution was allowed to warm to 20 °C internal and stirring continued for 1 h. The solvents were evaporated, the residue was diluted with water (180 mL) and saturated aqueous NaCl (180 mL), and the aqueous layer was extracted with EtOAc (700 mL, then 2 × 600 mL). The combined organic extracts were dried over sodium sulfate and concentrated to a light yellow-brown foam (43.8 g). This foam was dissolved in EtOAc (70 mL) and sonicated to induce precipitation. The resulting solid was collected by filtration, rinsed with EtOAc (10 mL), and dried to give 8-[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (21.4 g, 58%, >99% ee) as a white solid. The mother liquor from the precipitation was evaporated to dryness, the residue (24.5 g) was dissolved in EtOAc (30 mL), and the solution was sonicated to induce precipitation. After filtration and drying, a second crop of the product (4.70 g, 13%, >99% ee) was obtained as a white solid. The total yield for both crops was 26.1 g (71%, >99% ee) after crystallization. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.61 (s, 1H), 7.56 (d, 1H, <i>J</i> = 9.4 Hz), 6.60 (d, 1H, <i>J</i> = 9.4 Hz), 5.84 (t, 1H, <i>J</i> = 8.6 Hz), 2.92–2.76 (m, 1H), 2.64 (s, 3H), 2.34–2.19 (m, 2H), 2.13–2.01 (m, 2H), 2.00–1.81 (m, 2H), 1.16 (s, 3H); [α]<sub class="stack">D</sub><sup class="stack">22</sup> −12.9 (<i>c</i> 1.0, MeOH). >99% ee by analytical chiral SFC/MS [Chiralpak AD-3, 4.6 × 100 mm, 3 μm column heated to 25 °C and eluted with a mobile phase of CO<sub>2</sub> and 40% methanol flowing at 4.0 mL/min and maintained at 120 bar outlet pressure]; LCMS <i>m</i>/<i>z</i>: 292.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 8-[(1<i>R</i>,2<i>R</i>)-2-Hydroxy-2-methylcyclopentyl]-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>19</b>)</h4><div class="NLM_p last">A solution of 8-[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]-2-(methylthio)-pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>27</b>) (2.33 g, 8.0 mmol), 2-MeTHF (40 mL), water (8 mL), and oxone (12.3 g, 20 mmol) was stirred at rt for 4 h. The solution was cooled in a water bath, diluted with water (10 mL) and saturated aqueous NaCl (10 mL), and extracted with EtOAc (3 × 80 mL). The combined organic extracts were dried over sodium sulfate, evaporated to dark oil (3.76 g), and purified by silica gel chromatography (eluting with a gradient of 20–100% EtOAc in heptane) to give 8-[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]-2-(methylsulfonyl)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (2.2 g, 84%) as a foamy solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.96 (s, 1H), 7.74 (d, 1H, <i>J</i> = 9.5 Hz), 6.90 (d, 1H, <i>J</i> = 9.4 Hz), 5.77 (t, 1H, <i>J</i> = 8.5 Hz), 3.40 (s, 3H), 2.92–2.73 (m, 1H), 2.36–2.25 (m, 1H), 2.19–2.08 (m, 2H), 2.03–1.85 (m, 2H), 1.14 (s, 3H); LCMS <i>m</i>/<i>z</i>: 306.0 [M-18]<sup>+</sup>. A solution of this sulfone (800 mg, 2.47 mmol) and 1-(methylsulfonyl)piperidin-4-amine (970 mg, 5.44 mmol) in 2-MeTHF (12.4 mL) was heated in a 60 °C oil bath for 24 h. After cooling to rt, the mixture was partitioned between EtOAc (80 mL), water (10 mL), and saturated aqueous NaHCO<sub>3</sub> (10 mL). The aqueous layer was further extracted with EtOAc (2 × 60 mL). The combined organic extracts were dried over sodium sulfate and evaporated to dryness. The residue (1.23 g) was dissolved in EtOAc (11 mL), seed crystals were added, and the solution was allowed to stand at rt overnight. The resulting solid was collected by filtration, rinsed with EtOAc (3 mL), and dried to give 8-[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>19</b>) (680 mg, 63%, >99% ee) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.43 (s, 1H), 7.45 (d, 1H, <i>J</i> = 9.3 Hz), 6.36 (d, 1H, <i>J</i> = 9.4 Hz), 5.73 (t, 1H, <i>J</i> = 8.4 Hz), 5.34 (br s, 1H), 4.01 (br s, 1H), 3.88–3.74 (m, 2H), 3.01–2.89 (m, 2H), 2.83 (s, 4H), 2.36 (br s, 1H), 2.29–2.14 (m, 3H), 2.03 (dt, 2H, <i>J</i> = 2.9, 6.3 Hz), 1.98–1.89 (m, 1H), 1.88–1.81 (m, 1H), 1.78–1.60 (m, 2H), 1.18 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ162.86, 160.16, 158.50, 156.19, 135.88, 116.59, 104.88, 80.25, 62.96, 47.02, 43.92, 41.53, 34.83, 30.29/30.24, 26.68, 23.49, 22.83; [α]<sub class="stack">D</sub><sup class="stack">22</sup> −17.0 (<i>c</i> 1.0, CHCl<sub>3</sub>); >99% ee by chiral analytical SFC/MS [Lux Cellulose-1, 4.6 × 100 mm, 3 μm column heated to 25 °C and eluted with a mobile phase of CO<sub>2</sub> and 5–60% methanol gradient in 3.0 min flowing at 4.0 mL/min and maintained at 120 bar outlet pressure]; HRMS: calculated for C<sub>19</sub>H<sub>27</sub>N<sub>5</sub>O<sub>4</sub>S [M + H]<sup>+</sup>, 422.1857; found 422.1863.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 6-Chloro-8-[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>20</b>)</h4><div class="NLM_p last">A solution of 8-[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>19</b>) (4.22 g, 10 mmol) and <i>N</i>-chlorosuccinimide (1.53 g, 11 mmol) in 2-MeTHF (100 mL) was stirred in a 50 °C oil bath for 44 h. After cooling to rt, ethanol (1.75 mL, 30 mmol) was added and the mixture stirred at rt for 1 h. The solution was diluted with EtOAc (120 mL) and washed with a mixture of water (15 mL) and saturated aqueous NaHCO<sub>3</sub> (15 mL). The aqueous layer was further extracted with EtOAc (80 mL). The combined organic layers were washed with saturated aqueous NaCl (15 mL), dried over sodium sulfate, filtered, and concentrated to dryness. Ethanol (45 mL) was added to the residue, and the resulting suspension was stirred in a 55 °C oil bath for 1 h, then allowed to cool, while stirring, to rt overnight. The resulting white solid was collected by filtration, rinsed with EtOH (3 mL), and dried under vacuum (∼10 mmHg, 50 °C) to give <b>20</b> (3.86 g, 84%, >99% ee) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 8.60 (s, 1H), 8.02 (s, 1H), 7.61 (br s, 1H), 5.91 (dd, 1H, <i>J</i> = 7.4, 9.2 Hz), 4.09 (s, 1H), 4.04–3.94 (m, 1H), 3.70–3.49 (m, 2H), 2.97–2.88 (m, 2H), 2.87 (s, 3H), 2.48–2.42 (m, 1H), 2.20 (dt, 1H, <i>J</i> = 8.1, 11.4 Hz), 2.09 (d, 1H, <i>J</i> = 12.3 Hz), 2.05–1.96 (m, 2H), 1.96–1.84 (m, 2H), 1.79–1.66 (m, 2H), 1.65–1.51 (m, 1H), 1.01 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 160.06, 158.58, 158.46, 155.00, 133.82, 119.74, 104.18, 80.25, 64.05, 47.10, 43.88, 41.53, 34.83, 30.21, 30.14, 26.61, 23.42, 22.80; [α]<sub class="stack">D</sub><sup class="stack">22</sup> −31.4 (<i>c</i> 0.4 MeOH); >99% ee by chiral analytical SFC/MS [Phenomenex Lux Cellulose-1 4.6 × 100 mm 3μ column; rt; mobile phase 30% MeOH in CO<sub>2</sub>; 120 bar outlet pressure; flow at 4 mL/min]; HRMS: calculated for C<sub>19</sub>H<sub>26</sub>ClN<sub>5</sub>O<sub>4</sub>S [M + H]<sup>+</sup>, 456.1467; found 456.1472.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (−)-8-[(1<i>R</i>*,2<i>R</i>*)-2-Hydroxy-2-methylcyclopentyl]-6-methyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (21) and (+)-8-[(1<i>R</i>*,2<i>R</i>*)-2-Hydroxy-2-methylcyclopentyl]-6-methyl-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>ent-21</b>)</h4><div class="NLM_p">By the same two-step procedure used to make the single-enantiomer analogue 4-{[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]amino}-2-(methylthio)pyrimidine-5-carbaldehyde (<b>26</b>), [4-chloro-2-(methylthio)pyrimidin-5-yl]methanol (92 g, 0.48 mol) and <i>rac</i>-(1<i>R</i>*,2<i>R</i>*)-2-amino-1-methylcyclopentan-1-ol<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> (72 g, 0.625 mol) were used to prepare 82.6 g of <i>rac</i>-4-{[(1<i>R</i>*,2<i>R</i>*)-2-hydroxy-2-methylcyclopentyl]amino}-2-(methylthio)pyrimidine-5-carbaldehyde in 64% yield over 2 steps. This aldehyde (6.50 g, 24.3 mmol) was subjected to cyclization with ethyl propionate, sulfur oxidation, and amination using the methods described in the synthesis of compound <b>4</b>. This sequence gave 4.48 g of <i>rac</i>-8-[(1<i>R</i>*,2<i>R</i>*)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}-6-methylpyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one as a white solid in 42% yield over three steps. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (s, 1H), 7.33 (s, 1H), 5.74 (t, 1H, <i>J</i> = 8.4 Hz), 5.43–5.21 (m, 1H), 3.97 (br s, 1H), 3.82 (t, 2H, <i>J</i> = 10.3 Hz), 2.98–2.87 (m, 2H), 2.83 (s, 3H), 2.47 (br s, 1H), 2.32–2.18 (m, 3H), 2.15 (s, 3H), 2.08–1.57 (m, 7H), 1.16 (s, 3H); LCMS <i>m</i>/<i>z</i>: 436.1 [M + H]<sup>+</sup>. To separate the enantiomers, 200 mg of the racemate was submitted to chiral preparative SFC [Chiralpak AD-H 30 × 250 mm column at 36 °C; flow of 40% MeOH in CO<sub>2</sub> held at 100 bar, 80 mL/min; detection with UV 336 nm.]</div><div class="NLM_p">The earlier eluting peak afforded (+)-8-[(1<i>R</i>*,2<i>R</i>*)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}-6-methylpyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one <b>ent-21</b> (97.1 mg, >99% ee) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (br s, 1H), 7.33 (s, 1H), 5.75 (t, 1H, <i>J</i> = 8.4 Hz), 5.41 (br s, 1H), 4.00 (br s, 1H), 3.81 (t, 2H, <i>J</i> = 10.6 Hz), 3.02–2.88 (m, 2H), 2.83 (s, 4H), 2.33–2.18 (m, 3H), 2.16 (s, 3H), 2.09–1.80 (m, 4H), 1.77–1.58 (m, 3H), 1.16 (s, 3H); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 8.49 (s, 1H), 7.52 (s, 1H), 7.25 (d, 1H, <i>J</i> = 5.5 Hz), 5.87 (t, 1H, <i>J</i> = 7.8 Hz), 3.98 (br s, 2H), 3.61 (t, 2H, <i>J</i> = 10.8 Hz), 2.97–2.89 (m, 2H, <i>J</i> = 6.6 Hz), 2.87 (s, 3H), 2.59–2.52 (m, 1H), 2.33–2.17 (m, 1H), 2.14–2.06 (m, 1H), 2.03 (s, 3H), 2.01–1.82 (m, 4H), 1.76–1.53 (m, 3H), 1.00 (s, 3H); [α]<sub class="stack">D</sub><sup class="stack">22</sup> +31.5 (<i>c</i> 0.1 MeOH); >99% ee by chiral analytical SFC/MS [Chiralpak AD-3 4.6 × 100 mm column; 30% MeOH; 120 bar; 4 mL/min]; LCMS <i>m</i>/<i>z</i>: 435.9 [M + H]<sup>+</sup>.</div><div class="NLM_p last">The later eluting peak afforded (−)-8-[(1<i>R</i>*,2<i>R</i>*)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}-6-methylpyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one <b>21</b> (97.9 mg, ∼99% ee) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.39 (br s, 1H), 7.33 (s, 1H), 5.75 (t, 1H, <i>J</i> = 8.3 Hz), 5.35 (br s, 1H), 3.99 (br s, 1H), 3.81 (t, 2H, <i>J</i> = 10.6 Hz), 3.01–2.88 (m, 2H), 2.83 (s, 4H), 2.33–2.18 (m, 3H), 2.16 (s, 3H), 2.10–1.79 (m, 4H), 1.75–1.53 (m, 3H), 1.16 (s, 3H); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 8.49 (br s, 1H), 7.52 (br s, 1H), 7.24 (br s, 1H), 5.87 (t, 1H, <i>J</i> = 6.7 Hz), 3.98 (br s, 2H), 3.61 (br s, 2H), 2.91 (br s, 2H), 2.87 (br s, 3H), 2.29–2.17 (m, 1H, <i>J</i> = 9.4 Hz), 2.13–2.06 (m, 1H), 2.03 (br s, 3H), 2.00–1.81 (m, 4H), 1.77–1.49 (m, 3H), 1.00 (br s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 163.35, 159.66, 157.42, 155.34, 132.19, 124.32, 104.86, 80.27, 63.18, 46.95, 43.93, 41.54, 34.80, 30.33/30.28, 26.75, 23.50, 22.86, 15.94, [α]<sub class="stack">D</sub><sup class="stack">22</sup> −29.8 (<i>c</i> 0.1 MeOH); >99% ee by chiral analytical SFC/MS [Chiralpak AD-3 4.6 × 100 mm column; 30% MeOH; 120 bar; 4 mL/min]; HRMS: calculated for C<sub>20</sub>H<sub>29</sub>N<sub>5</sub>O<sub>4</sub>S [M + H]<sup>+</sup>, 436.2013; found 436.2018. The absolute stereochemistry was not determined for either enantiomer.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 6-(Difluoromethyl)-8-[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>22</b>)</h4><div class="NLM_p last">A 2 L, 4-necked flask equipped with an overhead stirrer, an internal thermometer, and a 250 mL dropping addition funnel was charged with DMSO (1000 mL) and 8-[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methanesulfonyl)piperidin-4-yl]amino}pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one <b>19</b> (26.38 g, 64.74 mmol). The mixture was stirred at rt (20 °C) until the solids dissolved completely, then sodium difluoromethanesulfinate (44.7 g, 324 mmol) was added portionwise. Iron(III) chloride on silica gel (105 g of 5 wt % loading, to deliver 5.25 g FeCl<sub>3</sub>, 32.4 mmol) was added portionwise, causing a slight exotherm, raising the internal temperature to 25 °C. The dropping addition funnel was charged with a <i>tert</i>-butyl hydroperoxide solution (70 wt % in water, 41.7 g, 324 mmol) dissolved in DMSO (100 mL). This solution was added dropwise to the reaction flask at a rate of 1 mL/min, causing the internal temperature to rise to 40 °C by the end of the addition. The mixture was stirred and allowed to cool to rt for 3 h, then poured into saturated aqueous NaCl, and extracted with EtOAc (3 × 100 mL). The combined organic extracts were washed with saturated aqueous NaCl (3 × 100 mL), dried over sodium sulfate, concentrated, and purified by silica gel chromatography (eluting with 20–80% EtOAc in heptane) to give <b>22</b> (17.53 g, 57%) as a yellow foam. Two batches of chromatographed <b>22</b> (28 g total) were dissolved in acetone, combined, and concentrated to ∼300 mL. MTBE (500 mL) was added and the solution was heated to 50 °C until crystallization occurred. The suspension was sonicated, more MTBE was added (300 mL), and the suspension was allowed to stand at rt for 30 min. Heptane (500 mL total) was added in portions with sonication, then the solids were collected by filtration and washed with heptane. The filtered solids were dissolved in hot ethanol (300 mL). The solution was concentrated under reduced pressure until crystallization began to occur and then allowed to stand at rt for 24 h. Heptane (500 mL) was added, then the solids were collected by filtration and rinsed with additional heptane. The ethanol/heptane filtrate was concentrated to dryness, and the residue was recrystallized in the same manner to afford a second crop. The two crops of precipitate were combined, slurried in hot ethanol (100 mL), sonicated, and allowed to stand at rt for 30 min before heptane (300 mL) was added, and the suspension was allowed to stand at rt for 1.5 h. The resulting crystals were collected by filtration, washed with heptane, and dried to constant volume, affording <b>22</b> (18.59 g, 66% for the recrystallization procedure) as a colorless solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 8.73 (s, 1H), 8.04 (s, 1H), 7.81 (br s, 1H), 6.83 (t, 1H, <i>J</i> = 55.3 Hz), 5.87 (dd, 1H, <i>J</i> = 7.6, 9.3 Hz), 4.11 (s, 1H), 4.07–3.94 (m, 1H), 3.68–3.56 (m, 2H), 2.97–2.89 (m, 2H), 2.88 (s, 3H), 2.20 (dt, 1H, <i>J</i> = 8.8, 11.0 Hz), 2.14–2.05 (m, 1H), 2.05–1.93 (m, 2H), 1.93–1.85 (m, 2H), 1.77–1.66 (m, 2H), 1.66–1.52 (m, 1H), 1.02 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 161.82–161.61 (m, 1C), 161.55, 161.41, 157.22, 135.42 (t, 1C<i>, J</i> = 5.9 Hz), 120.25 (t, 1C<i>, J</i> = 20.5 Hz), 112.40 (t, 1C<i>, J</i> = 235.5 Hz), 104.48 (br s, 1C), 81.16, 64.24, 48.10, 44.84 (s, 2C), 42.45, 35.73, 31.08 (br d, <i>J</i> = 6.4 Hz, 2C), 27.53, 24.38, 23.77. <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ −116.90 (s, 2F). [α]<sub class="stack">D</sub><sup class="stack">22</sup> −22.1 (<i>c</i> 0.5 CHCl<sub>3</sub>); <sup><i>t</i></sup>R 2.68 min, >99.5% ee by chiral analytical SFC/MS [Phenomenex Lux Cellulose-1 4.6 × 100 mm 3μ column; rt; mobile phase: 15% MeOH in CO<sub>2</sub>; 120 bar; 4 mL/min]; Anal. Calcd for C<sub>20</sub>H<sub>27</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub>S: C, 50.95; H, 5.77; N, 14.85; F, 8.06; S, 6.80. Found: C, 51.03; H, 5.78; N, 14.63; F, 7.92; S, 6.75. LCMS <i>m</i>/<i>z</i>: 472.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Methyl 4,4-Difluorobutanoate</h4><div class="NLM_p last">To a solution of 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum’s acid, 14.4 g, 52 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (200 mL) at 0 °C was added difluoroacetic anhydride (17 g, 98 mmol), followed by triethylamine (24.7 g, 245 mmol). The cooling bath was removed and stirring continued at rt for 3 h. The reaction was poured into a separatory funnel, washed with saturated aqueous NaCl (100 mL), dried over sodium sulfate, filtered, and concentrated to crude brown oil (24 g). This oil was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (400 mL), cooled to 0 °C, and acidified with acetic acid (38.9 g, 648 mmol). Sodium borohydride (4.50 g, 119 mmol) was added in five portions over 30 min. The reaction was refrigerated at 4 °C overnight, then cooled to 0 °C, quenched with saturated aqueous NaCl (100 mL), and stirred vigorously at 0 °C for 30 min. Additional water was added as necessary to dissolve solids, then the layers were separated. The organic layer washed with saturated aqueous NaCl (100 mL), dried over sodium sulfate, filtered, and concentrated to dryness. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (200 mL), cooled to 0 °C, washed with 4 M HCl (100 mL) and saturated aqueous NaCl (100 mL), dried over sodium sulfate, filtered, and concentrated to give 5-(2,2-difluoroethyl)-2,2-dimethyl-1,3-dioxane-4,6-dione (11.6 g, 57%, ∼90% pure by NMR) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.32 (tt, 1H, <i>J</i> = 5.0, 57.4 Hz) 3.70 (tt, 1H, <i>J</i> = 1.1, 6.2 Hz), 2.62 (ddt, 2H, <i>J</i> = 5.1, 6.2, 15.6 Hz), 1.86 (s, 3H), 1.80 (s, 3H); <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>): δ −117.59 (s, 2F). Two sealable 350 mL reaction vessels were each charged with 5-(2,2-difluoroethyl)-2,2-dimethyl-1,3-dioxane-4,6-dione (5.3 g, 25 mmol), copper powder (243 mg, 3.82 mmol), pyridine (180 mL), and methanol (20 mL). The suspensions were degassed with nitrogen (3 cycles), sealed, and heated to 120 °C for 4 h. The contents of the two vessels were combined, cooled in an ice/water bath, diluted with CH<sub>2</sub>Cl<sub>2</sub> (200 mL), and acidified to pH 2 with 6 M HCl. The organic layer was separated, dried over sodium sulfate, filtered, concentrated, and purified by silica gel chromatography (eluting with CH<sub>2</sub>Cl<sub>2</sub>) to give methyl 4,4-difluorobutanoate (5.4 g, 70%) as yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 5.93 (tt, 1H, <i>J</i> = 4.3, 56.7 Hz), 3.71 (s, 3H), 2.52 (t, 2H, <i>J</i> = 7.5 Hz), 2.17 (dtt, 2H, <i>J</i> = 4.3, 7.4, 17.3 Hz); <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ −117.73 (s, 2F); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 172.43, 116.02 (t, <i>J</i> = 238.8 Hz), 51.91, 29.29 (t, <i>J</i> = 22.0 Hz), 26.55 (t, <i>J</i> = 6.2 Hz).</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 6-(2,2-Difluoroethyl)-8-[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one</h4><div class="NLM_p last">Condensation and cyclization were achieved by using a similar method to the one used in the synthesis of 8-[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one but using methyl 4,4-difluorobutanoate (1.34 g, 9.73 mmol) instead of EtOAc and using 4-{[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]amino}-2-(methylthio)pyrimidine-5-carbaldehyde (<b>26</b>) (1.00 g, 3.74 mmol). This yielded, after purification by silica gel chromatography, 6-(2,2-difluoroethyl)-8-[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (589 mg, 44%, 70% purity by NMR) as a bright yellow solid, contaminated with a small amount of what appeared to be a vinyl fluoride/H-F elimination side product. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.63 (s, 1H), 7.59 (s, 1H), 6.13 (tt, 1H, <i>J</i> = 4.6, 57.0 Hz), 5.88 (t, 1H, <i>J</i> = 8.6 Hz), 3.15 (dt, 2H, <i>J</i> = 4.5, 16.3 Hz), 2.87–2.72 (m, 1H), 2.64 (s, 3H), 2.32–2.21 (m, 2H), 2.12–2.06 (m, 1H), 2.04–2.01 (m, 1H), 2.00–1.91 (m, 1H), 1.91–1.82 (m, 1H), 1.14 (s, 3H).</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 6-(2-Fluoropropyl)-8-((1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (<b>23</b>)</h4><div class="NLM_p last">By the method of <b>19</b>, the oxidation of 6-(2,2-difluoroethyl)-8-[(1<i>R</i>,2<i>R</i>)-2-hydroxy-2-methylcyclopentyl]-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (70% pure, 580 mg, 1.1 mmol), followed by the displacement of the resulting sulfone by 1-(methylsulfonyl)piperidin-4-amine, afforded <b>23</b> (389 mg, 70%) as a crystalline solid after recrystallization from EtOAc. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 8.58 (s, 1H), 7.70 (s, 1H), 7.48 (d, 1H, <i>J</i> = 8.4 Hz), 6.19 (tt, 1H, <i>J</i> = 4.6, 57.2 Hz), 5.89 (dd, 1H, <i>J</i> = 7.5, 9.4 Hz), 4.09–4.03 (m, 1H), 4.02–3.91 (m, 1H), 3.68–3.53 (m, 2H), 3.11–3.04 (m, 2H), 3.00 (d, 1H, <i>J</i> = 4.6 Hz), 2.96–2.88 (m, 2H), 2.87 (s, 3H), 2.22 (dt, 1H, <i>J</i> = 8.6, 11.2 Hz), 2.10 (d, 1H, <i>J</i> = 10.8 Hz), 2.04–1.99 (m, 1H), 1.96 (d, 1H, <i>J</i> = 4.2 Hz), 1.93–1.80 (m, 2H), 1.77–1.46 (m, 3H), 1.00 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ 162.87, 160.04, 158.44, 155.61, 135.39, 119.36 (t, <i>J</i> = 5.9 Hz, 1C), 115.42 (t, <i>J</i> = 239.2 Hz, 1C), 104.57, 80.27, 63.35, 47.06, 43.92, 41.55, 34.89, 34.59 (t, <i>J</i> = 24.9 Hz, 1C), 30.27/30.22, 26.68, 23.45, 22.86; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 80 °C): δ −114.46 (s, 2F); [α]<sub class="stack">D</sub><sup class="stack">22</sup> −25.1 (<i>c</i> 0.6 MeOH); >99% ee by chiral analytical SFC/MS; HRMS: calcd for C<sub>21</sub>H<sub>29</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub>S [M + H]<sup>+</sup>, 486.1981; found 486.1985.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Purification of Cell Cycle Proteins</h3><div class="NLM_p last">Purified CDK/cyclin protein complexes were made in-house for CDK1/2/4/6/9 proteins, which were found to be highly active by active site titrations. The details of this work have been previously published.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Active recombinant human GSK3β (H350L) expressed by baculovirus in Sf21 insect cells was purchased from Millipore Sigma.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Biochemical Potency Determination by a Mobility Shift Assays</h3><div class="NLM_p last">Compounds were tested toward untagged CDK/cyclin kinase complexes produced in-house with a mobility shift assay (MSA) that combines the basic principles of capillary electrophoresis in a microfluidic environment and was performed on a Caliper LabChip EZ Reader II (Caliper Life Science, Hopkinton, MA).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> For example, CDK6/cyclin D1 reactions monitor the phosphorylation of 3 μM 5-carboxyfluorescein (5 FAM)-peptide 34, “Dyrktide” (5-FAM-RRRFRPASPLRGPPK). Inhibitor <i>K</i><sub>i</sub> reactions (45 min) are initiated with 2 mM ATP after a pre-incubation (12 min, 22 °C). Inhibition constant (<i>K</i><sub>i</sub>) values are derived from a fit to the Morrison equation.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> CDK1/2/4/9 was tested similarly. A detailed method has been previously published.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Compounds were also tested toward GSK3β (H350L) with a MSA. GSK3β (H350L) reactions monitor the phosphorylation of 2 μM 5 FAM-Peptide 15 (5-FAM-KRREILSRRPpSYR-COOH). Inhibitor <i>K</i><sub>i</sub> reactions (30 min) are initiated with 40 μM ATP after a pre-incubation (15 min, 22 °C).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Cell Culture</h3><div class="NLM_p last">OVCAR3 cells were obtained from the American Type Culture Collection (ATCC) and maintained in the Roswell Park Memorial Institute (RPMI) 1640 media supplemented with 10% fetal bovine serum and penicillin–streptomycin. All cells were maintained in a humidified incubator at 37 °C with 5% CO<sub>2</sub>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Phospho-Serine 807/811 RB1 ELISA</h3><div class="NLM_p last">OVCAR3 cells were seeded in growth media and allowed to adhere at 37 °C with 5% CO<sub>2</sub> overnight. OVCAR3 cells were treated overnight with 1 mM hydroxyurea (Sigma-Aldrich) to enrich for G1/S phase cells. OVCAR3 cells were treated with the test compound for 1 h at 37 °C with 5% CO<sub>2</sub>. Cells were lysed, transferred to pre-coated and blocked anti-phospho-Ser807/811 RB1 (Cell Signaling Technology, 8516) ELISA plates for overnight incubation. Plates were washed and total RB1 detection (Cell Signaling Technology, 9309) antibody added. HRP-tagged detection antibody (Cell Signaling Technology, 7076) and Glo substrate reagent (R&D Systems, DY993) was added and incubated. Plates were read in luminescence mode and IC<sub>50</sub> values calculated using GraphPad Prism v7.02 or Activity Base v8.4.0.154 software by concentration–response nonlinear regression curve fitting utilizing a four-parameter analytical method.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> CyQuant Anti-proliferation Assay</h3><div class="NLM_p last">OVCAR3 cells were seeded in growth media in 96-well cell culture plates and allowed to adhere at 37 °C with 5% CO<sub>2</sub> overnight. The following day, cells were treated with test compounds for 6 days at 37 °C with 5% CO<sub>2</sub>. CyQUANT Direct nucleic acid stain (Invitrogen, C35011) was performed following the manufacturer’s recommendations to determine the relative viable cell numbers on the Perkin Elmer Envision 2104 Multi Label Reader with a FITC filter in bottom setting. 508/527 nM values were exported and used for IC50 calculation using GraphPad Prism v7.02 or Activity Base v8.4.0.154 software by concentration–response nonlinear regression curve fitting utilizing a four-parameter analytical method.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Protein Structure Preparation and MD Simulations</h3><div class="NLM_p">A homology model of the human CDK9 structure and a complex with cyclinT1 were constructed using Prime module in Schrödinger suite 2016–1. The reference coordinates for the complex were obtained from the Protein Data Bank: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCH">4BCH</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TN8">3TN8</a>. The modeled complex was used for ligand docking to identify favorable interactions between the ligand molecules and receptor protein. The docking simulation was performed using Glide in Schrödinger, and selected ligand poses were used for MD simulations. A co-crystal structure of CDK2/cyclinE with compound <b>19</b> (data not shown) was prepared using Protein preparation wizard in Maestro and used for simulations.</div><div class="NLM_p">MD simulations were performed using the Desmond module in Schrödinger. Each protein–ligand complex was solvated in a box of TIP3P water molecules using an orthorhombic box under periodic boundary conditions. The overall charge of each system was neutralized by adding Na<sup>+</sup> or Cl<sup>–</sup> ions.</div><div class="NLM_p last">The default system relaxation was performed before each simulation, and the temperature and pressure were kept constant at 300 K and 1 bar throughout the simulations. The Simulation Interaction Diagram tool in Schrödinger was used to analyze the detailed interactions between the ligand and protein and root-mean-square deviations (rmsd).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Animal Studies</h3><div class="NLM_p last">All animal studies and handling were performed in accordance with Pfizer’s Institutional Animal Care and Use Committee guidelines.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Single Dose Intravenous (IV) and Oral (PO) 22 (PF-06873600) PK in Mice</h3><div class="NLM_p last">Municipal water further purified by reverse osmosis and rodent diet were provided ad libitum in this single dose-fed mouse study. PF-06873600 was prepared in 10% <i>N</i>-methyl-2-pyrrolidone (NMP)/40% polyethylene glycol 300 (PEG 300)/50% 10 mM citrate buffer to yield concentrations of 0.6 and 1.0 mg/mL for the IV and PO formulations, respectively. <i>N</i> = 3 mice each were dosed at 3 mg/kg <i>via</i> tail vein (IV) and at 10 mg/kg <i>via</i> oral gavage (PO). Approximately, 0.05 mL of blood was collected <i>via</i> retro-orbital bleeds in tubes containing K3 EDTA at 0.083, 0.25, 0.5, 1, 3, 7 and, 24 h post-IV dose and 0.25, 0.5, 1, 2, 4, 7, and 24 h post PO dose. Plasma samples were obtained <i>via</i> centrifugation and sample cleanup was conducted by protein precipitation with acetonitrile that contained terfenadine as the internal standard (IS). LCMS/MS (AB Sciex QTrap 5500 and Acquity UPLC, USA) quantitation of PF-06873600 and IS was achieved with positive ion MRM transitions of 472.2/354.1 and 472.1/436, respectively. The reversed-phase chromatographic system consisted of a gradient mobile phase at a flow rate of 0.6 mL/min, containing 0.1% formic acid in water and acetonitrile and a Waters HSS T3 1.8 μM 2.1 × 50 mm column. Analyst version 1.6.2 was used to measure peak areas and peak area ratios of PF-06873600 to IS. A calibration curve was constructed from the peak area ratios (PF-06873600 to IS) with a weighted (1/<i>x</i><sup>2</sup>) linear regression using Watson version 7.5 LIMS and a calibration curve ranging between 0.5 and 1000 ng/mL. The PK parameters were determined from individual animal data using noncompartmental analysis in Watson LIMS version 7.5.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Single Dose Intravenous (IV) and Oral (PO) (22) PF-06873600 PK in Dogs</h3><div class="NLM_p last">PF-06873600 was prepared in 10% NMP/40% PEG 300/50% 10 mM citrate buffer to yield a concentration of 0. 5 mg/mL for the intravenous formulation and in 0.5% methylcellulose containing 0.1% Tween 80 at a concentration of 0.5 mg/mL for the PO formulation. <i>N</i> = 2 dogs each were dosed at 0.25 mg/kg <i>via</i> cephalic vein (IV) and at 0.5 mg/kg <i>via</i> oral gavage (PO). Approximately, 2 mL of blood was collected <i>via</i> jugular vein bleeds in tubes containing K3 EDTA at 0.083, 0.25, 0.5, 1, 2, 4, 7, and 24 h post-IV dose and 0.25, 0.5, 1, 2, 4, 7, and 24 h post-PO dose. Plasma samples were obtained <i>via</i> centrifugation and sample cleanup was conducted by protein precipitation with acetonitrile that contained propranolol as the IS. LCMS/MS (AB Sciex 6500 and Acquity UPLC, USA) quantitation of PF-06873600 and IS was achieved with positive ion MRM transitions of 472.2/374.1 and 260.2/116.2, respectively. The reversed-phase chromatographic system consisted of a gradient mobile phase at a flow rate of 0.6 mL/min containing 0.1% formic acid in water and acetonitrile and a Waters HSS T3 1.8 μM 2.1 × 50 mm column. Analyst version 1.5.2 was used to measure peak areas and peak area ratios of PF-06873600 to IS. A calibration curve was constructed from the peak area ratios (PF-06873600 to IS) with a weighted (1/<i>x</i><sup>2</sup>) linear regression using Watson version 7.5 LIMS and a calibration curve ranging between 0.5 and 1000 ng/mL. The PK parameters were determined from individual animal data using noncompartmental analysis in Watson LIMS version 7.5.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Tumor Growth Inhibition Studies</h3><div class="NLM_p last">Athymic immunocompromised female mice between 6 and 8 weeks of age were implanted with tumor cells from the various Champions TumorGraft models. After the tumors reached 1000–1500 mm<sup>3</sup>, they were harvested and the tumor fragments were implanted SC in the left flank of the female study mice. Each animal was implanted with a passage lot 7 for CTG-0192, CTG-0464 tumor growth was monitored twice a week using digital calipers and the tumor volume (TV) was calculated using the formula (0.52 × [length × width<sup>2</sup>]). When the TV reached an average volume of 150–300 mm<sup>3</sup>, animals were matched by the tumor size and assigned into the vehicle control and PF-06873600 30 mg/kg groups (<i>n</i> = 5) and dosing was initiated on day 0 using a BID schedule for vehicle control and PF-06873600. After the initiation of dosing on day 0, animals were weighed twice per week using a digital scale and TV was measured twice per week and also on the final day of study or on the day moribund animals were euthanized. The study was terminated when the mean tumor volume of the vehicle control group reached 1500 mm<sup>3</sup> or day 60, whichever happened sooner.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Single-Crystal X-ray Structure of 22 at 100 K</h3><div class="NLM_p">The single-crystal X-ray diffraction studies were carried out on a Bruker Kappa APEX-II CCD diffractometer equipped with Cu Kα radiation (λ = 1.5478). Crystals of the subject compound were grown by dissolving approximately 1 mg of the sample in 350 μ L of dichloroethane, which was then vapor diffused with pentane over 2 days. A 0.251 × 0.079 × 0.064 mm piece of a colorless block was mounted on a cryoloop with paratone oil. Data were collected in a nitrogen gas stream at 100(2) K using ϕ and ϖ scans. Crystal-to-detector distance was 40 mm using variable exposure time (2s–5s), depending on θ with a scan width of 2.0°. Data collection was 99.5% complete to 68.00° in θ. A total of 37376 reflections were collected covering the indices, −29 ≤ <i>h</i> ≤ 30, −7 ≤ <i>k</i> ≤ 7, −30 ≤ l ≤ 28. 7702 reflections were found to be symmetry independent, with a <i>R</i><sub>int</sub> of 0.0601. Indexing and unit cell refinement indicated a <i>C</i>-centered, monoclinic lattice. The space group was found to be <i>C</i>2. The data were integrated using the Bruker SAINT software program and scaled using the SADABS software program. Solution by direct methods (SHELXT) produced a complete phasing model consistent with the proposed structure.</div><div class="NLM_p last">All nonhydrogen atoms were refined anisotropically by full-matrix least-squares (SHELXL-2014). All hydrogen atoms were placed using a riding model. Their positions were constrained relative to their parent atom using the appropriate HFIX command in SHELXL-2014. The absolute stereochemistry of the molecule was established by anomalous dispersion using the Parson’s method with a Flack parameter of 0.022(12). Crystallographic data are summarized in the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00159/suppl_file/jm1c00159_si_001.csv" class="ext-link">Supporting Information</a>.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> CDK2/CyclinE1 Protein Production and Crystallography</h3><div class="NLM_p last">The cDNAs encoding human full-length CDK2 and residues 96–378 of human cyclin E1 with an N-terminal His tag were synthesized and cloned into pFastBack1 and pKRIC-N6, respectively, and then expressed separately in insect cells. Cells were mixed, lysed in lysis buffer (40 mM HEPES, pH 7.5, 150 mM NaCl, 0.01% 1-thioglycerol, and 25 mM imidazole), and lysates were cleared by centrifugation. The complex was purified on a Probond column with lysis buffer wash, followed by step elution at 250 mM imidazole. His tags were cleaved from cyclinE1 with TEV and dialyzed overnight. The proteins flowed over a Probond column again. The complexes were phosphorylated by CDK7/cyclinH1/Mat1 in a final buffer supplemented with 5 mM ATP and 10 mM MgCl2 and incubated for 1 h at room temperature. The proteins flowed over a Probond column to remove the His-tagged CDK7 complex; the complex was then loaded on a Superdex 200 in a final buffer of 40 mM HEPES, pH7.5, 150 mM NaCl, 0.01% 1-thioglycerol. The phosphorylated CDK2/cyclinE1 complex at a concentration of 13.25 mg/mL (combined) was filtered with a low-protein binding 0.45 μM membrane and set up for crystallization in MRC 48-well plates. Sitting drops in a 1:1 ratio (protein/well solution) with a well solution containing 0.1 M MES at pH 6, 0.18 M magnesium formate, and 9.0% (w/v) PEG 20000 were incubated at 21 °C for 24 h. After one day, drops were streak-seeded using a probe that was dipped into a “seed stock” solution (a previously grown CDK2/cyclinE1 crystal crushed into 1 mL of well solution). Data quality crystals grew 5–7 days after seeding. Apo crystals were then introduced to 1 mM (final concentration) of the inhibitor compound (<b>2</b>, <b>4</b>, or <b>22</b>) in 100% DMSO, <i>in situ</i>. After a 2 h soak, the crystals were then placed into a cryoprotectant-containing well solution + 22% glycerol before they were flash-frozen in liquid N2. X-ray diffraction data were collected at the Advanced Photon Source beamline 17-ID and processed with autoPROC from Global Phasing.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Structure solution and refinement were done using BUSTER<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> and COOT.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The final refined 2.4 Å resolution structure with <b>22</b> has been deposited to the Protein Data Bank (<a href="http://www.pdb.org" class="extLink">www.pdb.org</a>) with ID code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KJS">7KJS</a>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00159" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84245" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84245" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00159?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00159</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00159/suppl_file/jm1c00159_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">CDK2/cyclinE1/inhibitor complex crystal structure statistics for <b>22</b>, single-crystal X-ray structure data for <b>22</b>, <i>in vitro</i> biochemical activity of <b>22</b>, kinase inhibition panel data for <b>22</b>, <sup>1</sup>H and <sup>13</sup>C NMR spectra of compounds <b>8</b> and <b>22</b>, and <sup>19</sup>F NMR spectrum of <b>22</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00159/suppl_file/jm1c00159_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00159/suppl_file/jm1c00159_si_001.csv">jm1c00159_si_001.csv (2.64 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00159/suppl_file/jm1c00159_si_002.pdf">jm1c00159_si_002.pdf (809.71 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00159" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20344" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20344" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin D. Freeman-Cook</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-9014-2309" title="Orcid link">https://orcid.org/0000-0001-9014-2309</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f69d93809f98d8908493939b9798db9599999db686909f8c9384d895999b"><span class="__cf_email__" data-cfemail="deb5bba8b7b0f0b8acbbbbb3bfb0f3bdb1b1b59eaeb8b7a4bbacf0bdb1b3">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert L. Hoffman</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-2030-9094" title="Orcid link">https://orcid.org/0000-0002-2030-9094</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas C. Behenna</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Britton Boras</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jordan Carelli</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wade Diehl</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rose Ann Ferre</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">You-Ai He</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Hui</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Buwen Huang</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nanni Huser</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rhys Jones</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan E. Kephart</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Lapek</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-6578-5350" title="Orcid link">https://orcid.org/0000-0002-6578-5350</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michele McTigue</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nichol Miller</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brion W. Murray</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Asako Nagata</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa Nguyen</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sherry Niessen</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sacha Ninkovic</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Inish O’Doherty</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martha A. Ornelas</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Solowiej</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott C. Sutton</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Khanh Tran</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elaine Tseng</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ravi Visswanathan</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meirong Xu</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luke Zehnder</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qin Zhang</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cathy Zhang</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Dann</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52272" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52272" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank the Pfizer La Jolla Discovery Technology group who were responsible for all HRMS, preparative HPLC, and SFC separations. The authors would also like to thank Alex Yanovsky and the UCSD X-ray facility for small-molecule X-ray crystal structure determination. We also thank Martin Edwards for extraordinary mentorship, advice, and editing of the manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">APCI</td><td class="NLM_def"><p class="first last">atmospheric-pressure chemical ionization</p></td></tr><tr><td class="NLM_term">br s</td><td class="NLM_def"><p class="first last">broad singlet</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">d</td><td class="NLM_def"><p class="first last">doublet</p></td></tr><tr><td class="NLM_term">dd</td><td class="NLM_def"><p class="first last">doublet of doublets</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">dt</td><td class="NLM_def"><p class="first last">doublet of triplets</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">ee</td><td class="NLM_def"><p class="first last">enantiomeric excess</p></td></tr><tr><td class="NLM_term">ER+</td><td class="NLM_def"><p class="first last">estrogen receptor positive</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">GI</td><td class="NLM_def"><p class="first last">gastrointestinal</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">hour(s)</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term">LiHMDS</td><td class="NLM_def"><p class="first last">lithium hexamethyldisilazide</p></td></tr><tr><td class="NLM_term">LOO</td><td class="NLM_def"><p class="first last">leave-one-out</p></td></tr><tr><td class="NLM_term">MDCK-LE</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney low efflux cell line</p></td></tr><tr><td class="NLM_term">MD</td><td class="NLM_def"><p class="first last">molecular dynamics</p></td></tr><tr><td class="NLM_term">MMP</td><td class="NLM_def"><p class="first last">matched molecular pair</p></td></tr><tr><td class="NLM_term">MSA</td><td class="NLM_def"><p class="first last">mobility shift assay</p></td></tr><tr><td class="NLM_term">MTBE</td><td class="NLM_def"><p class="first last">methyl <i>tert</i>-butyl ether</p></td></tr><tr><td class="NLM_term">min</td><td class="NLM_def"><p class="first last">minute(s)</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small cell lung cancer</p></td></tr><tr><td class="NLM_term">ppm</td><td class="NLM_def"><p class="first last">part per million</p></td></tr><tr><td class="NLM_term">q</td><td class="NLM_def"><p class="first last">quartet</p></td></tr><tr><td class="NLM_term">quint</td><td class="NLM_def"><p class="first last">quintet</p></td></tr><tr><td class="NLM_term">RB1</td><td class="NLM_def"><p class="first last">retinoblastoma protein</p></td></tr><tr><td class="NLM_term">rmsd</td><td class="NLM_def"><p class="first last">root-mean-squared deviation of atomic distance</p></td></tr><tr><td class="NLM_term">RRCK</td><td class="NLM_def"><p class="first last">Ralph Russ canine kidney cell based</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">s</td><td class="NLM_def"><p class="first last">singlet</p></td></tr><tr><td class="NLM_term">sept</td><td class="NLM_def"><p class="first last">septet</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">t</td><td class="NLM_def"><p class="first last">triplet</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TIC</td><td class="NLM_def"><p class="first last">total ion chromatogram</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68781" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68781" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 58 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaldis, P.</span></span> <span> </span><span class="NLM_article-title">Cdks, cyclins; CKIs roles beyond cell cycle regulation</span>. <i>Development</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">3079</span>– <span class="NLM_lpage">3093</span>, <span class="refDoi"> DOI: 10.1242/dev.091744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1242%2Fdev.091744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=23861057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGktL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2013&pages=3079-3093&author=S.+Limauthor=P.+Kaldis&title=Cdks%2C+cyclins%3B+CKIs+roles+beyond+cell+cycle+regulation&doi=10.1242%2Fdev.091744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cdks, cyclins and CKIs: roles beyond cell cycle regulation</span></div><div class="casAuthors">Lim, Shuhui; Kaldis, Philipp</div><div class="citationInfo"><span class="NLM_cas:title">Development (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3079-3093</span>CODEN:
                <span class="NLM_cas:coden">DEVPED</span>;
        ISSN:<span class="NLM_cas:issn">0950-1991</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinases (Cdks) are serine/threonine kinases and their catalytic activities are modulated by interactions with cyclins and Cdk inhibitors (CKIs).  Close cooperation between this trio is necessary for ensuring orderly progression through the cell cycle.  In addn. to their well-established function in cell cycle control, it is becoming increasingly apparent that mammalian Cdks, cyclins and CKIs play indispensable roles in processes such as transcription, epigenetic regulation, metab., stem cell self-renewal, neuronal functions and spermatogenesis.  Even more remarkably, they can accomplish some of these tasks individually, without the need for Cdk/cyclin complex formation or kinase activity.  In this Review, we discuss the latest revelations about Cdks, cyclins and CKIs with the goal of showcasing their functional diversity beyond cell cycle regulation and their impact on development and disease in mammals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp5LNcD6NywLVg90H21EOLACvtfcHk0lgKUEBLFZfw9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGktL%252FF&md5=8095fc798a0e7efeab60d36ee414596f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1242%2Fdev.091744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fdev.091744%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%26aulast%3DKaldis%26aufirst%3DP.%26atitle%3DCdks%252C%2520cyclins%253B%2520CKIs%2520roles%2520beyond%2520cell%2520cycle%2520regulation%26jtitle%3DDevelopment%26date%3D2013%26volume%3D140%26spage%3D3079%26epage%3D3093%26doi%3D10.1242%2Fdev.091744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinases</span>. <i>Genome Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">122</span>, <span class="refDoi"> DOI: 10.1186/gb4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1186%2Fgb4184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=25180339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=122&author=M.+Malumbres&title=Cyclin-dependent+kinases&doi=10.1186%2Fgb4184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinases</span></div><div class="casAuthors">Malumbres Marcos</div><div class="citationInfo"><span class="NLM_cas:title">Genome biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">122</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are protein kinases characterized by needing a separate subunit - a cyclin - that provides domains essential for enzymatic activity.  CDKs play important roles in the control of cell division and modulate transcription in response to several extra- and intracellular cues.  The evolutionary expansion of the CDK family in mammals led to the division of CDKs into three cell-cycle-related subfamilies (Cdk1, Cdk4 and Cdk5) and five transcriptional subfamilies (Cdk7, Cdk8, Cdk9, Cdk11 and Cdk20).  Unlike the prototypical Cdc28 kinase of budding yeast, most of these CDKs bind one or a few cyclins, consistent with functional specialization during evolution.  This review summarizes how, although CDKs are traditionally separated into cell-cycle or transcriptional CDKs, these activities are frequently combined in many family members.  Not surprisingly, deregulation of this family of proteins is a hallmark of several diseases, including cancer, and drug-targeted inhibition of specific members has generated very encouraging results in clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQodaug4zJdjgHqQV89nF-2fW6udTcc2ebmrMieYnD3Lrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D&md5=9fd79ec8f495f712bada681b0a0b5afe</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1186%2Fgb4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb4184%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26atitle%3DCyclin-dependent%2520kinases%26jtitle%3DGenome%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D122%26doi%3D10.1186%2Fgb4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. A.</span></span> <span> </span><span class="NLM_article-title">Targeting the cell cycle: a new approach to cancer therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">9408</span>– <span class="NLM_lpage">9421</span>, <span class="refDoi"> DOI: 10.1200/jco.2005.01.5594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1200%2FJCO.2005.01.5594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=16361640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1ymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=9408-9421&author=G.+K.+Schwartzauthor=M.+A.+Shah&title=Targeting+the+cell+cycle%3A+a+new+approach+to+cancer+therapy&doi=10.1200%2Fjco.2005.01.5594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cell cycle: a new approach to cancer therapy</span></div><div class="casAuthors">Schwartz, Gary K.; Shah, Manish A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9408-9421</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The cell cycle represents a series of tightly integrated events that allow the cell to grow and proliferate.  Crit. parts of the cell cycle machinery are the cyclin-dependent kinases (CDKs), which, when activated, provide a means for the cell to move from one phase of the cell cycle to the next.  The CDKs are regulated pos. by cyclins and regulated neg. by naturally occurring CDK inhibitors (CDKIs).  Cancer represents a dysregulation of the cell cycle such that cells that overexpress cyclins or do not express the CDKIs continue to undergo unregulated cell growth.  The cell cycle also serves to protect the cell from DNA damage.  Thus, cell cycle arrest, in fact, represents a survival mechanism that provides the tumor cell the opportunity to repair its own damaged DNA.  Thus, abrogation of cell cycle checkpoints, before DNA repair is complete, can activate the apoptotic cascade, leading to cell death.  Now in clin. trials are a series of targeted agents that directly inhibit the CDKs, inhibit unrestricted cell growth, and induce growth arrest.  Recent attention has also focused on these drugs as inhibitors of transcription.  In addn., there are now agents that abrogate the cell cycle checkpoints at crit. time points that make the tumor cell susceptible to apoptosis.  An understanding of the cell cycle is crit. to understanding how best to clin. develop these agents, both as single agents and in combination with chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAmpAkG9yEhLVg90H21EOLACvtfcHk0lgKUEBLFZfw9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1ymtA%253D%253D&md5=e3085a43360bfd59b1be9cbd30d581fa</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.01.5594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.01.5594%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DShah%26aufirst%3DM.%2BA.%26atitle%3DTargeting%2520the%2520cell%2520cycle%253A%2520a%2520new%2520approach%2520to%2520cancer%2520therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D9408%26epage%3D9421%26doi%3D10.1200%2Fjco.2005.01.5594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pines, J.</span></span> <span> </span><span class="NLM_article-title">Cyclins and cancer II: cyclin D and CDK inhibitors come of age</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(94)90543-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2F0092-8674%2894%2990543-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=7954824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADyaK2MXit1Glu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1994&pages=573-582&author=T.+Hunterauthor=J.+Pines&title=Cyclins+and+cancer+II%3A+cyclin+D+and+CDK+inhibitors+come+of+age&doi=10.1016%2F0092-8674%2894%2990543-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclins and cancer II: cyclin D and CDK inhibitors come of age</span></div><div class="casAuthors">Hunter, Tony; Pines, Jonathon</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">573-82</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with > 150 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGu8XRAqRgKLVg90H21EOLACvtfcHk0liv6gmLA5aU9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXit1Glu7k%253D&md5=0aded71b9c6d8ff7278648b844e63b67</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2894%2990543-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252894%252990543-6%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DPines%26aufirst%3DJ.%26atitle%3DCyclins%2520and%2520cancer%2520II%253A%2520cyclin%2520D%2520and%2520CDK%2520inhibitors%2520come%2520of%2520age%26jtitle%3DCell%26date%3D1994%26volume%3D79%26spage%3D573%26epage%3D582%26doi%3D10.1016%2F0092-8674%2894%2990543-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1038/35106065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1038%2F35106065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=11902577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=222-231&author=M.+Malumbresauthor=M.+Barbacid&title=Milestones+in+cell+division%3A+to+cycle+or+not+to+cycle%3A+a+critical+decision+in+cancer&doi=10.1038%2F35106065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor cells undergo uncontrolled proliferation, yet tumors most often originate from adult tissues, in which most cells are quiescent.  So, the proliferative advantage of tumor cells arises from their ability to bypass quiescence.  This can be due to increased mitogenic signaling and/or alterations that lower the threshold required for cell-cycle commitment.  Understanding the mol. mechanisms that underlie this commitment should provide important insights into how normal cells become tumorigenic and how new anticancer strategies can be devised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI2EOLFB2ULbVg90H21EOLACvtfcHk0liv6gmLA5aU9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D&md5=2bd8961854332a30c814f8ac2f9bd6f4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2F35106065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35106065%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DMilestones%2520in%2520cell%2520division%253A%2520to%2520cycle%2520or%2520not%2520to%2520cycle%253A%2520a%2520critical%2520decision%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D222%26epage%3D231%26doi%3D10.1038%2F35106065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of cancer: the next generation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+cancer%3A+the+next+generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0liv6gmLA5aU9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520cancer%253A%2520the%2520next%2520generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1038/nrc2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm&doi=10.1038%2Fnrc2602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0liv6gmLA5aU9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166%26doi%3D10.1038%2Fnrc2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musgrove, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barraclough, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, R. L.</span></span> <span> </span><span class="NLM_article-title">Cyclin D as a therapeutic target in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1038/nrc3090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1038%2Fnrc3090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=21734724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Srsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=558-572&author=E.+A.+Musgroveauthor=C.+E.+Caldonauthor=J.+Barracloughauthor=A.+Stoneauthor=R.+L.+Sutherland&title=Cyclin+D+as+a+therapeutic+target+in+cancer&doi=10.1038%2Fnrc3090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin D as a therapeutic target in cancer</span></div><div class="casAuthors">Musgrove, Elizabeth A.; Caldon, C. Elizabeth; Barraclough, Jane; Stone, Andrew; Sutherland, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">558-572</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression.  The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target.  Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofR_LZiUkU-LVg90H21EOLACvtfcHk0lg91V7KR7IwVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Srsr0%253D&md5=1bc2dcea427c5650263a5438ecddb5f9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc3090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3090%26sid%3Dliteratum%253Aachs%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26aulast%3DCaldon%26aufirst%3DC.%2BE.%26aulast%3DBarraclough%26aufirst%3DJ.%26aulast%3DStone%26aufirst%3DA.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26atitle%3DCyclin%2520D%2520as%2520a%2520therapeutic%2520target%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D558%26epage%3D572%26doi%3D10.1038%2Fnrc3090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">VanArsdale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arndt, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span> <span> </span><span class="NLM_article-title">Molecular Pathways: Targeting the cyclin D-CDK4/6 axis for cancer treatment</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2905</span>– <span class="NLM_lpage">2910</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-14-0816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1158%2F1078-0432.CCR-14-0816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=25941111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A280%3ADC%252BC2Mfgs1Wisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2905-2910&author=T.+VanArsdaleauthor=C.+Boshoffauthor=K.+T.+Arndtauthor=R.+T.+Abraham&title=Molecular+Pathways%3A+Targeting+the+cyclin+D-CDK4%2F6+axis+for+cancer+treatment&doi=10.1158%2F1078-0432.ccr-14-0816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment</span></div><div class="casAuthors">VanArsdale Todd; Abraham Robert T; Boshoff Chris; Arndt Kim T</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2905-10</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">Cancer cells bypass normal controls over mitotic cell-cycle progression to achieve a deregulated state of proliferation.  The retinoblastoma tumor suppressor protein (pRb) governs a key cell-cycle checkpoint that normally prevents G1-phase cells from entering S-phase in the absence of appropriate mitogenic signals.  Cancer cells frequently overcome pRb-dependent growth suppression via constitutive phosphorylation and inactivation of pRb function by cyclin-dependent kinase (CDK) 4 or CDK6 partnered with D-type cyclins.  Three selective CDK4/6 inhibitors, palbociclib (Ibrance; Pfizer), ribociclib (Novartis), and abemaciclib (Lilly), are in various stages of development in a variety of pRb-positive tumor types, including breast cancer, melanoma, liposarcoma, and non-small cell lung cancer.  The emerging, positive clinical data obtained to date finally validate the two decades-old hypothesis that the cyclin D-CDK4/6 pathway is a rational target for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6Rstlwhprintlzo9xastyfW6udTcc2eZ3kcK9qPYZ37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mfgs1Wisg%253D%253D&md5=5b3443d0ec58550d8ef4f1993726fb5e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0816%26sid%3Dliteratum%253Aachs%26aulast%3DVanArsdale%26aufirst%3DT.%26aulast%3DBoshoff%26aufirst%3DC.%26aulast%3DArndt%26aufirst%3DK.%2BT.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26atitle%3DMolecular%2520Pathways%253A%2520Targeting%2520the%2520cyclin%2520D-CDK4%252F6%2520axis%2520for%2520cancer%2520treatment%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2905%26epage%3D2910%26doi%3D10.1158%2F1078-0432.ccr-14-0816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustachio, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekula, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freemantle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dmitrovsky, E.</span></span> <span> </span><span class="NLM_article-title">Specific CP110 phosphorylation sites mediate anaphase catastrophe after CDK2 inhibition: evidence for cooperation with USP33 knockdown</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2576</span>– <span class="NLM_lpage">2585</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-15-0443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1158%2F1535-7163.MCT-15-0443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=26304236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOgt7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2576-2585&author=S.+Huauthor=Y.+Luauthor=B.+Orrauthor=K.+Godekauthor=L.+M.+Mustachioauthor=M.+Kawakamiauthor=D.+Sekulaauthor=D.+A.+Comptonauthor=S.+Freemantleauthor=E.+Dmitrovsky&title=Specific+CP110+phosphorylation+sites+mediate+anaphase+catastrophe+after+CDK2+inhibition%3A+evidence+for+cooperation+with+USP33+knockdown&doi=10.1158%2F1535-7163.mct-15-0443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown</span></div><div class="casAuthors">Hu, Shanhu; Lu, Yun; Orr, Bernardo; Godek, Kristina; Mustachio, Lisa Maria; Kawakami, Masanori; Sekula, David; Compton, Duane A.; Freemantle, Sarah; Dmitrovsky, Ethan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2576-2585</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Chromosomal instability (CIN) is a hallmark of solid tumor biol. and is implicated in carcinogenesis.  Preferentially eliminating malignant cells by targeting CIN and aneuploidy is an attractive antineoplastic strategy.  We previously reported that CDK2 antagonism causes lung cancer cells to undergo anaphase catastrophe and apoptosis through inhibition of phosphorylation of the centrosomal protein CP110.  Cells with activating KRAS mutations were particularly sensitive to CDK2 inhibition due to downregulation of CP110 protein levels.  This study investigated mechanisms of CDK2 antagonism that mediate anaphase catastrophe via changes in CP110 protein expression and how activated KRAS affects CP110 levels in lung cancers.  Site-directed mutagenesis revealed candidate CDK phosphorylation sites of CP110 (residues Ser 170 and Thr 194) crit. for conferring anaphase catastrophe by altering centrosome clustering in mitosis.  Intriguingly, KRAS mutation can promote CP110 protein degrdn. by upregulating the ubiquitin ligase SCFcyclinF, which targets CP110 protein for destabilization.  Finally, CDK2 inhibitor response was enhanced when combined with knockdown of the deubiquitinase USP33 that in turn accelerates CP110 protein degrdn.  Thus, this study provides mol. pharmacol. insights into how CP110 expression regulates response to CDK2 inhibition.  An improved understanding of in vitro antineoplastic mechanisms of combining CDK2 antagonism with induced CP110 repression provides a rationale for exploring clin. consequences of this strategy.  Taken together, preclin. findings obtained from combining CDK2 inhibition with USP33 repression have implications for treating patients with non-small cell lung cancers.  Mol Cancer Ther; 14(11); 2576-85. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWB2T3vMoX87Vg90H21EOLACvtfcHk0lg91V7KR7IwVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOgt7zJ&md5=3426ae1dcbdd54def483fb95afda5eaa</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0443%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DOrr%26aufirst%3DB.%26aulast%3DGodek%26aufirst%3DK.%26aulast%3DMustachio%26aufirst%3DL.%2BM.%26aulast%3DKawakami%26aufirst%3DM.%26aulast%3DSekula%26aufirst%3DD.%26aulast%3DCompton%26aufirst%3DD.%2BA.%26aulast%3DFreemantle%26aufirst%3DS.%26aulast%3DDmitrovsky%26aufirst%3DE.%26atitle%3DSpecific%2520CP110%2520phosphorylation%2520sites%2520mediate%2520anaphase%2520catastrophe%2520after%2520CDK2%2520inhibition%253A%2520evidence%2520for%2520cooperation%2520with%2520USP33%2520knockdown%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D2576%26epage%3D2585%26doi%3D10.1158%2F1535-7163.mct-15-0443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molenaar, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebus, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geerts, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koster, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentijn, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerhout, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versteeg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H. N.</span></span> <span> </span><span class="NLM_article-title">Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">12968</span>– <span class="NLM_lpage">12973</span>, <span class="refDoi"> DOI: 10.1073/pnas.0901418106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1073%2Fpnas.0901418106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=19525400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=12968-12973&author=J.+J.+Molenaarauthor=M.+E.+Ebusauthor=D.+Geertsauthor=J.+Kosterauthor=F.+Lamersauthor=L.+J.+Valentijnauthor=E.+M.+Westerhoutauthor=R.+Versteegauthor=H.+N.+Caron&title=Inactivation+of+CDK2+is+synthetically+lethal+to+MYCN+over-expressing+cancer+cells&doi=10.1073%2Fpnas.0901418106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells</span></div><div class="casAuthors">Molenaar, Jan J.; Ebus, Marli E.; Geerts, Dirk; Koster, Jan; Lamers, Fieke; Valentijn, Linda J.; Westerhout, Ellen M.; Versteeg, Rogier; Caron, Huib N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">12968-12973</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Two genes have a synthetically lethal relationship when the silencing or inhibiting of 1 gene is only lethal in the context of a mutation or activation of the second gene.  This situation offers an attractive therapeutic strategy, as inhibition of such a gene will only trigger cell death in tumor cells with an activated second oncogene but spare normal cells without activation of the second oncogene.  Here we present evidence that CDK2 is synthetically lethal to neuroblastoma cells with MYCN amplification and over-expression.  Neuroblastomas are childhood tumors with an often lethal outcome.  Twenty percent of the tumors have MYCN amplification, and these tumors are ultimately refractory to any therapy.  Targeted silencing of CDK2 by 3 RNA interference techniques induced apoptosis in MYCN-amplified neuroblastoma cell lines, but not in MYCN single copy cells.  Silencing of MYCN abrogated this apoptotic response in MYCN-amplified cells.  Inversely, silencing of CDK2 in MYCN single copy cells did not trigger apoptosis, unless a MYCN transgene was activated.  The MYCN induced apoptosis after CDK2 silencing was accompanied by nuclear stabilization of P53, and mRNA profiling showed up-regulation of P53 target genes.  Silencing of P53 rescued the cells from MYCN-driven apoptosis.  The synthetic lethality of CDK2 silencing in MYCN activated neuroblastoma cells can also be triggered by inhibition of CDK2 with a small mol. drug.  Treatment of neuroblastoma cells with roscovitine, a CDK inhibitor, at clin. achievable concns. induced MYCN-dependent apoptosis.  The synthetically lethal relationship between CDK2 and MYCN indicates CDK2 inhibitors as potential MYCN-selective cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr48u4K0MeszLVg90H21EOLACvtfcHk0lielq4tG-Mwyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKru77P&md5=016ebf4ccc1f5c6e3b965e999cca58c7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0901418106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0901418106%26sid%3Dliteratum%253Aachs%26aulast%3DMolenaar%26aufirst%3DJ.%2BJ.%26aulast%3DEbus%26aufirst%3DM.%2BE.%26aulast%3DGeerts%26aufirst%3DD.%26aulast%3DKoster%26aufirst%3DJ.%26aulast%3DLamers%26aufirst%3DF.%26aulast%3DValentijn%26aufirst%3DL.%2BJ.%26aulast%3DWesterhout%26aufirst%3DE.%2BM.%26aulast%3DVersteeg%26aufirst%3DR.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26atitle%3DInactivation%2520of%2520CDK2%2520is%2520synthetically%2520lethal%2520to%2520MYCN%2520over-expressing%2520cancer%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D12968%26epage%3D12973%26doi%3D10.1073%2Fpnas.0901418106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widlund, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horstmann, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. E.</span></span> <span> </span><span class="NLM_article-title">Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2004.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.ccr.2004.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=15607961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktVantA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=565-576&author=J.+Duauthor=H.+R.+Widlundauthor=M.+A.+Horstmannauthor=S.+Ramaswamyauthor=K.+Rossauthor=W.+E.+Huberauthor=E.+K.+Nishimuraauthor=T.+R.+Golubauthor=D.+E.+Fisher&title=Critical+role+of+CDK2+for+melanoma+growth+linked+to+its+melanocyte-specific+transcriptional+regulation+by+MITF&doi=10.1016%2Fj.ccr.2004.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF</span></div><div class="casAuthors">Du, Jinyan; Widlund, Hans R.; Horstmann, Martin A.; Ramaswamy, Sridhar; Ross, Ken; Huber, Wade E.; Nishimura, Emi K.; Golub, Todd R.; Fisher, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-576</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The genomic organization of the CDK2 gene, which overlaps the melanocyte-specific gene SILV/PMEL17, poses an interesting regulatory challenge.  The authors show that, despite its ubiquitous expression, CDK2 exhibits tissue-specific regulation by the essential melanocyte lineage transcription factor MITF.  In addn., functional studies revealed this regulation to be crit. for maintaining CDK2 kinase activity and growth of melanoma cells.  Expression levels of MITF and CDK2 are tightly correlated in primary melanoma specimens and predict susceptibility to the CDK2 inhibitor roscovitine.  CDK2 depletion suppressed growth and cell cycle progression in melanoma, but not other cancers, corroborating previous results.  Collectively, these data indicate that CDK2 activity in melanoma is largely maintained at the transcriptional level by MITF, and unlike other malignancies, it may be a suitable drug target in melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzGPfKfEQmWLVg90H21EOLACvtfcHk0lielq4tG-Mwyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktVantA%253D%253D&md5=0fdd6a6f788af5fb429c464358782881</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2004.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2004.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DWidlund%26aufirst%3DH.%2BR.%26aulast%3DHorstmann%26aufirst%3DM.%2BA.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DK.%26aulast%3DHuber%26aufirst%3DW.%2BE.%26aulast%3DNishimura%26aufirst%3DE.%2BK.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DFisher%26aufirst%3DD.%2BE.%26atitle%3DCritical%2520role%2520of%2520CDK2%2520for%2520melanoma%2520growth%2520linked%2520to%2520its%2520melanocyte-specific%2520transcriptional%2520regulation%2520by%2520MITF%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D6%26spage%3D565%26epage%3D576%26doi%3D10.1016%2Fj.ccr.2004.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ying, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin-dependent degradation of cdk2 drives the therapeutic differentiation of aml by targeting prdx2</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">2698</span>– <span class="NLM_lpage">2711</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-10-813139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1182%2Fblood-2017-10-813139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=29720484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOiu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=2698-2711&author=M.+Yingauthor=X.+Shaoauthor=H.+Jingauthor=Y.+Liuauthor=X.+Qiauthor=J.+Caoauthor=Y.+Chenauthor=S.+Xiangauthor=H.+Songauthor=R.+Huauthor=G.+Weiauthor=B.+Yangauthor=Q.+He&title=Ubiquitin-dependent+degradation+of+cdk2+drives+the+therapeutic+differentiation+of+aml+by+targeting+prdx2&doi=10.1182%2Fblood-2017-10-813139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-dependent degradation of cdk2 drives the therapeutic differentiation of aml by targeting prdx2</span></div><div class="casAuthors">Ying, Meidan; Shao, Xuejing; Jing, Hui; Liu, Yujia; Qi, Xiaotian; Cao, Ji; Chen, Yingqian; Xiang, Senfeng; Song, Hua; Hu, Ronggui; Wei, Guoqing; Yang, Bo; He, Qiaojun</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2698-2711</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A distinct hallmark of acute myeloid leukemia (AML) is the arrest of leukemic myeloblasts at an immature stage of development.  Therapies that overcome differentiation arrest have emerged as a powerful strategy for treating AML, but targeting leukemia differentiation remains challenging, mainly because of an incomplete mechanistic understanding of the process.  Here, we unveil a new role for cyclin-dependent kinase 2 (CDK2) in blocking myeloid differentiation in AML.  We show that among several interphase CDK, only CDK2 undergoes ubiquitin-dependent proteasome degrdn., which is accompanied by AML cell differentiation.  By using the yeast 2-hybrid system and functional analyses, KLHL6 was identified as a specific E3 ubiquitin ligase regulating the degrdn. of CDK2.  Importantly, inhibiting CDK2, but not other cyclin-dependent kinases CDK1/4/6, effectively induced granulocytic differentiation in AML cell lines and 5 major subtypes of primary patientderived AML samples.  Mechanistically, CDK2 depletion led to the reactivation of differentiation pathway translation, and the differentiation blockade function of CDK2 may be achieved directly by maintaining the activity of PRDX2.  Finally, CDK2 depletion arrested tumor growth of AML cells in nude mice and extended survival in both AML cell line and PDX-AML cells derived xenograft mouse models.  Thus, our work not only provides exptl. evidence for validating CDK2 as a potential therapeutic target for differentiation, but also uncovers the biol. function of the CDK2-PRDX2 axis in blocking AML differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL-1GnzdaOHrVg90H21EOLACvtfcHk0lhZnr_uE6IKIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOiu77M&md5=0f3345fd7dba32cf4809bfb302a037dd</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-10-813139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-10-813139%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DM.%26aulast%3DShao%26aufirst%3DX.%26aulast%3DJing%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DQ.%26atitle%3DUbiquitin-dependent%2520degradation%2520of%2520cdk2%2520drives%2520the%2520therapeutic%2520differentiation%2520of%2520aml%2520by%2520targeting%2520prdx2%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D2698%26epage%3D2711%26doi%3D10.1182%2Fblood-2017-10-813139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span> <span> </span><span class="NLM_article-title">HOXA7 stimulates human hepatocellular carcinoma proliferation through cyclin E1/CDK2</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">990</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.3892/or.2014.3668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.3892%2For.2014.3668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=25501982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVyiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=990-996&author=Y.+Liauthor=X.+H.+Yangauthor=S.+J.+Fangauthor=C.+F.+Qinauthor=R.+L.+Sunauthor=Z.+Y.+Liuauthor=B.+Y.+Jiangauthor=X.+Wuauthor=G.+Li&title=HOXA7+stimulates+human+hepatocellular+carcinoma+proliferation+through+cyclin+E1%2FCDK2&doi=10.3892%2For.2014.3668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">HOXA7 stimulates human hepatocellular carcinoma proliferation through cyclin E1/CDK2</span></div><div class="casAuthors">Li, Yuehui; Yang, Xiao Hui; Fang, Shu Juang; Qin, Chang Fei; Sun, Rui Li; Liu, Zhao Yang; Jiang, Bin Yuan; Wu, Xiang; Li, Guancheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">990-996</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">HOX genes are transcription factors that control morphogenesis, organogenesis and differentiation.  Increasing evidence suggests that HOX genes play a role in hepatocellular carcinoma (HCC) progression; however few studies have defined the functional roles and mechanisms of action.  In the present study, we used siRNA and forced-expression in multiple cell lines to define the role of HOXA7 in the regulation of proliferation of HCC in vitro and in vivo.  Knockdown of endogenous HOXA7 decreased the proliferation of HepG2 and QGY-7703 cells.  These changes were not assocd. with significant changes in cyclin D1 and CDK4.  However, down-regulation of HOXA7 significantly reduced cyclin E1 and CDK2 protein levels.  Conversely, overexpression of HOXA7 in QSG-7701 cells stimulated proliferation and increased cyclin E1 and CDK2 protein levels.  Our results confirmed that HOXA7 promoted cell proliferation, and these changes were mediated by cyclin E1/CDK2.  These observations contribute to our understanding of the important roles of HOXA7 in HCC development and progression and HOXA7 could be a promising mol. target for the development of new diagnostic and therapeutic strategies for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0l6a-l8_-GrVg90H21EOLACvtfcHk0lhZnr_uE6IKIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVyiu78%253D&md5=d5d441e42812540323143f763b5e2520</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3892%2For.2014.3668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2014.3668%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%2BH.%26aulast%3DFang%26aufirst%3DS.%2BJ.%26aulast%3DQin%26aufirst%3DC.%2BF.%26aulast%3DSun%26aufirst%3DR.%2BL.%26aulast%3DLiu%26aufirst%3DZ.%2BY.%26aulast%3DJiang%26aufirst%3DB.%2BY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DG.%26atitle%3DHOXA7%2520stimulates%2520human%2520hepatocellular%2520carcinoma%2520proliferation%2520through%2520cyclin%2520E1%252FCDK2%26jtitle%3DOncol.%2520Rep.%26date%3D2015%26volume%3D33%26spage%3D990%26epage%3D996%26doi%3D10.3892%2For.2014.3668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase 2 promotes tumor proliferation and induces radio resistance in glioblastoma</span>. <i>Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1016/j.tranon.2016.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.tranon.2016.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=27863310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A280%3ADC%252BC2snotVWqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=548-556&author=J.+Wangauthor=T.+Yangauthor=G.+Xuauthor=H.+Liuauthor=C.+Renauthor=W.+Xieauthor=M.+Wang&title=Cyclin-dependent+kinase+2+promotes+tumor+proliferation+and+induces+radio+resistance+in+glioblastoma&doi=10.1016%2Fj.tranon.2016.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma</span></div><div class="casAuthors">Wang Jia; Yang Tong; Xu Gaofeng; Liu Hao; Ren Chunying; Xie Wanfu; Wang Maode</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">548-556</span>
        ISSN:<span class="NLM_cas:issn">1936-5233</span>.
    </div><div class="casAbstract">Accumulating evidence indicates that CDK2 promotes hyperproliferation and is associated to poor prognosis in multiple cancer cells.  However, the physiological role of CDK2 in GBM and the biological mechanism still remains unclear.  In this study, we identified that CDK2 expression was significantly enriched in GBM tumors compared with normal brain.  Additionally, CDK2 was functionally required for tumor proliferation and its expression was associated to poor prognosis in GBM patients.  Mechanically, CDK2 induced radio resistance in GBM cells and CDK2 knock down increased cell apoptosis when combined with radiotherapy.  Therapeutically, we found that CDK2 inhibitor attenuated tumor growth both in vitro and in vivo.  Collectively, CDK2 promotes proliferation, induces radio resistance in GBM, and could become a therapeutic target for GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9a1Ej-CIqi7mQt-ICR3qNfW6udTcc2eYBszcmOprudrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snotVWqsQ%253D%253D&md5=e994dad0c2785ed5a8d7ca0fe87f98d7</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.tranon.2016.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tranon.2016.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DM.%26atitle%3DCyclin-dependent%2520kinase%25202%2520promotes%2520tumor%2520proliferation%2520and%2520induces%2520radio%2520resistance%2520in%2520glioblastoma%26jtitle%3DTransl.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D548%26epage%3D556%26doi%3D10.1016%2Fj.tranon.2016.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span> <span> </span><span class="NLM_article-title">Identification of CDK2 as a novel target in treatment of prostate cancer</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.2217/fon-2017-0561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.2217%2Ffon-2017-0561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=29323532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntlegurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=709-718&author=X.+Yinauthor=J.+Yuauthor=Y.+Zhouauthor=C.+Wangauthor=Z.+Jiaoauthor=Z.+Qianauthor=H.+Sunauthor=B.+Chen&title=Identification+of+CDK2+as+a+novel+target+in+treatment+of+prostate+cancer&doi=10.2217%2Ffon-2017-0561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of CDK2 as a novel target in treatment of prostate cancer</span></div><div class="casAuthors">Yin, Xifeng; Yu, Jun; Zhou, Yang; Wang, Chengyue; Jiao, Zhimin; Qian, Zhounan; Sun, Hao; Chen, Binghai</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">709-718</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1744-8301</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">This study aims the potential gene involved in the metastasis of prostate cancer (Pca).  PubMed GEO datasets (GSE6605 and GSE6606) were downloaded.  It used multiple bioinformatics methods to screen differentially expressed genes in Pca.  Gene network was built by STRING and visualized by Cytoscape.  All of the hub genes were analyzed by cBioPortal.  Inhibition of CDK2 including siRNA, inhibitor and cas9-induced CDK2 knockout was followed by an invasion assay.  Downstream genes of CDK2 were analyzed by western blot.  Sequencing data were analyzed to screen the genes with expression alterations.  The top genes were validated in our samples.  11 Hub genes were screened out.  Among these genes, STAT3 and CDK2 were significantly assocd. with recurrence.  Further study suggested that inhibition of CDK2 reduced invasion of Pca cell lines.  The invasion ability was rescued after reintroduction of CDK2.  These data indicated that CDK2 was a crucial factor in metastasis of Pca and might be a novel therapy target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo42ZzW6tNPUbVg90H21EOLACvtfcHk0lgmFK2us09-6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntlegurk%253D&md5=c91131983f10d0ef4458d1bcec32b2d4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2217%2Ffon-2017-0561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2017-0561%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJiao%26aufirst%3DZ.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DB.%26atitle%3DIdentification%2520of%2520CDK2%2520as%2520a%2520novel%2520target%2520in%2520treatment%2520of%2520prostate%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2018%26volume%3D14%26spage%3D709%26epage%3D718%26doi%3D10.2217%2Ffon-2017-0561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caldon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sergio, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthukaruppan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boersma, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barraclough, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Print, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musgrove, E. A.</span></span> <span> </span><span class="NLM_article-title">Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1488</span>– <span class="NLM_lpage">1499</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-11-0963</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1158%2F1535-7163.MCT-11-0963" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=22564725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVKrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1488-1499&author=C.+E.+Caldonauthor=C.+M.+Sergioauthor=J.+Kangauthor=A.+Muthukaruppanauthor=M.+N.+Boersmaauthor=A.+Stoneauthor=J.+Barracloughauthor=C.+S.+Leeauthor=M.+A.+Blackauthor=L.+D.+Millerauthor=J.+M.+Geeauthor=R.+I.+Nicholsonauthor=R.+L.+Sutherlandauthor=C.+G.+Printauthor=E.+A.+Musgrove&title=Cyclin+E2+overexpression+is+associated+with+endocrine+resistance+but+not+insensitivity+to+CDK2+inhibition+in+human+breast+cancer+cells&doi=10.1158%2F1535-7163.mct-11-0963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells</span></div><div class="casAuthors">Caldon, C. Elizabeth; Sergio, C. Marcelo; Kang, Jian; Muthukaruppan, Anita; Boersma, Marijke N.; Stone, Andrew; Barraclough, Jane; Lee, Christine S.; Black, Michael A.; Miller, Lance D.; Gee, Julia M.; Nicholson, Rob I.; Sutherland, Robert L.; Print, Cristin G.; Musgrove, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1488-1499</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin E2, but not cyclin E1, is included in several gene signatures that predict disease progression in either tamoxifen-resistant or metastatic breast cancer.  We therefore examd. the role of cyclin E2 in antiestrogen resistance in vitro and its potential for therapeutic targeting through cyclin-dependent kinase (CDK) inhibition.  High expression of CCNE2, but not CCNE1, was characteristic of the luminal B and HER2 subtypes of breast cancer and was strongly predictive of shorter distant metastasis-free survival following endocrine therapy.  After antiestrogen treatment of MCF-7 breast cancer cells, cyclin E2 mRNA and protein were downregulated and cyclin E2-CDK2 activity decreased.  However, this regulation was lost in tamoxifen-resistant (MCF-7 TAMR) cells, which overexpressed cyclin E2.  Expression of either cyclin E1 or E2 in T-47D breast cancer cells conferred acute antiestrogen resistance, suggesting that cyclin E overexpression contributes to the antiestrogen resistance of tamoxifen-resistant cells.  Ectopic expression of cyclin E1 or E2 also reduced sensitivity to CDK4, but not CDK2, inhibition.  Proliferation of tamoxifen-resistant cells was inhibited by RNAi-mediated knockdown of cyclin E1, cyclin E2, or CDK2.  Furthermore, CDK2 inhibition of E-cyclin overexpressing cells and tamoxifen-resistant cells restored sensitivity to tamoxifen or CDK4 inhibition.  Cyclin E2 overexpression is therefore a potential mechanism of resistance to both endocrine therapy and CDK4 inhibition.  CDK2 inhibitors hold promise as a component of combination therapies in endocrine-resistant disease as they effectively inhibit cyclin E1 and E2 overexpressing cells and enhance the efficacy of other therapeutics.  Mol Cancer Ther; 11(7); 1488-99. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOrjoY6RnTk7Vg90H21EOLACvtfcHk0lgmFK2us09-6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVKrtbw%253D&md5=0d1b47e6b62a4fce919aa5fcf40c227a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0963%26sid%3Dliteratum%253Aachs%26aulast%3DCaldon%26aufirst%3DC.%2BE.%26aulast%3DSergio%26aufirst%3DC.%2BM.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DMuthukaruppan%26aufirst%3DA.%26aulast%3DBoersma%26aufirst%3DM.%2BN.%26aulast%3DStone%26aufirst%3DA.%26aulast%3DBarraclough%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%2BS.%26aulast%3DBlack%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DL.%2BD.%26aulast%3DGee%26aufirst%3DJ.%2BM.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DPrint%26aufirst%3DC.%2BG.%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26atitle%3DCyclin%2520E2%2520overexpression%2520is%2520associated%2520with%2520endocrine%2520resistance%2520but%2520not%2520insensitivity%2520to%2520CDK2%2520inhibition%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1488%26epage%3D1499%26doi%3D10.1158%2F1535-7163.mct-11-0963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trowbridge, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogatsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garabedian, M. J.</span></span> <span> </span><span class="NLM_article-title">Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">10132</span>– <span class="NLM_lpage">10137</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.19.10132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1073%2Fpnas.94.19.10132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=9294175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADyaK2sXmt1Cqu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=10132-10137&author=J.+M.+Trowbridgeauthor=I.+Rogatskyauthor=M.+J.+Garabedian&title=Regulation+of+estrogen+receptor+transcriptional+enhancement+by+the+cyclin+A%2FCdk2+complex&doi=10.1073%2Fpnas.94.19.10132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex</span></div><div class="casAuthors">Trowbridge, Janet M.; Rogatsky, Inez; Garabedian, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10132-10137</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The authors have found that ectopic expression of cyclin A increases hormone-dependent and hormone-independent transcriptional activation by the estrogen receptor in vivo in a no. of cell lines, including HeLa cells, U-2 OS osteosarcoma cells and Hs 578Bst breast epithelial cells.  This effect can be further enhanced in HeLa cells by the concurrent expression of the cyclin-dependent kinase activator, cyclin H, and cdk7, and abolished by expression of the cdk inhibitor, p27KIPI, or by the expression of a dominant neg. catalytically inactive cdk2 mutant.  ER is phosphorylated between amino acids 82 and 121 in vitro by the cyclin A/cdk2 complex and incorporation of phosphate into ER is stimulated by ectopic expression of cyclin A in vivo.  Together, these results strongly suggest a direct role for the cyclin A/cdk2 complex in phosphorylating ER and regulating its transcriptional activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOpi2Mjjhy1LVg90H21EOLACvtfcHk0ljMV5IH9Ny-XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmt1Cqu7k%253D&md5=b8a8e2916b409988346b8decb8973d77</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.19.10132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.19.10132%26sid%3Dliteratum%253Aachs%26aulast%3DTrowbridge%26aufirst%3DJ.%2BM.%26aulast%3DRogatsky%26aufirst%3DI.%26aulast%3DGarabedian%26aufirst%3DM.%2BJ.%26atitle%3DRegulation%2520of%2520estrogen%2520receptor%2520transcriptional%2520enhancement%2520by%2520the%2520cyclin%2520A%252FCdk2%2520complex%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1997%26volume%3D94%26spage%3D10132%26epage%3D10137%26doi%3D10.1073%2Fpnas.94.19.10132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierson-Mullany, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C. A.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">10542</span>– <span class="NLM_lpage">10557</span>, <span class="refDoi"> DOI: 10.1128/mcb.24.24.10542-10557.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1128%2FMCB.24.24.10542-10557.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=15572662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFShu7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=10542-10557&author=L.+K.+Pierson-Mullanyauthor=C.+A.+Lange&title=Phosphorylation+of+progesterone+receptor+serine+400+mediates+ligand-independent+transcriptional+activity+in+response+to+activation+of+cyclin-dependent+protein+kinase+2&doi=10.1128%2Fmcb.24.24.10542-10557.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2</span></div><div class="casAuthors">Pierson-Mullany, Lisa K.; Lange, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10542-10557</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human progesterone receptors (PR) are phosphorylated by cyclin-dependent protein kinase 2 (CDK2) at multiple sites, including Ser400.  Herein, we have addressed the significance of phosphorylation of this residue.  PR phospho-Ser400-specific antibodies revealed regulated phosphorylation of Ser400 in response to progestins and mitogens, and this correlated with increased CDK2 levels and activity.  Expression of cyclin E elevated CDK2 activity and downregulated PR independently of ligand.  Similarly, overexpression of activated mutant CDK2 increased PR transcriptional activity in the absence and presence of progestin.  Mutation of PR Ser400 to alanine (S400A) blocked CDK2-induced PR activity in the absence, but not in the presence, of progestin.  PR was unresponsive to activated CDK2 in breast cancer cells with elevated p27, and RNA interference knock-down of p27 partially restored CDK2-induced ligand-independent PR activation.  Similarly, in p27-/- mouse embryonic fibroblasts, elevated CDK2 activity increased wild-type (wt) but not S400A PR transcriptional activity in the absence of progestin.  CDK2 induced nuclear localization of unliganded wt but not S400A PR; liganded S400A PR exhibited delayed nuclear accumulation.  These studies demonstrate that CDK2 regulates PR in the absence of progestins via phosphorylation of Ser400, thus revealing a novel mechanism for upregulated PR transcriptional activity in human breast cancer cells expressing altered cell cycle regulatory mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtFBJTUucg5LVg90H21EOLACvtfcHk0ljMV5IH9Ny-XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFShu7bI&md5=9389bfbb80fcf468cc99194a9a6afb25</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.24.10542-10557.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.24.10542-10557.2004%26sid%3Dliteratum%253Aachs%26aulast%3DPierson-Mullany%26aufirst%3DL.%2BK.%26aulast%3DLange%26aufirst%3DC.%2BA.%26atitle%3DPhosphorylation%2520of%2520progesterone%2520receptor%2520serine%2520400%2520mediates%2520ligand-independent%2520transcriptional%2520activity%2520in%2520response%2520to%2520activation%2520of%2520cyclin-dependent%2520protein%2520kinase%25202%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D10542%26epage%3D10557%26doi%3D10.1128%2Fmcb.24.24.10542-10557.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Pelt, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyomarsi, K.</span></span> <span> </span><span class="NLM_article-title">Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin. E</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">3377</span>– <span class="NLM_lpage">3386</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-10-4086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1158%2F0008-5472.CAN-10-4086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=21385896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlGhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3377-3386&author=S.+Akliauthor=C.+S.+Van+Peltauthor=T.+Buiauthor=L.+Meijerauthor=K.+Keyomarsi&title=Cdk2+is+required+for+breast+cancer+mediated+by+the+low-molecular-weight+isoform+of+cyclin.+E&doi=10.1158%2F0008-5472.can-10-4086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Cdk2 is Required for Breast Cancer Mediated by the Low-Molecular-Weight Isoform of Cyclin E</span></div><div class="casAuthors">Akli, Said; Van Pelt, Carolyn S.; Bui, Tuyen; Meijer, Laurent; Keyomarsi, Khandan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3377-3386</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin E activates Cdk2, controls centrosome duplication, and regulates histone gene transcription.  Cyclin E is deregulated in cancer and appears as low-mol.-wt. (LMW) isoforms that correlate strongly with decreased survival in breast cancer patients.  Transgenic mice overexpressing LMW-cyclin E have increased incidence of mammary tumors and distant metastasis when compared with mice that had full-length cyclin E.  To specifically test the requirement for Cdk2 in LMW-cyclin E-mediated mammary tumorigenesis, we generated transgenic mice, which expressed LMW-cyclin E in a Cdk2-deficient background.  We found that mammary gland development proceeds relatively normally in these animals, indicating that Cdk2 kinase activity is largely dispensable for this process.  However, Cdk2-deficient mice were completely resistant to LMW-cyclin E-mediated mammary tumors.  Cdk2 wild-type or heterozygous mice succumbed to mammary tumors with mean latencies of 16 and 19.5 mo, resp., but Cdk2 nullizygous littermates did not display tumors through 24 mo.  Similarly, continuous administration of two different Cdk inhibitors significantly delayed LMW-cyclin E-induced mammary tumor progression.  Triple transgenic mice generated in a p53 heterozygous background also displayed no tumors.  Finally, we found that Cdk2 silencing induced cell death in LMW-overexpressing breast cancer cell lines, but not in cell lines lacking LMW expression.  Our findings establish a requirement for Cdk2 in LMW-cyclin E-mediated mammary tumorigenesis, arguing that human breast tumors overexpressing LMW-cyclin E are prime candidates for anti-Cdk2 therapy.  Cancer Res; 71(9); 3377-86.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWLccE8zVYrLVg90H21EOLACvtfcHk0ljMV5IH9Ny-XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlGhuro%253D&md5=8dcba927024b8307917566071f999734</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4086%26sid%3Dliteratum%253Aachs%26aulast%3DAkli%26aufirst%3DS.%26aulast%3DVan%2BPelt%26aufirst%3DC.%2BS.%26aulast%3DBui%26aufirst%3DT.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DKeyomarsi%26aufirst%3DK.%26atitle%3DCdk2%2520is%2520required%2520for%2520breast%2520cancer%2520mediated%2520by%2520the%2520low-molecular-weight%2520isoform%2520of%2520cyclin.%2520E%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3377%26epage%3D3386%26doi%3D10.1158%2F0008-5472.can-10-4086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deavers, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malpica, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavanagh, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1925</span>– <span class="NLM_lpage">1932</span>, <span class="refDoi"> DOI: 10.1002/cncr.21767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1002%2Fcncr.21767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=16568440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvFGhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2006&pages=1925-1932&author=D.+G.+Rosenauthor=G.+Yangauthor=M.+T.+Deaversauthor=A.+Malpicaauthor=J.+J.+Kavanaghauthor=G.+B.+Millsauthor=J.+Liu&title=Cyclin+E+expression+is+correlated+with+tumor+progression+and+predicts+a+poor+prognosis+in+patients+with+ovarian+carcinoma&doi=10.1002%2Fcncr.21767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma</span></div><div class="casAuthors">Rosen, Daniel G.; Yang, Gong; Deavers, Michael T.; Malpica, Anais; Kavanagh, John J.; Mills, Gordon B.; Liu, Jinsong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1925-1932</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">BACKGROUND: Cyclins, cyclin dependent kinases (cdks), and their inhibitors act in combination to regulate progression through the cell cycle and often are dysregulated in carcinoma.  The authors hypothesized that cyclin E plays an important role in ovarian carcinogenesis and that its overexpression may be an indicator of a poor prognosis.  METHODS: Immunohistochem. anal. of cyclin E expression was performed by image anal. in normal ovaries, cystadenomas, tumors of low malignant potential, and 405 primary ovarian carcinomas by using tissue microarray technol.  RESULTS: Overexpression of cyclin E was found in 63.2% of the samples and was assocd. with clear cell, poorly differentiated, and serous carcinoma (P ≤ .001), high-grade tumors (P ≤ .001), late-stage disease (P = .002), age older than 60 years at the time of diagnosis (P = .04), and suboptimal cytoredn. (P = .001).  A high percentage of cyclin E-expressing cells was assocd. with a poor outcome in univariate and in multivariate analyses.  In addn., cyclin E levels also reduced survival in the late-stage disease group and in patients who underwent suboptimal debulking.  CONCLUSIONS: Cyclin E was identified as an independent prognostic factor in patients with ovarian carcinoma.  The accumulation of cyclin E protein may be a late event in tumorigenesis and may contribute to disease progression in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVj31v_bK72bVg90H21EOLACvtfcHk0liO_88bfJgc9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvFGhs78%253D&md5=ba303518605c55fcd818c4970de5baae</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fcncr.21767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.21767%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DD.%2BG.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DDeavers%26aufirst%3DM.%2BT.%26aulast%3DMalpica%26aufirst%3DA.%26aulast%3DKavanagh%26aufirst%3DJ.%2BJ.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DCyclin%2520E%2520expression%2520is%2520correlated%2520with%2520tumor%2520progression%2520and%2520predicts%2520a%2520poor%2520prognosis%2520in%2520patients%2520with%2520ovarian%2520carcinoma%26jtitle%3DCancer%26date%3D2006%26volume%3D106%26spage%3D1925%26epage%3D1932%26doi%3D10.1002%2Fcncr.21767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanArsdale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span> <span> </span><span class="NLM_article-title">Spectrum and degree of CDK drug interactions predicts clinical performance</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2273</span>– <span class="NLM_lpage">2281</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-16-0300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1158%2F1535-7163.MCT-16-0300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=27496135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGisbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2273-2281&author=P.+Chenauthor=N.+V.+Leeauthor=W.+Huauthor=M.+Xuauthor=R.+A.+Ferreauthor=H.+Lamauthor=S.+Bergqvistauthor=J.+Solowiejauthor=W.+Diehlauthor=Y.-A.+Heauthor=X.+Yuauthor=A.+Nagataauthor=T.+VanArsdaleauthor=B.+W.+Murray&title=Spectrum+and+degree+of+CDK+drug+interactions+predicts+clinical+performance&doi=10.1158%2F1535-7163.mct-16-0300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance</span></div><div class="casAuthors">Chen, Ping; Lee, Nathan V.; Hu, Wenyue; Xu, Meirong; Ferre, Rose Ann; Lam, Hieu; Bergqvist, Simon; Solowiej, James; Diehl, Wade; He, You-Ai; Yu, Xiu; Nagata, Asako; Van Arsdale, Todd; Murray, Brion W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2273-2281</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biol. perspective but drug development is often hindered by toxicities and inadequate efficacy.  Predicting drug behaviors using cellular and animal models is confounded by redundant kinase activities, a lack of unique substrates, and cell-specific signaling networks.  Cyclin-dependent kinase (CDK) drugs exemplify this phenomenon because they are reported to target common processes yet have distinct clin. activities.  Tumor cell studies of ATP-competitive CDK drugs (dinaciclib, AG-024322, abemaciclib, palbociclib, ribociclib) indicate similar pharmacol. while analyses in untransformed cells illuminates significant differences.  To resolve this apparent disconnect, drug behaviors are described at the mol. level.  Nonkinase binding studies and kinome interaction anal. (recombinant and endogenous kinases) reveal that proteins outside of the CDK family appear to have little role in dinaciclib/palbociclib/ribociclib pharmacol., may contribute for abemaciclib, and confounds AG-024322 anal.  CDK2 and CDK6 cocrystal structures with the drugs identify the mol. interactions responsible for potency and kinase selectivity.  Efficient drug binding to the unique hinge architecture of CDKs enables selectivity toward most of the human kinome.  Selectivity between CDK family members is achieved through interactions with nonconserved elements of the ATP-binding pocket.  Integrating clin. drug exposures into the anal. predicts that both palbociclib and ribociclib are CDK4/6 inhibitors, abemaciclib inhibits CDK4/6/9, and dinaciclib is a broad-spectrum CDK inhibitor (CDK2/3/4/6/9).  Understanding the mol. components of potency and selectivity also facilitates rational design of future generations of kinase-directed drugs.  Mol Cancer Ther; 15(10); 2273-81.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3TbbI98T8v7Vg90H21EOLACvtfcHk0liO_88bfJgc9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGisbjK&md5=112e9e46bb33393516fa94620e6383c6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0300%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DN.%2BV.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DY.-A.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DVanArsdale%26aufirst%3DT.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DSpectrum%2520and%2520degree%2520of%2520CDK%2520drug%2520interactions%2520predicts%2520clinical%2520performance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2273%26epage%3D2281%26doi%3D10.1158%2F1535-7163.mct-16-0300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herrera-Abreu, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palafox, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asghar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutts, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Murillas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grueso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pancholi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, L.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span> <span> </span><span class="NLM_article-title">Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">2301</span>– <span class="NLM_lpage">2313</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-15-0728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1158%2F0008-5472.CAN-15-0728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=27020857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVags74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=2301-2313&author=M.+T.+Herrera-Abreuauthor=M.+Palafoxauthor=U.+Asgharauthor=M.+A.+Rivasauthor=R.+J.+Cuttsauthor=I.+Garcia-Murillasauthor=A.+Pearsonauthor=M.+Guzmanauthor=O.+Rodriguezauthor=J.+Gruesoauthor=M.+Belletauthor=J.+Cort%C3%A9sauthor=R.+Elliottauthor=S.+Pancholiauthor=C.+J.+Lordauthor=J.+Baselgaauthor=M.+Dowsettauthor=L.-A.+Martinauthor=N.+C.+Turnerauthor=V.+Serra&title=Early+adaptation+and+acquired+resistance+to+CDK4%2F6+inhibition+in+estrogen+receptor-positive+breast+cancer&doi=10.1158%2F0008-5472.can-15-0728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer</span></div><div class="casAuthors">Herrera-Abreu, Maria Teresa; Palafox, Marta; Asghar, Uzma; Rivas, Martin A.; Cutts, Rosalind J.; Garcia-Murillas, Isaac; Pearson, Alex; Guzman, Marta; Rodriguez, Olga; Grueso, Judit; Bellet, Meritxell; Corties, Javier; Elliott, Richard; Pancholi, Sunil; Baselga, Josiee; Dowsett, Mitch; Martin, Lesley-Ann; Turner, Nicholas C.; Serra, Violeta</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2301-2313</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Small-mol. inhibitors of the CDK4/6 cell-cycle kinases have shown clin. efficacy in estrogen receptor (ER)-pos. metastatic breast cancer, although their cytostatic effects are limited by primary and acquired resistance.  Here we report that ER-pos. breast cancer cells can adapt quickly to CDK4/6 inhibition and evade cytostasis, in part, via noncanonical cyclin D1-CDK2-mediated S-phase entry.  This adaptation was prevented by cotreatment with hormone therapies or PI3K inhibitors, which reduced the levels of cyclin D1 (CCND1) and other G1-S cyclins, abolished pRb phosphorylation, and inhibited activation of S-phase transcriptional programs.  Combined targeting of both CDK4/6 and PI3K triggered cancer cell apoptosis in vitro and in patient-derived tumor xenograft (PDX) models, resulting in tumor regression and improved disease control.  Furthermore, a triple combination of endocrine therapy, CDK4/6, and PI3K inhibition was more effective than paired combinations, provoking rapid tumor regressions in a PDX model.  Mechanistic investigations showed that acquired resistance to CDK4/6 inhibition resulted from bypass of cyclin D1-CDK4/6 dependency through selection of CCNE1 amplification or RB1 loss.  Notably, although PI3K inhibitors could prevent resistance to CDK4/6 inhibitors, they failed to resensitize cells once resistance had been acquired.  However, we found that cells acquiring resistance to CDK4/6 inhibitors due to CCNE1 amplification could be resensitized by targeting CDK2.  Overall, our results illustrate convergent mechanisms of early adaptation and acquired resistance to CDK4/6 inhibitors that enable alternate means of S-phase entry, highlighting strategies to prevent the acquisition of therapeutic resistance to these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHNNElBQntOLVg90H21EOLACvtfcHk0liO_88bfJgc9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVags74%253D&md5=675a4562d545338fa16347c0a2f076f0</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-0728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-0728%26sid%3Dliteratum%253Aachs%26aulast%3DHerrera-Abreu%26aufirst%3DM.%2BT.%26aulast%3DPalafox%26aufirst%3DM.%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DRivas%26aufirst%3DM.%2BA.%26aulast%3DCutts%26aufirst%3DR.%2BJ.%26aulast%3DGarcia-Murillas%26aufirst%3DI.%26aulast%3DPearson%26aufirst%3DA.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DRodriguez%26aufirst%3DO.%26aulast%3DGrueso%26aufirst%3DJ.%26aulast%3DBellet%26aufirst%3DM.%26aulast%3DCort%25C3%25A9s%26aufirst%3DJ.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DPancholi%26aufirst%3DS.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DDowsett%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DL.-A.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DSerra%26aufirst%3DV.%26atitle%3DEarly%2520adaptation%2520and%2520acquired%2520resistance%2520to%2520CDK4%252F6%2520inhibition%2520in%2520estrogen%2520receptor-positive%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D2301%26epage%3D2313%26doi%3D10.1158%2F0008-5472.can-15-0728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahadirli-Talbott, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, I.-M.</span></span> <span> </span><span class="NLM_article-title">Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma</span>. <i>Mod. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1014</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1038/modpathol.2013.209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1038%2Fmodpathol.2013.209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=24309323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFCqsLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=1014-1019&author=E.+Kuhnauthor=A.+Bahadirli-Talbottauthor=I.-M.+Shih&title=Frequent+CCNE1+amplification+in+endometrial+intraepithelial+carcinoma+and+uterine+serous+carcinoma&doi=10.1038%2Fmodpathol.2013.209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma</span></div><div class="casAuthors">Kuhn, Elisabetta; Bahadirli-Talbott, Asli; Shih, Ie-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Modern Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1014-1019</span>CODEN:
                <span class="NLM_cas:coden">MODPEO</span>;
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Uterine serous carcinoma accounts for only 10̂ of all uterine epithelial cancers, but is the leading cause of death among them.  The pathogenesis of this aggressive neoplasm has been largely elusive until recently, when comprehensive genome-wide analyses of uterine serous carcinoma have been performed.  Among amplified cancer-related genes, CCNE1, encoding for cyclin E1, is frequently amplified in uterine serous carcinoma.  In the current study we applied fluorescence in situ hybridization (FISH) to det. CCNE1 copy no. in uterine serous carcinoma and concurrent endometrial intraepithelial carcinoma, the noninvasive component of uterine serous carcinoma, and the results were correlated with clinicopathol. and mol. features.  We found that 20 (45̂) of 44 uterine serous carcinomas and 11 (41̂) of 27 endometrial intraepithelial carcinomas showed CCNE1 amplification.  Overall, we found high concordance in CCNE1 copy no. in concurrent uterine serous carcinoma and endometrial intraepithelial carcinoma pairs (P-value=0.0003).  No correlation was obsd. between CCNE1 copy no. and clinicopathol. features, as well as common mutations previously reported in uterine serous carcinoma.  In summary, we confirm that amplification of CCNE1 is a frequent mol. genetic change in uterine serous carcinoma.  Moreover, the identification of CCNE1 amplification in many endometrial intraepithelial carcinomas suggests that this genetic event occurs early during tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6KzMRpOMks7Vg90H21EOLACvtfcHk0lg0jrh3yIdmkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFCqsLjN&md5=ead0e4246b936027da34a62b70a1d8aa</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.2013.209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.2013.209%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DE.%26aulast%3DBahadirli-Talbott%26aufirst%3DA.%26aulast%3DShih%26aufirst%3DI.-M.%26atitle%3DFrequent%2520CCNE1%2520amplification%2520in%2520endometrial%2520intraepithelial%2520carcinoma%2520and%2520uterine%2520serous%2520carcinoma%26jtitle%3DMod.%2520Pathol.%26date%3D2014%26volume%3D27%26spage%3D1014%26epage%3D1019%26doi%3D10.1038%2Fmodpathol.2013.209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colleoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loibl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demichele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayar, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michiels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnedos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang Bartlett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofanilli, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1169</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1200/jco.18.00925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1200%2FJCO.18.00925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=30807234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1WntLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=1169-1178&author=N.+C.+Turnerauthor=Y.+Liuauthor=Z.+Zhuauthor=S.+Loiauthor=M.+Colleoniauthor=S.+Loiblauthor=A.+Demicheleauthor=N.+Harbeckauthor=F.+Andr%C3%A9author=M.+A.+Bayarauthor=S.+Michielsauthor=Z.+Zhangauthor=C.+Giorgettiauthor=M.+Arnedosauthor=C.+Huang+Bartlettauthor=M.+Cristofanilli&title=Cyclin+E1+expression+and+palbociclib+efficacy+in+previously+treated+hormone+receptor-positive+metastatic+breast+cancer&doi=10.1200%2Fjco.18.00925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer</span></div><div class="casAuthors">Turner, Nicholas C.; Liu, Yuan; Zhu, Zhou; Loi, Sherene; Colleoni, Marco; Loibl, Sibylle; Demichele, Angela; Harbeck, Nadia; Andre, Fabrice; Bayar, Mohamed Amine; Michiels, Stefan; Zhang, Zhe; Giorgetti, Carla; Arnedos, Monica; Bartlett, Cynthia Huang; Cristofanilli, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1169-1179</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">PURPOSE A large-panel gene expression anal. was conducted to identify biomarkers assocd. with the effectiveness of adding palbociclib to fulvestrant.  METHODS The PALOMA-3 (ClinicalTrials.gov identifier: NCT01942135) trial randomly assigned 521 endocrinepretreated patients with metastatic breast cancer to receive palbociclib plus fulvestrant or placebo plus fulvestrant.  Primary anal. was first conducted on 10 genes on the basis of pathway biol. and evidence from previous studies followed by a systematic panel-wide search among 2,534 cancer-related genes.  The assocn. of gene expression with the effect of palbociclib on progression-free survival (PFS) was evaluated using Cox proportional hazards regression anal., with gene expression as a continuous variable or dichotomized by median.  An independent breast cancer cohort from the Preoperative Palbociclib (POP) Clin. Trial (ClinicalTrials.gov identifier: NCT02008734) was used for validation, in 61 patients with primary breast cancer treated with 2 wk of palbociclib.  RESULTS In the PALOMA-3 trial, 302 patients had tumor tissue analyzed (palbociclib arm, 194 patients; placebo arm, 108 patients).  Palbociclib efficacy was lower in patients with high vs. low cyclin E1 (CCNE1) mRNA expression (median PFS: palbociclib arm, 7.6 v 14.1 mo; placebo arm, 4.0 v 4.8 mo, resp.; interaction P unadjusted = .00238; false discovery rate-adjusted P = .0238).  CCNE1 mRNA was more predictive in metastatic than in archival primary biopsy tissue samples.  No significant interaction was found between treatment and expression levels of CDK4, CDK6, cyclin D1, and RB1.  Palbociclib was efficacious in both luminal A and luminal B tumors.  High CCNE1 mRNA expression was assocd. with poor antiproliferative activity of palbociclib in the POP trial (P = .005).  CONCLUSION Addn. of palbociclib to fulvestrant demonstrated efficacy in all biomarker groups, although high CCNE1 mRNA expression was assocd. with relative resistance to palbociclib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf1mJPZBY8SrVg90H21EOLACvtfcHk0lg0jrh3yIdmkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1WntLnO&md5=a781177c1bb0f2557eab56f7a3a899bc</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1200%2FJCO.18.00925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.18.00925%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DColleoni%26aufirst%3DM.%26aulast%3DLoibl%26aufirst%3DS.%26aulast%3DDemichele%26aufirst%3DA.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DBayar%26aufirst%3DM.%2BA.%26aulast%3DMichiels%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGiorgetti%26aufirst%3DC.%26aulast%3DArnedos%26aufirst%3DM.%26aulast%3DHuang%2BBartlett%26aufirst%3DC.%26aulast%3DCristofanilli%26aufirst%3DM.%26atitle%3DCyclin%2520E1%2520expression%2520and%2520palbociclib%2520efficacy%2520in%2520previously%2520treated%2520hormone%2520receptor-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3D1169%26epage%3D1178%26doi%3D10.1200%2Fjco.18.00925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintanilla-Martinez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensley, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutkind, J. S.</span></span> <span> </span><span class="NLM_article-title">Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">1674</span>– <span class="NLM_lpage">1681</span>, <span class="refDoi"> DOI: 10.1172/jci3661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1172%2FJCI3661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=9802881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1Oqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=1674-1681&author=V.+Patelauthor=A.+M.+Senderowiczauthor=D.+Pintoauthor=T.+Igishiauthor=M.+Raffeldauthor=L.+Quintanilla-Martinezauthor=J.+F.+Ensleyauthor=E.+A.+Sausvilleauthor=J.+S.+Gutkind&title=Flavopiridol%2C+a+novel+cyclin-dependent+kinase+inhibitor%2C+suppresses+the+growth+of+head+and+neck+squamous+cell+carcinomas+by+inducing+apoptosis&doi=10.1172%2Fjci3661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis</span></div><div class="casAuthors">Patel, Vyomesh; Senderowicz, Adrian M.; Pinto, Decio, Jr.; Igishi, Tadashi; Raffeld, Mark; Quintanilla-Martinez, Leticia; Ensley, John F.; Sausville, Edward A.; Gutkind, J. Silvio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1674-1681</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Flavopiridol (HMR 1275) has been identified recently as a novel antineoplastic agent in the primary screen conducted by the Developmental Therapeutics Program, National Cancer Institute.  Flavopiridol inhibits most cyclin-dependent kinases (cdks) and displays unique anticancer properties.  Here, we investigated whether this compd. was effective against head and neck squamous cell carcinomas (HNSCC).  Exposure of HNSCC cells to flavopiridol diminished cdc2 and cdk2 activity and potently inhibited cell proliferation (IC50 43-83 nM), which was concomitant with the appearance of cells with a sub-G1 DNA content.  Moreover, DNA fragmentation and TUNEL (terminal deoxynucleotidyl transferase-mediated nick end labeling) reaction confirmed that flavopiridol induces apoptosis in all cell lines, even on certain HNSCC cells that are insensitive to apoptosis to DNA-damaging agents (γ-irradn. and bleomycin).  A tumorigenic HNSCC cell line was used to assess the effect of flavopiridol in vivo.  Treatment (5 mg/kg per day, i.p.) for 5 d led to the appearance of apoptotic cells in the tumor xenografts and caused a 60-70% redn. in tumor size, which was sustained over a period of 10 wk.  Flavopiridol treatment also resulted in a remarkable redn. of cyclin D1 expression in HNSCC cells and tumor xenografts.  Our data indicate that flavopiridol exerts antitumor activity in HNSCC, and thus it can be considered a suitable candidate drug for testing in the treatment of refractory carcinomas of the head and neck.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-lF748dX347Vg90H21EOLACvtfcHk0lj1xjAPlm0Exg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1Oqtrc%253D&md5=549f97c62f21c1b194856d237823a2b7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1172%2FJCI3661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI3661%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26aulast%3DPinto%26aufirst%3DD.%26aulast%3DIgishi%26aufirst%3DT.%26aulast%3DRaffeld%26aufirst%3DM.%26aulast%3DQuintanilla-Martinez%26aufirst%3DL.%26aulast%3DEnsley%26aufirst%3DJ.%2BF.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DGutkind%26aufirst%3DJ.%2BS.%26atitle%3DFlavopiridol%252C%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520suppresses%2520the%2520growth%2520of%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinomas%2520by%2520inducing%2520apoptosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D102%26spage%3D1674%26epage%3D1681%26doi%3D10.1172%2Fjci3661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A. M.</span></span> <span> </span><span class="NLM_article-title">Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1023/a:1006353008903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1023%2FA%3A1006353008903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10665481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtFartLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=313-320&author=A.+M.+Senderowicz&title=Flavopiridol%3A+the+first+cyclin-dependent+kinase+inhibitor+in+human+clinical+trials&doi=10.1023%2Fa%3A1006353008903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials</span></div><div class="casAuthors">Senderowicz, Adrian M.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">313-320</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review with 55 refs.  The discovery and cloning of the cyclin-dependent kinases (cdks), main regulators of cell cycle progression, allowed several investigators to design novel modulators of cdk activity.  Flavopiridol (HMR 1275, L86-8275), a flavonoid derived from an indigenous plant from India, demonstrated potent and specific in vitro inhibition of all cdks tested (cdks 1, 2, 4 and 7) with clear block in cell cycle progression at the G1/S and G2/M boundaries.  Moreover, preclin. studies demonstrated the capacity of flavopiridol to induce programmed cell death, promote differentiation, inhibit angiogenic processes and modulate transcriptional events.  The relationship between the latter effects and cdk inhibition is still unclear.  Initial testing in early clin. human trials with infusional flavopiridol showed activity in some patients with non-Hodgkin's lymphoma, renal, prostate, colon and gastric carcinomas.  Main side effects were secretory diarrhea and a pro-inflammatory syndrome assocd. with hypotension.  Biol. active plasma concns. of flavopiridol (∼300-500 nM) are easily achievable in patients receiving infusional flavopiridol.  Phase 2 trials with infusional flavopiridol in several tumor types, other schedules and combination with std. chemotherapies are being assessed.  In conclusion, flavopiridol is the first cdk inhibitor to be tested in clin. trials.  Although important questions remain to be answered, this pos. experience will stimulate the development of novel cdk modulators for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJEkms561BuLVg90H21EOLACvtfcHk0lj1xjAPlm0Exg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtFartLw%253D&md5=c540be99618350739adafa8746922c38</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1023%2FA%3A1006353008903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1006353008903%26sid%3Dliteratum%253Aachs%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26atitle%3DFlavopiridol%253A%2520the%2520first%2520cyclin-dependent%2520kinase%2520inhibitor%2520in%2520human%2520clinical%2520trials%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D1999%26volume%3D17%26spage%3D313%26epage%3D320%26doi%3D10.1023%2Fa%3A1006353008903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrychová, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Řezníčková, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gucký, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryštof, V.</span></span> <span> </span><span class="NLM_article-title">How selective are pharmacological inhibitors of cell-cycle-regulating cyclin-dependent kinases?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9105</span>– <span class="NLM_lpage">9120</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00049</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00049" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKqtr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9105-9120&author=R.+Jordaauthor=D.+Hendrychov%C3%A1author=J.+Vollerauthor=E.+%C5%98ezn%C3%AD%C4%8Dkov%C3%A1author=T.+Guck%C3%BDauthor=V.+Kry%C5%A1tof&title=How+selective+are+pharmacological+inhibitors+of+cell-cycle-regulating+cyclin-dependent+kinases%3F&doi=10.1021%2Facs.jmedchem.8b00049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?</span></div><div class="casAuthors">Jorda, Radek; Hendrychova, Denisa; Voller, Jiri; Reznickova, Eva; Gucky, Tomas; Krystof, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9105-9120</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are an important and emerging class of drug targets for which many small-mol. inhibitors have been developed.  However, there is often insufficient data available on the selectivity of CDK inhibitors (CDKi) to attribute the effects on the presumed target CDK to these inhibitors.  Here, we highlight discrepancies between the kinase selectivity of CDKi and the phenotype exhibited; we evaluated 31 CDKi (claimed to target CDK1-4) for activity toward CDKs 1, 2, 4, 5, 7, 9 and for effects on the cell cycle.  Our results suggest that most CDKi should be reclassified as pan-selective and should not be used as a tool.  In addn., some compds. did not even inhibit CDKs as their primary cellular targets; for example, NU6140 showed potent inhibition of Aurora kinases.  We also established an online database of com. available CDKi for crit. evaluation of their utility as mol. probes.  Our results should help researchers select the most relevant chem. tools for their specific applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopxhyveeEDKLVg90H21EOLACvtfcHk0lh3yPLl1nAN4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKqtr3F&md5=75d6b8beee8e6ac2aeb604ada9ed5895</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00049%26sid%3Dliteratum%253Aachs%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DHendrychov%25C3%25A1%26aufirst%3DD.%26aulast%3DVoller%26aufirst%3DJ.%26aulast%3D%25C5%2598ezn%25C3%25AD%25C4%258Dkov%25C3%25A1%26aufirst%3DE.%26aulast%3DGuck%25C3%25BD%26aufirst%3DT.%26aulast%3DKry%25C5%25A1tof%26aufirst%3DV.%26atitle%3DHow%2520selective%2520are%2520pharmacological%2520inhibitors%2520of%2520cell-cycle-regulating%2520cyclin-dependent%2520kinases%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9105%26epage%3D9120%26doi%3D10.1021%2Facs.jmedchem.8b00049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burdette-Radoux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tozer, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quirt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colevas, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhauer, E. A.</span></span> <span> </span><span class="NLM_article-title">Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1023/b:drug.0000026258.02846.1c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1023%2FB%3ADRUG.0000026258.02846.1c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=15122079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsF2isro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2004&pages=315-322&author=S.+Burdette-Radouxauthor=R.+G.+Tozerauthor=R.+C.+Lohmannauthor=I.+Quirtauthor=D.+S.+Ernstauthor=W.+Walshauthor=N.+Wainmanauthor=A.+D.+Colevasauthor=E.+A.+Eisenhauer&title=Phase+II+trial+of+flavopiridol%2C+a+cyclin+dependent+kinase+inhibitor%2C+in+untreated+metastatic+malignant+melanoma&doi=10.1023%2Fb%3Adrug.0000026258.02846.1c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma</span></div><div class="casAuthors">Burdette-Radoux, Susan; Tozer, Richard G.; Lohmann, Reinhard C.; Quirt, Ian; Ernst, D. Scott; Walsh, Wendy; Wainman, Nancy; Colevas, A. Dimitrios; Eisenhauer, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">315-322</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">Purpose: To test the activity of the cyclin dependent kinase (cdk) inhibitor flavopiridol in malignant melanoma, a disease with frequent abnormalities of the cyclin dependent kinase system.  Patients and methods: Patients had histol. proven, unidimensionally measurable malignant melanoma, incurable by std. therapy.  Prior adjuvant immunotherapy was allowed, but patients were otherwise untreated for advanced disease.  Flavopiridol was administered at a dose of 50 mg/m2 IV over 1 h daily × 3 days every 3 wk.  Patients were assessed for response every 2 cycles.  Results: 17 patients were accrued over 5 mo.  No objective responses were documented in the 16 patients evaluable for response.  Seven patients (44%) had stable disease after 2 cycles, with a median of 2.8 mo (range 1.8-9.2).  The most common treatment-related non-hematol. toxicities were diarrhea (82%), nausea (47%), fatigue (41%), anorexia (35%) and vomiting (29%).  Most treatment-related toxicities were mild, except for diarrhea (grade 3 in 3 patients, grade 4 in 1 patient), nausea (grade 3 in 1 patient) and tumor pain (grade 3 in 1 patient).  Hematol. toxicities were minimal, none worse than grade 2.  Eighty-eight percent of patients received ≥90% planned dose intensity; 2 patients had dose redns. for gastrointestinal (GI) toxicity.  Conclusions: Flavopiridol is well tolerated at the dose regimen used in this study, with an acceptable (primarily GI) toxicity profile.  Although 7 of the 16 patients had stable disease ranging from 1.8 to 9.2 mo in duration, there was no evidence of significant clin. activity in malignant melanoma by objective response criteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMAEJ71nRMTLVg90H21EOLACvtfcHk0lh3yPLl1nAN4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsF2isro%253D&md5=a145b2fc86199a7dd54f44c76dd9b1c5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1023%2FB%3ADRUG.0000026258.02846.1c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253ADRUG.0000026258.02846.1c%26sid%3Dliteratum%253Aachs%26aulast%3DBurdette-Radoux%26aufirst%3DS.%26aulast%3DTozer%26aufirst%3DR.%2BG.%26aulast%3DLohmann%26aufirst%3DR.%2BC.%26aulast%3DQuirt%26aufirst%3DI.%26aulast%3DErnst%26aufirst%3DD.%2BS.%26aulast%3DWalsh%26aufirst%3DW.%26aulast%3DWainman%26aufirst%3DN.%26aulast%3DColevas%26aufirst%3DA.%2BD.%26aulast%3DEisenhauer%26aufirst%3DE.%2BA.%26atitle%3DPhase%2520II%2520trial%2520of%2520flavopiridol%252C%2520a%2520cyclin%2520dependent%2520kinase%2520inhibitor%252C%2520in%2520untreated%2520metastatic%2520malignant%2520melanoma%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2004%26volume%3D22%26spage%3D315%26epage%3D322%26doi%3D10.1023%2Fb%3Adrug.0000026258.02846.1c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, G. J.</span></span> <span> </span><span class="NLM_article-title">Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors</span>. <i>J. Appl. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1002/jat.1177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1002%2Fjat.1177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=17211896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksF2nt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=133-142&author=B.+A.+Jessenauthor=L.+Leeauthor=T.+Koudriakovaauthor=M.+Hainesauthor=K.+Lundgrenauthor=S.+Priceauthor=J.+Nonomiyaauthor=C.+Lewisauthor=G.+J.+Stevens&title=Peripheral+white+blood+cell+toxicity+induced+by+broad+spectrum+cyclin-dependent+kinase+inhibitors&doi=10.1002%2Fjat.1177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors</span></div><div class="casAuthors">Jessen, Bart A.; Lee, Leo; Koudriakova, Tatiana; Haines, Morgan; Lundgren, Karen; Price, Sharon; Nonomiya, Jim; Lewis, Cristina; Stevens, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-142</span>CODEN:
                <span class="NLM_cas:coden">JJATDK</span>;
        ISSN:<span class="NLM_cas:issn">0260-437X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) were pursued for more than a decade for the treatment of cancer.  CDK inhibitors are expected to slow the rate of cell division and potentially increase the apoptotic fraction of rapidly dividing cells.  Although CDK activity is often increased in tumors, normal dividing tissues are also susceptible to the cytostatic and cytotoxic effects of CDK inhibitor action.  Therefore the typical toxicity profile assocd. with cytotoxic anti-cancer therapy, bone marrow suppression and gastrointestinal toxicity, is expected with CDK inhibitors.  Bone marrow toxicity and the ensuing delayed peripheral leukocyte suppression often limit the therapeutic application of cytotoxic anticancer drugs.  Here we characterize an unusual bone marrow-independent acute toxicity toward leukocytes from broad spectrum CDK inhibitors in monkeys and rodents.  The potential combination of both acute and delayed immunosuppression would likely further restrict the application of these particular compds.  Since the cells targeted were non-proliferating, it was assumed that the toxicity was not driven by the intended pharmacol. mechanism thereby facilitating the development of a testing strategy to identify compds. with a reduced potential for acute leukocyte toxicity.  This testing strategy resulted in a CDK inhibitor void of bone marrow-independent leukocyte toxicity that is currently undergoing clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiTrhjO_2vsbVg90H21EOLACvtfcHk0lh3yPLl1nAN4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksF2nt70%253D&md5=d8d707eaa40d555e176c15336c8e885b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fjat.1177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjat.1177%26sid%3Dliteratum%253Aachs%26aulast%3DJessen%26aufirst%3DB.%2BA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DHaines%26aufirst%3DM.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DStevens%26aufirst%3DG.%2BJ.%26atitle%3DPeripheral%2520white%2520blood%2520cell%2520toxicity%2520induced%2520by%2520broad%2520spectrum%2520cyclin-dependent%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Appl.%2520Toxicol.%26date%3D2007%26volume%3D27%26spage%3D133%26epage%3D142%26doi%3D10.1002%2Fjat.1177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santamaría, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrière, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerqueira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cáceres, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Cdk1 is sufficient to drive the mammalian cell cycle</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">811</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1038/nature06046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1038%2Fnature06046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=17700700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=811-815&author=D.+Santamar%C3%ADaauthor=C.+Barri%C3%A8reauthor=A.+Cerqueiraauthor=S.+Huntauthor=C.+Tardyauthor=K.+Newtonauthor=J.+F.+C%C3%A1ceresauthor=P.+Dubusauthor=M.+Malumbresauthor=M.+Barbacid&title=Cdk1+is+sufficient+to+drive+the+mammalian+cell+cycle&doi=10.1038%2Fnature06046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cdk1 is sufficient to drive the mammalian cell cycle</span></div><div class="casAuthors">Santamaria, David; Barriere, Cedric; Cerqueira, Antonio; Hunt, Sarah; Tardy, Claudine; Newton, Kathryn; Caceres, Javier F.; Dubus, Pierre; Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7155</span>),
    <span class="NLM_cas:pages">811-815</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Unicellular organisms such as yeasts require a single cyclin-dependent kinase, Cdk1, to drive cell division.  In contrast, mammalian cells are thought to require the sequential activation of at least four different cyclin-dependent kinases, Cdk2, Cdk3, Cdk4 and Cdk6, to drive cells through interphase, as well as Cdk1 to proceed through mitosis.  This model has been challenged by recent genetic evidence that mice survive in the absence of individual interphase Cdks.  Moreover, most mouse cell types proliferate in the absence of two or even three interphase Cdks.  Similar results have been obtained on ablation of some of the activating subunits of Cdks, such as the D-type and E-type cyclins.  Here we show that mouse embryos lacking all interphase Cdks (Cdk2, Cdk3, Cdk4 and Cdk6) undergo organogenesis and develop to midgestation.  In these embryos, Cdk1 binds to all cyclins, resulting in the phosphorylation of the retinoblastoma protein pRb and the expression of genes that are regulated by E2F transcription factors.  Mouse embryonic fibroblasts derived from these embryos proliferate in vitro, albeit with an extended cell cycle due to inefficient inactivation of Rb proteins.  However, they become immortal on continuous passage.  We also report that embryos fail to develop to the morula and blastocyst stages in the absence of Cdk1.  These results indicate that Cdk1 is the only essential cell cycle Cdk.  Moreover, they show that in the absence of interphase Cdks, Cdk1 can execute all the events that are required to drive cell division.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhEdshMg-kRLVg90H21EOLACvtfcHk0likKgIT-Z7kFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGrsL8%253D&md5=d427cb68fc6c8758df24423761a89264</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnature06046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06046%26sid%3Dliteratum%253Aachs%26aulast%3DSantamar%25C3%25ADa%26aufirst%3DD.%26aulast%3DBarri%25C3%25A8re%26aufirst%3DC.%26aulast%3DCerqueira%26aufirst%3DA.%26aulast%3DHunt%26aufirst%3DS.%26aulast%3DTardy%26aufirst%3DC.%26aulast%3DNewton%26aufirst%3DK.%26aulast%3DC%25C3%25A1ceres%26aufirst%3DJ.%2BF.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCdk1%2520is%2520sufficient%2520to%2520drive%2520the%2520mammalian%2520cell%2520cycle%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D811%26epage%3D815%26doi%3D10.1038%2Fnature06046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinisch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fligge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T.</span></span> <span> </span><span class="NLM_article-title">A consistent dataset of kinetic solubilities for early-phase drug discovery</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1529</span>– <span class="NLM_lpage">1536</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1002%2Fcmdc.200900205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=19588473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKgtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1529-1536&author=C.+Kramerauthor=T.+Heinischauthor=T.+Fliggeauthor=B.+Beckauthor=T.+Clark&title=A+consistent+dataset+of+kinetic+solubilities+for+early-phase+drug+discovery&doi=10.1002%2Fcmdc.200900205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A Consistent Dataset of Kinetic Solubilities for Early-Phase Drug Discovery</span></div><div class="casAuthors">Kramer, Christian; Heinisch, Tilmann; Fligge, Thilo; Beck, Bernd; Clark, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1529-1536</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein, we describe a new dataset of kinetic aq. solubilities detd. by nephelometry for 711 druglike compds.  The solubilities are reported in twelve classes ranging from <2 μg mL-1 to >250 μg mL-1.  The measurements were designed to provide the appropriate data for applications in the early phases of drug discovery.  Three class classification models (insol., moderately sol., sol.) were built using the random forest algorithm and their performance for this dataset was analyzed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5DAHS8E_FV7Vg90H21EOLACvtfcHk0likKgIT-Z7kFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKgtb%252FN&md5=2035434a4259a5a2e5a2eb5d34d121e3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900205%26sid%3Dliteratum%253Aachs%26aulast%3DKramer%26aufirst%3DC.%26aulast%3DHeinisch%26aufirst%3DT.%26aulast%3DFligge%26aufirst%3DT.%26aulast%3DBeck%26aufirst%3DB.%26aulast%3DClark%26aufirst%3DT.%26atitle%3DA%2520consistent%2520dataset%2520of%2520kinetic%2520solubilities%2520for%2520early-phase%2520drug%2520discovery%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D1529%26epage%3D1536%26doi%3D10.1002%2Fcmdc.200900205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span> <span> </span><span class="NLM_article-title">Defining optimum lipophilicity and molecular weight ranges for drug candidates-molecular weight dependent lower log D limits based on permeability</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2844</span>– <span class="NLM_lpage">2851</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.03.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.bmcl.2009.03.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=19361989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltl2rtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2844-2851&author=M.+J.+Waring&title=Defining+optimum+lipophilicity+and+molecular+weight+ranges+for+drug+candidates-molecular+weight+dependent+lower+log+D+limits+based+on+permeability&doi=10.1016%2Fj.bmcl.2009.03.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower log D limits based on permeability</span></div><div class="casAuthors">Waring, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2844-2851</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Anal. of a large, structurally diverse Caco-2 permeability dataset using a variety of statistical techniques suggests that log D and mol. wt. are the most important factors in detg. the permeability of drug candidates.  The limit for log D is shown to be dependent on mol. wt.  These limits are shown to be potentially superior to current guidelines in increasing the chances of finding highly permeable compds.  When combined with suggested upper limits for lipophilicity suggested in the literature based on the avoidance of toxicol. and other adverse effects, this helps define a lipophilicity range that is optimum for drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXwn3KyrzERrVg90H21EOLACvtfcHk0lg_KXD0ZrxWUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltl2rtr0%253D&md5=1f04795ddf6e6b84d132a81e554c2516</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.03.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.03.109%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DDefining%2520optimum%2520lipophilicity%2520and%2520molecular%2520weight%2520ranges%2520for%2520drug%2520candidates-molecular%2520weight%2520dependent%2520lower%2520log%2520D%2520limits%2520based%2520on%2520permeability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2844%26epage%3D2851%26doi%3D10.1016%2Fj.bmcl.2009.03.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dress, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span> <span> </span><span class="NLM_article-title">Using the golden triangle to optimize clearance and oral absorption</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5560</span>– <span class="NLM_lpage">5564</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.08.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.bmcl.2009.08.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=19720530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFaktbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5560-5564&author=T.+W.+Johnsonauthor=K.+R.+Dressauthor=M.+Edwards&title=Using+the+golden+triangle+to+optimize+clearance+and+oral+absorption&doi=10.1016%2Fj.bmcl.2009.08.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Using the Golden Triangle to optimize clearance and oral absorption</span></div><div class="casAuthors">Johnson, Ted W.; Dress, Klaus R.; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5560-5564</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The Golden Triangle is a visualization tool developed from in vitro permeability, in vitro clearance and computational data designed to aid medicinal chemists in achieving metabolically stable, permeable and potent drug candidates.  Classifying compds. as permeable and stable and plotting mol. wt. (MW) vs. octanol:buffer (pH 7.4) distribution coeffs. (log D) or estd. octanol:buffer (pH 7.4) distribution coeffs. (elog D) reveals useful trends.  Anal. of at least 2 orthogonal trends, such as permeability and clearance, can be extremely effective in balancing and optimizing multiple properties.  In addn., mol. wt. and log D impact potency-efficiency calcns., allowing potency, clearance and permeability to be optimized simultaneously.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjGjEaOp0237Vg90H21EOLACvtfcHk0lg_KXD0ZrxWUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFaktbfE&md5=3cfed1288ec451eb4419f1db753ae4b4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.08.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.08.045%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DDress%26aufirst%3DK.%2BR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DUsing%2520the%2520golden%2520triangle%2520to%2520optimize%2520clearance%2520and%2520oral%2520absorption%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5560%26epage%3D5564%26doi%3D10.1016%2Fj.bmcl.2009.08.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattei, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent roche compounds</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">686</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200800411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1002%2Fcmdc.200800411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=19266525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltlCgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=680-686&author=J.-U.+Petersauthor=P.+Schniderauthor=P.+Matteiauthor=M.+Kansy&title=Pharmacological+promiscuity%3A+dependence+on+compound+properties+and+target+specificity+in+a+set+of+recent+roche+compounds&doi=10.1002%2Fcmdc.200800411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds</span></div><div class="casAuthors">Peters, Jens-Uwe; Schnider, Patrick; Mattei, Patrizio; Kansy, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">680-686</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">What parameters det. promiscuity A compd.'s potential for promiscuity (pharmacol. activity at multiple targets) may be influenced by mol. parameters such as ionization state, lipophilicity, and mol. wt.  In an anal. of recent Roche compds. we found that a pos. charge is an important determinant for potential promiscuity; aminergic activity was the main reason for overt promiscuity.  The term "pharmacol. promiscuity" describes a compd.'s pharmacol. activity at multiple targets.  Pharmacol. promiscuity is undesired in typical drug discovery projects, which focus on the "one drug-one target" paradigm.  Off-target activity can lead to adverse drug reactions, or can obscure pharmacodynamic effects in animal models.  Therefore, advanced lead compds., pharmacol. tool compds., and drug candidates are usually screened against panels of safety-relevant targets to detect unwanted pharmacol. activities.  To identify determinants of pharmacol. promiscuity, we compared the panel screening outcomes of 213 recent Roche compds. with their mol. properties.  Pronounced promiscuity was not obsd. below a threshold Clog P value of 2.  For basic compds., the propensity for weak off-target activity was found to increase with calcd. basicities, whereas the potential for strong off-target activity depends more qual. on the presence of a pos. charge at physiol. pH.  Compds. originating from projects with an aminergic receptor or transporter as a therapeutic target are particularly prone to promiscuity; the promiscuity of such compds. is mainly caused by their activity at other aminergic targets in the screening panel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXk5b2yXWf27Vg90H21EOLACvtfcHk0lg_KXD0ZrxWUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltlCgsbc%253D&md5=6169ec58443249fb4fc8b2d694ba4164</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200800411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200800411%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26aulast%3DSchnider%26aufirst%3DP.%26aulast%3DMattei%26aufirst%3DP.%26aulast%3DKansy%26aufirst%3DM.%26atitle%3DPharmacological%2520promiscuity%253A%2520dependence%2520on%2520compound%2520properties%2520and%2520target%2520specificity%2520in%2520a%2520set%2520of%2520recent%2520roche%2520compounds%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D680%26epage%3D686%26doi%3D10.1002%2Fcmdc.200800411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman-Cook, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span> <span> </span><span class="NLM_article-title">Lipophilic efficiency: the most important efficiency metric in medicinal chemistry</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.4155/fmc.12.208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.4155%2Ffmc.12.208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=23360135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1aiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=113-115&author=K.+D.+Freeman-Cookauthor=R.+L.+Hoffmanauthor=T.+W.+Johnson&title=Lipophilic+efficiency%3A+the+most+important+efficiency+metric+in+medicinal+chemistry&doi=10.4155%2Ffmc.12.208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic efficiency: the most important efficiency metric in medicinal chemistry</span></div><div class="casAuthors">Freeman-Cook, Kevin D.; Hoffman, Robert L.; Johnson, Ted W.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-115</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review is given on the crit. role of lipophilicity in drug discovery and optimization of general absorption, distribution, metab. and excretion properties, toxicol. profiles and ultimately pharmacol. response.  Math. equations are presented concerning the impact of lipophilicity on the dose and the calcn. of the lipophilic ligand efficiency (LipE).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKhEHH7Hf1qbVg90H21EOLACvtfcHk0lgBRD1c5H2S0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1aiu7g%253D&md5=36170decfa1f1e3ef09ecf772322a210</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.208%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman-Cook%26aufirst%3DK.%2BD.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26atitle%3DLipophilic%2520efficiency%253A%2520the%2520most%2520important%2520efficiency%2520metric%2520in%2520medicinal%2520chemistry%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26spage%3D113%26epage%3D115%26doi%3D10.4155%2Ffmc.12.208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlingame, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Broad-spectrum kinase profiling in live cells with lysine-targeted sulfonyl fluoride probes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">685</span>, <span class="refDoi"> DOI: 10.1021/jacs.6b08536</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b08536" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=680-685&author=Q.+Zhaoauthor=X.+Ouyangauthor=X.+Wanauthor=K.+S.+Gajiwalaauthor=J.+C.+Kathauthor=L.+H.+Jonesauthor=A.+L.+Burlingameauthor=J.+Taunton&title=Broad-spectrum+kinase+profiling+in+live+cells+with+lysine-targeted+sulfonyl+fluoride+probes&doi=10.1021%2Fjacs.6b08536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes</span></div><div class="casAuthors">Zhao, Qian; Ouyang, Xiaohu; Wan, Xiaobo; Gajiwala, Ketan S.; Kath, John C.; Jones, Lyn H.; Burlingame, Alma L.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">680-685</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein kinases comprise a large family of structurally related enzymes.  A major goal in kinase inhibitor development is to selectively engage the desired kinase while avoiding myriad off-target kinases.  However, quantifying inhibitor interactions with multiple endogenous kinases in live cells remains an unmet challenge.  Here, we report the design of sulfonyl fluoride probes that covalently label a broad swath of the intracellular kinome with high efficiency.  Protein crystallog. and mass spectrometry (MS) confirmed a chemoselective reaction between the sulfonyl fluoride and a conserved lysine in the ATP binding site.  Optimized probe 2 (XO44) covalently modified up to 133 endogenous kinases, efficiently competing with high intracellular concns. of ATP.  We employed probe 2 and label-free mass spectrometry to quantify intracellular kinase engagement by the approved drug, dasatinib.  The data revealed saturable dasatinib binding to a small subset of kinase targets at clin. relevant concns., highlighting the utility of lysine-targeted sulfonyl fluoride probes in demanding chemoproteomic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHvHZRDHN2IbVg90H21EOLACvtfcHk0lgBRD1c5H2S0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWisA%253D%253D&md5=3f643a1b32c83fa05932f42b54e96e47</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b08536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b08536%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DOuyang%26aufirst%3DX.%26aulast%3DWan%26aufirst%3DX.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DBurlingame%26aufirst%3DA.%2BL.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DBroad-spectrum%2520kinase%2520profiling%2520in%2520live%2520cells%2520with%2520lysine-targeted%2520sulfonyl%2520fluoride%2520probes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2017%26volume%3D139%26spage%3D680%26epage%3D685%26doi%3D10.1021%2Fjacs.6b08536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Free, S. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. W.</span></span> <span> </span><span class="NLM_article-title">A mathematical contribution to structure-activity studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1964</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1021/jm00334a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00334a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADyaF2cXkt1OltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1964&pages=395-399&author=S.+M.+Freeauthor=J.+W.+Wilson&title=A+mathematical+contribution+to+structure-activity+studies&doi=10.1021%2Fjm00334a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A mathematical contribution to structure-activity studies</span></div><div class="casAuthors">Free, Spencer M., Jr.; Wilson, James W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1964</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">395-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A math. technique is suggested as a means of describing structure-activity relation of a series of chem. analogs.  The data requirements included specific side chain arrangements and performance characteristics of all analogs tested.  Two examples illustrate the use of the additive math. model where the performance characteristics are measures of biol. activity.  The results rank the structural changes per position by estg. the amt. of biol. response attributed to each change.  The estimates are both pos. and neg.  Several uses for the math. soln. are suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRyTj3xI-aH7Vg90H21EOLACvtfcHk0lgBRD1c5H2S0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2cXkt1OltbY%253D&md5=88fabb64d7a5635506a11418a2744bd6</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm00334a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00334a001%26sid%3Dliteratum%253Aachs%26aulast%3DFree%26aufirst%3DS.%2BM.%26aulast%3DWilson%26aufirst%3DJ.%2BW.%26atitle%3DA%2520mathematical%2520contribution%2520to%2520structure-activity%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1964%26volume%3D7%26spage%3D395%26epage%3D399%26doi%3D10.1021%2Fjm00334a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman-Cook, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzon, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirico, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henegar, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houser, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limberakis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loomis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPherson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murdande, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillion, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugarman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span> <span> </span><span class="NLM_article-title">Maximizing lipophilic efficiency: The use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1021/jm201503u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201503u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=935-942&author=K.+D.+Freeman-Cookauthor=P.+Amorauthor=S.+Baderauthor=L.+M.+Buzonauthor=S.+B.+Coffeyauthor=J.+W.+Corbettauthor=K.+J.+Diricoauthor=S.+D.+Doranauthor=R.+L.+Elliottauthor=W.+Eslerauthor=A.+Guzman-Perezauthor=K.+E.+Henegarauthor=J.+A.+Houserauthor=C.+S.+Jonesauthor=C.+Limberakisauthor=K.+Loomisauthor=K.+McPhersonauthor=S.+Murdandeauthor=K.+L.+Nelsonauthor=D.+Phillionauthor=B.+S.+Pierceauthor=W.+Songauthor=E.+Sugarmanauthor=S.+Tapleyauthor=M.+Tuauthor=Z.+Zhao&title=Maximizing+lipophilic+efficiency%3A+The+use+of+Free-Wilson+analysis+in+the+design+of+inhibitors+of+acetyl-CoA+carboxylase&doi=10.1021%2Fjm201503u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Maximizing lipophilic efficiency: The use of free-wilson analysis in the design of inhibitors of acetyl-CoA carboxylase</span></div><div class="casAuthors">Freeman-Cook, Kevin D.; Amor, Paul; Bader, Scott; Buzon, Leanne M.; Coffey, Steven B.; Corbett, Jeffrey W.; Dirico, Kenneth J.; Doran, Shawn D.; Elliott, Richard L.; Esler, William; Guzman-Perez, Angel; Henegar, Kevin E.; Houser, Janet A.; Jones, Christopher S.; Limberakis, Chris; Loomis, Katherine; McPherson, Kirk; Murdande, Sharad; Nelson, Kendra L.; Phillion, Dennis; Pierce, Betsy S.; Song, Wei; Sugarman, Eliot; Tapley, Susan; Tu, Meihua; Zhao, Zhengrong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">935-942</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper describes the design and synthesis of a novel series of dual inhibitors of acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2).  Key findings include the discovery of an initial lead that was modestly potent and subsequent medicinal chem. optimization with a focus on lipophilic efficiency (LipE) to balance overall drug-like properties.  Free-Wilson methodol. provided a clear breakdown of the contributions of specific structural elements to the overall LipE, a rationale for prioritization of virtual compds. for synthesis, and a highly successful prediction of the LipE of the resulting analogs.  Further preclin. assays, including in vivo malonyl-CoA redn. in both rat liver (ACC1) and rat muscle (ACC2), identified an advanced analog that progressed to regulatory toxicity studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGo75v6CKldrVg90H21EOLACvtfcHk0ljuKtAfOsp8hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurjO&md5=ba269e25003f009951bb595741655ea2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm201503u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201503u%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman-Cook%26aufirst%3DK.%2BD.%26aulast%3DAmor%26aufirst%3DP.%26aulast%3DBader%26aufirst%3DS.%26aulast%3DBuzon%26aufirst%3DL.%2BM.%26aulast%3DCoffey%26aufirst%3DS.%2BB.%26aulast%3DCorbett%26aufirst%3DJ.%2BW.%26aulast%3DDirico%26aufirst%3DK.%2BJ.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DElliott%26aufirst%3DR.%2BL.%26aulast%3DEsler%26aufirst%3DW.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DHenegar%26aufirst%3DK.%2BE.%26aulast%3DHouser%26aufirst%3DJ.%2BA.%26aulast%3DJones%26aufirst%3DC.%2BS.%26aulast%3DLimberakis%26aufirst%3DC.%26aulast%3DLoomis%26aufirst%3DK.%26aulast%3DMcPherson%26aufirst%3DK.%26aulast%3DMurdande%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DK.%2BL.%26aulast%3DPhillion%26aufirst%3DD.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSong%26aufirst%3DW.%26aulast%3DSugarman%26aufirst%3DE.%26aulast%3DTapley%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DZ.%26atitle%3DMaximizing%2520lipophilic%2520efficiency%253A%2520The%2520use%2520of%2520Free-Wilson%2520analysis%2520in%2520the%2520design%2520of%2520inhibitors%2520of%2520acetyl-CoA%2520carboxylase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D935%26epage%3D942%26doi%3D10.1021%2Fjm201503u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman-Cook, K.</span>; <span class="NLM_string-name">Hoffman, R. L.</span>; <span class="NLM_string-name">Miller, N.</span>; <span class="NLM_string-name">Nguyen, L.</span>; <span class="NLM_string-name">Wang, T.</span>; <span class="NLM_string-name">Almaden, J.</span>; <span class="NLM_string-name">Chionis, J.</span>; <span class="NLM_string-name">Eisele, K.</span>; <span class="NLM_string-name">Liu, C.</span>; <span class="NLM_string-name">Zhang, Q.</span>; <span class="NLM_string-name">Niessen, S.</span>; <span class="NLM_string-name">Lapek, J.</span>; <span class="NLM_string-name">Weinrich, S. L.</span>; <span class="NLM_string-name">Wei, P.</span>; <span class="NLM_string-name">Carelli, J.</span>; <span class="NLM_string-name">Lee, N.</span>; <span class="NLM_string-name">Zhang, C.</span>; <span class="NLM_string-name">Huser, N.</span>; <span class="NLM_string-name">Looper, D.</span>; <span class="NLM_string-name">Ninkovic, S.</span>; <span class="NLM_string-name">McTigue, M.</span>; <span class="NLM_string-name">Behenna, D.</span>; <span class="NLM_string-name">Ferre, R. A.</span>; <span class="NLM_string-name">He, Y.</span>; <span class="NLM_string-name">Tran, K. T.</span>; <span class="NLM_string-name">Sutton, S.</span>; <span class="NLM_string-name">Zehnder, L. R.</span>; <span class="NLM_string-name">Kephart, S. E.</span>; <span class="NLM_string-name">Nagata, A.</span>; <span class="NLM_string-name">Ornelas, M. A.</span>; <span class="NLM_string-name">Murray, B.</span>; <span class="NLM_string-name">Xu, M.</span>; <span class="NLM_string-name">Solowiej, J. E.</span>; <span class="NLM_string-name">Visswanathan, R.</span>; <span class="NLM_string-name">Boras, B.</span>; <span class="NLM_string-name">Wilson, E.</span>; <span class="NLM_string-name">Oderup, C.</span>; <span class="NLM_string-name">Salek-Ardakani, S.</span>; <span class="NLM_string-name">Zhu, Z.</span>; <span class="NLM_string-name">McMillan, E.</span>; <span class="NLM_string-name">Mu, X. J.</span>; <span class="NLM_string-name">Ding, Y.</span>; <span class="NLM_string-name">Kan, Z.</span>; <span class="NLM_string-name">Bienkowska, J. R.</span>; <span class="NLM_string-name">VanArsdale, T.</span>; <span class="NLM_string-name">White, M. A.</span>; <span class="NLM_string-name">Dann, S. G.</span></span> <span> </span><span class="NLM_article-title">Expanding control of the tumor cell cycle; discovery of the CDK2/4/6 inhibitor PF-06873600</span> <i>Cancer Cell</i>. Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Freeman-Cook%2C+K.%3B+Hoffman%2C+R.+L.%3B+Miller%2C+N.%3B+Nguyen%2C+L.%3B+Wang%2C+T.%3B+Almaden%2C+J.%3B+Chionis%2C+J.%3B+Eisele%2C+K.%3B+Liu%2C+C.%3B+Zhang%2C+Q.%3B+Niessen%2C+S.%3B+Lapek%2C+J.%3B+Weinrich%2C+S.+L.%3B+Wei%2C+P.%3B+Carelli%2C+J.%3B+Lee%2C+N.%3B+Zhang%2C+C.%3B+Huser%2C+N.%3B+Looper%2C+D.%3B+Ninkovic%2C+S.%3B+McTigue%2C+M.%3B+Behenna%2C+D.%3B+Ferre%2C+R.+A.%3B+He%2C+Y.%3B+Tran%2C+K.+T.%3B+Sutton%2C+S.%3B+Zehnder%2C+L.+R.%3B+Kephart%2C+S.+E.%3B+Nagata%2C+A.%3B+Ornelas%2C+M.+A.%3B+Murray%2C+B.%3B+Xu%2C+M.%3B+Solowiej%2C+J.+E.%3B+Visswanathan%2C+R.%3B+Boras%2C+B.%3B+Wilson%2C+E.%3B+Oderup%2C+C.%3B+Salek-Ardakani%2C+S.%3B+Zhu%2C+Z.%3B+McMillan%2C+E.%3B+Mu%2C+X.+J.%3B+Ding%2C+Y.%3B+Kan%2C+Z.%3B+Bienkowska%2C+J.+R.%3B+VanArsdale%2C+T.%3B+White%2C+M.+A.%3B+Dann%2C+S.+G.+Expanding+control+of+the+tumor+cell+cycle%3B+discovery+of+the+CDK2%2F4%2F6+inhibitor+PF-06873600+Cancer+Cell.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman-Cook%26aufirst%3DK.%26atitle%3DExpanding%2520control%2520of%2520the%2520tumor%2520cell%2520cycle%253B%2520discovery%2520of%2520the%2520CDK2%252F4%252F6%2520inhibitor%2520PF-06873600%26jtitle%3DCancer%2520Cell" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney-Pickett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umland, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhard, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federico, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-kattan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span> <span> </span><span class="NLM_article-title">Development of a new permeability assay using low-efflux MDCKII cells</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">4974</span>– <span class="NLM_lpage">4985</span>, <span class="refDoi"> DOI: 10.1002/jps.22674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&author=L.+Diauthor=C.+Whitney-Pickettauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+new+permeability+assay+using+low-efflux+MDCKII+cells&doi=10.1002%2Fjps.22674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0ljuKtAfOsp8hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520new%2520permeability%2520assay%2520using%2520low-efflux%2520MDCKII%2520cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26spage%3D4974%26epage%3D4985%26doi%3D10.1002%2Fjps.22674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welcker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clurman, B. E.</span></span> <span> </span><span class="NLM_article-title">Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2014.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.ccell.2014.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=25314076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGnsLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=455-464&author=R.+J.+Davisauthor=M.+Welckerauthor=B.+E.+Clurman&title=Tumor+suppression+by+the+Fbw7+ubiquitin+ligase%3A+mechanisms+and+opportunities&doi=10.1016%2Fj.ccell.2014.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor Suppression by the Fbw7 Ubiquitin Ligase: Mechanisms and Opportunities</span></div><div class="casAuthors">Davis, Ryan J.; Welcker, Markus; Clurman, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">455-464</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Tumor suppressors with widespread impact on carcinogenesis control broad spectra of oncogenic pathways.  Protein degrdn. is an emerging mechanism by which tumor suppressors regulate a diversity of pathways and is exemplified by the SCFFbw7 ubiquitin ligase.  Rapidly accumulating data indicate that SCFFbw7 regulates a network of crucial oncoproteins.  Importantly, the FBXW7 gene, which encodes Fbw7, is one of the most frequently mutated genes in human cancers.  These studies are yielding important new insights into tumorigenesis and may soon enable therapies targeting the Fbw7 pathway.  Here, we focus on the mechanisms and consequences of Fbw7 deregulation in cancers and discuss possible therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1yVPOzpMverVg90H21EOLACvtfcHk0ljvq7GZpVODdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGnsLzL&md5=4a336cec1030cdeab7ef4e99aa24767a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2014.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2014.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BJ.%26aulast%3DWelcker%26aufirst%3DM.%26aulast%3DClurman%26aufirst%3DB.%2BE.%26atitle%3DTumor%2520suppression%2520by%2520the%2520Fbw7%2520ubiquitin%2520ligase%253A%2520mechanisms%2520and%2520opportunities%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26spage%3D455%26epage%3D464%26doi%3D10.1016%2Fj.ccell.2014.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inuzuka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpen, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">FBW7 loss promotes chromosomal instability and tumorigenesis via cyclin E1/CDK2-mediated phosphorylation of CENP-A</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">4881</span>– <span class="NLM_lpage">4893</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-17-1240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1158%2F0008-5472.CAN-17-1240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=28760857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsV2lsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4881-4893&author=M.+Takadaauthor=W.+Zhangauthor=A.+Suzukiauthor=T.+S.+Kurodaauthor=Z.+Yuauthor=H.+Inuzukaauthor=D.+Gaoauthor=L.+Wanauthor=M.+Zhuangauthor=L.+Huauthor=B.+Zhaiauthor=C.+J.+Fryauthor=K.+Bloomauthor=G.+Liauthor=G.+H.+Karpenauthor=W.+Weiauthor=Q.+Zhang&title=FBW7+loss+promotes+chromosomal+instability+and+tumorigenesis+via+cyclin+E1%2FCDK2-mediated+phosphorylation+of+CENP-A&doi=10.1158%2F0008-5472.can-17-1240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">FBW7 Loss Promotes Chromosomal Instability and Tumorigenesis via Cyclin E1/CDK2-Mediated Phosphorylation of CENP-A</span></div><div class="casAuthors">Takada, Mamoru; Zhang, Weiguo; Suzuki, Aussie; Kuroda, Taruho S.; Yu, Zhouliang; Inuzuka, Hiroyuki; Gao, Daming; Wan, Lixin; Zhuang, Ming; Hu, Lianxin; Zhai, Bo; Fry, Christopher J.; Bloom, Kerry; Li, Guohong; Karpen, Gary H.; Wei, Wenyi; Zhang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4881-4893</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The centromere regulates proper chromosome segregation, and its dysfunction is implicated in chromosomal instability (CIN).  However, relatively little is known about how centromere dysfunction occurs in cancer.  Here, we define the consequences of phosphorylation by cyclin E1/CDK2 on a conserved Ser18 residue of centromere-assocd. protein CENP-A, an essential histone H3 variant that specifies centromere identity.  Ser18 hyperphosphorylation in cells occurred upon loss of FBW7, a tumor suppressor whose inactivation leads to CIN.  This event on CENP-A reduced its centromeric localization, increased CIN, and promoted anchorage-independent growth and xenograft tumor formation.  Overall, our results revealed a pathway that cyclin E1/CDK2 activation coupled with FBW7 loss promotes CIN and tumor progression via CENP-A-mediated centromere dysfunction.  Cancer Res; 77(18); 4881-93. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZBe5nL7w7gLVg90H21EOLACvtfcHk0ljvq7GZpVODdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsV2lsrbP&md5=fd7ba5b64b4d17f2b6c19ce77259bd1b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-1240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-1240%26sid%3Dliteratum%253Aachs%26aulast%3DTakada%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DKuroda%26aufirst%3DT.%2BS.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DInuzuka%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DZhuang%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DB.%26aulast%3DFry%26aufirst%3DC.%2BJ.%26aulast%3DBloom%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DKarpen%26aufirst%3DG.%2BH.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DFBW7%2520loss%2520promotes%2520chromosomal%2520instability%2520and%2520tumorigenesis%2520via%2520cyclin%2520E1%252FCDK2-mediated%2520phosphorylation%2520of%2520CENP-A%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D4881%26epage%3D4893%26doi%3D10.1158%2F0008-5472.can-17-1240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokheim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta-Pardo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerasinghe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colaprico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendl, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reardon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, P. K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mularoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubio-Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarajan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Ciriano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yellapantula, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamborero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suphavilai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khurana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Allen, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godzik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Bigas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karchin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span> <span> </span><span class="NLM_article-title">Comprehensive characterization of cancer driver genes and mutations</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.02.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.cell.2018.02.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=29625053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntFaiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2018&pages=371-385&author=M.+H.+Baileyauthor=C.+Tokheimauthor=E.+Porta-Pardoauthor=S.+Senguptaauthor=D.+Bertrandauthor=A.+Weerasingheauthor=A.+Colapricoauthor=M.+C.+Wendlauthor=J.+Kimauthor=B.+Reardonauthor=P.+K.-S.+Ngauthor=K.+J.+Jeongauthor=S.+Caoauthor=Z.+Wangauthor=J.+Gaoauthor=Q.+Gaoauthor=F.+Wangauthor=E.+M.+Liuauthor=L.+Mularoniauthor=C.+Rubio-Perezauthor=N.+Nagarajanauthor=I.+Cortes-Cirianoauthor=D.+C.+Zhouauthor=W.-W.+Liangauthor=J.+M.+Hessauthor=V.+D.+Yellapantulaauthor=D.+Tamboreroauthor=A.+Gonzalez-Perezauthor=C.+Suphavilaiauthor=J.+Y.+Koauthor=E.+Khuranaauthor=P.+J.+Parkauthor=E.+M.+Van+Allenauthor=H.+Liangauthor=M.+S.+Lawrenceauthor=A.+Godzikauthor=N.+Lopez-Bigasauthor=J.+Stuartauthor=D.+Wheelerauthor=G.+Getzauthor=K.+Chenauthor=A.+J.+Lazarauthor=G.+B.+Millsauthor=R.+Karchinauthor=L.+Ding&title=Comprehensive+characterization+of+cancer+driver+genes+and+mutations&doi=10.1016%2Fj.cell.2018.02.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive Characterization of Cancer Driver Genes and Mutations</span></div><div class="casAuthors">Bailey, Matthew H.; Tokheim, Collin; Porta-Pardo, Eduard; Sengupta, Sohini; Bertrand, Denis; Weerasinghe, Amila; Colaprico, Antonio; Wendl, Michael C.; Kim, Jaegil; Reardon, Brendan; Ng, Patrick Kwok-Shing; Jeong, Kang Jin; Cao, Song; Wang, Zixing; Gao, Jianjiong; Gao, Qingsong; Wang, Fang; Liu, Eric Minwei; Mularoni, Loris; Rubio-Perez, Carlota; Nagarajan, Niranjan; Cortes-Ciriano, Isidro; Zhou, Daniel Cui; Liang, Wen-Wei; Hess, Julian M.; Yellapantula, Venkata D.; Tamborero, David; Gonzalez-Perez, Abel; Suphavilai, Chayaporn; Ko, Jia Yu; Khurana, Ekta; Park, Peter J.; Van Allen, Eliezer M.; Liang, Han; Lawrence, Michael S.; Godzik, Adam; Lopez-Bigas, Nuria; Stuart, Josh; Wheeler, David; Getz, Gad; Chen, Ken; Lazar, Alexander J.; Mills, Gordon B.; Karchin, Rachel; Ding, Li</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">371-385.e18</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Identifying mol. cancer drivers is crit. for precision oncol.  Multiple advanced algorithms to identify drivers now exist, but systematic attempts to combine and optimize them on large datasets are few.  We report a PanCancer and PanSoftware anal. spanning 9,423 tumor exomes (comprising all 33 of The Cancer Genome Atlas projects) and using 26 computational tools to catalog driver genes and mutations.  We identify 299 driver genes with implications regarding their anatomical sites and cancer/cell types.  Sequence- and structure-based analyses identified >3,400 putative missense driver mutations supported by multiple lines of evidence.  Exptl. validation confirmed 60%-85% of predicted mutations as likely drivers.  We found that >300 MSI tumors are assocd. with high PD-1/PD-L1, and 57% of tumors analyzed harbor putative clin. actionable events.  Our study represents the most comprehensive discovery of cancer genes and mutations to date and will serve as a blueprint for future biol. and clin. endeavors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonwISc8tVS-LVg90H21EOLACvtfcHk0ljJw8puZ1iyZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntFaiu7c%253D&md5=6478ef37b82611e5687dcdc102cc6e98</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.02.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.02.060%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DM.%2BH.%26aulast%3DTokheim%26aufirst%3DC.%26aulast%3DPorta-Pardo%26aufirst%3DE.%26aulast%3DSengupta%26aufirst%3DS.%26aulast%3DBertrand%26aufirst%3DD.%26aulast%3DWeerasinghe%26aufirst%3DA.%26aulast%3DColaprico%26aufirst%3DA.%26aulast%3DWendl%26aufirst%3DM.%2BC.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DReardon%26aufirst%3DB.%26aulast%3DNg%26aufirst%3DP.%2BK.-S.%26aulast%3DJeong%26aufirst%3DK.%2BJ.%26aulast%3DCao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DE.%2BM.%26aulast%3DMularoni%26aufirst%3DL.%26aulast%3DRubio-Perez%26aufirst%3DC.%26aulast%3DNagarajan%26aufirst%3DN.%26aulast%3DCortes-Ciriano%26aufirst%3DI.%26aulast%3DZhou%26aufirst%3DD.%2BC.%26aulast%3DLiang%26aufirst%3DW.-W.%26aulast%3DHess%26aufirst%3DJ.%2BM.%26aulast%3DYellapantula%26aufirst%3DV.%2BD.%26aulast%3DTamborero%26aufirst%3DD.%26aulast%3DGonzalez-Perez%26aufirst%3DA.%26aulast%3DSuphavilai%26aufirst%3DC.%26aulast%3DKo%26aufirst%3DJ.%2BY.%26aulast%3DKhurana%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DP.%2BJ.%26aulast%3DVan%2BAllen%26aufirst%3DE.%2BM.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DLawrence%26aufirst%3DM.%2BS.%26aulast%3DGodzik%26aufirst%3DA.%26aulast%3DLopez-Bigas%26aufirst%3DN.%26aulast%3DStuart%26aufirst%3DJ.%26aulast%3DWheeler%26aufirst%3DD.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DLazar%26aufirst%3DA.%2BJ.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DKarchin%26aufirst%3DR.%26aulast%3DDing%26aufirst%3DL.%26atitle%3DComprehensive%2520characterization%2520of%2520cancer%2520driver%2520genes%2520and%2520mutations%26jtitle%3DCell%26date%3D2018%26volume%3D173%26spage%3D371%26epage%3D385%26doi%3D10.1016%2Fj.cell.2018.02.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greene, T. W.</span>; <span class="NLM_string-name">Wuts, P. G. M.</span></span> <i>Protective Groups in Organic Synthesis</i>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_publisher-name">John Wiley and Sons, Inc.</span>, <span class="NLM_year">1991</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&author=T.+W.+Greene&author=P.+G.+M.+Wuts&title=Protective+Groups+in+Organic+Synthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DT.%2BW.%26btitle%3DProtective%2520Groups%2520in%2520Organic%2520Synthesis%26pub%3DJohn%2520Wiley%2520and%2520Sons%252C%2520Inc%26date%3D1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">VanderWel, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repine, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quin, J.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booth, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrusin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span> <span> </span><span class="NLM_article-title">Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2371</span>– <span class="NLM_lpage">2387</span>, <span class="refDoi"> DOI: 10.1021/jm049355+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049355%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2371-2387&author=S.+N.+VanderWelauthor=P.+J.+Harveyauthor=D.+J.+McNamaraauthor=J.+T.+Repineauthor=P.+R.+Kellerauthor=J.+Quinauthor=R.+J.+Boothauthor=W.+L.+Elliottauthor=E.+M.+Dobrusinauthor=D.+W.+Fryauthor=P.+L.+Toogood&title=Pyrido%5B2%2C3-d%5Dpyrimidin-7-ones+as+specific+inhibitors+of+cyclin-dependent+kinase+4&doi=10.1021%2Fjm049355%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrido[2,3-d]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4</span></div><div class="casAuthors">VanderWel, Scott N.; Harvey, Patricia J.; McNamara, Dennis J.; Repine, Joseph T.; Keller, Paul R.; Quin, John, III; Booth, R. John; Elliott, William L.; Dobrusin, Ellen M.; Fry, David W.; Toogood, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2371-2387</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the cell cycle kinase, cyclin-dependent kinase-4 (Cdk4), is expected to provide an effective method for the treatment of proliferative diseases such as cancer.  The pyrido[2,3-d]pyrimidin-7-one template has been identified previously as a privileged structure for the inhibition of ATP-dependent kinases, and good potency against Cdks has been reported for representative examples.  Obtaining selectivity for individual Cdk enzymes, particularly Cdk4, has been challenging.  A series of pyrido[2,3-d]pyrimidin-7-ones I (R1 = Me2CH, Et2CH, cyclopentyl; R2 = H, Me, Et, F3C; R3 = H, Me, F, Cl, COMe, MeO2C, etc.; X = HOCH, H2NCH, CH2N, CH2CH2, etc.) was synthesized and investigated as selective inhibitors of Cdk4.  The introduction of a Me substituent at the C-5 position of the pyrido[2,3-d]pyrimidin-7-one template is sufficient to confer excellent selectivity for Cdk4 vs other Cdks and representative tyrosine kinases.  Further optimization led to the identification of highly potent and selective inhibitors of Cdk4 that exhibit potent antiproliferative activity against human tumor cells in vitro.  The most selective Cdk4 inhibitors were evaluated for antitumor activity against MDA-MB-435 human breast carcinoma xenografts in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKNHZHOwd7c7Vg90H21EOLACvtfcHk0ljJw8puZ1iyZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisLo%253D&md5=ef3c86bbdfaea0080d1103313d094ccd</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm049355%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049355%252B%26sid%3Dliteratum%253Aachs%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DQuin%26aufirst%3DJ.%26aulast%3DBooth%26aufirst%3DR.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26atitle%3DPyrido%255B2%252C3-d%255Dpyrimidin-7-ones%2520as%2520specific%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25204%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2371%26epage%3D2387%26doi%3D10.1021%2Fjm049355%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boschelli, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrusin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattaey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trumpp-Kallmeyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span> <span> </span><span class="NLM_article-title">Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4606</span>– <span class="NLM_lpage">4616</span>, <span class="refDoi"> DOI: 10.1021/jm000271k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000271k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvFarsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4606-4616&author=M.+Barvianauthor=D.+H.+Boschelliauthor=J.+Cossrowauthor=E.+Dobrusinauthor=A.+Fattaeyauthor=A.+Fritschauthor=D.+Fryauthor=P.+Harveyauthor=P.+Kellerauthor=M.+Garrettauthor=F.+Laauthor=W.+Leopoldauthor=D.+McNamaraauthor=M.+Quinauthor=S.+Trumpp-Kallmeyerauthor=P.+Toogoodauthor=Z.+Wuauthor=E.+Zhang&title=Pyrido%5B2%2C3-d%5Dpyrimidin-7-one+inhibitors+of+cyclin-dependent+kinases&doi=10.1021%2Fjm000271k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases</span></div><div class="casAuthors">Barvian, Mark; Boschelli, Dianne; Cossrow, Jennifer; Dobrusin, Ellen; Fattaey, Ali; Fritsch, Alex; Fry, David; Harvey, Patricia; Keller, Paul; Garrett, Michelle; La, Frances; Leopold, Wilbur; McNamara, Dennis; Quin, Marie; Trumpp-Kallmeyer, Susanne; Toogood, Peter; Wu, Zhipei; Zhang, Erli</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4606-4616</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The identification of 8-ethyl-2-phenylamino-8H-pyrido[2,3-d]pyrimidin-7-one as an inhibitor of Cdk4 led to the initiation of a program to evaluate related pyrido[2,3-d]pyrimidin-7-ones for inhibition of cyclin-dependent kinases (Cdks).  Anal. of more than 60 analogs has identified some clear SAR trends that may be exploited in the design of more potent Cdk inhibitors.  The most potent Cdk4 inhibitors reported in this study inhibit Cdk4 with IC50 = 0.004 μM ([ATP] = 25 μM).  X-ray crystallog. anal. of representative compds. bound to the related kinase, Cdk2, reveals that they occupy the ATP binding site.  Modest selectivity between Cdks is exhibited by some compds., and Cdk4-selective inhibitors block pRb+ cells in the G1-phase of the cell division cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2uxmolw6ZhLVg90H21EOLACvtfcHk0lh85txE4kyYXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvFarsbw%253D&md5=e200a37965f81edea7aecf673f33b837</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm000271k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000271k%26sid%3Dliteratum%253Aachs%26aulast%3DBarvian%26aufirst%3DM.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DCossrow%26aufirst%3DJ.%26aulast%3DDobrusin%26aufirst%3DE.%26aulast%3DFattaey%26aufirst%3DA.%26aulast%3DFritsch%26aufirst%3DA.%26aulast%3DFry%26aufirst%3DD.%26aulast%3DHarvey%26aufirst%3DP.%26aulast%3DKeller%26aufirst%3DP.%26aulast%3DGarrett%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DF.%26aulast%3DLeopold%26aufirst%3DW.%26aulast%3DMcNamara%26aufirst%3DD.%26aulast%3DQuin%26aufirst%3DM.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DToogood%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DE.%26atitle%3DPyrido%255B2%252C3-d%255Dpyrimidin-7-one%2520inhibitors%2520of%2520cyclin-dependent%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4606%26epage%3D4616%26doi%3D10.1021%2Fjm000271k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repine, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanderWel, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and selective inhibitor of cyclin-dependent Kinase 4/6</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2388</span>– <span class="NLM_lpage">2406</span>, <span class="refDoi"> DOI: 10.1021/jm049354h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+potent+and+selective+inhibitor+of+cyclin-dependent+Kinase+4%2F6&doi=10.1021%2Fjm049354h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0lg1ZczbPPouMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520Kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406%26doi%3D10.1021%2Fjm049354h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackmond, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, P. S.</span></span> <span> </span><span class="NLM_article-title">A new reagent for direct difluoromethylation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">1494</span>– <span class="NLM_lpage">1497</span>, <span class="refDoi"> DOI: 10.1021/ja211422g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja211422g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=1494-1497&author=Y.+Fujiwaraauthor=J.+A.+Dixonauthor=R.+A.+Rodriguezauthor=R.+D.+Baxterauthor=D.+D.+Dixonauthor=M.+R.+Collinsauthor=D.+G.+Blackmondauthor=P.+S.+Baran&title=A+new+reagent+for+direct+difluoromethylation&doi=10.1021%2Fja211422g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A New Reagent for Direct Difluoromethylation</span></div><div class="casAuthors">Fujiwara, Yuta; Dixon, Janice A.; Rodriguez, Rodrigo A.; Baxter, Ryan D.; Dixon, Darryl D.; Collins, Michael R.; Blackmond, Donna G.; Baran, Phil S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1494-1497</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. scaffolds contg. alkylfluorine substituents are desired in many areas of chem. research from materials to pharmaceuticals.  Herein, we report the invention of a new reagent (Zn(SO2CF2H)2, DFMS) for the innate difluoromethylation of org. substrates via a radical process.  This mild, operationally simple, chemoselective, and scalable difluoromethylation method is compatible with a range of nitrogen-contg. heteroarene substrates of varying complexity as well as select classes of conjugated π-systems and thiols.  Regiochem. comparisons suggest that the CF2H radical generated from the new reagent possesses nucleophilic character.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBZLaYVgv3d7Vg90H21EOLACvtfcHk0lg1ZczbPPouMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKlsA%253D%253D&md5=12c62a8451805995591a0fad95fa54f4</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fja211422g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja211422g%26sid%3Dliteratum%253Aachs%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DDixon%26aufirst%3DJ.%2BA.%26aulast%3DRodriguez%26aufirst%3DR.%2BA.%26aulast%3DBaxter%26aufirst%3DR.%2BD.%26aulast%3DDixon%26aufirst%3DD.%2BD.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DBlackmond%26aufirst%3DD.%2BG.%26aulast%3DBaran%26aufirst%3DP.%2BS.%26atitle%3DA%2520new%2520reagent%2520for%2520direct%2520difluoromethylation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D1494%26epage%3D1497%26doi%3D10.1021%2Fja211422g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Hara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackmond, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, P. S.</span></span> <span> </span><span class="NLM_article-title">Radical-based regioselective C-H functionalization of electron-deficient heteroarenes: scope, tunability, and predictability</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">12122</span>, <span class="refDoi"> DOI: 10.1021/ja406223k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja406223k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFamsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=12122&author=F.+O%E2%80%99Haraauthor=D.+G.+Blackmondauthor=P.+S.+Baran&title=Radical-based+regioselective+C-H+functionalization+of+electron-deficient+heteroarenes%3A+scope%2C+tunability%2C+and+predictability&doi=10.1021%2Fja406223k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Radical-Based Regioselective C-H Functionalization of Electron-Deficient Heteroarenes: Scope, Tunability, and Predictability</span></div><div class="casAuthors">O'Hara, Fionn; Blackmond, Donna G.; Baran, Phil S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">12122-12134</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Radical addn. processes can be ideally suited for the direct functionalization of heteroarom. bases, yet these processes are only sparsely used due to the perception of poor or unreliable control of regiochem.  A systematic investigation of factors affecting the regiochem. of radical functionalization of heterocycles using alkylsulfinate salts revealed that certain types of substituents exert consistent and additive effects on the regioselectivity of substitution.  This allowed us to establish guidelines for predicting regioselectivity on complex π-deficient heteroarenes, including pyridines, pyrimidines, pyridazines, and pyrazines.  Since the relative contribution from opposing directing factors was dependent on solvent and pH, it was sometimes possible to tune the regiochem. to a desired result by modifying reaction conditions.  This methodol. was applied to the direct, regioselective introduction of iso-Pr groups into complex, biol. active mols., such as diflufenican (I; R = H → R = iso-Pr) and nevirapine (II; R = H → R = iso-Pr).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEOGesZTIMOrVg90H21EOLACvtfcHk0lg1ZczbPPouMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFamsb3M&md5=e12331edd20ef03aafe3c7a7145a8f6e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fja406223k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja406223k%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hara%26aufirst%3DF.%26aulast%3DBlackmond%26aufirst%3DD.%2BG.%26aulast%3DBaran%26aufirst%3DP.%2BS.%26atitle%3DRadical-based%2520regioselective%2520C-H%2520functionalization%2520of%2520electron-deficient%2520heteroarenes%253A%2520scope%252C%2520tunability%252C%2520and%2520predictability%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D12122%26doi%3D10.1021%2Fja406223k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frahm, A. W.</span></span> <span> </span><span class="NLM_article-title">Asymmetric reductive amination of cycloalkanones. 5. Synthesis and absolute configuration of 2-substituted cyclopentanamines</span>. <i>Chem. Ber.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2668</span>– <span class="NLM_lpage">2677</span>, <span class="refDoi"> DOI: 10.1002/cber.19861190823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1002%2Fcber.19861190823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADyaL28XltFClsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=1986&pages=2668-2677&author=W.+Wiehlauthor=A.+W.+Frahm&title=Asymmetric+reductive+amination+of+cycloalkanones.+5.+Synthesis+and+absolute+configuration+of+2-substituted+cyclopentanamines&doi=10.1002%2Fcber.19861190823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric reductive amination of cycloalkanones.  5.  Synthesis and absolute configuration of 2-substituted cyclopentanamines</span></div><div class="casAuthors">Wiehl, Wolfgang; Frahm, August W.</div><div class="citationInfo"><span class="NLM_cas:title">Chemische Berichte</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2668-77</span>CODEN:
                <span class="NLM_cas:coden">CHBEAM</span>;
        ISSN:<span class="NLM_cas:issn">0009-2940</span>.
    </div><div class="casAbstract">In an asym. synthesis 2-substituted cyclopentanamines are obtained from racemic cyclopentanones I (R = Me, Et, Me2CH, Ph, PhCH2) by means of reductive amination in a three-step procedure.  Condensation of the ketones I with optically active 1-phenylethylamines yields imine mixts. II, which are hydrogenated with Raney-Ni to give the optically active, diastereomerically pure secondary amines III.  Hydrogenolysis with Pd-C leads to high grade enantiomerically pure primary amines IV with good yields.  The relative configuration of III and IV is elucidated by 1H and 13C NMR.  The abs. configuration is detd. by x-ray anal. of the 4-bromobenzamide of the primary amine (+)-IV (R = Ph) and with the help of CD of the salicylidene derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4M0WyznwkRbVg90H21EOLACvtfcHk0lgoh7Zstkn5mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XltFClsLk%253D&md5=02e289df55dfaeac46a41a5b67dc5869</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2Fcber.19861190823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcber.19861190823%26sid%3Dliteratum%253Aachs%26aulast%3DWiehl%26aufirst%3DW.%26aulast%3DFrahm%26aufirst%3DA.%2BW.%26atitle%3DAsymmetric%2520reductive%2520amination%2520of%2520cycloalkanones.%25205.%2520Synthesis%2520and%2520absolute%2520configuration%2520of%25202-substituted%2520cyclopentanamines%26jtitle%3DChem.%2520Ber.%26date%3D1986%26volume%3D119%26spage%3D2668%26epage%3D2677%26doi%3D10.1002%2Fcber.19861190823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Behenna, D. C.</span>; <span class="NLM_string-name">Chen, P.</span>; <span class="NLM_string-name">Freeman-Cook, K. D.</span>; <span class="NLM_string-name">Hoffman, R. L.</span>; <span class="NLM_string-name">Jalaie, M.</span>; <span class="NLM_string-name">Nagata, A.</span>; <span class="NLM_string-name">Nair, S. K.</span>; <span class="NLM_string-name">Ninkovic, S.</span>; <span class="NLM_string-name">Ornelas, M. A.</span>; <span class="NLM_string-name">Palmer, C. L.</span>; <span class="NLM_string-name">Rui, E. Y.</span></span> <span> </span><span class="NLM_article-title">Preparation of heterocyclylaminopyrido[2,3-d]pyrimidin-7(8H)-one compounds as cyclin-dependent kinase inhibitors for treatment of proliferative diseases such as cancer</span>. U.S. Patent <span class="NLM_patent">20,180,044,344 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=D.+C.+Behenna&author=P.+Chen&author=K.+D.+Freeman-Cook&author=R.+L.+Hoffman&author=M.+Jalaie&author=A.+Nagata&author=S.+K.+Nair&author=S.+Ninkovic&author=M.+A.+Ornelas&author=C.+L.+Palmer&author=E.+Y.+Rui&title=Preparation+of+heterocyclylaminopyrido%5B2%2C3-d%5Dpyrimidin-7%288H%29-one+compounds+as+cyclin-dependent+kinase+inhibitors+for+treatment+of+proliferative+diseases+such+as+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBehenna%26aufirst%3DD.%2BC.%26atitle%3DPreparation%2520of%2520heterocyclylaminopyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-one%2520compounds%2520as%2520cyclin-dependent%2520kinase%2520inhibitors%2520for%2520treatment%2520of%2520proliferative%2520diseases%2520such%2520as%2520cancer%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frémaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shutes, A.</span></span> <span> </span><span class="NLM_article-title">Capillary microfluidic electrophoretic mobility shift assays: application to enzymatic assays in drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1517/17460440903493431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1517%2F17460440903493431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=22823971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1aqtLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=51-63&author=D.+Perrinauthor=C.+Fr%C3%A9mauxauthor=A.+Shutes&title=Capillary+microfluidic+electrophoretic+mobility+shift+assays%3A+application+to+enzymatic+assays+in+drug+discovery&doi=10.1517%2F17460440903493431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Capillary microfluidic electrophoretic mobility shift assays: application to enzymatic assays in drug discovery</span></div><div class="casAuthors">Perrin, Dominique; Fremaux, Christele; Shutes, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-63</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Microfluidic electrophoretic mobility shift assays are becoming increasingly popular with screening groups throughout the pharmaceutical industry due to their excellent data quality and target flexibility.  Areas covered in this review: This review summarizes our experience of the microfluidic electrophoretic mobility shift technique at Merck Serono as well as from the published literature.  We assess the advantages and limitations of electrophoretic mobility shift assays in this context.What the reader will gain: Published literature on the topic is scarce.  The reader will gain an insight into the techniques and issues with the use of this technol. in a pharmaceutical setting.Take home message: This technol. has reached maturity, providing reliable and robust results.  Current limitations are the lower-than-desired throughput capacity for primary screening campaigns, and its current restriction to enzyme classes catalyzing a significant change in mass/charge of the substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoEZg_o4UvtbVg90H21EOLACvtfcHk0lgoh7Zstkn5mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1aqtLnM&md5=ebb7b4778d113c5eae0e8520c3e75683</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1517%2F17460440903493431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460440903493431%26sid%3Dliteratum%253Aachs%26aulast%3DPerrin%26aufirst%3DD.%26aulast%3DFr%25C3%25A9maux%26aufirst%3DC.%26aulast%3DShutes%26aufirst%3DA.%26atitle%3DCapillary%2520microfluidic%2520electrophoretic%2520mobility%2520shift%2520assays%253A%2520application%2520to%2520enzymatic%2520assays%2520in%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2010%26volume%3D5%26spage%3D51%26epage%3D63%26doi%3D10.1517%2F17460440903493431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, J. F.</span></span> <span> </span><span class="NLM_article-title">Kinetics of the reversible inhibition of enzyme-catalyzed reactions by tight-binding inhibitors</span>. <i>Biochim. Biophys. Acta, Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1016/0005-2744(69)90420-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2F0005-2744%2869%2990420-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=4980133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADyaF1MXkvVOqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=1969&pages=269-286&author=J.+F.+Morrison&title=Kinetics+of+the+reversible+inhibition+of+enzyme-catalyzed+reactions+by+tight-binding+inhibitors&doi=10.1016%2F0005-2744%2869%2990420-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of the reversible inhibition of enzyme-catalyzed reactions by tight-binding inhibitors</span></div><div class="casAuthors">Morrison, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Enzymology</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">269-86</span>CODEN:
                <span class="NLM_cas:coden">BBEZAD</span>;
        ISSN:<span class="NLM_cas:issn">0924-1086</span>.
    </div><div class="casAbstract">A theoretical kinetic study has been undertaken to det. the kinetic characteristics of enzymic reactions that are reversibly inhibited by a substrate analog. at concns. comparable to that of the enzyme.  A general rate equation, that allows for the combination of such a tight-binding inhibitor with one or more enzyme forms of any reaction mechanism, has been derived and shown to be quadratic with sq. and linear terms in υ which represents the true initial steady-state velocity.  From plots of υ against total enzyme concn. at fixed total inhibitor concn., the concn. of enzyme catalytic sites can be detd. irrespective of the nature of the inhibition and the reaction mechanism.  However, plots of υ (or I/υ) against total inhibitor concn. can be used for this purpose only if the dissocn. const. assocd. with the inhibitor is virtually zero.  Particular initial rate equations have been obtained for the cases in which the tight-binding inhibitor gives rise to competitive, noncompetitive, and uncompetitive inhibition with respect to one of the substrates of a bireactant mechanism.  From these equations it has been deduced that, in the presence of inhibitor, plots of I/υ against the reciprocals of the substrate concns. yield families of concave-down, nonrectangular hyperbolas.  The difficulties assocd. with the detn. of inhibition consts. for tight-binding inhibitors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj4s_N2iV3CLVg90H21EOLACvtfcHk0lgoh7Zstkn5mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXkvVOqsbo%253D&md5=74d467477385488dfbb053358534ada6</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2F0005-2744%2869%2990420-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0005-2744%252869%252990420-3%26sid%3Dliteratum%253Aachs%26aulast%3DMorrison%26aufirst%3DJ.%2BF.%26atitle%3DKinetics%2520of%2520the%2520reversible%2520inhibition%2520of%2520enzyme-catalyzed%2520reactions%2520by%2520tight-binding%2520inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Enzymol.%26date%3D1969%26volume%3D185%26spage%3D269%26epage%3D286%26doi%3D10.1016%2F0005-2744%2869%2990420-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D. J.</span></span> <span> </span><span class="NLM_article-title">Determination of accurate KI values for tight-binding enzyme inhibitors: an in silico study of experimental error and assay design</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2003.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.ab.2003.12.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=15033511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFKhtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2004&pages=61-67&author=D.+J.+Murphy&title=Determination+of+accurate+KI+values+for+tight-binding+enzyme+inhibitors%3A+an+in+silico+study+of+experimental+error+and+assay+design&doi=10.1016%2Fj.ab.2003.12.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of accurate KI values for tight-binding enzyme inhibitors: an in silico study of experimental error and assay design</span></div><div class="casAuthors">Murphy, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-67</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">Detn. of accurate KI values for tight-binding enzyme inhibitors is important from both a basic biochem. point of view (understanding the differences in affinity of related mols.) and a medicinal chem. vantage (developing structure-activity relationships (SAR)).  It is advantageous to directly fit the quadratic equation describing tight-binding behavior, known commonly as the Morrison equation, to obtain these KI values.  The results of simulated expts. that examine the effect of assay design and exptl. error on the ability to accurately det. KI values at several [E]0/KI-app ratios are described.  Input ("true") values of the uninhibited velocity, inhibition const., and total enzyme concn. were used to calc. the velocity at various inhibitor concns.  Gaussian error was introduced into the velocities and the simulated reactions were fit to est. v0, KI, and [E]0.  Recommendations for optimizing the inhibitor dilns. within the context of a 96-well-plate format and simple serial diln. steps are made.  These include using three points to det. the enzyme concn. ([I] = 0, 0.5[E]0, and [E]0), using a narrow diln. series with only two or three points to det. the asymptote at high inhibitor concn., and avoidance of fixing [E]0 to a const. value in the fitting if at all possible.  The risks and rewards of fixing [E]0 to a const. value, esp. the effect on SAR, are also examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGiaWGV4W5tLVg90H21EOLACvtfcHk0ljYcWZ2m5MIIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFKhtrg%253D&md5=f93d7f5648fc310736f4a80c10ef3edd</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2003.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2003.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DD.%2BJ.%26atitle%3DDetermination%2520of%2520accurate%2520KI%2520values%2520for%2520tight-binding%2520enzyme%2520inhibitors%253A%2520an%2520in%2520silico%2520study%2520of%2520experimental%2520error%2520and%2520assay%2520design%26jtitle%3DAnal.%2520Biochem.%26date%3D2004%26volume%3D327%26spage%3D61%26epage%3D67%26doi%3D10.1016%2Fj.ab.2003.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vonrhein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flensburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paciorek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span></span> <span> </span><span class="NLM_article-title">Data processing and analysis with the autoPROC toolbox</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1107/s0907444911007773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1107%2FS0907444911007773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=21460447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=293-302&author=C.+Vonrheinauthor=C.+Flensburgauthor=P.+Kellerauthor=A.+Sharffauthor=O.+Smartauthor=W.+Paciorekauthor=T.+Womackauthor=G.+Bricogne&title=Data+processing+and+analysis+with+the+autoPROC+toolbox&doi=10.1107%2Fs0907444911007773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Data processing and analysis with the autoPROC toolbox</span></div><div class="casAuthors">Vonrhein, Clemens; Flensburg, Claus; Keller, Peter; Sharff, Andrew; Smart, Oliver; Paciorek, Wlodek; Womack, Thomas; Bricogne, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">293-302</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A typical diffraction expt. will generate many images and data sets from different crystals in a very short time.  This creates a challenge for the high-throughput operation of modern synchrotron beamlines as well as for the subsequent data processing.  Novice users in particular may feel overwhelmed by the tables, plots and nos. that the different data-processing programs and software packages present to them.  Here, some of the more common problems that a user has to deal with when processing a set of images that will finally make up a processed data set are shown, concg. on difficulties that may often show up during the first steps along the path of turning the expt. (i.e. data collection) into a model (i.e. interpreted electron d.).  Difficulties such as unexpected crystal forms, issues in crystal handling and suboptimal choices of data-collection strategies can often be dealt with, or at least diagnosed, by analyzing specific data characteristics during processing.  In the end, one wants to distinguish problems over which one has no immediate control once the expt. is finished from problems that can be remedied a posteriori.  A new software package, autoPROC, is also presented that combines third-party processing programs with new tools and an automated workflow script that is intended to provide users with both guidance and insight into the offline processing of data affected by the difficulties mentioned above, with particular emphasis on the automated treatment of multi-sweep data sets collected on multi-axis goniostats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmah7iUrMLXLVg90H21EOLACvtfcHk0ljYcWZ2m5MIIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D&md5=a0a3579f6b371b6312819883864aa80d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1107%2FS0907444911007773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911007773%26sid%3Dliteratum%253Aachs%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DFlensburg%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DP.%26aulast%3DSharff%26aufirst%3DA.%26aulast%3DSmart%26aufirst%3DO.%26aulast%3DPaciorek%26aufirst%3DW.%26aulast%3DWomack%26aufirst%3DT.%26aulast%3DBricogne%26aufirst%3DG.%26atitle%3DData%2520processing%2520and%2520analysis%2520with%2520the%2520autoPROC%2520toolbox%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D293%26epage%3D302%26doi%3D10.1107%2Fs0907444911007773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span>; <span class="NLM_string-name">Blanc, E.</span>; <span class="NLM_string-name">Brandl, M.</span>; <span class="NLM_string-name">Flensburg, C.</span>; <span class="NLM_string-name">Keller, P.</span>; <span class="NLM_string-name">Paciorek, W.</span>; <span class="NLM_string-name">Roversi, P.</span>; <span class="NLM_string-name">Sharff, A.</span>; <span class="NLM_string-name">Smart, O.</span>; <span class="NLM_string-name">Vonrheim, C.</span></span> <i>BUSTER</i>; <span class="NLM_publisher-name">Global Phasing Ltd</span>: <span class="NLM_publisher-loc">Cambridge, United Kingdom</span>, <span class="NLM_year">2011–2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011%E2%80%932020&author=G.+Bricogne&author=E.+Blanc&author=M.+Brandl&author=C.+Flensburg&author=P.+Keller&author=W.+Paciorek&author=P.+Roversi&author=A.+Sharff&author=O.+Smart&author=C.+Vonrheim&title=BUSTER"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBricogne%26aufirst%3DG.%26btitle%3DBUSTER%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2011%25E2%2580%25932020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/s0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2Fs0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0ljYcWZ2m5MIIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2Fs0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Palbociclib (<b>1</b>) and early file screening hit for CDK2/cyclinE1 (<b>2</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Crystal structure of <b>2</b> in complex with CDK2. The protein surface is rendered in gray with key molecular interaction distances highlighted with dashed lines and measurements in Å. Sidechains of Phe80, Phe82, and Lys89 are bolded in the protein. The piperidine ring system orients a lipophilic edge toward Phe82. This group is similarly accommodated in other CDK isoforms as a relatively nonselective CDK inhibitor. (B) Crystal structure of palbociclib (<b>1</b>) in complex with CDK6. The protein surface is rendered in gray with key molecular interaction distances highlighted with dashed lines and measurements in Å. The His100 residue (bold) in CDK6 is aligned with the pyridyl nitrogen of palbociclib avoiding any de-solvation penalty between the protein and ligand.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Crystal structure of <b>4</b> in complex with CDK2. The protein surface is rendered in gray. Lys89, Phe82, and Phe80 are bolded in the protein. The 6-position methyl is oriented towards a pocket formed by the sidechains from the C-α-helix and the gatekeeper Phe80. (B) Matched pairs of compounds which differ only by the presence of a methyl group (blue circles) or hydrogen atom (yellow circles) and the effect on biochemical selectivity <i>vs</i> CDK1 (ratio of biochemical <i>K</i><sub>i</sub> CDK1/biochemical <i>K</i><sub>i</sub> CDK2). (C) Box and whisker plot of pairwise data from (B). (D) Surface representations of CDK2 (wireframe, teal) and CDK1 (solid, yellow) around the inhibitor binding pocket formed by <b>4</b>. Phenylalanine gatekeeper residues are also highlighted for CDK2 (teal) and CDK1 (yellow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Inhibition of the phosphorylation of RB1 in OVCAR3 cells for both palbociclib and <b>8</b>. (B) Inhibition of proliferation in OVCAR3 cells for both palbociclib and <b>8</b>. (C) BRDU cell cycle analysis of cell cycle arrest in OVCAR3 cells for <b>8</b> at 24 and 72 h. Compound concentration (nM) is shown below each bar, and the proportion of cells in G1 (black), S (red), and G2/M (blue) are shown. (D) Western blot of compound <b>8</b> showing the differential blocking of XO44 binding in CDK2 and CDK1 in Kuramochi cells demonstrating differential cellular target engagement. Compound concentration (nM) is shown above each lane of the blot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Free-Wilson schematic. 324 Pyridopyrimidinone analogues were computationally deconstructed to form hypothetical fragments and determine each fragment’s contribution to LipE. (B) Leave-one out analysis of 148 analogues. Blue circles designate compounds which differed in actual <i>vs</i> predicted LipE by more than 1 unit. 141/148 (95%) of analogues (green circles) differed by less than 1 LipE unit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Scatter plot of CDK2 <i>vs</i> CDK9 potency (<i>K</i><sub>i</sub> in μM). Lines of equal selectivity are plotted as diagonals, with selectivity increasing to the top left of the plot. Compounds containing the piperidine sulfonamide motif are plotted as blue dots, all other compounds are plotted as red dots. (B) Snapshots from MD simulation of compound <b>19</b> in CDK2 (top left) and CDK9 (top right). Root-mean-squared deviation (rmsd) plots showing movement over the course of the entire simulation are plotted below each snapshot <i>vs</i> time in picoseconds (CDK2 in green and CDK9 in blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Crystal structure of <b>22</b> in complex with CDK2. The protein surface is rendered in gray with key molecular interaction distances highlighted with dashed lines and measurements in Å. Lys89, Asp86, Phe82, Phe80, and Gln131 are bolded in the protein. The methyl group on the cyclopentyl ring is positioned in a lipophilic pocket formed by residues Val64, Leu134, and Ala144.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) <i>In vivo</i> tumor growth inhibition of <b>22</b> (PF-06873600) in PDX model CTG-0464 NSCLC. (B) <i>In vivo</i> tumor growth inhibition of <b>22</b> in PDX model CTG-0192 NSCLC. Both models are run with a vehicle arm and a twice daily dose of <b>22</b> given orally at 30 mg/kg.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of (1<i>R</i>,2<i>R</i>)-2-Amino-1-methylcyclopentan-1-ol (<b>25</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) BnNH<sub>2</sub> and H<sub>2</sub>O, 100 °C, 66%; (b) (2<i>S</i>)-[(3,5-dinitrobenzoyl)amino](phenyl) ethanoic acid (0.5 equiv) and EtOH, 80 °C to rt overnight, 82%, 96% ee; (c) repeat step b, but with 1 equiv of (2<i>S</i>)-[(3,5-dinitrobenzoyl)amino](phenyl) ethanoic acid, 97%, 98% ee; and (d) 20% Pd(OH)<sub>2</sub>/C H<sub>2</sub> (1 atm), and isopropanol, 23 °C.</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/medium/jm1c00159_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>22</b> (PF-06873600)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00159/20210629/images/large/jm1c00159_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00159&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) DIPEA and 2-propanol, 80 °C, 97%; (b) MnO<sub>2</sub> and EtOAc, 50 °C, 93%; (c) CH<sub>3</sub>CO<sub>2</sub>Et, LiHMDS, THF, −5 °C, EtOH, and AcOH, 71%; (d) oxone, 2-methyl-THF, and H<sub>2</sub>O, 84%; (e) 1-(methylsulfonyl)piperidin-4-amine and 2-methyl-THF, 60 °C, 63%, >99% ee; and (f) CHF<sub>2</sub>SO<sub>2</sub>Na, t-BuOOH, FeCl<sub>3</sub>/silica, DMSO, and H<sub>2</sub>O, 57%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i65">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42463" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42463" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 58 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaldis, P.</span></span> <span> </span><span class="NLM_article-title">Cdks, cyclins; CKIs roles beyond cell cycle regulation</span>. <i>Development</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">3079</span>– <span class="NLM_lpage">3093</span>, <span class="refDoi"> DOI: 10.1242/dev.091744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1242%2Fdev.091744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=23861057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGktL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2013&pages=3079-3093&author=S.+Limauthor=P.+Kaldis&title=Cdks%2C+cyclins%3B+CKIs+roles+beyond+cell+cycle+regulation&doi=10.1242%2Fdev.091744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cdks, cyclins and CKIs: roles beyond cell cycle regulation</span></div><div class="casAuthors">Lim, Shuhui; Kaldis, Philipp</div><div class="citationInfo"><span class="NLM_cas:title">Development (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3079-3093</span>CODEN:
                <span class="NLM_cas:coden">DEVPED</span>;
        ISSN:<span class="NLM_cas:issn">0950-1991</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinases (Cdks) are serine/threonine kinases and their catalytic activities are modulated by interactions with cyclins and Cdk inhibitors (CKIs).  Close cooperation between this trio is necessary for ensuring orderly progression through the cell cycle.  In addn. to their well-established function in cell cycle control, it is becoming increasingly apparent that mammalian Cdks, cyclins and CKIs play indispensable roles in processes such as transcription, epigenetic regulation, metab., stem cell self-renewal, neuronal functions and spermatogenesis.  Even more remarkably, they can accomplish some of these tasks individually, without the need for Cdk/cyclin complex formation or kinase activity.  In this Review, we discuss the latest revelations about Cdks, cyclins and CKIs with the goal of showcasing their functional diversity beyond cell cycle regulation and their impact on development and disease in mammals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp5LNcD6NywLVg90H21EOLACvtfcHk0lg4JyOZPZk-pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGktL%252FF&md5=8095fc798a0e7efeab60d36ee414596f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1242%2Fdev.091744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fdev.091744%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%26aulast%3DKaldis%26aufirst%3DP.%26atitle%3DCdks%252C%2520cyclins%253B%2520CKIs%2520roles%2520beyond%2520cell%2520cycle%2520regulation%26jtitle%3DDevelopment%26date%3D2013%26volume%3D140%26spage%3D3079%26epage%3D3093%26doi%3D10.1242%2Fdev.091744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinases</span>. <i>Genome Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">122</span>, <span class="refDoi"> DOI: 10.1186/gb4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1186%2Fgb4184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=25180339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=122&author=M.+Malumbres&title=Cyclin-dependent+kinases&doi=10.1186%2Fgb4184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinases</span></div><div class="casAuthors">Malumbres Marcos</div><div class="citationInfo"><span class="NLM_cas:title">Genome biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">122</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are protein kinases characterized by needing a separate subunit - a cyclin - that provides domains essential for enzymatic activity.  CDKs play important roles in the control of cell division and modulate transcription in response to several extra- and intracellular cues.  The evolutionary expansion of the CDK family in mammals led to the division of CDKs into three cell-cycle-related subfamilies (Cdk1, Cdk4 and Cdk5) and five transcriptional subfamilies (Cdk7, Cdk8, Cdk9, Cdk11 and Cdk20).  Unlike the prototypical Cdc28 kinase of budding yeast, most of these CDKs bind one or a few cyclins, consistent with functional specialization during evolution.  This review summarizes how, although CDKs are traditionally separated into cell-cycle or transcriptional CDKs, these activities are frequently combined in many family members.  Not surprisingly, deregulation of this family of proteins is a hallmark of several diseases, including cancer, and drug-targeted inhibition of specific members has generated very encouraging results in clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQodaug4zJdjgHqQV89nF-2fW6udTcc2ebQu83SWe8o-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D&md5=9fd79ec8f495f712bada681b0a0b5afe</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1186%2Fgb4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb4184%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26atitle%3DCyclin-dependent%2520kinases%26jtitle%3DGenome%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D122%26doi%3D10.1186%2Fgb4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. A.</span></span> <span> </span><span class="NLM_article-title">Targeting the cell cycle: a new approach to cancer therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">9408</span>– <span class="NLM_lpage">9421</span>, <span class="refDoi"> DOI: 10.1200/jco.2005.01.5594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1200%2FJCO.2005.01.5594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=16361640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1ymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=9408-9421&author=G.+K.+Schwartzauthor=M.+A.+Shah&title=Targeting+the+cell+cycle%3A+a+new+approach+to+cancer+therapy&doi=10.1200%2Fjco.2005.01.5594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cell cycle: a new approach to cancer therapy</span></div><div class="casAuthors">Schwartz, Gary K.; Shah, Manish A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9408-9421</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The cell cycle represents a series of tightly integrated events that allow the cell to grow and proliferate.  Crit. parts of the cell cycle machinery are the cyclin-dependent kinases (CDKs), which, when activated, provide a means for the cell to move from one phase of the cell cycle to the next.  The CDKs are regulated pos. by cyclins and regulated neg. by naturally occurring CDK inhibitors (CDKIs).  Cancer represents a dysregulation of the cell cycle such that cells that overexpress cyclins or do not express the CDKIs continue to undergo unregulated cell growth.  The cell cycle also serves to protect the cell from DNA damage.  Thus, cell cycle arrest, in fact, represents a survival mechanism that provides the tumor cell the opportunity to repair its own damaged DNA.  Thus, abrogation of cell cycle checkpoints, before DNA repair is complete, can activate the apoptotic cascade, leading to cell death.  Now in clin. trials are a series of targeted agents that directly inhibit the CDKs, inhibit unrestricted cell growth, and induce growth arrest.  Recent attention has also focused on these drugs as inhibitors of transcription.  In addn., there are now agents that abrogate the cell cycle checkpoints at crit. time points that make the tumor cell susceptible to apoptosis.  An understanding of the cell cycle is crit. to understanding how best to clin. develop these agents, both as single agents and in combination with chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAmpAkG9yEhLVg90H21EOLACvtfcHk0lgaVutRCCTF8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1ymtA%253D%253D&md5=e3085a43360bfd59b1be9cbd30d581fa</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.01.5594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.01.5594%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DShah%26aufirst%3DM.%2BA.%26atitle%3DTargeting%2520the%2520cell%2520cycle%253A%2520a%2520new%2520approach%2520to%2520cancer%2520therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D9408%26epage%3D9421%26doi%3D10.1200%2Fjco.2005.01.5594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pines, J.</span></span> <span> </span><span class="NLM_article-title">Cyclins and cancer II: cyclin D and CDK inhibitors come of age</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(94)90543-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2F0092-8674%2894%2990543-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=7954824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADyaK2MXit1Glu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1994&pages=573-582&author=T.+Hunterauthor=J.+Pines&title=Cyclins+and+cancer+II%3A+cyclin+D+and+CDK+inhibitors+come+of+age&doi=10.1016%2F0092-8674%2894%2990543-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclins and cancer II: cyclin D and CDK inhibitors come of age</span></div><div class="casAuthors">Hunter, Tony; Pines, Jonathon</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">573-82</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with > 150 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGu8XRAqRgKLVg90H21EOLACvtfcHk0lgaVutRCCTF8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXit1Glu7k%253D&md5=0aded71b9c6d8ff7278648b844e63b67</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2894%2990543-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252894%252990543-6%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DPines%26aufirst%3DJ.%26atitle%3DCyclins%2520and%2520cancer%2520II%253A%2520cyclin%2520D%2520and%2520CDK%2520inhibitors%2520come%2520of%2520age%26jtitle%3DCell%26date%3D1994%26volume%3D79%26spage%3D573%26epage%3D582%26doi%3D10.1016%2F0092-8674%2894%2990543-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1038/35106065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1038%2F35106065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=11902577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=222-231&author=M.+Malumbresauthor=M.+Barbacid&title=Milestones+in+cell+division%3A+to+cycle+or+not+to+cycle%3A+a+critical+decision+in+cancer&doi=10.1038%2F35106065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor cells undergo uncontrolled proliferation, yet tumors most often originate from adult tissues, in which most cells are quiescent.  So, the proliferative advantage of tumor cells arises from their ability to bypass quiescence.  This can be due to increased mitogenic signaling and/or alterations that lower the threshold required for cell-cycle commitment.  Understanding the mol. mechanisms that underlie this commitment should provide important insights into how normal cells become tumorigenic and how new anticancer strategies can be devised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI2EOLFB2ULbVg90H21EOLACvtfcHk0lgaVutRCCTF8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D&md5=2bd8961854332a30c814f8ac2f9bd6f4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2F35106065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35106065%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DMilestones%2520in%2520cell%2520division%253A%2520to%2520cycle%2520or%2520not%2520to%2520cycle%253A%2520a%2520critical%2520decision%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D222%26epage%3D231%26doi%3D10.1038%2F35106065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of cancer: the next generation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+cancer%3A+the+next+generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0lg2xW3_PXON9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520cancer%253A%2520the%2520next%2520generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1038/nrc2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm&doi=10.1038%2Fnrc2602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0lg2xW3_PXON9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166%26doi%3D10.1038%2Fnrc2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musgrove, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barraclough, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, R. L.</span></span> <span> </span><span class="NLM_article-title">Cyclin D as a therapeutic target in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1038/nrc3090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1038%2Fnrc3090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=21734724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Srsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=558-572&author=E.+A.+Musgroveauthor=C.+E.+Caldonauthor=J.+Barracloughauthor=A.+Stoneauthor=R.+L.+Sutherland&title=Cyclin+D+as+a+therapeutic+target+in+cancer&doi=10.1038%2Fnrc3090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin D as a therapeutic target in cancer</span></div><div class="casAuthors">Musgrove, Elizabeth A.; Caldon, C. Elizabeth; Barraclough, Jane; Stone, Andrew; Sutherland, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">558-572</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression.  The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target.  Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofR_LZiUkU-LVg90H21EOLACvtfcHk0lhf6Ub6FWF7HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Srsr0%253D&md5=1bc2dcea427c5650263a5438ecddb5f9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc3090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3090%26sid%3Dliteratum%253Aachs%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26aulast%3DCaldon%26aufirst%3DC.%2BE.%26aulast%3DBarraclough%26aufirst%3DJ.%26aulast%3DStone%26aufirst%3DA.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26atitle%3DCyclin%2520D%2520as%2520a%2520therapeutic%2520target%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D558%26epage%3D572%26doi%3D10.1038%2Fnrc3090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">VanArsdale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arndt, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span> <span> </span><span class="NLM_article-title">Molecular Pathways: Targeting the cyclin D-CDK4/6 axis for cancer treatment</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2905</span>– <span class="NLM_lpage">2910</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-14-0816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1158%2F1078-0432.CCR-14-0816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=25941111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A280%3ADC%252BC2Mfgs1Wisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2905-2910&author=T.+VanArsdaleauthor=C.+Boshoffauthor=K.+T.+Arndtauthor=R.+T.+Abraham&title=Molecular+Pathways%3A+Targeting+the+cyclin+D-CDK4%2F6+axis+for+cancer+treatment&doi=10.1158%2F1078-0432.ccr-14-0816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment</span></div><div class="casAuthors">VanArsdale Todd; Abraham Robert T; Boshoff Chris; Arndt Kim T</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2905-10</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">Cancer cells bypass normal controls over mitotic cell-cycle progression to achieve a deregulated state of proliferation.  The retinoblastoma tumor suppressor protein (pRb) governs a key cell-cycle checkpoint that normally prevents G1-phase cells from entering S-phase in the absence of appropriate mitogenic signals.  Cancer cells frequently overcome pRb-dependent growth suppression via constitutive phosphorylation and inactivation of pRb function by cyclin-dependent kinase (CDK) 4 or CDK6 partnered with D-type cyclins.  Three selective CDK4/6 inhibitors, palbociclib (Ibrance; Pfizer), ribociclib (Novartis), and abemaciclib (Lilly), are in various stages of development in a variety of pRb-positive tumor types, including breast cancer, melanoma, liposarcoma, and non-small cell lung cancer.  The emerging, positive clinical data obtained to date finally validate the two decades-old hypothesis that the cyclin D-CDK4/6 pathway is a rational target for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6Rstlwhprintlzo9xastyfW6udTcc2eZk0vQ4WBlxx7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mfgs1Wisg%253D%253D&md5=5b3443d0ec58550d8ef4f1993726fb5e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0816%26sid%3Dliteratum%253Aachs%26aulast%3DVanArsdale%26aufirst%3DT.%26aulast%3DBoshoff%26aufirst%3DC.%26aulast%3DArndt%26aufirst%3DK.%2BT.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26atitle%3DMolecular%2520Pathways%253A%2520Targeting%2520the%2520cyclin%2520D-CDK4%252F6%2520axis%2520for%2520cancer%2520treatment%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2905%26epage%3D2910%26doi%3D10.1158%2F1078-0432.ccr-14-0816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustachio, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekula, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freemantle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dmitrovsky, E.</span></span> <span> </span><span class="NLM_article-title">Specific CP110 phosphorylation sites mediate anaphase catastrophe after CDK2 inhibition: evidence for cooperation with USP33 knockdown</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2576</span>– <span class="NLM_lpage">2585</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-15-0443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1158%2F1535-7163.MCT-15-0443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=26304236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOgt7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2576-2585&author=S.+Huauthor=Y.+Luauthor=B.+Orrauthor=K.+Godekauthor=L.+M.+Mustachioauthor=M.+Kawakamiauthor=D.+Sekulaauthor=D.+A.+Comptonauthor=S.+Freemantleauthor=E.+Dmitrovsky&title=Specific+CP110+phosphorylation+sites+mediate+anaphase+catastrophe+after+CDK2+inhibition%3A+evidence+for+cooperation+with+USP33+knockdown&doi=10.1158%2F1535-7163.mct-15-0443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown</span></div><div class="casAuthors">Hu, Shanhu; Lu, Yun; Orr, Bernardo; Godek, Kristina; Mustachio, Lisa Maria; Kawakami, Masanori; Sekula, David; Compton, Duane A.; Freemantle, Sarah; Dmitrovsky, Ethan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2576-2585</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Chromosomal instability (CIN) is a hallmark of solid tumor biol. and is implicated in carcinogenesis.  Preferentially eliminating malignant cells by targeting CIN and aneuploidy is an attractive antineoplastic strategy.  We previously reported that CDK2 antagonism causes lung cancer cells to undergo anaphase catastrophe and apoptosis through inhibition of phosphorylation of the centrosomal protein CP110.  Cells with activating KRAS mutations were particularly sensitive to CDK2 inhibition due to downregulation of CP110 protein levels.  This study investigated mechanisms of CDK2 antagonism that mediate anaphase catastrophe via changes in CP110 protein expression and how activated KRAS affects CP110 levels in lung cancers.  Site-directed mutagenesis revealed candidate CDK phosphorylation sites of CP110 (residues Ser 170 and Thr 194) crit. for conferring anaphase catastrophe by altering centrosome clustering in mitosis.  Intriguingly, KRAS mutation can promote CP110 protein degrdn. by upregulating the ubiquitin ligase SCFcyclinF, which targets CP110 protein for destabilization.  Finally, CDK2 inhibitor response was enhanced when combined with knockdown of the deubiquitinase USP33 that in turn accelerates CP110 protein degrdn.  Thus, this study provides mol. pharmacol. insights into how CP110 expression regulates response to CDK2 inhibition.  An improved understanding of in vitro antineoplastic mechanisms of combining CDK2 antagonism with induced CP110 repression provides a rationale for exploring clin. consequences of this strategy.  Taken together, preclin. findings obtained from combining CDK2 inhibition with USP33 repression have implications for treating patients with non-small cell lung cancers.  Mol Cancer Ther; 14(11); 2576-85. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWB2T3vMoX87Vg90H21EOLACvtfcHk0lhGFhSywXpW5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOgt7zJ&md5=3426ae1dcbdd54def483fb95afda5eaa</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0443%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DOrr%26aufirst%3DB.%26aulast%3DGodek%26aufirst%3DK.%26aulast%3DMustachio%26aufirst%3DL.%2BM.%26aulast%3DKawakami%26aufirst%3DM.%26aulast%3DSekula%26aufirst%3DD.%26aulast%3DCompton%26aufirst%3DD.%2BA.%26aulast%3DFreemantle%26aufirst%3DS.%26aulast%3DDmitrovsky%26aufirst%3DE.%26atitle%3DSpecific%2520CP110%2520phosphorylation%2520sites%2520mediate%2520anaphase%2520catastrophe%2520after%2520CDK2%2520inhibition%253A%2520evidence%2520for%2520cooperation%2520with%2520USP33%2520knockdown%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D2576%26epage%3D2585%26doi%3D10.1158%2F1535-7163.mct-15-0443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molenaar, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebus, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geerts, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koster, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentijn, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerhout, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versteeg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H. N.</span></span> <span> </span><span class="NLM_article-title">Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">12968</span>– <span class="NLM_lpage">12973</span>, <span class="refDoi"> DOI: 10.1073/pnas.0901418106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1073%2Fpnas.0901418106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=19525400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=12968-12973&author=J.+J.+Molenaarauthor=M.+E.+Ebusauthor=D.+Geertsauthor=J.+Kosterauthor=F.+Lamersauthor=L.+J.+Valentijnauthor=E.+M.+Westerhoutauthor=R.+Versteegauthor=H.+N.+Caron&title=Inactivation+of+CDK2+is+synthetically+lethal+to+MYCN+over-expressing+cancer+cells&doi=10.1073%2Fpnas.0901418106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells</span></div><div class="casAuthors">Molenaar, Jan J.; Ebus, Marli E.; Geerts, Dirk; Koster, Jan; Lamers, Fieke; Valentijn, Linda J.; Westerhout, Ellen M.; Versteeg, Rogier; Caron, Huib N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">12968-12973</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Two genes have a synthetically lethal relationship when the silencing or inhibiting of 1 gene is only lethal in the context of a mutation or activation of the second gene.  This situation offers an attractive therapeutic strategy, as inhibition of such a gene will only trigger cell death in tumor cells with an activated second oncogene but spare normal cells without activation of the second oncogene.  Here we present evidence that CDK2 is synthetically lethal to neuroblastoma cells with MYCN amplification and over-expression.  Neuroblastomas are childhood tumors with an often lethal outcome.  Twenty percent of the tumors have MYCN amplification, and these tumors are ultimately refractory to any therapy.  Targeted silencing of CDK2 by 3 RNA interference techniques induced apoptosis in MYCN-amplified neuroblastoma cell lines, but not in MYCN single copy cells.  Silencing of MYCN abrogated this apoptotic response in MYCN-amplified cells.  Inversely, silencing of CDK2 in MYCN single copy cells did not trigger apoptosis, unless a MYCN transgene was activated.  The MYCN induced apoptosis after CDK2 silencing was accompanied by nuclear stabilization of P53, and mRNA profiling showed up-regulation of P53 target genes.  Silencing of P53 rescued the cells from MYCN-driven apoptosis.  The synthetic lethality of CDK2 silencing in MYCN activated neuroblastoma cells can also be triggered by inhibition of CDK2 with a small mol. drug.  Treatment of neuroblastoma cells with roscovitine, a CDK inhibitor, at clin. achievable concns. induced MYCN-dependent apoptosis.  The synthetically lethal relationship between CDK2 and MYCN indicates CDK2 inhibitors as potential MYCN-selective cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr48u4K0MeszLVg90H21EOLACvtfcHk0lhGFhSywXpW5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKru77P&md5=016ebf4ccc1f5c6e3b965e999cca58c7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0901418106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0901418106%26sid%3Dliteratum%253Aachs%26aulast%3DMolenaar%26aufirst%3DJ.%2BJ.%26aulast%3DEbus%26aufirst%3DM.%2BE.%26aulast%3DGeerts%26aufirst%3DD.%26aulast%3DKoster%26aufirst%3DJ.%26aulast%3DLamers%26aufirst%3DF.%26aulast%3DValentijn%26aufirst%3DL.%2BJ.%26aulast%3DWesterhout%26aufirst%3DE.%2BM.%26aulast%3DVersteeg%26aufirst%3DR.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26atitle%3DInactivation%2520of%2520CDK2%2520is%2520synthetically%2520lethal%2520to%2520MYCN%2520over-expressing%2520cancer%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D12968%26epage%3D12973%26doi%3D10.1073%2Fpnas.0901418106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widlund, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horstmann, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. E.</span></span> <span> </span><span class="NLM_article-title">Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2004.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.ccr.2004.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=15607961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktVantA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=565-576&author=J.+Duauthor=H.+R.+Widlundauthor=M.+A.+Horstmannauthor=S.+Ramaswamyauthor=K.+Rossauthor=W.+E.+Huberauthor=E.+K.+Nishimuraauthor=T.+R.+Golubauthor=D.+E.+Fisher&title=Critical+role+of+CDK2+for+melanoma+growth+linked+to+its+melanocyte-specific+transcriptional+regulation+by+MITF&doi=10.1016%2Fj.ccr.2004.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF</span></div><div class="casAuthors">Du, Jinyan; Widlund, Hans R.; Horstmann, Martin A.; Ramaswamy, Sridhar; Ross, Ken; Huber, Wade E.; Nishimura, Emi K.; Golub, Todd R.; Fisher, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-576</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The genomic organization of the CDK2 gene, which overlaps the melanocyte-specific gene SILV/PMEL17, poses an interesting regulatory challenge.  The authors show that, despite its ubiquitous expression, CDK2 exhibits tissue-specific regulation by the essential melanocyte lineage transcription factor MITF.  In addn., functional studies revealed this regulation to be crit. for maintaining CDK2 kinase activity and growth of melanoma cells.  Expression levels of MITF and CDK2 are tightly correlated in primary melanoma specimens and predict susceptibility to the CDK2 inhibitor roscovitine.  CDK2 depletion suppressed growth and cell cycle progression in melanoma, but not other cancers, corroborating previous results.  Collectively, these data indicate that CDK2 activity in melanoma is largely maintained at the transcriptional level by MITF, and unlike other malignancies, it may be a suitable drug target in melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzGPfKfEQmWLVg90H21EOLACvtfcHk0liG39pBbZsO2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktVantA%253D%253D&md5=0fdd6a6f788af5fb429c464358782881</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2004.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2004.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DWidlund%26aufirst%3DH.%2BR.%26aulast%3DHorstmann%26aufirst%3DM.%2BA.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DK.%26aulast%3DHuber%26aufirst%3DW.%2BE.%26aulast%3DNishimura%26aufirst%3DE.%2BK.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DFisher%26aufirst%3DD.%2BE.%26atitle%3DCritical%2520role%2520of%2520CDK2%2520for%2520melanoma%2520growth%2520linked%2520to%2520its%2520melanocyte-specific%2520transcriptional%2520regulation%2520by%2520MITF%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D6%26spage%3D565%26epage%3D576%26doi%3D10.1016%2Fj.ccr.2004.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ying, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin-dependent degradation of cdk2 drives the therapeutic differentiation of aml by targeting prdx2</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">2698</span>– <span class="NLM_lpage">2711</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-10-813139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1182%2Fblood-2017-10-813139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=29720484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOiu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=2698-2711&author=M.+Yingauthor=X.+Shaoauthor=H.+Jingauthor=Y.+Liuauthor=X.+Qiauthor=J.+Caoauthor=Y.+Chenauthor=S.+Xiangauthor=H.+Songauthor=R.+Huauthor=G.+Weiauthor=B.+Yangauthor=Q.+He&title=Ubiquitin-dependent+degradation+of+cdk2+drives+the+therapeutic+differentiation+of+aml+by+targeting+prdx2&doi=10.1182%2Fblood-2017-10-813139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-dependent degradation of cdk2 drives the therapeutic differentiation of aml by targeting prdx2</span></div><div class="casAuthors">Ying, Meidan; Shao, Xuejing; Jing, Hui; Liu, Yujia; Qi, Xiaotian; Cao, Ji; Chen, Yingqian; Xiang, Senfeng; Song, Hua; Hu, Ronggui; Wei, Guoqing; Yang, Bo; He, Qiaojun</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2698-2711</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A distinct hallmark of acute myeloid leukemia (AML) is the arrest of leukemic myeloblasts at an immature stage of development.  Therapies that overcome differentiation arrest have emerged as a powerful strategy for treating AML, but targeting leukemia differentiation remains challenging, mainly because of an incomplete mechanistic understanding of the process.  Here, we unveil a new role for cyclin-dependent kinase 2 (CDK2) in blocking myeloid differentiation in AML.  We show that among several interphase CDK, only CDK2 undergoes ubiquitin-dependent proteasome degrdn., which is accompanied by AML cell differentiation.  By using the yeast 2-hybrid system and functional analyses, KLHL6 was identified as a specific E3 ubiquitin ligase regulating the degrdn. of CDK2.  Importantly, inhibiting CDK2, but not other cyclin-dependent kinases CDK1/4/6, effectively induced granulocytic differentiation in AML cell lines and 5 major subtypes of primary patientderived AML samples.  Mechanistically, CDK2 depletion led to the reactivation of differentiation pathway translation, and the differentiation blockade function of CDK2 may be achieved directly by maintaining the activity of PRDX2.  Finally, CDK2 depletion arrested tumor growth of AML cells in nude mice and extended survival in both AML cell line and PDX-AML cells derived xenograft mouse models.  Thus, our work not only provides exptl. evidence for validating CDK2 as a potential therapeutic target for differentiation, but also uncovers the biol. function of the CDK2-PRDX2 axis in blocking AML differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL-1GnzdaOHrVg90H21EOLACvtfcHk0lhiZhXMe3UagQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOiu77M&md5=0f3345fd7dba32cf4809bfb302a037dd</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-10-813139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-10-813139%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DM.%26aulast%3DShao%26aufirst%3DX.%26aulast%3DJing%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DQ.%26atitle%3DUbiquitin-dependent%2520degradation%2520of%2520cdk2%2520drives%2520the%2520therapeutic%2520differentiation%2520of%2520aml%2520by%2520targeting%2520prdx2%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D2698%26epage%3D2711%26doi%3D10.1182%2Fblood-2017-10-813139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span> <span> </span><span class="NLM_article-title">HOXA7 stimulates human hepatocellular carcinoma proliferation through cyclin E1/CDK2</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">990</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.3892/or.2014.3668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.3892%2For.2014.3668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=25501982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVyiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=990-996&author=Y.+Liauthor=X.+H.+Yangauthor=S.+J.+Fangauthor=C.+F.+Qinauthor=R.+L.+Sunauthor=Z.+Y.+Liuauthor=B.+Y.+Jiangauthor=X.+Wuauthor=G.+Li&title=HOXA7+stimulates+human+hepatocellular+carcinoma+proliferation+through+cyclin+E1%2FCDK2&doi=10.3892%2For.2014.3668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">HOXA7 stimulates human hepatocellular carcinoma proliferation through cyclin E1/CDK2</span></div><div class="casAuthors">Li, Yuehui; Yang, Xiao Hui; Fang, Shu Juang; Qin, Chang Fei; Sun, Rui Li; Liu, Zhao Yang; Jiang, Bin Yuan; Wu, Xiang; Li, Guancheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">990-996</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">HOX genes are transcription factors that control morphogenesis, organogenesis and differentiation.  Increasing evidence suggests that HOX genes play a role in hepatocellular carcinoma (HCC) progression; however few studies have defined the functional roles and mechanisms of action.  In the present study, we used siRNA and forced-expression in multiple cell lines to define the role of HOXA7 in the regulation of proliferation of HCC in vitro and in vivo.  Knockdown of endogenous HOXA7 decreased the proliferation of HepG2 and QGY-7703 cells.  These changes were not assocd. with significant changes in cyclin D1 and CDK4.  However, down-regulation of HOXA7 significantly reduced cyclin E1 and CDK2 protein levels.  Conversely, overexpression of HOXA7 in QSG-7701 cells stimulated proliferation and increased cyclin E1 and CDK2 protein levels.  Our results confirmed that HOXA7 promoted cell proliferation, and these changes were mediated by cyclin E1/CDK2.  These observations contribute to our understanding of the important roles of HOXA7 in HCC development and progression and HOXA7 could be a promising mol. target for the development of new diagnostic and therapeutic strategies for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0l6a-l8_-GrVg90H21EOLACvtfcHk0lhiZhXMe3UagQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVyiu78%253D&md5=d5d441e42812540323143f763b5e2520</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3892%2For.2014.3668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2014.3668%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%2BH.%26aulast%3DFang%26aufirst%3DS.%2BJ.%26aulast%3DQin%26aufirst%3DC.%2BF.%26aulast%3DSun%26aufirst%3DR.%2BL.%26aulast%3DLiu%26aufirst%3DZ.%2BY.%26aulast%3DJiang%26aufirst%3DB.%2BY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DG.%26atitle%3DHOXA7%2520stimulates%2520human%2520hepatocellular%2520carcinoma%2520proliferation%2520through%2520cyclin%2520E1%252FCDK2%26jtitle%3DOncol.%2520Rep.%26date%3D2015%26volume%3D33%26spage%3D990%26epage%3D996%26doi%3D10.3892%2For.2014.3668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase 2 promotes tumor proliferation and induces radio resistance in glioblastoma</span>. <i>Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1016/j.tranon.2016.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.tranon.2016.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=27863310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A280%3ADC%252BC2snotVWqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=548-556&author=J.+Wangauthor=T.+Yangauthor=G.+Xuauthor=H.+Liuauthor=C.+Renauthor=W.+Xieauthor=M.+Wang&title=Cyclin-dependent+kinase+2+promotes+tumor+proliferation+and+induces+radio+resistance+in+glioblastoma&doi=10.1016%2Fj.tranon.2016.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma</span></div><div class="casAuthors">Wang Jia; Yang Tong; Xu Gaofeng; Liu Hao; Ren Chunying; Xie Wanfu; Wang Maode</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">548-556</span>
        ISSN:<span class="NLM_cas:issn">1936-5233</span>.
    </div><div class="casAbstract">Accumulating evidence indicates that CDK2 promotes hyperproliferation and is associated to poor prognosis in multiple cancer cells.  However, the physiological role of CDK2 in GBM and the biological mechanism still remains unclear.  In this study, we identified that CDK2 expression was significantly enriched in GBM tumors compared with normal brain.  Additionally, CDK2 was functionally required for tumor proliferation and its expression was associated to poor prognosis in GBM patients.  Mechanically, CDK2 induced radio resistance in GBM cells and CDK2 knock down increased cell apoptosis when combined with radiotherapy.  Therapeutically, we found that CDK2 inhibitor attenuated tumor growth both in vitro and in vivo.  Collectively, CDK2 promotes proliferation, induces radio resistance in GBM, and could become a therapeutic target for GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9a1Ej-CIqi7mQt-ICR3qNfW6udTcc2eZAY4JukC74PLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snotVWqsQ%253D%253D&md5=e994dad0c2785ed5a8d7ca0fe87f98d7</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.tranon.2016.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tranon.2016.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DM.%26atitle%3DCyclin-dependent%2520kinase%25202%2520promotes%2520tumor%2520proliferation%2520and%2520induces%2520radio%2520resistance%2520in%2520glioblastoma%26jtitle%3DTransl.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D548%26epage%3D556%26doi%3D10.1016%2Fj.tranon.2016.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span> <span> </span><span class="NLM_article-title">Identification of CDK2 as a novel target in treatment of prostate cancer</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.2217/fon-2017-0561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.2217%2Ffon-2017-0561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=29323532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntlegurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=709-718&author=X.+Yinauthor=J.+Yuauthor=Y.+Zhouauthor=C.+Wangauthor=Z.+Jiaoauthor=Z.+Qianauthor=H.+Sunauthor=B.+Chen&title=Identification+of+CDK2+as+a+novel+target+in+treatment+of+prostate+cancer&doi=10.2217%2Ffon-2017-0561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of CDK2 as a novel target in treatment of prostate cancer</span></div><div class="casAuthors">Yin, Xifeng; Yu, Jun; Zhou, Yang; Wang, Chengyue; Jiao, Zhimin; Qian, Zhounan; Sun, Hao; Chen, Binghai</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">709-718</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1744-8301</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">This study aims the potential gene involved in the metastasis of prostate cancer (Pca).  PubMed GEO datasets (GSE6605 and GSE6606) were downloaded.  It used multiple bioinformatics methods to screen differentially expressed genes in Pca.  Gene network was built by STRING and visualized by Cytoscape.  All of the hub genes were analyzed by cBioPortal.  Inhibition of CDK2 including siRNA, inhibitor and cas9-induced CDK2 knockout was followed by an invasion assay.  Downstream genes of CDK2 were analyzed by western blot.  Sequencing data were analyzed to screen the genes with expression alterations.  The top genes were validated in our samples.  11 Hub genes were screened out.  Among these genes, STAT3 and CDK2 were significantly assocd. with recurrence.  Further study suggested that inhibition of CDK2 reduced invasion of Pca cell lines.  The invasion ability was rescued after reintroduction of CDK2.  These data indicated that CDK2 was a crucial factor in metastasis of Pca and might be a novel therapy target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo42ZzW6tNPUbVg90H21EOLACvtfcHk0lhH5pMFTrMjTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntlegurk%253D&md5=c91131983f10d0ef4458d1bcec32b2d4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2217%2Ffon-2017-0561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2017-0561%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJiao%26aufirst%3DZ.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DB.%26atitle%3DIdentification%2520of%2520CDK2%2520as%2520a%2520novel%2520target%2520in%2520treatment%2520of%2520prostate%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2018%26volume%3D14%26spage%3D709%26epage%3D718%26doi%3D10.2217%2Ffon-2017-0561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caldon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sergio, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthukaruppan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boersma, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barraclough, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Print, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musgrove, E. A.</span></span> <span> </span><span class="NLM_article-title">Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1488</span>– <span class="NLM_lpage">1499</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-11-0963</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1158%2F1535-7163.MCT-11-0963" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=22564725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVKrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1488-1499&author=C.+E.+Caldonauthor=C.+M.+Sergioauthor=J.+Kangauthor=A.+Muthukaruppanauthor=M.+N.+Boersmaauthor=A.+Stoneauthor=J.+Barracloughauthor=C.+S.+Leeauthor=M.+A.+Blackauthor=L.+D.+Millerauthor=J.+M.+Geeauthor=R.+I.+Nicholsonauthor=R.+L.+Sutherlandauthor=C.+G.+Printauthor=E.+A.+Musgrove&title=Cyclin+E2+overexpression+is+associated+with+endocrine+resistance+but+not+insensitivity+to+CDK2+inhibition+in+human+breast+cancer+cells&doi=10.1158%2F1535-7163.mct-11-0963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells</span></div><div class="casAuthors">Caldon, C. Elizabeth; Sergio, C. Marcelo; Kang, Jian; Muthukaruppan, Anita; Boersma, Marijke N.; Stone, Andrew; Barraclough, Jane; Lee, Christine S.; Black, Michael A.; Miller, Lance D.; Gee, Julia M.; Nicholson, Rob I.; Sutherland, Robert L.; Print, Cristin G.; Musgrove, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1488-1499</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin E2, but not cyclin E1, is included in several gene signatures that predict disease progression in either tamoxifen-resistant or metastatic breast cancer.  We therefore examd. the role of cyclin E2 in antiestrogen resistance in vitro and its potential for therapeutic targeting through cyclin-dependent kinase (CDK) inhibition.  High expression of CCNE2, but not CCNE1, was characteristic of the luminal B and HER2 subtypes of breast cancer and was strongly predictive of shorter distant metastasis-free survival following endocrine therapy.  After antiestrogen treatment of MCF-7 breast cancer cells, cyclin E2 mRNA and protein were downregulated and cyclin E2-CDK2 activity decreased.  However, this regulation was lost in tamoxifen-resistant (MCF-7 TAMR) cells, which overexpressed cyclin E2.  Expression of either cyclin E1 or E2 in T-47D breast cancer cells conferred acute antiestrogen resistance, suggesting that cyclin E overexpression contributes to the antiestrogen resistance of tamoxifen-resistant cells.  Ectopic expression of cyclin E1 or E2 also reduced sensitivity to CDK4, but not CDK2, inhibition.  Proliferation of tamoxifen-resistant cells was inhibited by RNAi-mediated knockdown of cyclin E1, cyclin E2, or CDK2.  Furthermore, CDK2 inhibition of E-cyclin overexpressing cells and tamoxifen-resistant cells restored sensitivity to tamoxifen or CDK4 inhibition.  Cyclin E2 overexpression is therefore a potential mechanism of resistance to both endocrine therapy and CDK4 inhibition.  CDK2 inhibitors hold promise as a component of combination therapies in endocrine-resistant disease as they effectively inhibit cyclin E1 and E2 overexpressing cells and enhance the efficacy of other therapeutics.  Mol Cancer Ther; 11(7); 1488-99. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOrjoY6RnTk7Vg90H21EOLACvtfcHk0lhxDt_N_rPYQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVKrtbw%253D&md5=0d1b47e6b62a4fce919aa5fcf40c227a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0963%26sid%3Dliteratum%253Aachs%26aulast%3DCaldon%26aufirst%3DC.%2BE.%26aulast%3DSergio%26aufirst%3DC.%2BM.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DMuthukaruppan%26aufirst%3DA.%26aulast%3DBoersma%26aufirst%3DM.%2BN.%26aulast%3DStone%26aufirst%3DA.%26aulast%3DBarraclough%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%2BS.%26aulast%3DBlack%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DL.%2BD.%26aulast%3DGee%26aufirst%3DJ.%2BM.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DPrint%26aufirst%3DC.%2BG.%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26atitle%3DCyclin%2520E2%2520overexpression%2520is%2520associated%2520with%2520endocrine%2520resistance%2520but%2520not%2520insensitivity%2520to%2520CDK2%2520inhibition%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1488%26epage%3D1499%26doi%3D10.1158%2F1535-7163.mct-11-0963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trowbridge, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogatsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garabedian, M. J.</span></span> <span> </span><span class="NLM_article-title">Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">10132</span>– <span class="NLM_lpage">10137</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.19.10132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1073%2Fpnas.94.19.10132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=9294175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADyaK2sXmt1Cqu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=10132-10137&author=J.+M.+Trowbridgeauthor=I.+Rogatskyauthor=M.+J.+Garabedian&title=Regulation+of+estrogen+receptor+transcriptional+enhancement+by+the+cyclin+A%2FCdk2+complex&doi=10.1073%2Fpnas.94.19.10132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex</span></div><div class="casAuthors">Trowbridge, Janet M.; Rogatsky, Inez; Garabedian, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10132-10137</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The authors have found that ectopic expression of cyclin A increases hormone-dependent and hormone-independent transcriptional activation by the estrogen receptor in vivo in a no. of cell lines, including HeLa cells, U-2 OS osteosarcoma cells and Hs 578Bst breast epithelial cells.  This effect can be further enhanced in HeLa cells by the concurrent expression of the cyclin-dependent kinase activator, cyclin H, and cdk7, and abolished by expression of the cdk inhibitor, p27KIPI, or by the expression of a dominant neg. catalytically inactive cdk2 mutant.  ER is phosphorylated between amino acids 82 and 121 in vitro by the cyclin A/cdk2 complex and incorporation of phosphate into ER is stimulated by ectopic expression of cyclin A in vivo.  Together, these results strongly suggest a direct role for the cyclin A/cdk2 complex in phosphorylating ER and regulating its transcriptional activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOpi2Mjjhy1LVg90H21EOLACvtfcHk0lhxDt_N_rPYQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmt1Cqu7k%253D&md5=b8a8e2916b409988346b8decb8973d77</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.19.10132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.19.10132%26sid%3Dliteratum%253Aachs%26aulast%3DTrowbridge%26aufirst%3DJ.%2BM.%26aulast%3DRogatsky%26aufirst%3DI.%26aulast%3DGarabedian%26aufirst%3DM.%2BJ.%26atitle%3DRegulation%2520of%2520estrogen%2520receptor%2520transcriptional%2520enhancement%2520by%2520the%2520cyclin%2520A%252FCdk2%2520complex%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1997%26volume%3D94%26spage%3D10132%26epage%3D10137%26doi%3D10.1073%2Fpnas.94.19.10132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierson-Mullany, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C. A.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">10542</span>– <span class="NLM_lpage">10557</span>, <span class="refDoi"> DOI: 10.1128/mcb.24.24.10542-10557.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1128%2FMCB.24.24.10542-10557.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=15572662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFShu7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=10542-10557&author=L.+K.+Pierson-Mullanyauthor=C.+A.+Lange&title=Phosphorylation+of+progesterone+receptor+serine+400+mediates+ligand-independent+transcriptional+activity+in+response+to+activation+of+cyclin-dependent+protein+kinase+2&doi=10.1128%2Fmcb.24.24.10542-10557.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2</span></div><div class="casAuthors">Pierson-Mullany, Lisa K.; Lange, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10542-10557</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human progesterone receptors (PR) are phosphorylated by cyclin-dependent protein kinase 2 (CDK2) at multiple sites, including Ser400.  Herein, we have addressed the significance of phosphorylation of this residue.  PR phospho-Ser400-specific antibodies revealed regulated phosphorylation of Ser400 in response to progestins and mitogens, and this correlated with increased CDK2 levels and activity.  Expression of cyclin E elevated CDK2 activity and downregulated PR independently of ligand.  Similarly, overexpression of activated mutant CDK2 increased PR transcriptional activity in the absence and presence of progestin.  Mutation of PR Ser400 to alanine (S400A) blocked CDK2-induced PR activity in the absence, but not in the presence, of progestin.  PR was unresponsive to activated CDK2 in breast cancer cells with elevated p27, and RNA interference knock-down of p27 partially restored CDK2-induced ligand-independent PR activation.  Similarly, in p27-/- mouse embryonic fibroblasts, elevated CDK2 activity increased wild-type (wt) but not S400A PR transcriptional activity in the absence of progestin.  CDK2 induced nuclear localization of unliganded wt but not S400A PR; liganded S400A PR exhibited delayed nuclear accumulation.  These studies demonstrate that CDK2 regulates PR in the absence of progestins via phosphorylation of Ser400, thus revealing a novel mechanism for upregulated PR transcriptional activity in human breast cancer cells expressing altered cell cycle regulatory mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtFBJTUucg5LVg90H21EOLACvtfcHk0lhxDt_N_rPYQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFShu7bI&md5=9389bfbb80fcf468cc99194a9a6afb25</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.24.10542-10557.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.24.10542-10557.2004%26sid%3Dliteratum%253Aachs%26aulast%3DPierson-Mullany%26aufirst%3DL.%2BK.%26aulast%3DLange%26aufirst%3DC.%2BA.%26atitle%3DPhosphorylation%2520of%2520progesterone%2520receptor%2520serine%2520400%2520mediates%2520ligand-independent%2520transcriptional%2520activity%2520in%2520response%2520to%2520activation%2520of%2520cyclin-dependent%2520protein%2520kinase%25202%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D10542%26epage%3D10557%26doi%3D10.1128%2Fmcb.24.24.10542-10557.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Pelt, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyomarsi, K.</span></span> <span> </span><span class="NLM_article-title">Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin. E</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">3377</span>– <span class="NLM_lpage">3386</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-10-4086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1158%2F0008-5472.CAN-10-4086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=21385896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlGhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3377-3386&author=S.+Akliauthor=C.+S.+Van+Peltauthor=T.+Buiauthor=L.+Meijerauthor=K.+Keyomarsi&title=Cdk2+is+required+for+breast+cancer+mediated+by+the+low-molecular-weight+isoform+of+cyclin.+E&doi=10.1158%2F0008-5472.can-10-4086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Cdk2 is Required for Breast Cancer Mediated by the Low-Molecular-Weight Isoform of Cyclin E</span></div><div class="casAuthors">Akli, Said; Van Pelt, Carolyn S.; Bui, Tuyen; Meijer, Laurent; Keyomarsi, Khandan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3377-3386</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin E activates Cdk2, controls centrosome duplication, and regulates histone gene transcription.  Cyclin E is deregulated in cancer and appears as low-mol.-wt. (LMW) isoforms that correlate strongly with decreased survival in breast cancer patients.  Transgenic mice overexpressing LMW-cyclin E have increased incidence of mammary tumors and distant metastasis when compared with mice that had full-length cyclin E.  To specifically test the requirement for Cdk2 in LMW-cyclin E-mediated mammary tumorigenesis, we generated transgenic mice, which expressed LMW-cyclin E in a Cdk2-deficient background.  We found that mammary gland development proceeds relatively normally in these animals, indicating that Cdk2 kinase activity is largely dispensable for this process.  However, Cdk2-deficient mice were completely resistant to LMW-cyclin E-mediated mammary tumors.  Cdk2 wild-type or heterozygous mice succumbed to mammary tumors with mean latencies of 16 and 19.5 mo, resp., but Cdk2 nullizygous littermates did not display tumors through 24 mo.  Similarly, continuous administration of two different Cdk inhibitors significantly delayed LMW-cyclin E-induced mammary tumor progression.  Triple transgenic mice generated in a p53 heterozygous background also displayed no tumors.  Finally, we found that Cdk2 silencing induced cell death in LMW-overexpressing breast cancer cell lines, but not in cell lines lacking LMW expression.  Our findings establish a requirement for Cdk2 in LMW-cyclin E-mediated mammary tumorigenesis, arguing that human breast tumors overexpressing LMW-cyclin E are prime candidates for anti-Cdk2 therapy.  Cancer Res; 71(9); 3377-86.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWLccE8zVYrLVg90H21EOLACvtfcHk0lhztcn6Hi8VIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlGhuro%253D&md5=8dcba927024b8307917566071f999734</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4086%26sid%3Dliteratum%253Aachs%26aulast%3DAkli%26aufirst%3DS.%26aulast%3DVan%2BPelt%26aufirst%3DC.%2BS.%26aulast%3DBui%26aufirst%3DT.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DKeyomarsi%26aufirst%3DK.%26atitle%3DCdk2%2520is%2520required%2520for%2520breast%2520cancer%2520mediated%2520by%2520the%2520low-molecular-weight%2520isoform%2520of%2520cyclin.%2520E%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3377%26epage%3D3386%26doi%3D10.1158%2F0008-5472.can-10-4086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deavers, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malpica, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavanagh, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1925</span>– <span class="NLM_lpage">1932</span>, <span class="refDoi"> DOI: 10.1002/cncr.21767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1002%2Fcncr.21767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=16568440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvFGhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2006&pages=1925-1932&author=D.+G.+Rosenauthor=G.+Yangauthor=M.+T.+Deaversauthor=A.+Malpicaauthor=J.+J.+Kavanaghauthor=G.+B.+Millsauthor=J.+Liu&title=Cyclin+E+expression+is+correlated+with+tumor+progression+and+predicts+a+poor+prognosis+in+patients+with+ovarian+carcinoma&doi=10.1002%2Fcncr.21767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma</span></div><div class="casAuthors">Rosen, Daniel G.; Yang, Gong; Deavers, Michael T.; Malpica, Anais; Kavanagh, John J.; Mills, Gordon B.; Liu, Jinsong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1925-1932</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">BACKGROUND: Cyclins, cyclin dependent kinases (cdks), and their inhibitors act in combination to regulate progression through the cell cycle and often are dysregulated in carcinoma.  The authors hypothesized that cyclin E plays an important role in ovarian carcinogenesis and that its overexpression may be an indicator of a poor prognosis.  METHODS: Immunohistochem. anal. of cyclin E expression was performed by image anal. in normal ovaries, cystadenomas, tumors of low malignant potential, and 405 primary ovarian carcinomas by using tissue microarray technol.  RESULTS: Overexpression of cyclin E was found in 63.2% of the samples and was assocd. with clear cell, poorly differentiated, and serous carcinoma (P ≤ .001), high-grade tumors (P ≤ .001), late-stage disease (P = .002), age older than 60 years at the time of diagnosis (P = .04), and suboptimal cytoredn. (P = .001).  A high percentage of cyclin E-expressing cells was assocd. with a poor outcome in univariate and in multivariate analyses.  In addn., cyclin E levels also reduced survival in the late-stage disease group and in patients who underwent suboptimal debulking.  CONCLUSIONS: Cyclin E was identified as an independent prognostic factor in patients with ovarian carcinoma.  The accumulation of cyclin E protein may be a late event in tumorigenesis and may contribute to disease progression in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVj31v_bK72bVg90H21EOLACvtfcHk0lhztcn6Hi8VIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvFGhs78%253D&md5=ba303518605c55fcd818c4970de5baae</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fcncr.21767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.21767%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DD.%2BG.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DDeavers%26aufirst%3DM.%2BT.%26aulast%3DMalpica%26aufirst%3DA.%26aulast%3DKavanagh%26aufirst%3DJ.%2BJ.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DCyclin%2520E%2520expression%2520is%2520correlated%2520with%2520tumor%2520progression%2520and%2520predicts%2520a%2520poor%2520prognosis%2520in%2520patients%2520with%2520ovarian%2520carcinoma%26jtitle%3DCancer%26date%3D2006%26volume%3D106%26spage%3D1925%26epage%3D1932%26doi%3D10.1002%2Fcncr.21767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanArsdale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span> <span> </span><span class="NLM_article-title">Spectrum and degree of CDK drug interactions predicts clinical performance</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2273</span>– <span class="NLM_lpage">2281</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-16-0300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1158%2F1535-7163.MCT-16-0300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=27496135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGisbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2273-2281&author=P.+Chenauthor=N.+V.+Leeauthor=W.+Huauthor=M.+Xuauthor=R.+A.+Ferreauthor=H.+Lamauthor=S.+Bergqvistauthor=J.+Solowiejauthor=W.+Diehlauthor=Y.-A.+Heauthor=X.+Yuauthor=A.+Nagataauthor=T.+VanArsdaleauthor=B.+W.+Murray&title=Spectrum+and+degree+of+CDK+drug+interactions+predicts+clinical+performance&doi=10.1158%2F1535-7163.mct-16-0300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance</span></div><div class="casAuthors">Chen, Ping; Lee, Nathan V.; Hu, Wenyue; Xu, Meirong; Ferre, Rose Ann; Lam, Hieu; Bergqvist, Simon; Solowiej, James; Diehl, Wade; He, You-Ai; Yu, Xiu; Nagata, Asako; Van Arsdale, Todd; Murray, Brion W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2273-2281</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biol. perspective but drug development is often hindered by toxicities and inadequate efficacy.  Predicting drug behaviors using cellular and animal models is confounded by redundant kinase activities, a lack of unique substrates, and cell-specific signaling networks.  Cyclin-dependent kinase (CDK) drugs exemplify this phenomenon because they are reported to target common processes yet have distinct clin. activities.  Tumor cell studies of ATP-competitive CDK drugs (dinaciclib, AG-024322, abemaciclib, palbociclib, ribociclib) indicate similar pharmacol. while analyses in untransformed cells illuminates significant differences.  To resolve this apparent disconnect, drug behaviors are described at the mol. level.  Nonkinase binding studies and kinome interaction anal. (recombinant and endogenous kinases) reveal that proteins outside of the CDK family appear to have little role in dinaciclib/palbociclib/ribociclib pharmacol., may contribute for abemaciclib, and confounds AG-024322 anal.  CDK2 and CDK6 cocrystal structures with the drugs identify the mol. interactions responsible for potency and kinase selectivity.  Efficient drug binding to the unique hinge architecture of CDKs enables selectivity toward most of the human kinome.  Selectivity between CDK family members is achieved through interactions with nonconserved elements of the ATP-binding pocket.  Integrating clin. drug exposures into the anal. predicts that both palbociclib and ribociclib are CDK4/6 inhibitors, abemaciclib inhibits CDK4/6/9, and dinaciclib is a broad-spectrum CDK inhibitor (CDK2/3/4/6/9).  Understanding the mol. components of potency and selectivity also facilitates rational design of future generations of kinase-directed drugs.  Mol Cancer Ther; 15(10); 2273-81.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3TbbI98T8v7Vg90H21EOLACvtfcHk0lhztcn6Hi8VIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGisbjK&md5=112e9e46bb33393516fa94620e6383c6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0300%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DN.%2BV.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DY.-A.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DVanArsdale%26aufirst%3DT.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DSpectrum%2520and%2520degree%2520of%2520CDK%2520drug%2520interactions%2520predicts%2520clinical%2520performance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2273%26epage%3D2281%26doi%3D10.1158%2F1535-7163.mct-16-0300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herrera-Abreu, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palafox, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asghar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutts, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Murillas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grueso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pancholi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, L.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span> <span> </span><span class="NLM_article-title">Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">2301</span>– <span class="NLM_lpage">2313</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-15-0728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1158%2F0008-5472.CAN-15-0728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=27020857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVags74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=2301-2313&author=M.+T.+Herrera-Abreuauthor=M.+Palafoxauthor=U.+Asgharauthor=M.+A.+Rivasauthor=R.+J.+Cuttsauthor=I.+Garcia-Murillasauthor=A.+Pearsonauthor=M.+Guzmanauthor=O.+Rodriguezauthor=J.+Gruesoauthor=M.+Belletauthor=J.+Cort%C3%A9sauthor=R.+Elliottauthor=S.+Pancholiauthor=C.+J.+Lordauthor=J.+Baselgaauthor=M.+Dowsettauthor=L.-A.+Martinauthor=N.+C.+Turnerauthor=V.+Serra&title=Early+adaptation+and+acquired+resistance+to+CDK4%2F6+inhibition+in+estrogen+receptor-positive+breast+cancer&doi=10.1158%2F0008-5472.can-15-0728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer</span></div><div class="casAuthors">Herrera-Abreu, Maria Teresa; Palafox, Marta; Asghar, Uzma; Rivas, Martin A.; Cutts, Rosalind J.; Garcia-Murillas, Isaac; Pearson, Alex; Guzman, Marta; Rodriguez, Olga; Grueso, Judit; Bellet, Meritxell; Corties, Javier; Elliott, Richard; Pancholi, Sunil; Baselga, Josiee; Dowsett, Mitch; Martin, Lesley-Ann; Turner, Nicholas C.; Serra, Violeta</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2301-2313</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Small-mol. inhibitors of the CDK4/6 cell-cycle kinases have shown clin. efficacy in estrogen receptor (ER)-pos. metastatic breast cancer, although their cytostatic effects are limited by primary and acquired resistance.  Here we report that ER-pos. breast cancer cells can adapt quickly to CDK4/6 inhibition and evade cytostasis, in part, via noncanonical cyclin D1-CDK2-mediated S-phase entry.  This adaptation was prevented by cotreatment with hormone therapies or PI3K inhibitors, which reduced the levels of cyclin D1 (CCND1) and other G1-S cyclins, abolished pRb phosphorylation, and inhibited activation of S-phase transcriptional programs.  Combined targeting of both CDK4/6 and PI3K triggered cancer cell apoptosis in vitro and in patient-derived tumor xenograft (PDX) models, resulting in tumor regression and improved disease control.  Furthermore, a triple combination of endocrine therapy, CDK4/6, and PI3K inhibition was more effective than paired combinations, provoking rapid tumor regressions in a PDX model.  Mechanistic investigations showed that acquired resistance to CDK4/6 inhibition resulted from bypass of cyclin D1-CDK4/6 dependency through selection of CCNE1 amplification or RB1 loss.  Notably, although PI3K inhibitors could prevent resistance to CDK4/6 inhibitors, they failed to resensitize cells once resistance had been acquired.  However, we found that cells acquiring resistance to CDK4/6 inhibitors due to CCNE1 amplification could be resensitized by targeting CDK2.  Overall, our results illustrate convergent mechanisms of early adaptation and acquired resistance to CDK4/6 inhibitors that enable alternate means of S-phase entry, highlighting strategies to prevent the acquisition of therapeutic resistance to these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHNNElBQntOLVg90H21EOLACvtfcHk0lgjAhPbR7wSPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVags74%253D&md5=675a4562d545338fa16347c0a2f076f0</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-0728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-0728%26sid%3Dliteratum%253Aachs%26aulast%3DHerrera-Abreu%26aufirst%3DM.%2BT.%26aulast%3DPalafox%26aufirst%3DM.%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DRivas%26aufirst%3DM.%2BA.%26aulast%3DCutts%26aufirst%3DR.%2BJ.%26aulast%3DGarcia-Murillas%26aufirst%3DI.%26aulast%3DPearson%26aufirst%3DA.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DRodriguez%26aufirst%3DO.%26aulast%3DGrueso%26aufirst%3DJ.%26aulast%3DBellet%26aufirst%3DM.%26aulast%3DCort%25C3%25A9s%26aufirst%3DJ.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DPancholi%26aufirst%3DS.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DDowsett%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DL.-A.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DSerra%26aufirst%3DV.%26atitle%3DEarly%2520adaptation%2520and%2520acquired%2520resistance%2520to%2520CDK4%252F6%2520inhibition%2520in%2520estrogen%2520receptor-positive%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D2301%26epage%3D2313%26doi%3D10.1158%2F0008-5472.can-15-0728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahadirli-Talbott, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, I.-M.</span></span> <span> </span><span class="NLM_article-title">Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma</span>. <i>Mod. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1014</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1038/modpathol.2013.209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1038%2Fmodpathol.2013.209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=24309323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFCqsLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=1014-1019&author=E.+Kuhnauthor=A.+Bahadirli-Talbottauthor=I.-M.+Shih&title=Frequent+CCNE1+amplification+in+endometrial+intraepithelial+carcinoma+and+uterine+serous+carcinoma&doi=10.1038%2Fmodpathol.2013.209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma</span></div><div class="casAuthors">Kuhn, Elisabetta; Bahadirli-Talbott, Asli; Shih, Ie-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Modern Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1014-1019</span>CODEN:
                <span class="NLM_cas:coden">MODPEO</span>;
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Uterine serous carcinoma accounts for only 10̂ of all uterine epithelial cancers, but is the leading cause of death among them.  The pathogenesis of this aggressive neoplasm has been largely elusive until recently, when comprehensive genome-wide analyses of uterine serous carcinoma have been performed.  Among amplified cancer-related genes, CCNE1, encoding for cyclin E1, is frequently amplified in uterine serous carcinoma.  In the current study we applied fluorescence in situ hybridization (FISH) to det. CCNE1 copy no. in uterine serous carcinoma and concurrent endometrial intraepithelial carcinoma, the noninvasive component of uterine serous carcinoma, and the results were correlated with clinicopathol. and mol. features.  We found that 20 (45̂) of 44 uterine serous carcinomas and 11 (41̂) of 27 endometrial intraepithelial carcinomas showed CCNE1 amplification.  Overall, we found high concordance in CCNE1 copy no. in concurrent uterine serous carcinoma and endometrial intraepithelial carcinoma pairs (P-value=0.0003).  No correlation was obsd. between CCNE1 copy no. and clinicopathol. features, as well as common mutations previously reported in uterine serous carcinoma.  In summary, we confirm that amplification of CCNE1 is a frequent mol. genetic change in uterine serous carcinoma.  Moreover, the identification of CCNE1 amplification in many endometrial intraepithelial carcinomas suggests that this genetic event occurs early during tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6KzMRpOMks7Vg90H21EOLACvtfcHk0lgjAhPbR7wSPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFCqsLjN&md5=ead0e4246b936027da34a62b70a1d8aa</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.2013.209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.2013.209%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DE.%26aulast%3DBahadirli-Talbott%26aufirst%3DA.%26aulast%3DShih%26aufirst%3DI.-M.%26atitle%3DFrequent%2520CCNE1%2520amplification%2520in%2520endometrial%2520intraepithelial%2520carcinoma%2520and%2520uterine%2520serous%2520carcinoma%26jtitle%3DMod.%2520Pathol.%26date%3D2014%26volume%3D27%26spage%3D1014%26epage%3D1019%26doi%3D10.1038%2Fmodpathol.2013.209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colleoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loibl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demichele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayar, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michiels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnedos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang Bartlett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofanilli, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1169</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1200/jco.18.00925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1200%2FJCO.18.00925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=30807234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1WntLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=1169-1178&author=N.+C.+Turnerauthor=Y.+Liuauthor=Z.+Zhuauthor=S.+Loiauthor=M.+Colleoniauthor=S.+Loiblauthor=A.+Demicheleauthor=N.+Harbeckauthor=F.+Andr%C3%A9author=M.+A.+Bayarauthor=S.+Michielsauthor=Z.+Zhangauthor=C.+Giorgettiauthor=M.+Arnedosauthor=C.+Huang+Bartlettauthor=M.+Cristofanilli&title=Cyclin+E1+expression+and+palbociclib+efficacy+in+previously+treated+hormone+receptor-positive+metastatic+breast+cancer&doi=10.1200%2Fjco.18.00925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer</span></div><div class="casAuthors">Turner, Nicholas C.; Liu, Yuan; Zhu, Zhou; Loi, Sherene; Colleoni, Marco; Loibl, Sibylle; Demichele, Angela; Harbeck, Nadia; Andre, Fabrice; Bayar, Mohamed Amine; Michiels, Stefan; Zhang, Zhe; Giorgetti, Carla; Arnedos, Monica; Bartlett, Cynthia Huang; Cristofanilli, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1169-1179</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">PURPOSE A large-panel gene expression anal. was conducted to identify biomarkers assocd. with the effectiveness of adding palbociclib to fulvestrant.  METHODS The PALOMA-3 (ClinicalTrials.gov identifier: NCT01942135) trial randomly assigned 521 endocrinepretreated patients with metastatic breast cancer to receive palbociclib plus fulvestrant or placebo plus fulvestrant.  Primary anal. was first conducted on 10 genes on the basis of pathway biol. and evidence from previous studies followed by a systematic panel-wide search among 2,534 cancer-related genes.  The assocn. of gene expression with the effect of palbociclib on progression-free survival (PFS) was evaluated using Cox proportional hazards regression anal., with gene expression as a continuous variable or dichotomized by median.  An independent breast cancer cohort from the Preoperative Palbociclib (POP) Clin. Trial (ClinicalTrials.gov identifier: NCT02008734) was used for validation, in 61 patients with primary breast cancer treated with 2 wk of palbociclib.  RESULTS In the PALOMA-3 trial, 302 patients had tumor tissue analyzed (palbociclib arm, 194 patients; placebo arm, 108 patients).  Palbociclib efficacy was lower in patients with high vs. low cyclin E1 (CCNE1) mRNA expression (median PFS: palbociclib arm, 7.6 v 14.1 mo; placebo arm, 4.0 v 4.8 mo, resp.; interaction P unadjusted = .00238; false discovery rate-adjusted P = .0238).  CCNE1 mRNA was more predictive in metastatic than in archival primary biopsy tissue samples.  No significant interaction was found between treatment and expression levels of CDK4, CDK6, cyclin D1, and RB1.  Palbociclib was efficacious in both luminal A and luminal B tumors.  High CCNE1 mRNA expression was assocd. with poor antiproliferative activity of palbociclib in the POP trial (P = .005).  CONCLUSION Addn. of palbociclib to fulvestrant demonstrated efficacy in all biomarker groups, although high CCNE1 mRNA expression was assocd. with relative resistance to palbociclib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf1mJPZBY8SrVg90H21EOLACvtfcHk0lgoS37rD1FBfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1WntLnO&md5=a781177c1bb0f2557eab56f7a3a899bc</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1200%2FJCO.18.00925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.18.00925%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DColleoni%26aufirst%3DM.%26aulast%3DLoibl%26aufirst%3DS.%26aulast%3DDemichele%26aufirst%3DA.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DBayar%26aufirst%3DM.%2BA.%26aulast%3DMichiels%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGiorgetti%26aufirst%3DC.%26aulast%3DArnedos%26aufirst%3DM.%26aulast%3DHuang%2BBartlett%26aufirst%3DC.%26aulast%3DCristofanilli%26aufirst%3DM.%26atitle%3DCyclin%2520E1%2520expression%2520and%2520palbociclib%2520efficacy%2520in%2520previously%2520treated%2520hormone%2520receptor-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3D1169%26epage%3D1178%26doi%3D10.1200%2Fjco.18.00925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintanilla-Martinez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensley, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutkind, J. S.</span></span> <span> </span><span class="NLM_article-title">Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">1674</span>– <span class="NLM_lpage">1681</span>, <span class="refDoi"> DOI: 10.1172/jci3661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1172%2FJCI3661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=9802881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1Oqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=1674-1681&author=V.+Patelauthor=A.+M.+Senderowiczauthor=D.+Pintoauthor=T.+Igishiauthor=M.+Raffeldauthor=L.+Quintanilla-Martinezauthor=J.+F.+Ensleyauthor=E.+A.+Sausvilleauthor=J.+S.+Gutkind&title=Flavopiridol%2C+a+novel+cyclin-dependent+kinase+inhibitor%2C+suppresses+the+growth+of+head+and+neck+squamous+cell+carcinomas+by+inducing+apoptosis&doi=10.1172%2Fjci3661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis</span></div><div class="casAuthors">Patel, Vyomesh; Senderowicz, Adrian M.; Pinto, Decio, Jr.; Igishi, Tadashi; Raffeld, Mark; Quintanilla-Martinez, Leticia; Ensley, John F.; Sausville, Edward A.; Gutkind, J. Silvio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1674-1681</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Flavopiridol (HMR 1275) has been identified recently as a novel antineoplastic agent in the primary screen conducted by the Developmental Therapeutics Program, National Cancer Institute.  Flavopiridol inhibits most cyclin-dependent kinases (cdks) and displays unique anticancer properties.  Here, we investigated whether this compd. was effective against head and neck squamous cell carcinomas (HNSCC).  Exposure of HNSCC cells to flavopiridol diminished cdc2 and cdk2 activity and potently inhibited cell proliferation (IC50 43-83 nM), which was concomitant with the appearance of cells with a sub-G1 DNA content.  Moreover, DNA fragmentation and TUNEL (terminal deoxynucleotidyl transferase-mediated nick end labeling) reaction confirmed that flavopiridol induces apoptosis in all cell lines, even on certain HNSCC cells that are insensitive to apoptosis to DNA-damaging agents (γ-irradn. and bleomycin).  A tumorigenic HNSCC cell line was used to assess the effect of flavopiridol in vivo.  Treatment (5 mg/kg per day, i.p.) for 5 d led to the appearance of apoptotic cells in the tumor xenografts and caused a 60-70% redn. in tumor size, which was sustained over a period of 10 wk.  Flavopiridol treatment also resulted in a remarkable redn. of cyclin D1 expression in HNSCC cells and tumor xenografts.  Our data indicate that flavopiridol exerts antitumor activity in HNSCC, and thus it can be considered a suitable candidate drug for testing in the treatment of refractory carcinomas of the head and neck.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-lF748dX347Vg90H21EOLACvtfcHk0lgoS37rD1FBfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1Oqtrc%253D&md5=549f97c62f21c1b194856d237823a2b7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1172%2FJCI3661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI3661%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26aulast%3DPinto%26aufirst%3DD.%26aulast%3DIgishi%26aufirst%3DT.%26aulast%3DRaffeld%26aufirst%3DM.%26aulast%3DQuintanilla-Martinez%26aufirst%3DL.%26aulast%3DEnsley%26aufirst%3DJ.%2BF.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DGutkind%26aufirst%3DJ.%2BS.%26atitle%3DFlavopiridol%252C%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520suppresses%2520the%2520growth%2520of%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinomas%2520by%2520inducing%2520apoptosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D102%26spage%3D1674%26epage%3D1681%26doi%3D10.1172%2Fjci3661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A. M.</span></span> <span> </span><span class="NLM_article-title">Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1023/a:1006353008903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1023%2FA%3A1006353008903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10665481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtFartLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=313-320&author=A.+M.+Senderowicz&title=Flavopiridol%3A+the+first+cyclin-dependent+kinase+inhibitor+in+human+clinical+trials&doi=10.1023%2Fa%3A1006353008903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials</span></div><div class="casAuthors">Senderowicz, Adrian M.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">313-320</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review with 55 refs.  The discovery and cloning of the cyclin-dependent kinases (cdks), main regulators of cell cycle progression, allowed several investigators to design novel modulators of cdk activity.  Flavopiridol (HMR 1275, L86-8275), a flavonoid derived from an indigenous plant from India, demonstrated potent and specific in vitro inhibition of all cdks tested (cdks 1, 2, 4 and 7) with clear block in cell cycle progression at the G1/S and G2/M boundaries.  Moreover, preclin. studies demonstrated the capacity of flavopiridol to induce programmed cell death, promote differentiation, inhibit angiogenic processes and modulate transcriptional events.  The relationship between the latter effects and cdk inhibition is still unclear.  Initial testing in early clin. human trials with infusional flavopiridol showed activity in some patients with non-Hodgkin's lymphoma, renal, prostate, colon and gastric carcinomas.  Main side effects were secretory diarrhea and a pro-inflammatory syndrome assocd. with hypotension.  Biol. active plasma concns. of flavopiridol (∼300-500 nM) are easily achievable in patients receiving infusional flavopiridol.  Phase 2 trials with infusional flavopiridol in several tumor types, other schedules and combination with std. chemotherapies are being assessed.  In conclusion, flavopiridol is the first cdk inhibitor to be tested in clin. trials.  Although important questions remain to be answered, this pos. experience will stimulate the development of novel cdk modulators for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJEkms561BuLVg90H21EOLACvtfcHk0lgoS37rD1FBfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtFartLw%253D&md5=c540be99618350739adafa8746922c38</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1023%2FA%3A1006353008903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1006353008903%26sid%3Dliteratum%253Aachs%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26atitle%3DFlavopiridol%253A%2520the%2520first%2520cyclin-dependent%2520kinase%2520inhibitor%2520in%2520human%2520clinical%2520trials%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D1999%26volume%3D17%26spage%3D313%26epage%3D320%26doi%3D10.1023%2Fa%3A1006353008903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrychová, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Řezníčková, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gucký, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryštof, V.</span></span> <span> </span><span class="NLM_article-title">How selective are pharmacological inhibitors of cell-cycle-regulating cyclin-dependent kinases?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9105</span>– <span class="NLM_lpage">9120</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00049</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00049" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKqtr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9105-9120&author=R.+Jordaauthor=D.+Hendrychov%C3%A1author=J.+Vollerauthor=E.+%C5%98ezn%C3%AD%C4%8Dkov%C3%A1author=T.+Guck%C3%BDauthor=V.+Kry%C5%A1tof&title=How+selective+are+pharmacological+inhibitors+of+cell-cycle-regulating+cyclin-dependent+kinases%3F&doi=10.1021%2Facs.jmedchem.8b00049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?</span></div><div class="casAuthors">Jorda, Radek; Hendrychova, Denisa; Voller, Jiri; Reznickova, Eva; Gucky, Tomas; Krystof, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9105-9120</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are an important and emerging class of drug targets for which many small-mol. inhibitors have been developed.  However, there is often insufficient data available on the selectivity of CDK inhibitors (CDKi) to attribute the effects on the presumed target CDK to these inhibitors.  Here, we highlight discrepancies between the kinase selectivity of CDKi and the phenotype exhibited; we evaluated 31 CDKi (claimed to target CDK1-4) for activity toward CDKs 1, 2, 4, 5, 7, 9 and for effects on the cell cycle.  Our results suggest that most CDKi should be reclassified as pan-selective and should not be used as a tool.  In addn., some compds. did not even inhibit CDKs as their primary cellular targets; for example, NU6140 showed potent inhibition of Aurora kinases.  We also established an online database of com. available CDKi for crit. evaluation of their utility as mol. probes.  Our results should help researchers select the most relevant chem. tools for their specific applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopxhyveeEDKLVg90H21EOLACvtfcHk0lhhe5g_SdCwZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKqtr3F&md5=75d6b8beee8e6ac2aeb604ada9ed5895</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00049%26sid%3Dliteratum%253Aachs%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DHendrychov%25C3%25A1%26aufirst%3DD.%26aulast%3DVoller%26aufirst%3DJ.%26aulast%3D%25C5%2598ezn%25C3%25AD%25C4%258Dkov%25C3%25A1%26aufirst%3DE.%26aulast%3DGuck%25C3%25BD%26aufirst%3DT.%26aulast%3DKry%25C5%25A1tof%26aufirst%3DV.%26atitle%3DHow%2520selective%2520are%2520pharmacological%2520inhibitors%2520of%2520cell-cycle-regulating%2520cyclin-dependent%2520kinases%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9105%26epage%3D9120%26doi%3D10.1021%2Facs.jmedchem.8b00049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burdette-Radoux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tozer, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quirt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colevas, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhauer, E. A.</span></span> <span> </span><span class="NLM_article-title">Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1023/b:drug.0000026258.02846.1c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1023%2FB%3ADRUG.0000026258.02846.1c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=15122079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsF2isro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2004&pages=315-322&author=S.+Burdette-Radouxauthor=R.+G.+Tozerauthor=R.+C.+Lohmannauthor=I.+Quirtauthor=D.+S.+Ernstauthor=W.+Walshauthor=N.+Wainmanauthor=A.+D.+Colevasauthor=E.+A.+Eisenhauer&title=Phase+II+trial+of+flavopiridol%2C+a+cyclin+dependent+kinase+inhibitor%2C+in+untreated+metastatic+malignant+melanoma&doi=10.1023%2Fb%3Adrug.0000026258.02846.1c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma</span></div><div class="casAuthors">Burdette-Radoux, Susan; Tozer, Richard G.; Lohmann, Reinhard C.; Quirt, Ian; Ernst, D. Scott; Walsh, Wendy; Wainman, Nancy; Colevas, A. Dimitrios; Eisenhauer, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">315-322</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">Purpose: To test the activity of the cyclin dependent kinase (cdk) inhibitor flavopiridol in malignant melanoma, a disease with frequent abnormalities of the cyclin dependent kinase system.  Patients and methods: Patients had histol. proven, unidimensionally measurable malignant melanoma, incurable by std. therapy.  Prior adjuvant immunotherapy was allowed, but patients were otherwise untreated for advanced disease.  Flavopiridol was administered at a dose of 50 mg/m2 IV over 1 h daily × 3 days every 3 wk.  Patients were assessed for response every 2 cycles.  Results: 17 patients were accrued over 5 mo.  No objective responses were documented in the 16 patients evaluable for response.  Seven patients (44%) had stable disease after 2 cycles, with a median of 2.8 mo (range 1.8-9.2).  The most common treatment-related non-hematol. toxicities were diarrhea (82%), nausea (47%), fatigue (41%), anorexia (35%) and vomiting (29%).  Most treatment-related toxicities were mild, except for diarrhea (grade 3 in 3 patients, grade 4 in 1 patient), nausea (grade 3 in 1 patient) and tumor pain (grade 3 in 1 patient).  Hematol. toxicities were minimal, none worse than grade 2.  Eighty-eight percent of patients received ≥90% planned dose intensity; 2 patients had dose redns. for gastrointestinal (GI) toxicity.  Conclusions: Flavopiridol is well tolerated at the dose regimen used in this study, with an acceptable (primarily GI) toxicity profile.  Although 7 of the 16 patients had stable disease ranging from 1.8 to 9.2 mo in duration, there was no evidence of significant clin. activity in malignant melanoma by objective response criteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMAEJ71nRMTLVg90H21EOLACvtfcHk0lhhe5g_SdCwZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsF2isro%253D&md5=a145b2fc86199a7dd54f44c76dd9b1c5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1023%2FB%3ADRUG.0000026258.02846.1c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253ADRUG.0000026258.02846.1c%26sid%3Dliteratum%253Aachs%26aulast%3DBurdette-Radoux%26aufirst%3DS.%26aulast%3DTozer%26aufirst%3DR.%2BG.%26aulast%3DLohmann%26aufirst%3DR.%2BC.%26aulast%3DQuirt%26aufirst%3DI.%26aulast%3DErnst%26aufirst%3DD.%2BS.%26aulast%3DWalsh%26aufirst%3DW.%26aulast%3DWainman%26aufirst%3DN.%26aulast%3DColevas%26aufirst%3DA.%2BD.%26aulast%3DEisenhauer%26aufirst%3DE.%2BA.%26atitle%3DPhase%2520II%2520trial%2520of%2520flavopiridol%252C%2520a%2520cyclin%2520dependent%2520kinase%2520inhibitor%252C%2520in%2520untreated%2520metastatic%2520malignant%2520melanoma%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2004%26volume%3D22%26spage%3D315%26epage%3D322%26doi%3D10.1023%2Fb%3Adrug.0000026258.02846.1c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, G. J.</span></span> <span> </span><span class="NLM_article-title">Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors</span>. <i>J. Appl. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1002/jat.1177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1002%2Fjat.1177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=17211896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksF2nt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=133-142&author=B.+A.+Jessenauthor=L.+Leeauthor=T.+Koudriakovaauthor=M.+Hainesauthor=K.+Lundgrenauthor=S.+Priceauthor=J.+Nonomiyaauthor=C.+Lewisauthor=G.+J.+Stevens&title=Peripheral+white+blood+cell+toxicity+induced+by+broad+spectrum+cyclin-dependent+kinase+inhibitors&doi=10.1002%2Fjat.1177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors</span></div><div class="casAuthors">Jessen, Bart A.; Lee, Leo; Koudriakova, Tatiana; Haines, Morgan; Lundgren, Karen; Price, Sharon; Nonomiya, Jim; Lewis, Cristina; Stevens, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-142</span>CODEN:
                <span class="NLM_cas:coden">JJATDK</span>;
        ISSN:<span class="NLM_cas:issn">0260-437X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) were pursued for more than a decade for the treatment of cancer.  CDK inhibitors are expected to slow the rate of cell division and potentially increase the apoptotic fraction of rapidly dividing cells.  Although CDK activity is often increased in tumors, normal dividing tissues are also susceptible to the cytostatic and cytotoxic effects of CDK inhibitor action.  Therefore the typical toxicity profile assocd. with cytotoxic anti-cancer therapy, bone marrow suppression and gastrointestinal toxicity, is expected with CDK inhibitors.  Bone marrow toxicity and the ensuing delayed peripheral leukocyte suppression often limit the therapeutic application of cytotoxic anticancer drugs.  Here we characterize an unusual bone marrow-independent acute toxicity toward leukocytes from broad spectrum CDK inhibitors in monkeys and rodents.  The potential combination of both acute and delayed immunosuppression would likely further restrict the application of these particular compds.  Since the cells targeted were non-proliferating, it was assumed that the toxicity was not driven by the intended pharmacol. mechanism thereby facilitating the development of a testing strategy to identify compds. with a reduced potential for acute leukocyte toxicity.  This testing strategy resulted in a CDK inhibitor void of bone marrow-independent leukocyte toxicity that is currently undergoing clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiTrhjO_2vsbVg90H21EOLACvtfcHk0lhhe5g_SdCwZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksF2nt70%253D&md5=d8d707eaa40d555e176c15336c8e885b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fjat.1177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjat.1177%26sid%3Dliteratum%253Aachs%26aulast%3DJessen%26aufirst%3DB.%2BA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DHaines%26aufirst%3DM.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DStevens%26aufirst%3DG.%2BJ.%26atitle%3DPeripheral%2520white%2520blood%2520cell%2520toxicity%2520induced%2520by%2520broad%2520spectrum%2520cyclin-dependent%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Appl.%2520Toxicol.%26date%3D2007%26volume%3D27%26spage%3D133%26epage%3D142%26doi%3D10.1002%2Fjat.1177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santamaría, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrière, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerqueira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cáceres, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Cdk1 is sufficient to drive the mammalian cell cycle</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">811</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1038/nature06046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1038%2Fnature06046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=17700700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=811-815&author=D.+Santamar%C3%ADaauthor=C.+Barri%C3%A8reauthor=A.+Cerqueiraauthor=S.+Huntauthor=C.+Tardyauthor=K.+Newtonauthor=J.+F.+C%C3%A1ceresauthor=P.+Dubusauthor=M.+Malumbresauthor=M.+Barbacid&title=Cdk1+is+sufficient+to+drive+the+mammalian+cell+cycle&doi=10.1038%2Fnature06046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cdk1 is sufficient to drive the mammalian cell cycle</span></div><div class="casAuthors">Santamaria, David; Barriere, Cedric; Cerqueira, Antonio; Hunt, Sarah; Tardy, Claudine; Newton, Kathryn; Caceres, Javier F.; Dubus, Pierre; Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7155</span>),
    <span class="NLM_cas:pages">811-815</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Unicellular organisms such as yeasts require a single cyclin-dependent kinase, Cdk1, to drive cell division.  In contrast, mammalian cells are thought to require the sequential activation of at least four different cyclin-dependent kinases, Cdk2, Cdk3, Cdk4 and Cdk6, to drive cells through interphase, as well as Cdk1 to proceed through mitosis.  This model has been challenged by recent genetic evidence that mice survive in the absence of individual interphase Cdks.  Moreover, most mouse cell types proliferate in the absence of two or even three interphase Cdks.  Similar results have been obtained on ablation of some of the activating subunits of Cdks, such as the D-type and E-type cyclins.  Here we show that mouse embryos lacking all interphase Cdks (Cdk2, Cdk3, Cdk4 and Cdk6) undergo organogenesis and develop to midgestation.  In these embryos, Cdk1 binds to all cyclins, resulting in the phosphorylation of the retinoblastoma protein pRb and the expression of genes that are regulated by E2F transcription factors.  Mouse embryonic fibroblasts derived from these embryos proliferate in vitro, albeit with an extended cell cycle due to inefficient inactivation of Rb proteins.  However, they become immortal on continuous passage.  We also report that embryos fail to develop to the morula and blastocyst stages in the absence of Cdk1.  These results indicate that Cdk1 is the only essential cell cycle Cdk.  Moreover, they show that in the absence of interphase Cdks, Cdk1 can execute all the events that are required to drive cell division.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhEdshMg-kRLVg90H21EOLACvtfcHk0lgXpJ_i6R02bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGrsL8%253D&md5=d427cb68fc6c8758df24423761a89264</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnature06046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06046%26sid%3Dliteratum%253Aachs%26aulast%3DSantamar%25C3%25ADa%26aufirst%3DD.%26aulast%3DBarri%25C3%25A8re%26aufirst%3DC.%26aulast%3DCerqueira%26aufirst%3DA.%26aulast%3DHunt%26aufirst%3DS.%26aulast%3DTardy%26aufirst%3DC.%26aulast%3DNewton%26aufirst%3DK.%26aulast%3DC%25C3%25A1ceres%26aufirst%3DJ.%2BF.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCdk1%2520is%2520sufficient%2520to%2520drive%2520the%2520mammalian%2520cell%2520cycle%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D811%26epage%3D815%26doi%3D10.1038%2Fnature06046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinisch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fligge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T.</span></span> <span> </span><span class="NLM_article-title">A consistent dataset of kinetic solubilities for early-phase drug discovery</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1529</span>– <span class="NLM_lpage">1536</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1002%2Fcmdc.200900205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=19588473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKgtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1529-1536&author=C.+Kramerauthor=T.+Heinischauthor=T.+Fliggeauthor=B.+Beckauthor=T.+Clark&title=A+consistent+dataset+of+kinetic+solubilities+for+early-phase+drug+discovery&doi=10.1002%2Fcmdc.200900205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A Consistent Dataset of Kinetic Solubilities for Early-Phase Drug Discovery</span></div><div class="casAuthors">Kramer, Christian; Heinisch, Tilmann; Fligge, Thilo; Beck, Bernd; Clark, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1529-1536</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein, we describe a new dataset of kinetic aq. solubilities detd. by nephelometry for 711 druglike compds.  The solubilities are reported in twelve classes ranging from <2 μg mL-1 to >250 μg mL-1.  The measurements were designed to provide the appropriate data for applications in the early phases of drug discovery.  Three class classification models (insol., moderately sol., sol.) were built using the random forest algorithm and their performance for this dataset was analyzed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5DAHS8E_FV7Vg90H21EOLACvtfcHk0lgXpJ_i6R02bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKgtb%252FN&md5=2035434a4259a5a2e5a2eb5d34d121e3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900205%26sid%3Dliteratum%253Aachs%26aulast%3DKramer%26aufirst%3DC.%26aulast%3DHeinisch%26aufirst%3DT.%26aulast%3DFligge%26aufirst%3DT.%26aulast%3DBeck%26aufirst%3DB.%26aulast%3DClark%26aufirst%3DT.%26atitle%3DA%2520consistent%2520dataset%2520of%2520kinetic%2520solubilities%2520for%2520early-phase%2520drug%2520discovery%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D1529%26epage%3D1536%26doi%3D10.1002%2Fcmdc.200900205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span> <span> </span><span class="NLM_article-title">Defining optimum lipophilicity and molecular weight ranges for drug candidates-molecular weight dependent lower log D limits based on permeability</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2844</span>– <span class="NLM_lpage">2851</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.03.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.bmcl.2009.03.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=19361989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltl2rtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2844-2851&author=M.+J.+Waring&title=Defining+optimum+lipophilicity+and+molecular+weight+ranges+for+drug+candidates-molecular+weight+dependent+lower+log+D+limits+based+on+permeability&doi=10.1016%2Fj.bmcl.2009.03.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower log D limits based on permeability</span></div><div class="casAuthors">Waring, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2844-2851</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Anal. of a large, structurally diverse Caco-2 permeability dataset using a variety of statistical techniques suggests that log D and mol. wt. are the most important factors in detg. the permeability of drug candidates.  The limit for log D is shown to be dependent on mol. wt.  These limits are shown to be potentially superior to current guidelines in increasing the chances of finding highly permeable compds.  When combined with suggested upper limits for lipophilicity suggested in the literature based on the avoidance of toxicol. and other adverse effects, this helps define a lipophilicity range that is optimum for drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXwn3KyrzERrVg90H21EOLACvtfcHk0lgXpJ_i6R02bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltl2rtr0%253D&md5=1f04795ddf6e6b84d132a81e554c2516</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.03.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.03.109%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DDefining%2520optimum%2520lipophilicity%2520and%2520molecular%2520weight%2520ranges%2520for%2520drug%2520candidates-molecular%2520weight%2520dependent%2520lower%2520log%2520D%2520limits%2520based%2520on%2520permeability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2844%26epage%3D2851%26doi%3D10.1016%2Fj.bmcl.2009.03.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dress, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span> <span> </span><span class="NLM_article-title">Using the golden triangle to optimize clearance and oral absorption</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5560</span>– <span class="NLM_lpage">5564</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.08.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.bmcl.2009.08.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=19720530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFaktbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5560-5564&author=T.+W.+Johnsonauthor=K.+R.+Dressauthor=M.+Edwards&title=Using+the+golden+triangle+to+optimize+clearance+and+oral+absorption&doi=10.1016%2Fj.bmcl.2009.08.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Using the Golden Triangle to optimize clearance and oral absorption</span></div><div class="casAuthors">Johnson, Ted W.; Dress, Klaus R.; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5560-5564</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The Golden Triangle is a visualization tool developed from in vitro permeability, in vitro clearance and computational data designed to aid medicinal chemists in achieving metabolically stable, permeable and potent drug candidates.  Classifying compds. as permeable and stable and plotting mol. wt. (MW) vs. octanol:buffer (pH 7.4) distribution coeffs. (log D) or estd. octanol:buffer (pH 7.4) distribution coeffs. (elog D) reveals useful trends.  Anal. of at least 2 orthogonal trends, such as permeability and clearance, can be extremely effective in balancing and optimizing multiple properties.  In addn., mol. wt. and log D impact potency-efficiency calcns., allowing potency, clearance and permeability to be optimized simultaneously.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjGjEaOp0237Vg90H21EOLACvtfcHk0lhr6xfU3RWFAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFaktbfE&md5=3cfed1288ec451eb4419f1db753ae4b4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.08.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.08.045%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DDress%26aufirst%3DK.%2BR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DUsing%2520the%2520golden%2520triangle%2520to%2520optimize%2520clearance%2520and%2520oral%2520absorption%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5560%26epage%3D5564%26doi%3D10.1016%2Fj.bmcl.2009.08.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattei, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent roche compounds</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">686</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200800411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1002%2Fcmdc.200800411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=19266525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltlCgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=680-686&author=J.-U.+Petersauthor=P.+Schniderauthor=P.+Matteiauthor=M.+Kansy&title=Pharmacological+promiscuity%3A+dependence+on+compound+properties+and+target+specificity+in+a+set+of+recent+roche+compounds&doi=10.1002%2Fcmdc.200800411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds</span></div><div class="casAuthors">Peters, Jens-Uwe; Schnider, Patrick; Mattei, Patrizio; Kansy, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">680-686</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">What parameters det. promiscuity A compd.'s potential for promiscuity (pharmacol. activity at multiple targets) may be influenced by mol. parameters such as ionization state, lipophilicity, and mol. wt.  In an anal. of recent Roche compds. we found that a pos. charge is an important determinant for potential promiscuity; aminergic activity was the main reason for overt promiscuity.  The term "pharmacol. promiscuity" describes a compd.'s pharmacol. activity at multiple targets.  Pharmacol. promiscuity is undesired in typical drug discovery projects, which focus on the "one drug-one target" paradigm.  Off-target activity can lead to adverse drug reactions, or can obscure pharmacodynamic effects in animal models.  Therefore, advanced lead compds., pharmacol. tool compds., and drug candidates are usually screened against panels of safety-relevant targets to detect unwanted pharmacol. activities.  To identify determinants of pharmacol. promiscuity, we compared the panel screening outcomes of 213 recent Roche compds. with their mol. properties.  Pronounced promiscuity was not obsd. below a threshold Clog P value of 2.  For basic compds., the propensity for weak off-target activity was found to increase with calcd. basicities, whereas the potential for strong off-target activity depends more qual. on the presence of a pos. charge at physiol. pH.  Compds. originating from projects with an aminergic receptor or transporter as a therapeutic target are particularly prone to promiscuity; the promiscuity of such compds. is mainly caused by their activity at other aminergic targets in the screening panel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXk5b2yXWf27Vg90H21EOLACvtfcHk0lhr6xfU3RWFAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltlCgsbc%253D&md5=6169ec58443249fb4fc8b2d694ba4164</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200800411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200800411%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26aulast%3DSchnider%26aufirst%3DP.%26aulast%3DMattei%26aufirst%3DP.%26aulast%3DKansy%26aufirst%3DM.%26atitle%3DPharmacological%2520promiscuity%253A%2520dependence%2520on%2520compound%2520properties%2520and%2520target%2520specificity%2520in%2520a%2520set%2520of%2520recent%2520roche%2520compounds%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D680%26epage%3D686%26doi%3D10.1002%2Fcmdc.200800411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman-Cook, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span> <span> </span><span class="NLM_article-title">Lipophilic efficiency: the most important efficiency metric in medicinal chemistry</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.4155/fmc.12.208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.4155%2Ffmc.12.208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=23360135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1aiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=113-115&author=K.+D.+Freeman-Cookauthor=R.+L.+Hoffmanauthor=T.+W.+Johnson&title=Lipophilic+efficiency%3A+the+most+important+efficiency+metric+in+medicinal+chemistry&doi=10.4155%2Ffmc.12.208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic efficiency: the most important efficiency metric in medicinal chemistry</span></div><div class="casAuthors">Freeman-Cook, Kevin D.; Hoffman, Robert L.; Johnson, Ted W.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-115</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review is given on the crit. role of lipophilicity in drug discovery and optimization of general absorption, distribution, metab. and excretion properties, toxicol. profiles and ultimately pharmacol. response.  Math. equations are presented concerning the impact of lipophilicity on the dose and the calcn. of the lipophilic ligand efficiency (LipE).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKhEHH7Hf1qbVg90H21EOLACvtfcHk0lhr6xfU3RWFAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1aiu7g%253D&md5=36170decfa1f1e3ef09ecf772322a210</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.208%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman-Cook%26aufirst%3DK.%2BD.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26atitle%3DLipophilic%2520efficiency%253A%2520the%2520most%2520important%2520efficiency%2520metric%2520in%2520medicinal%2520chemistry%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26spage%3D113%26epage%3D115%26doi%3D10.4155%2Ffmc.12.208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlingame, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Broad-spectrum kinase profiling in live cells with lysine-targeted sulfonyl fluoride probes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">685</span>, <span class="refDoi"> DOI: 10.1021/jacs.6b08536</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b08536" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=680-685&author=Q.+Zhaoauthor=X.+Ouyangauthor=X.+Wanauthor=K.+S.+Gajiwalaauthor=J.+C.+Kathauthor=L.+H.+Jonesauthor=A.+L.+Burlingameauthor=J.+Taunton&title=Broad-spectrum+kinase+profiling+in+live+cells+with+lysine-targeted+sulfonyl+fluoride+probes&doi=10.1021%2Fjacs.6b08536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes</span></div><div class="casAuthors">Zhao, Qian; Ouyang, Xiaohu; Wan, Xiaobo; Gajiwala, Ketan S.; Kath, John C.; Jones, Lyn H.; Burlingame, Alma L.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">680-685</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein kinases comprise a large family of structurally related enzymes.  A major goal in kinase inhibitor development is to selectively engage the desired kinase while avoiding myriad off-target kinases.  However, quantifying inhibitor interactions with multiple endogenous kinases in live cells remains an unmet challenge.  Here, we report the design of sulfonyl fluoride probes that covalently label a broad swath of the intracellular kinome with high efficiency.  Protein crystallog. and mass spectrometry (MS) confirmed a chemoselective reaction between the sulfonyl fluoride and a conserved lysine in the ATP binding site.  Optimized probe 2 (XO44) covalently modified up to 133 endogenous kinases, efficiently competing with high intracellular concns. of ATP.  We employed probe 2 and label-free mass spectrometry to quantify intracellular kinase engagement by the approved drug, dasatinib.  The data revealed saturable dasatinib binding to a small subset of kinase targets at clin. relevant concns., highlighting the utility of lysine-targeted sulfonyl fluoride probes in demanding chemoproteomic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHvHZRDHN2IbVg90H21EOLACvtfcHk0liaEWDJDNFM6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWisA%253D%253D&md5=3f643a1b32c83fa05932f42b54e96e47</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b08536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b08536%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DOuyang%26aufirst%3DX.%26aulast%3DWan%26aufirst%3DX.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DBurlingame%26aufirst%3DA.%2BL.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DBroad-spectrum%2520kinase%2520profiling%2520in%2520live%2520cells%2520with%2520lysine-targeted%2520sulfonyl%2520fluoride%2520probes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2017%26volume%3D139%26spage%3D680%26epage%3D685%26doi%3D10.1021%2Fjacs.6b08536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Free, S. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. W.</span></span> <span> </span><span class="NLM_article-title">A mathematical contribution to structure-activity studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1964</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1021/jm00334a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00334a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADyaF2cXkt1OltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1964&pages=395-399&author=S.+M.+Freeauthor=J.+W.+Wilson&title=A+mathematical+contribution+to+structure-activity+studies&doi=10.1021%2Fjm00334a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A mathematical contribution to structure-activity studies</span></div><div class="casAuthors">Free, Spencer M., Jr.; Wilson, James W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1964</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">395-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A math. technique is suggested as a means of describing structure-activity relation of a series of chem. analogs.  The data requirements included specific side chain arrangements and performance characteristics of all analogs tested.  Two examples illustrate the use of the additive math. model where the performance characteristics are measures of biol. activity.  The results rank the structural changes per position by estg. the amt. of biol. response attributed to each change.  The estimates are both pos. and neg.  Several uses for the math. soln. are suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRyTj3xI-aH7Vg90H21EOLACvtfcHk0liaEWDJDNFM6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2cXkt1OltbY%253D&md5=88fabb64d7a5635506a11418a2744bd6</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm00334a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00334a001%26sid%3Dliteratum%253Aachs%26aulast%3DFree%26aufirst%3DS.%2BM.%26aulast%3DWilson%26aufirst%3DJ.%2BW.%26atitle%3DA%2520mathematical%2520contribution%2520to%2520structure-activity%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1964%26volume%3D7%26spage%3D395%26epage%3D399%26doi%3D10.1021%2Fjm00334a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman-Cook, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzon, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirico, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henegar, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houser, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limberakis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loomis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPherson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murdande, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillion, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugarman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span> <span> </span><span class="NLM_article-title">Maximizing lipophilic efficiency: The use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1021/jm201503u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201503u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=935-942&author=K.+D.+Freeman-Cookauthor=P.+Amorauthor=S.+Baderauthor=L.+M.+Buzonauthor=S.+B.+Coffeyauthor=J.+W.+Corbettauthor=K.+J.+Diricoauthor=S.+D.+Doranauthor=R.+L.+Elliottauthor=W.+Eslerauthor=A.+Guzman-Perezauthor=K.+E.+Henegarauthor=J.+A.+Houserauthor=C.+S.+Jonesauthor=C.+Limberakisauthor=K.+Loomisauthor=K.+McPhersonauthor=S.+Murdandeauthor=K.+L.+Nelsonauthor=D.+Phillionauthor=B.+S.+Pierceauthor=W.+Songauthor=E.+Sugarmanauthor=S.+Tapleyauthor=M.+Tuauthor=Z.+Zhao&title=Maximizing+lipophilic+efficiency%3A+The+use+of+Free-Wilson+analysis+in+the+design+of+inhibitors+of+acetyl-CoA+carboxylase&doi=10.1021%2Fjm201503u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Maximizing lipophilic efficiency: The use of free-wilson analysis in the design of inhibitors of acetyl-CoA carboxylase</span></div><div class="casAuthors">Freeman-Cook, Kevin D.; Amor, Paul; Bader, Scott; Buzon, Leanne M.; Coffey, Steven B.; Corbett, Jeffrey W.; Dirico, Kenneth J.; Doran, Shawn D.; Elliott, Richard L.; Esler, William; Guzman-Perez, Angel; Henegar, Kevin E.; Houser, Janet A.; Jones, Christopher S.; Limberakis, Chris; Loomis, Katherine; McPherson, Kirk; Murdande, Sharad; Nelson, Kendra L.; Phillion, Dennis; Pierce, Betsy S.; Song, Wei; Sugarman, Eliot; Tapley, Susan; Tu, Meihua; Zhao, Zhengrong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">935-942</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper describes the design and synthesis of a novel series of dual inhibitors of acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2).  Key findings include the discovery of an initial lead that was modestly potent and subsequent medicinal chem. optimization with a focus on lipophilic efficiency (LipE) to balance overall drug-like properties.  Free-Wilson methodol. provided a clear breakdown of the contributions of specific structural elements to the overall LipE, a rationale for prioritization of virtual compds. for synthesis, and a highly successful prediction of the LipE of the resulting analogs.  Further preclin. assays, including in vivo malonyl-CoA redn. in both rat liver (ACC1) and rat muscle (ACC2), identified an advanced analog that progressed to regulatory toxicity studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGo75v6CKldrVg90H21EOLACvtfcHk0liaEWDJDNFM6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurjO&md5=ba269e25003f009951bb595741655ea2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm201503u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201503u%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman-Cook%26aufirst%3DK.%2BD.%26aulast%3DAmor%26aufirst%3DP.%26aulast%3DBader%26aufirst%3DS.%26aulast%3DBuzon%26aufirst%3DL.%2BM.%26aulast%3DCoffey%26aufirst%3DS.%2BB.%26aulast%3DCorbett%26aufirst%3DJ.%2BW.%26aulast%3DDirico%26aufirst%3DK.%2BJ.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DElliott%26aufirst%3DR.%2BL.%26aulast%3DEsler%26aufirst%3DW.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DHenegar%26aufirst%3DK.%2BE.%26aulast%3DHouser%26aufirst%3DJ.%2BA.%26aulast%3DJones%26aufirst%3DC.%2BS.%26aulast%3DLimberakis%26aufirst%3DC.%26aulast%3DLoomis%26aufirst%3DK.%26aulast%3DMcPherson%26aufirst%3DK.%26aulast%3DMurdande%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DK.%2BL.%26aulast%3DPhillion%26aufirst%3DD.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSong%26aufirst%3DW.%26aulast%3DSugarman%26aufirst%3DE.%26aulast%3DTapley%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DZ.%26atitle%3DMaximizing%2520lipophilic%2520efficiency%253A%2520The%2520use%2520of%2520Free-Wilson%2520analysis%2520in%2520the%2520design%2520of%2520inhibitors%2520of%2520acetyl-CoA%2520carboxylase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D935%26epage%3D942%26doi%3D10.1021%2Fjm201503u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman-Cook, K.</span>; <span class="NLM_string-name">Hoffman, R. L.</span>; <span class="NLM_string-name">Miller, N.</span>; <span class="NLM_string-name">Nguyen, L.</span>; <span class="NLM_string-name">Wang, T.</span>; <span class="NLM_string-name">Almaden, J.</span>; <span class="NLM_string-name">Chionis, J.</span>; <span class="NLM_string-name">Eisele, K.</span>; <span class="NLM_string-name">Liu, C.</span>; <span class="NLM_string-name">Zhang, Q.</span>; <span class="NLM_string-name">Niessen, S.</span>; <span class="NLM_string-name">Lapek, J.</span>; <span class="NLM_string-name">Weinrich, S. L.</span>; <span class="NLM_string-name">Wei, P.</span>; <span class="NLM_string-name">Carelli, J.</span>; <span class="NLM_string-name">Lee, N.</span>; <span class="NLM_string-name">Zhang, C.</span>; <span class="NLM_string-name">Huser, N.</span>; <span class="NLM_string-name">Looper, D.</span>; <span class="NLM_string-name">Ninkovic, S.</span>; <span class="NLM_string-name">McTigue, M.</span>; <span class="NLM_string-name">Behenna, D.</span>; <span class="NLM_string-name">Ferre, R. A.</span>; <span class="NLM_string-name">He, Y.</span>; <span class="NLM_string-name">Tran, K. T.</span>; <span class="NLM_string-name">Sutton, S.</span>; <span class="NLM_string-name">Zehnder, L. R.</span>; <span class="NLM_string-name">Kephart, S. E.</span>; <span class="NLM_string-name">Nagata, A.</span>; <span class="NLM_string-name">Ornelas, M. A.</span>; <span class="NLM_string-name">Murray, B.</span>; <span class="NLM_string-name">Xu, M.</span>; <span class="NLM_string-name">Solowiej, J. E.</span>; <span class="NLM_string-name">Visswanathan, R.</span>; <span class="NLM_string-name">Boras, B.</span>; <span class="NLM_string-name">Wilson, E.</span>; <span class="NLM_string-name">Oderup, C.</span>; <span class="NLM_string-name">Salek-Ardakani, S.</span>; <span class="NLM_string-name">Zhu, Z.</span>; <span class="NLM_string-name">McMillan, E.</span>; <span class="NLM_string-name">Mu, X. J.</span>; <span class="NLM_string-name">Ding, Y.</span>; <span class="NLM_string-name">Kan, Z.</span>; <span class="NLM_string-name">Bienkowska, J. R.</span>; <span class="NLM_string-name">VanArsdale, T.</span>; <span class="NLM_string-name">White, M. A.</span>; <span class="NLM_string-name">Dann, S. G.</span></span> <span> </span><span class="NLM_article-title">Expanding control of the tumor cell cycle; discovery of the CDK2/4/6 inhibitor PF-06873600</span> <i>Cancer Cell</i>. Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Freeman-Cook%2C+K.%3B+Hoffman%2C+R.+L.%3B+Miller%2C+N.%3B+Nguyen%2C+L.%3B+Wang%2C+T.%3B+Almaden%2C+J.%3B+Chionis%2C+J.%3B+Eisele%2C+K.%3B+Liu%2C+C.%3B+Zhang%2C+Q.%3B+Niessen%2C+S.%3B+Lapek%2C+J.%3B+Weinrich%2C+S.+L.%3B+Wei%2C+P.%3B+Carelli%2C+J.%3B+Lee%2C+N.%3B+Zhang%2C+C.%3B+Huser%2C+N.%3B+Looper%2C+D.%3B+Ninkovic%2C+S.%3B+McTigue%2C+M.%3B+Behenna%2C+D.%3B+Ferre%2C+R.+A.%3B+He%2C+Y.%3B+Tran%2C+K.+T.%3B+Sutton%2C+S.%3B+Zehnder%2C+L.+R.%3B+Kephart%2C+S.+E.%3B+Nagata%2C+A.%3B+Ornelas%2C+M.+A.%3B+Murray%2C+B.%3B+Xu%2C+M.%3B+Solowiej%2C+J.+E.%3B+Visswanathan%2C+R.%3B+Boras%2C+B.%3B+Wilson%2C+E.%3B+Oderup%2C+C.%3B+Salek-Ardakani%2C+S.%3B+Zhu%2C+Z.%3B+McMillan%2C+E.%3B+Mu%2C+X.+J.%3B+Ding%2C+Y.%3B+Kan%2C+Z.%3B+Bienkowska%2C+J.+R.%3B+VanArsdale%2C+T.%3B+White%2C+M.+A.%3B+Dann%2C+S.+G.+Expanding+control+of+the+tumor+cell+cycle%3B+discovery+of+the+CDK2%2F4%2F6+inhibitor+PF-06873600+Cancer+Cell.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman-Cook%26aufirst%3DK.%26atitle%3DExpanding%2520control%2520of%2520the%2520tumor%2520cell%2520cycle%253B%2520discovery%2520of%2520the%2520CDK2%252F4%252F6%2520inhibitor%2520PF-06873600%26jtitle%3DCancer%2520Cell" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney-Pickett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umland, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhard, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federico, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-kattan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span> <span> </span><span class="NLM_article-title">Development of a new permeability assay using low-efflux MDCKII cells</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">4974</span>– <span class="NLM_lpage">4985</span>, <span class="refDoi"> DOI: 10.1002/jps.22674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&author=L.+Diauthor=C.+Whitney-Pickettauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+new+permeability+assay+using+low-efflux+MDCKII+cells&doi=10.1002%2Fjps.22674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0lg3O4mfXNqleQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520new%2520permeability%2520assay%2520using%2520low-efflux%2520MDCKII%2520cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26spage%3D4974%26epage%3D4985%26doi%3D10.1002%2Fjps.22674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welcker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clurman, B. E.</span></span> <span> </span><span class="NLM_article-title">Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2014.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.ccell.2014.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=25314076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGnsLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=455-464&author=R.+J.+Davisauthor=M.+Welckerauthor=B.+E.+Clurman&title=Tumor+suppression+by+the+Fbw7+ubiquitin+ligase%3A+mechanisms+and+opportunities&doi=10.1016%2Fj.ccell.2014.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor Suppression by the Fbw7 Ubiquitin Ligase: Mechanisms and Opportunities</span></div><div class="casAuthors">Davis, Ryan J.; Welcker, Markus; Clurman, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">455-464</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Tumor suppressors with widespread impact on carcinogenesis control broad spectra of oncogenic pathways.  Protein degrdn. is an emerging mechanism by which tumor suppressors regulate a diversity of pathways and is exemplified by the SCFFbw7 ubiquitin ligase.  Rapidly accumulating data indicate that SCFFbw7 regulates a network of crucial oncoproteins.  Importantly, the FBXW7 gene, which encodes Fbw7, is one of the most frequently mutated genes in human cancers.  These studies are yielding important new insights into tumorigenesis and may soon enable therapies targeting the Fbw7 pathway.  Here, we focus on the mechanisms and consequences of Fbw7 deregulation in cancers and discuss possible therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1yVPOzpMverVg90H21EOLACvtfcHk0lg3O4mfXNqleQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGnsLzL&md5=4a336cec1030cdeab7ef4e99aa24767a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2014.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2014.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BJ.%26aulast%3DWelcker%26aufirst%3DM.%26aulast%3DClurman%26aufirst%3DB.%2BE.%26atitle%3DTumor%2520suppression%2520by%2520the%2520Fbw7%2520ubiquitin%2520ligase%253A%2520mechanisms%2520and%2520opportunities%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26spage%3D455%26epage%3D464%26doi%3D10.1016%2Fj.ccell.2014.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inuzuka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpen, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">FBW7 loss promotes chromosomal instability and tumorigenesis via cyclin E1/CDK2-mediated phosphorylation of CENP-A</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">4881</span>– <span class="NLM_lpage">4893</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-17-1240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1158%2F0008-5472.CAN-17-1240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=28760857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsV2lsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4881-4893&author=M.+Takadaauthor=W.+Zhangauthor=A.+Suzukiauthor=T.+S.+Kurodaauthor=Z.+Yuauthor=H.+Inuzukaauthor=D.+Gaoauthor=L.+Wanauthor=M.+Zhuangauthor=L.+Huauthor=B.+Zhaiauthor=C.+J.+Fryauthor=K.+Bloomauthor=G.+Liauthor=G.+H.+Karpenauthor=W.+Weiauthor=Q.+Zhang&title=FBW7+loss+promotes+chromosomal+instability+and+tumorigenesis+via+cyclin+E1%2FCDK2-mediated+phosphorylation+of+CENP-A&doi=10.1158%2F0008-5472.can-17-1240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">FBW7 Loss Promotes Chromosomal Instability and Tumorigenesis via Cyclin E1/CDK2-Mediated Phosphorylation of CENP-A</span></div><div class="casAuthors">Takada, Mamoru; Zhang, Weiguo; Suzuki, Aussie; Kuroda, Taruho S.; Yu, Zhouliang; Inuzuka, Hiroyuki; Gao, Daming; Wan, Lixin; Zhuang, Ming; Hu, Lianxin; Zhai, Bo; Fry, Christopher J.; Bloom, Kerry; Li, Guohong; Karpen, Gary H.; Wei, Wenyi; Zhang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4881-4893</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The centromere regulates proper chromosome segregation, and its dysfunction is implicated in chromosomal instability (CIN).  However, relatively little is known about how centromere dysfunction occurs in cancer.  Here, we define the consequences of phosphorylation by cyclin E1/CDK2 on a conserved Ser18 residue of centromere-assocd. protein CENP-A, an essential histone H3 variant that specifies centromere identity.  Ser18 hyperphosphorylation in cells occurred upon loss of FBW7, a tumor suppressor whose inactivation leads to CIN.  This event on CENP-A reduced its centromeric localization, increased CIN, and promoted anchorage-independent growth and xenograft tumor formation.  Overall, our results revealed a pathway that cyclin E1/CDK2 activation coupled with FBW7 loss promotes CIN and tumor progression via CENP-A-mediated centromere dysfunction.  Cancer Res; 77(18); 4881-93. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZBe5nL7w7gLVg90H21EOLACvtfcHk0lj62S1GQHoI8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsV2lsrbP&md5=fd7ba5b64b4d17f2b6c19ce77259bd1b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-1240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-1240%26sid%3Dliteratum%253Aachs%26aulast%3DTakada%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DKuroda%26aufirst%3DT.%2BS.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DInuzuka%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DZhuang%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DB.%26aulast%3DFry%26aufirst%3DC.%2BJ.%26aulast%3DBloom%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DKarpen%26aufirst%3DG.%2BH.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DFBW7%2520loss%2520promotes%2520chromosomal%2520instability%2520and%2520tumorigenesis%2520via%2520cyclin%2520E1%252FCDK2-mediated%2520phosphorylation%2520of%2520CENP-A%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D4881%26epage%3D4893%26doi%3D10.1158%2F0008-5472.can-17-1240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokheim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta-Pardo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerasinghe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colaprico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendl, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reardon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, P. K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mularoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubio-Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarajan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Ciriano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yellapantula, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamborero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suphavilai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khurana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Allen, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godzik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Bigas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karchin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span> <span> </span><span class="NLM_article-title">Comprehensive characterization of cancer driver genes and mutations</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.02.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.cell.2018.02.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=29625053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntFaiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2018&pages=371-385&author=M.+H.+Baileyauthor=C.+Tokheimauthor=E.+Porta-Pardoauthor=S.+Senguptaauthor=D.+Bertrandauthor=A.+Weerasingheauthor=A.+Colapricoauthor=M.+C.+Wendlauthor=J.+Kimauthor=B.+Reardonauthor=P.+K.-S.+Ngauthor=K.+J.+Jeongauthor=S.+Caoauthor=Z.+Wangauthor=J.+Gaoauthor=Q.+Gaoauthor=F.+Wangauthor=E.+M.+Liuauthor=L.+Mularoniauthor=C.+Rubio-Perezauthor=N.+Nagarajanauthor=I.+Cortes-Cirianoauthor=D.+C.+Zhouauthor=W.-W.+Liangauthor=J.+M.+Hessauthor=V.+D.+Yellapantulaauthor=D.+Tamboreroauthor=A.+Gonzalez-Perezauthor=C.+Suphavilaiauthor=J.+Y.+Koauthor=E.+Khuranaauthor=P.+J.+Parkauthor=E.+M.+Van+Allenauthor=H.+Liangauthor=M.+S.+Lawrenceauthor=A.+Godzikauthor=N.+Lopez-Bigasauthor=J.+Stuartauthor=D.+Wheelerauthor=G.+Getzauthor=K.+Chenauthor=A.+J.+Lazarauthor=G.+B.+Millsauthor=R.+Karchinauthor=L.+Ding&title=Comprehensive+characterization+of+cancer+driver+genes+and+mutations&doi=10.1016%2Fj.cell.2018.02.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive Characterization of Cancer Driver Genes and Mutations</span></div><div class="casAuthors">Bailey, Matthew H.; Tokheim, Collin; Porta-Pardo, Eduard; Sengupta, Sohini; Bertrand, Denis; Weerasinghe, Amila; Colaprico, Antonio; Wendl, Michael C.; Kim, Jaegil; Reardon, Brendan; Ng, Patrick Kwok-Shing; Jeong, Kang Jin; Cao, Song; Wang, Zixing; Gao, Jianjiong; Gao, Qingsong; Wang, Fang; Liu, Eric Minwei; Mularoni, Loris; Rubio-Perez, Carlota; Nagarajan, Niranjan; Cortes-Ciriano, Isidro; Zhou, Daniel Cui; Liang, Wen-Wei; Hess, Julian M.; Yellapantula, Venkata D.; Tamborero, David; Gonzalez-Perez, Abel; Suphavilai, Chayaporn; Ko, Jia Yu; Khurana, Ekta; Park, Peter J.; Van Allen, Eliezer M.; Liang, Han; Lawrence, Michael S.; Godzik, Adam; Lopez-Bigas, Nuria; Stuart, Josh; Wheeler, David; Getz, Gad; Chen, Ken; Lazar, Alexander J.; Mills, Gordon B.; Karchin, Rachel; Ding, Li</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">371-385.e18</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Identifying mol. cancer drivers is crit. for precision oncol.  Multiple advanced algorithms to identify drivers now exist, but systematic attempts to combine and optimize them on large datasets are few.  We report a PanCancer and PanSoftware anal. spanning 9,423 tumor exomes (comprising all 33 of The Cancer Genome Atlas projects) and using 26 computational tools to catalog driver genes and mutations.  We identify 299 driver genes with implications regarding their anatomical sites and cancer/cell types.  Sequence- and structure-based analyses identified >3,400 putative missense driver mutations supported by multiple lines of evidence.  Exptl. validation confirmed 60%-85% of predicted mutations as likely drivers.  We found that >300 MSI tumors are assocd. with high PD-1/PD-L1, and 57% of tumors analyzed harbor putative clin. actionable events.  Our study represents the most comprehensive discovery of cancer genes and mutations to date and will serve as a blueprint for future biol. and clin. endeavors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonwISc8tVS-LVg90H21EOLACvtfcHk0lj62S1GQHoI8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntFaiu7c%253D&md5=6478ef37b82611e5687dcdc102cc6e98</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.02.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.02.060%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DM.%2BH.%26aulast%3DTokheim%26aufirst%3DC.%26aulast%3DPorta-Pardo%26aufirst%3DE.%26aulast%3DSengupta%26aufirst%3DS.%26aulast%3DBertrand%26aufirst%3DD.%26aulast%3DWeerasinghe%26aufirst%3DA.%26aulast%3DColaprico%26aufirst%3DA.%26aulast%3DWendl%26aufirst%3DM.%2BC.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DReardon%26aufirst%3DB.%26aulast%3DNg%26aufirst%3DP.%2BK.-S.%26aulast%3DJeong%26aufirst%3DK.%2BJ.%26aulast%3DCao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DE.%2BM.%26aulast%3DMularoni%26aufirst%3DL.%26aulast%3DRubio-Perez%26aufirst%3DC.%26aulast%3DNagarajan%26aufirst%3DN.%26aulast%3DCortes-Ciriano%26aufirst%3DI.%26aulast%3DZhou%26aufirst%3DD.%2BC.%26aulast%3DLiang%26aufirst%3DW.-W.%26aulast%3DHess%26aufirst%3DJ.%2BM.%26aulast%3DYellapantula%26aufirst%3DV.%2BD.%26aulast%3DTamborero%26aufirst%3DD.%26aulast%3DGonzalez-Perez%26aufirst%3DA.%26aulast%3DSuphavilai%26aufirst%3DC.%26aulast%3DKo%26aufirst%3DJ.%2BY.%26aulast%3DKhurana%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DP.%2BJ.%26aulast%3DVan%2BAllen%26aufirst%3DE.%2BM.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DLawrence%26aufirst%3DM.%2BS.%26aulast%3DGodzik%26aufirst%3DA.%26aulast%3DLopez-Bigas%26aufirst%3DN.%26aulast%3DStuart%26aufirst%3DJ.%26aulast%3DWheeler%26aufirst%3DD.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DLazar%26aufirst%3DA.%2BJ.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DKarchin%26aufirst%3DR.%26aulast%3DDing%26aufirst%3DL.%26atitle%3DComprehensive%2520characterization%2520of%2520cancer%2520driver%2520genes%2520and%2520mutations%26jtitle%3DCell%26date%3D2018%26volume%3D173%26spage%3D371%26epage%3D385%26doi%3D10.1016%2Fj.cell.2018.02.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greene, T. W.</span>; <span class="NLM_string-name">Wuts, P. G. M.</span></span> <i>Protective Groups in Organic Synthesis</i>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_publisher-name">John Wiley and Sons, Inc.</span>, <span class="NLM_year">1991</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&author=T.+W.+Greene&author=P.+G.+M.+Wuts&title=Protective+Groups+in+Organic+Synthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DT.%2BW.%26btitle%3DProtective%2520Groups%2520in%2520Organic%2520Synthesis%26pub%3DJohn%2520Wiley%2520and%2520Sons%252C%2520Inc%26date%3D1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">VanderWel, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repine, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quin, J.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booth, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrusin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span> <span> </span><span class="NLM_article-title">Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2371</span>– <span class="NLM_lpage">2387</span>, <span class="refDoi"> DOI: 10.1021/jm049355+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049355%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2371-2387&author=S.+N.+VanderWelauthor=P.+J.+Harveyauthor=D.+J.+McNamaraauthor=J.+T.+Repineauthor=P.+R.+Kellerauthor=J.+Quinauthor=R.+J.+Boothauthor=W.+L.+Elliottauthor=E.+M.+Dobrusinauthor=D.+W.+Fryauthor=P.+L.+Toogood&title=Pyrido%5B2%2C3-d%5Dpyrimidin-7-ones+as+specific+inhibitors+of+cyclin-dependent+kinase+4&doi=10.1021%2Fjm049355%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrido[2,3-d]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4</span></div><div class="casAuthors">VanderWel, Scott N.; Harvey, Patricia J.; McNamara, Dennis J.; Repine, Joseph T.; Keller, Paul R.; Quin, John, III; Booth, R. John; Elliott, William L.; Dobrusin, Ellen M.; Fry, David W.; Toogood, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2371-2387</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the cell cycle kinase, cyclin-dependent kinase-4 (Cdk4), is expected to provide an effective method for the treatment of proliferative diseases such as cancer.  The pyrido[2,3-d]pyrimidin-7-one template has been identified previously as a privileged structure for the inhibition of ATP-dependent kinases, and good potency against Cdks has been reported for representative examples.  Obtaining selectivity for individual Cdk enzymes, particularly Cdk4, has been challenging.  A series of pyrido[2,3-d]pyrimidin-7-ones I (R1 = Me2CH, Et2CH, cyclopentyl; R2 = H, Me, Et, F3C; R3 = H, Me, F, Cl, COMe, MeO2C, etc.; X = HOCH, H2NCH, CH2N, CH2CH2, etc.) was synthesized and investigated as selective inhibitors of Cdk4.  The introduction of a Me substituent at the C-5 position of the pyrido[2,3-d]pyrimidin-7-one template is sufficient to confer excellent selectivity for Cdk4 vs other Cdks and representative tyrosine kinases.  Further optimization led to the identification of highly potent and selective inhibitors of Cdk4 that exhibit potent antiproliferative activity against human tumor cells in vitro.  The most selective Cdk4 inhibitors were evaluated for antitumor activity against MDA-MB-435 human breast carcinoma xenografts in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKNHZHOwd7c7Vg90H21EOLACvtfcHk0lgVLDbnxP5gyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisLo%253D&md5=ef3c86bbdfaea0080d1103313d094ccd</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm049355%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049355%252B%26sid%3Dliteratum%253Aachs%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DQuin%26aufirst%3DJ.%26aulast%3DBooth%26aufirst%3DR.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26atitle%3DPyrido%255B2%252C3-d%255Dpyrimidin-7-ones%2520as%2520specific%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25204%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2371%26epage%3D2387%26doi%3D10.1021%2Fjm049355%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boschelli, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrusin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattaey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trumpp-Kallmeyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span> <span> </span><span class="NLM_article-title">Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4606</span>– <span class="NLM_lpage">4616</span>, <span class="refDoi"> DOI: 10.1021/jm000271k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000271k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvFarsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4606-4616&author=M.+Barvianauthor=D.+H.+Boschelliauthor=J.+Cossrowauthor=E.+Dobrusinauthor=A.+Fattaeyauthor=A.+Fritschauthor=D.+Fryauthor=P.+Harveyauthor=P.+Kellerauthor=M.+Garrettauthor=F.+Laauthor=W.+Leopoldauthor=D.+McNamaraauthor=M.+Quinauthor=S.+Trumpp-Kallmeyerauthor=P.+Toogoodauthor=Z.+Wuauthor=E.+Zhang&title=Pyrido%5B2%2C3-d%5Dpyrimidin-7-one+inhibitors+of+cyclin-dependent+kinases&doi=10.1021%2Fjm000271k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases</span></div><div class="casAuthors">Barvian, Mark; Boschelli, Dianne; Cossrow, Jennifer; Dobrusin, Ellen; Fattaey, Ali; Fritsch, Alex; Fry, David; Harvey, Patricia; Keller, Paul; Garrett, Michelle; La, Frances; Leopold, Wilbur; McNamara, Dennis; Quin, Marie; Trumpp-Kallmeyer, Susanne; Toogood, Peter; Wu, Zhipei; Zhang, Erli</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4606-4616</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The identification of 8-ethyl-2-phenylamino-8H-pyrido[2,3-d]pyrimidin-7-one as an inhibitor of Cdk4 led to the initiation of a program to evaluate related pyrido[2,3-d]pyrimidin-7-ones for inhibition of cyclin-dependent kinases (Cdks).  Anal. of more than 60 analogs has identified some clear SAR trends that may be exploited in the design of more potent Cdk inhibitors.  The most potent Cdk4 inhibitors reported in this study inhibit Cdk4 with IC50 = 0.004 μM ([ATP] = 25 μM).  X-ray crystallog. anal. of representative compds. bound to the related kinase, Cdk2, reveals that they occupy the ATP binding site.  Modest selectivity between Cdks is exhibited by some compds., and Cdk4-selective inhibitors block pRb+ cells in the G1-phase of the cell division cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2uxmolw6ZhLVg90H21EOLACvtfcHk0lgVLDbnxP5gyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvFarsbw%253D&md5=e200a37965f81edea7aecf673f33b837</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm000271k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000271k%26sid%3Dliteratum%253Aachs%26aulast%3DBarvian%26aufirst%3DM.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DCossrow%26aufirst%3DJ.%26aulast%3DDobrusin%26aufirst%3DE.%26aulast%3DFattaey%26aufirst%3DA.%26aulast%3DFritsch%26aufirst%3DA.%26aulast%3DFry%26aufirst%3DD.%26aulast%3DHarvey%26aufirst%3DP.%26aulast%3DKeller%26aufirst%3DP.%26aulast%3DGarrett%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DF.%26aulast%3DLeopold%26aufirst%3DW.%26aulast%3DMcNamara%26aufirst%3DD.%26aulast%3DQuin%26aufirst%3DM.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DToogood%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DE.%26atitle%3DPyrido%255B2%252C3-d%255Dpyrimidin-7-one%2520inhibitors%2520of%2520cyclin-dependent%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4606%26epage%3D4616%26doi%3D10.1021%2Fjm000271k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repine, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanderWel, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and selective inhibitor of cyclin-dependent Kinase 4/6</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2388</span>– <span class="NLM_lpage">2406</span>, <span class="refDoi"> DOI: 10.1021/jm049354h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+potent+and+selective+inhibitor+of+cyclin-dependent+Kinase+4%2F6&doi=10.1021%2Fjm049354h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0litDsQCtIJfnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520Kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406%26doi%3D10.1021%2Fjm049354h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackmond, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, P. S.</span></span> <span> </span><span class="NLM_article-title">A new reagent for direct difluoromethylation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">1494</span>– <span class="NLM_lpage">1497</span>, <span class="refDoi"> DOI: 10.1021/ja211422g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja211422g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=1494-1497&author=Y.+Fujiwaraauthor=J.+A.+Dixonauthor=R.+A.+Rodriguezauthor=R.+D.+Baxterauthor=D.+D.+Dixonauthor=M.+R.+Collinsauthor=D.+G.+Blackmondauthor=P.+S.+Baran&title=A+new+reagent+for+direct+difluoromethylation&doi=10.1021%2Fja211422g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A New Reagent for Direct Difluoromethylation</span></div><div class="casAuthors">Fujiwara, Yuta; Dixon, Janice A.; Rodriguez, Rodrigo A.; Baxter, Ryan D.; Dixon, Darryl D.; Collins, Michael R.; Blackmond, Donna G.; Baran, Phil S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1494-1497</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. scaffolds contg. alkylfluorine substituents are desired in many areas of chem. research from materials to pharmaceuticals.  Herein, we report the invention of a new reagent (Zn(SO2CF2H)2, DFMS) for the innate difluoromethylation of org. substrates via a radical process.  This mild, operationally simple, chemoselective, and scalable difluoromethylation method is compatible with a range of nitrogen-contg. heteroarene substrates of varying complexity as well as select classes of conjugated π-systems and thiols.  Regiochem. comparisons suggest that the CF2H radical generated from the new reagent possesses nucleophilic character.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBZLaYVgv3d7Vg90H21EOLACvtfcHk0litDsQCtIJfnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKlsA%253D%253D&md5=12c62a8451805995591a0fad95fa54f4</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fja211422g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja211422g%26sid%3Dliteratum%253Aachs%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DDixon%26aufirst%3DJ.%2BA.%26aulast%3DRodriguez%26aufirst%3DR.%2BA.%26aulast%3DBaxter%26aufirst%3DR.%2BD.%26aulast%3DDixon%26aufirst%3DD.%2BD.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DBlackmond%26aufirst%3DD.%2BG.%26aulast%3DBaran%26aufirst%3DP.%2BS.%26atitle%3DA%2520new%2520reagent%2520for%2520direct%2520difluoromethylation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D1494%26epage%3D1497%26doi%3D10.1021%2Fja211422g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Hara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackmond, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, P. S.</span></span> <span> </span><span class="NLM_article-title">Radical-based regioselective C-H functionalization of electron-deficient heteroarenes: scope, tunability, and predictability</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">12122</span>, <span class="refDoi"> DOI: 10.1021/ja406223k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja406223k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFamsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=12122&author=F.+O%E2%80%99Haraauthor=D.+G.+Blackmondauthor=P.+S.+Baran&title=Radical-based+regioselective+C-H+functionalization+of+electron-deficient+heteroarenes%3A+scope%2C+tunability%2C+and+predictability&doi=10.1021%2Fja406223k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Radical-Based Regioselective C-H Functionalization of Electron-Deficient Heteroarenes: Scope, Tunability, and Predictability</span></div><div class="casAuthors">O'Hara, Fionn; Blackmond, Donna G.; Baran, Phil S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">12122-12134</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Radical addn. processes can be ideally suited for the direct functionalization of heteroarom. bases, yet these processes are only sparsely used due to the perception of poor or unreliable control of regiochem.  A systematic investigation of factors affecting the regiochem. of radical functionalization of heterocycles using alkylsulfinate salts revealed that certain types of substituents exert consistent and additive effects on the regioselectivity of substitution.  This allowed us to establish guidelines for predicting regioselectivity on complex π-deficient heteroarenes, including pyridines, pyrimidines, pyridazines, and pyrazines.  Since the relative contribution from opposing directing factors was dependent on solvent and pH, it was sometimes possible to tune the regiochem. to a desired result by modifying reaction conditions.  This methodol. was applied to the direct, regioselective introduction of iso-Pr groups into complex, biol. active mols., such as diflufenican (I; R = H → R = iso-Pr) and nevirapine (II; R = H → R = iso-Pr).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEOGesZTIMOrVg90H21EOLACvtfcHk0litDsQCtIJfnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFamsb3M&md5=e12331edd20ef03aafe3c7a7145a8f6e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fja406223k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja406223k%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hara%26aufirst%3DF.%26aulast%3DBlackmond%26aufirst%3DD.%2BG.%26aulast%3DBaran%26aufirst%3DP.%2BS.%26atitle%3DRadical-based%2520regioselective%2520C-H%2520functionalization%2520of%2520electron-deficient%2520heteroarenes%253A%2520scope%252C%2520tunability%252C%2520and%2520predictability%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D12122%26doi%3D10.1021%2Fja406223k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frahm, A. W.</span></span> <span> </span><span class="NLM_article-title">Asymmetric reductive amination of cycloalkanones. 5. Synthesis and absolute configuration of 2-substituted cyclopentanamines</span>. <i>Chem. Ber.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2668</span>– <span class="NLM_lpage">2677</span>, <span class="refDoi"> DOI: 10.1002/cber.19861190823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1002%2Fcber.19861190823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADyaL28XltFClsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=1986&pages=2668-2677&author=W.+Wiehlauthor=A.+W.+Frahm&title=Asymmetric+reductive+amination+of+cycloalkanones.+5.+Synthesis+and+absolute+configuration+of+2-substituted+cyclopentanamines&doi=10.1002%2Fcber.19861190823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric reductive amination of cycloalkanones.  5.  Synthesis and absolute configuration of 2-substituted cyclopentanamines</span></div><div class="casAuthors">Wiehl, Wolfgang; Frahm, August W.</div><div class="citationInfo"><span class="NLM_cas:title">Chemische Berichte</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2668-77</span>CODEN:
                <span class="NLM_cas:coden">CHBEAM</span>;
        ISSN:<span class="NLM_cas:issn">0009-2940</span>.
    </div><div class="casAbstract">In an asym. synthesis 2-substituted cyclopentanamines are obtained from racemic cyclopentanones I (R = Me, Et, Me2CH, Ph, PhCH2) by means of reductive amination in a three-step procedure.  Condensation of the ketones I with optically active 1-phenylethylamines yields imine mixts. II, which are hydrogenated with Raney-Ni to give the optically active, diastereomerically pure secondary amines III.  Hydrogenolysis with Pd-C leads to high grade enantiomerically pure primary amines IV with good yields.  The relative configuration of III and IV is elucidated by 1H and 13C NMR.  The abs. configuration is detd. by x-ray anal. of the 4-bromobenzamide of the primary amine (+)-IV (R = Ph) and with the help of CD of the salicylidene derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4M0WyznwkRbVg90H21EOLACvtfcHk0lg8xcstLW6qEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XltFClsLk%253D&md5=02e289df55dfaeac46a41a5b67dc5869</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2Fcber.19861190823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcber.19861190823%26sid%3Dliteratum%253Aachs%26aulast%3DWiehl%26aufirst%3DW.%26aulast%3DFrahm%26aufirst%3DA.%2BW.%26atitle%3DAsymmetric%2520reductive%2520amination%2520of%2520cycloalkanones.%25205.%2520Synthesis%2520and%2520absolute%2520configuration%2520of%25202-substituted%2520cyclopentanamines%26jtitle%3DChem.%2520Ber.%26date%3D1986%26volume%3D119%26spage%3D2668%26epage%3D2677%26doi%3D10.1002%2Fcber.19861190823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Behenna, D. C.</span>; <span class="NLM_string-name">Chen, P.</span>; <span class="NLM_string-name">Freeman-Cook, K. D.</span>; <span class="NLM_string-name">Hoffman, R. L.</span>; <span class="NLM_string-name">Jalaie, M.</span>; <span class="NLM_string-name">Nagata, A.</span>; <span class="NLM_string-name">Nair, S. K.</span>; <span class="NLM_string-name">Ninkovic, S.</span>; <span class="NLM_string-name">Ornelas, M. A.</span>; <span class="NLM_string-name">Palmer, C. L.</span>; <span class="NLM_string-name">Rui, E. Y.</span></span> <span> </span><span class="NLM_article-title">Preparation of heterocyclylaminopyrido[2,3-d]pyrimidin-7(8H)-one compounds as cyclin-dependent kinase inhibitors for treatment of proliferative diseases such as cancer</span>. U.S. Patent <span class="NLM_patent">20,180,044,344 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=D.+C.+Behenna&author=P.+Chen&author=K.+D.+Freeman-Cook&author=R.+L.+Hoffman&author=M.+Jalaie&author=A.+Nagata&author=S.+K.+Nair&author=S.+Ninkovic&author=M.+A.+Ornelas&author=C.+L.+Palmer&author=E.+Y.+Rui&title=Preparation+of+heterocyclylaminopyrido%5B2%2C3-d%5Dpyrimidin-7%288H%29-one+compounds+as+cyclin-dependent+kinase+inhibitors+for+treatment+of+proliferative+diseases+such+as+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBehenna%26aufirst%3DD.%2BC.%26atitle%3DPreparation%2520of%2520heterocyclylaminopyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-one%2520compounds%2520as%2520cyclin-dependent%2520kinase%2520inhibitors%2520for%2520treatment%2520of%2520proliferative%2520diseases%2520such%2520as%2520cancer%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frémaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shutes, A.</span></span> <span> </span><span class="NLM_article-title">Capillary microfluidic electrophoretic mobility shift assays: application to enzymatic assays in drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1517/17460440903493431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1517%2F17460440903493431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=22823971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1aqtLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=51-63&author=D.+Perrinauthor=C.+Fr%C3%A9mauxauthor=A.+Shutes&title=Capillary+microfluidic+electrophoretic+mobility+shift+assays%3A+application+to+enzymatic+assays+in+drug+discovery&doi=10.1517%2F17460440903493431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Capillary microfluidic electrophoretic mobility shift assays: application to enzymatic assays in drug discovery</span></div><div class="casAuthors">Perrin, Dominique; Fremaux, Christele; Shutes, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-63</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Microfluidic electrophoretic mobility shift assays are becoming increasingly popular with screening groups throughout the pharmaceutical industry due to their excellent data quality and target flexibility.  Areas covered in this review: This review summarizes our experience of the microfluidic electrophoretic mobility shift technique at Merck Serono as well as from the published literature.  We assess the advantages and limitations of electrophoretic mobility shift assays in this context.What the reader will gain: Published literature on the topic is scarce.  The reader will gain an insight into the techniques and issues with the use of this technol. in a pharmaceutical setting.Take home message: This technol. has reached maturity, providing reliable and robust results.  Current limitations are the lower-than-desired throughput capacity for primary screening campaigns, and its current restriction to enzyme classes catalyzing a significant change in mass/charge of the substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoEZg_o4UvtbVg90H21EOLACvtfcHk0lg8xcstLW6qEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1aqtLnM&md5=ebb7b4778d113c5eae0e8520c3e75683</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1517%2F17460440903493431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460440903493431%26sid%3Dliteratum%253Aachs%26aulast%3DPerrin%26aufirst%3DD.%26aulast%3DFr%25C3%25A9maux%26aufirst%3DC.%26aulast%3DShutes%26aufirst%3DA.%26atitle%3DCapillary%2520microfluidic%2520electrophoretic%2520mobility%2520shift%2520assays%253A%2520application%2520to%2520enzymatic%2520assays%2520in%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2010%26volume%3D5%26spage%3D51%26epage%3D63%26doi%3D10.1517%2F17460440903493431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, J. F.</span></span> <span> </span><span class="NLM_article-title">Kinetics of the reversible inhibition of enzyme-catalyzed reactions by tight-binding inhibitors</span>. <i>Biochim. Biophys. Acta, Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1016/0005-2744(69)90420-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2F0005-2744%2869%2990420-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=4980133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADyaF1MXkvVOqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=1969&pages=269-286&author=J.+F.+Morrison&title=Kinetics+of+the+reversible+inhibition+of+enzyme-catalyzed+reactions+by+tight-binding+inhibitors&doi=10.1016%2F0005-2744%2869%2990420-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of the reversible inhibition of enzyme-catalyzed reactions by tight-binding inhibitors</span></div><div class="casAuthors">Morrison, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Enzymology</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">269-86</span>CODEN:
                <span class="NLM_cas:coden">BBEZAD</span>;
        ISSN:<span class="NLM_cas:issn">0924-1086</span>.
    </div><div class="casAbstract">A theoretical kinetic study has been undertaken to det. the kinetic characteristics of enzymic reactions that are reversibly inhibited by a substrate analog. at concns. comparable to that of the enzyme.  A general rate equation, that allows for the combination of such a tight-binding inhibitor with one or more enzyme forms of any reaction mechanism, has been derived and shown to be quadratic with sq. and linear terms in υ which represents the true initial steady-state velocity.  From plots of υ against total enzyme concn. at fixed total inhibitor concn., the concn. of enzyme catalytic sites can be detd. irrespective of the nature of the inhibition and the reaction mechanism.  However, plots of υ (or I/υ) against total inhibitor concn. can be used for this purpose only if the dissocn. const. assocd. with the inhibitor is virtually zero.  Particular initial rate equations have been obtained for the cases in which the tight-binding inhibitor gives rise to competitive, noncompetitive, and uncompetitive inhibition with respect to one of the substrates of a bireactant mechanism.  From these equations it has been deduced that, in the presence of inhibitor, plots of I/υ against the reciprocals of the substrate concns. yield families of concave-down, nonrectangular hyperbolas.  The difficulties assocd. with the detn. of inhibition consts. for tight-binding inhibitors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj4s_N2iV3CLVg90H21EOLACvtfcHk0lg8xcstLW6qEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXkvVOqsbo%253D&md5=74d467477385488dfbb053358534ada6</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2F0005-2744%2869%2990420-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0005-2744%252869%252990420-3%26sid%3Dliteratum%253Aachs%26aulast%3DMorrison%26aufirst%3DJ.%2BF.%26atitle%3DKinetics%2520of%2520the%2520reversible%2520inhibition%2520of%2520enzyme-catalyzed%2520reactions%2520by%2520tight-binding%2520inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Enzymol.%26date%3D1969%26volume%3D185%26spage%3D269%26epage%3D286%26doi%3D10.1016%2F0005-2744%2869%2990420-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D. J.</span></span> <span> </span><span class="NLM_article-title">Determination of accurate KI values for tight-binding enzyme inhibitors: an in silico study of experimental error and assay design</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2003.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1016%2Fj.ab.2003.12.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=15033511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFKhtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2004&pages=61-67&author=D.+J.+Murphy&title=Determination+of+accurate+KI+values+for+tight-binding+enzyme+inhibitors%3A+an+in+silico+study+of+experimental+error+and+assay+design&doi=10.1016%2Fj.ab.2003.12.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of accurate KI values for tight-binding enzyme inhibitors: an in silico study of experimental error and assay design</span></div><div class="casAuthors">Murphy, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-67</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">Detn. of accurate KI values for tight-binding enzyme inhibitors is important from both a basic biochem. point of view (understanding the differences in affinity of related mols.) and a medicinal chem. vantage (developing structure-activity relationships (SAR)).  It is advantageous to directly fit the quadratic equation describing tight-binding behavior, known commonly as the Morrison equation, to obtain these KI values.  The results of simulated expts. that examine the effect of assay design and exptl. error on the ability to accurately det. KI values at several [E]0/KI-app ratios are described.  Input ("true") values of the uninhibited velocity, inhibition const., and total enzyme concn. were used to calc. the velocity at various inhibitor concns.  Gaussian error was introduced into the velocities and the simulated reactions were fit to est. v0, KI, and [E]0.  Recommendations for optimizing the inhibitor dilns. within the context of a 96-well-plate format and simple serial diln. steps are made.  These include using three points to det. the enzyme concn. ([I] = 0, 0.5[E]0, and [E]0), using a narrow diln. series with only two or three points to det. the asymptote at high inhibitor concn., and avoidance of fixing [E]0 to a const. value in the fitting if at all possible.  The risks and rewards of fixing [E]0 to a const. value, esp. the effect on SAR, are also examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGiaWGV4W5tLVg90H21EOLACvtfcHk0lgktt43KxdxJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFKhtrg%253D&md5=f93d7f5648fc310736f4a80c10ef3edd</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2003.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2003.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DD.%2BJ.%26atitle%3DDetermination%2520of%2520accurate%2520KI%2520values%2520for%2520tight-binding%2520enzyme%2520inhibitors%253A%2520an%2520in%2520silico%2520study%2520of%2520experimental%2520error%2520and%2520assay%2520design%26jtitle%3DAnal.%2520Biochem.%26date%3D2004%26volume%3D327%26spage%3D61%26epage%3D67%26doi%3D10.1016%2Fj.ab.2003.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vonrhein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flensburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paciorek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span></span> <span> </span><span class="NLM_article-title">Data processing and analysis with the autoPROC toolbox</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1107/s0907444911007773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1107%2FS0907444911007773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=21460447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=293-302&author=C.+Vonrheinauthor=C.+Flensburgauthor=P.+Kellerauthor=A.+Sharffauthor=O.+Smartauthor=W.+Paciorekauthor=T.+Womackauthor=G.+Bricogne&title=Data+processing+and+analysis+with+the+autoPROC+toolbox&doi=10.1107%2Fs0907444911007773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Data processing and analysis with the autoPROC toolbox</span></div><div class="casAuthors">Vonrhein, Clemens; Flensburg, Claus; Keller, Peter; Sharff, Andrew; Smart, Oliver; Paciorek, Wlodek; Womack, Thomas; Bricogne, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">293-302</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A typical diffraction expt. will generate many images and data sets from different crystals in a very short time.  This creates a challenge for the high-throughput operation of modern synchrotron beamlines as well as for the subsequent data processing.  Novice users in particular may feel overwhelmed by the tables, plots and nos. that the different data-processing programs and software packages present to them.  Here, some of the more common problems that a user has to deal with when processing a set of images that will finally make up a processed data set are shown, concg. on difficulties that may often show up during the first steps along the path of turning the expt. (i.e. data collection) into a model (i.e. interpreted electron d.).  Difficulties such as unexpected crystal forms, issues in crystal handling and suboptimal choices of data-collection strategies can often be dealt with, or at least diagnosed, by analyzing specific data characteristics during processing.  In the end, one wants to distinguish problems over which one has no immediate control once the expt. is finished from problems that can be remedied a posteriori.  A new software package, autoPROC, is also presented that combines third-party processing programs with new tools and an automated workflow script that is intended to provide users with both guidance and insight into the offline processing of data affected by the difficulties mentioned above, with particular emphasis on the automated treatment of multi-sweep data sets collected on multi-axis goniostats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmah7iUrMLXLVg90H21EOLACvtfcHk0lgktt43KxdxJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D&md5=a0a3579f6b371b6312819883864aa80d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1107%2FS0907444911007773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911007773%26sid%3Dliteratum%253Aachs%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DFlensburg%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DP.%26aulast%3DSharff%26aufirst%3DA.%26aulast%3DSmart%26aufirst%3DO.%26aulast%3DPaciorek%26aufirst%3DW.%26aulast%3DWomack%26aufirst%3DT.%26aulast%3DBricogne%26aufirst%3DG.%26atitle%3DData%2520processing%2520and%2520analysis%2520with%2520the%2520autoPROC%2520toolbox%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D293%26epage%3D302%26doi%3D10.1107%2Fs0907444911007773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span>; <span class="NLM_string-name">Blanc, E.</span>; <span class="NLM_string-name">Brandl, M.</span>; <span class="NLM_string-name">Flensburg, C.</span>; <span class="NLM_string-name">Keller, P.</span>; <span class="NLM_string-name">Paciorek, W.</span>; <span class="NLM_string-name">Roversi, P.</span>; <span class="NLM_string-name">Sharff, A.</span>; <span class="NLM_string-name">Smart, O.</span>; <span class="NLM_string-name">Vonrheim, C.</span></span> <i>BUSTER</i>; <span class="NLM_publisher-name">Global Phasing Ltd</span>: <span class="NLM_publisher-loc">Cambridge, United Kingdom</span>, <span class="NLM_year">2011–2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011%E2%80%932020&author=G.+Bricogne&author=E.+Blanc&author=M.+Brandl&author=C.+Flensburg&author=P.+Keller&author=W.+Paciorek&author=P.+Roversi&author=A.+Sharff&author=O.+Smart&author=C.+Vonrheim&title=BUSTER"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBricogne%26aufirst%3DG.%26btitle%3DBUSTER%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2011%25E2%2580%25932020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/s0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2Fs0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lgktt43KxdxJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2Fs0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCH','PDB','4BCH'); return false;">PDB: 4BCH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TN8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TN8','PDB','3TN8'); return false;">PDB: 3TN8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KJS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KJS','PDB','7KJS'); return false;">PDB: 7KJS</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i62"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00159">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_45780"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00159?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00159</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00159/suppl_file/jm1c00159_si_001.csv">CSV</a>)</p></li><li><p class="inline">CDK2/cyclinE1/inhibitor complex crystal structure statistics for <b>22</b>, single-crystal X-ray structure data for <b>22</b>, <i>in vitro</i> biochemical activity of <b>22</b>, kinase inhibition panel data for <b>22</b>, <sup>1</sup>H and <sup>13</sup>C NMR spectra of compounds <b>8</b> and <b>22</b>, and <sup>19</sup>F NMR spectrum of <b>22</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00159/suppl_file/jm1c00159_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00159/suppl_file/jm1c00159_si_001.csv">jm1c00159_si_001.csv (2.64 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00159/suppl_file/jm1c00159_si_002.pdf">jm1c00159_si_002.pdf (809.71 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00159&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00159%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-13%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00159" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ac0263c2e2374","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
